



(51) International Patent Classification:

C07D 307/84 (2006.01) **C07D 413/12** (2006.01)
C07D 405/04 (2006.01) **C07D 417/10** (2006.01)
C07D 405/10 (2006.01) **C07D 417/12** (2006.01)
C07D 405/12 (2006.01) **C07D 453/00** (2006.01)
C07D 407/12 (2006.01) **C07D 491/10** (2006.01)
C07D 409/12 (2006.01) **A61K 31/14** (2006.01)
C07D 413/10 (2006.01) **A61P 31/14** (2006.01)

(21) International Application Number:

PCT/US2009/056166

(22) International Filing Date:

8 September 2009 (08.09.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/096,005 11 September 2008 (11.09.2008) US

(71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **YEUNG, Kap-Sun** [US/US]; c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **PARCELLA, Kyle E.** [US/US]; c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **BENDER, John A.** [US/US]; c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **BENO, Brett R.** [US/US]; c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **GRANT-YOUNG, Katharine A.** [US/US]; c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **HAN, Ying** [US/US]; c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **HEWAWASAM, Piyasena** [US/US]; c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US).

KADOW, John F. [US/US]; c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **NICKEL, Andrew** [US/US]; 572 S. Berkeley Avenue, San Marino, California 91108 (US).

(74) Agents: **EPPERSON, James** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

(57) Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.



COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. provisional application serial
5 number 61/096,005 filed September 11, 2008.

BACKGROUND OF THE INVENTION

[0002] The disclosure generally relates to the novel compounds of formula I,
including their salts, which have activity against hepatitis C virus (HCV) and are
10 useful in treating those infected with HCV. The disclosure also relates to
compositions and methods of using these compounds.

[0003] Hepatitis C virus (HCV) is a major human pathogen, infecting an
estimated 170 million persons worldwide - roughly five times the number infected by
human immunodeficiency virus type 1. A substantial fraction of these HCV infected
15 individuals develop serious progressive liver disease, including cirrhosis and
hepatocellular carcinoma (Lauer, G.M. et al., *N. Engl. J. Med.*, 345:41-52 (2001)).

[0004] HCV is a positive-stranded RNA virus. Based on a comparison of the
deduced amino acid sequence and the extensive similarity in the 5'-untranslated
region, HCV has been classified as a separate genus in the Flaviviridae family. All
20 members of the Flaviviridae family have enveloped virions that contain a positive
stranded RNA genome encoding all known virus-specific proteins via translation of a
single, uninterrupted, open reading frame.

[0005] Considerable heterogeneity is found within the nucleotide and encoded
amino acid sequence throughout the HCV genome. At least six major genotypes have
25 been characterized, and more than 50 subtypes have been described. The major
genotypes of HCV differ in their distribution worldwide, and the clinical significance
of the genetic heterogeneity of HCV remains elusive despite numerous studies of the
possible effect of genotypes on pathogenesis and therapy.

[0006] The single strand HCV RNA genome is approximately 9500 nucleotides
30 in length and has a single open reading frame (ORF) encoding a single large
polyprotein of about 3000 amino acids. In infected cells, this polyprotein is cleaved
at multiple sites by cellular and viral proteases to produce the structural and non-

structural (NS) proteins. In the case of HCV, the generation of mature non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) is effected by two viral proteases. The first one is believed to be a metalloprotease and cleaves at the NS2-NS3 junction; the second one is a serine protease contained within the N-terminal
5 region of NS3 (also referred to as NS3 protease) and mediates all the subsequent cleavages downstream of NS3, both in cis, at the NS3-NS4A cleavage site, and in trans, for the remaining NS4A-NS4B, NS4B-NS5A, NS5A-NS5B sites. The NS4A protein appears to serve multiple functions, acting as a cofactor for the NS3 protease and possibly assisting in the membrane localization of NS3 and other viral replicase
10 components. The complex formation of the NS3 protein with NS4A seems necessary to the processing events, enhancing the proteolytic efficiency at all of the sites. The NS3 protein also exhibits nucleoside triphosphatase and RNA helicase activities. NS5B (also referred to as HCV polymerase) is a RNA-dependent RNA polymerase that is involved in the replication of HCV. The HCV NS5B protein is described in
15 “Structural Analysis of the Hepatitis C Virus RNA Polymerase in Complex with Ribonucleotides (Bressanelli, S. et al., *J. Virol.*, 3482-3492 (2002); and Defrancesco et al., *Clinics in Liver Disease*, 7:211-242 (2003)).

[0007] Currently, the most effective HCV therapy employs a combination of alpha-interferon and ribavirin, leading to sustained efficacy in 40% of patients
20 (Poynard, T. et al., *Lancet*, 352:1426-1432 (1998)). Recent clinical results demonstrate that pegylated alpha-interferon is superior to unmodified alpha-interferon as monotherapy (Zeuzem, S. et al., *N. Engl. J. Med.*, 343:1666-1672 (2000)). However, even with experimental therapeutic regimens involving combinations of pegylated alpha-interferon and ribavirin, a substantial fraction of patients do not have
25 a sustained reduction in viral load. Thus, there is a clear and important need to develop effective therapeutics for treatment of HCV infection.


[0008] HCV-796, an HCV NS5B inhibitor, showed an ability to reduce HCV RNA levels in patients. The viral RNA levels decreased transiently and then rebounded during dosing when treatment was with the compound as a single agent
30 but levels dropped more robustly when combined with the standard of care which is a form of interferon and ribavirin. The development of this compound was suspended due to hepatic toxicity observed during extended dosing of the combination regimens.

U.S. Patent No. 7,265,152 and the corresponding PCT patent application WO 2004/041201 A2 describe compounds of the HCV-796 class.

[0009] The invention provides technical advantages, for example, the compounds are novel and are effective against hepatitis C. Additionally, the compounds provide advantages for pharmaceutical uses, for example, with regard to one or more of their mechanism of action, binding, inhibition efficacy, target selectivity, solubility, safety profiles, or bioavailability.

DESCRIPTION OF THE INVENTION

[0010] One aspect of the invention is a compound of formula I



I

R^1 is R^5R^6N ; alkoxy; (alkoxycarbonylamino)alkoxy; (alkylphenyl)alkoxy; (carboxy)alkenyl; (alkoxycarbonyl)alkenyl; (benzyloxycarbonyl)alkenyl; ((N-dimethylbenzyl)aminocarbonyl)alkenyl; or phenyl where said phenyl is substituted with 1-2 substituents selected from the group consisting of halo, cyano, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (carboxy)alkyl, alkoxy, hydroxyalkyloxy, alkoxyalkyloxy, benzyloxy, tetrahydropyranyloxy, carboxy, alkoxycarbonyl, alkylsulfonyl, (carboxy)alkenyl, (alkoxycarbonyl)alkenyl, alkylcarboxamido, alkoxycarboxamido, alkylsulfamido, (alkylsulfamido)alkyl, Ar^5 , $SO_2NR^{15}R^{16}$, and $CONR^7R^8$; and where said phenyl is also substituted with 0-2 substituents selected from the group consisting of halo; nitro; alkyl; cycloalkyl; haloalkyl; aminoalkyl; hydroxyalkyl; alkoxyalkyl; hydroxy; alkoxy; OR^{17} ; cycloalkoxy; amino; alkylamino; dialkylamino; alkylcarboxamido; alkoxycarboxamido; alkoxyalkylcarboxamido; furanyl, thienyl, or pyrazolyl substituted with 0-2 alkyl substituents; pyridinyl substituted with 0-2 halo, cyano, alkyl, hydroxy, alkoxy, amino, or alkylaminocarbonyl substituents; pyrimidinyl; pyrimidinedionyl; aminopyrimidinyl; indolyl; isoquinolinyl; or phenyl substituted with 0-2 substituents selected from halo, alkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxy, amino, carboxy,

alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarboxamido, carboxyalkenyl, and phenyl;

R^2 is hydrogen, halo, nitro, amino, phenyl, or R^5R^6N ;

R^3 is cyano, alkoxycarbonyl, (cycloalkyl)oxycarbonyl,

5 (alkylsulfonyl)aminocarbonyl, $CONR^{11}R^{12}$, $(R^{11})(R^{12})NCONH$, triazolyl, thiazolyl, or tetrazolyl;




R^4 is phenyl substituted with 0-2 halo substituents;


R^5 is hydrogen, alkyl, or alkylsulfonyl;

R^6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or alkylsulfonyl;

10 R^7 is hydrogen, alkyl, alkenyl, alkynyl, cyanoalkyl, haloalkyl, hydroxyalkyl, dihydroxyalkyl, alkoxyalkyl, oxoalkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkyl)alkyl, cycloalkyl, (alkyl)cycloalkyl, (hydroxyalkyl)cycloalkyl, (tetrahydrofuranyl)alkyl, (tetrahydropyranyl)alkyl, (carboxy)alkyl, (alkoxycarbonyl)alkyl, (alkenyloxycarbonyl)alkyl,

15 (alkoxycarbonyl)hydroxyalkyl, $(CONR^{13}R^{14})$ alkyl, $(CONR^{13}R^{14})(hydroxyalkyl)$ alkyl, $(CONR^{13}R^{14})$ cycloalkyl, (alkylcarbonyl)aminoalkyl, (phenyl)alkyl, (pyridinyl)alkyl,


alkylsulfonyl, phenylsulfonyl, Ar^2 , Ar^3 , , , , or




R^8 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;

20 or R^7R^8N taken together is azetidiny, pyrrolidiny, piperidiny, piperaziny, morpholiny, dihydroindolyl, or isoindoliny, and is substituted with 0-2 substituents selected from alkyl, hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxy, carboxy, alkoxycarbonyl, dialkylcarboxamido, alkylcarbonylamino, alkoxycarbonylamino, pyridiny, and phenyl where said phenyl is substituted with 0-2 halo or alkyl

25 substituents;

or where R^7R^8N taken together is , (quinuclidiny)amino, (quinuclidiny)(alkyl)amino, (methylpyrrolidiny)(alkyl)amino, ((imidazolyl)alkyl)(hydroxyalkyl)amino, (alkylthiazolyl)amino,

((carboxamido)cyclopentanyl)amino, ((halophenyl)cyclopentanyl)amino, 3H-



spiro(isobenzofuranyl)piperidinyl, (hydroxyindanyl)amino, or

R^9 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;

R^{10} is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;

5 or R^9 and R^{10} taken together is ethylene, propylene, butylene, pentylene, or hexylene;

R^{11} is hydrogen, alkyl, or cycloalkyl;

R^{12} is hydrogen, alkyl, or cycloalkyl;

or R^{11} and R^{12} taken together with the nitrogen to which they are attached is

10 azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl;

R^{13} is hydrogen, alkyl, cyanoalkyl, haloalkyl, alkenyl, alkynyl, or thiazolyl;

R^{14} is hydrogen or alkyl;

R^{15} is hydrogen, alkyl, hydroxyalkyl, cycloalkyl, or benzyl;

R^{16} is hydrogen or alkyl;

15 or R^{15} and R^{16} taken together with the nitrogen to which they are attached is azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl;

R^{17} is haloalkyl, cyanoalkyl, (cycloalkyl)alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, (R^{18})alkyl, (Ar^4)alkyl, alkynyl, or aminocycloalkyl;

R^{18} is $CONH_2$, H_2NCONH , dibenzylamino, phthalimido, amino, alkylamino,

20 dialkylamino, azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl where azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl is substituted with 0-3 alkyl or alkoxy carbonyl substituents;

R^{19} is cyano, hydroxyalkyl, morpholinylalkyl, carboxy, alkoxy carbonyl, cycloalkylsulfoxamido, ((alkyl)pyrazolyl)amino, ((alkyl)isoxazolyl)amino,

25 (thiadiazolyl)amino, (triazinyl)amino, or alkynylaminocarbonyl;

R^{20} is hydrogen, halo, alkyl, or alkoxy;

R^{21} is hydrogen, halo, alkyl, or alkoxy;

Ar^1 is phenyl, naphthalenyl, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, oxadiathiazolyl,

30 triazolyl, tetrazolyl, pyrazinyl, pyrimidinyl, or benzothiazolyl, and is substituted with

0-2 substituents selected from halo, alkyl, cycloalkyl, haloalkyl, alkoxyalkyl, hydroxy, alkoxy, amino, alkylamino, dialkylamino, aminocarbonyl, pyridinyl, phenyl, halophenyl, alkylphenyl, and alkoxyphenyl;

Ar² is phenyl, biphenyl, or pyridinyl and is substituted with 0-2 substituents
5 selected from halo, alkyl, cyano, hydroxy, alkoxy, and carboxy;

Ar³ is pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, oxathiadiazolyl, pyrimidinyl, or pyridinyl and is substituted with 0-2 substituents selected from hydroxy, alkyl, hydroxyalkyl, and CONR¹³R¹⁴;

Ar⁴ is furanyl, thienyl, pyrrolyl, pyrazolyl, isoxazolyl, isothiazolyl,
10 imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridinyl, indolyl, or phenyl and is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, hydroxyl, and alkoxy; and

Ar⁵ is pyrrolyl, imidazolyl, or oxadiazolyl and is substituted with 0-2 substituents selected from alkyl, carboxy, alkoxycarbonyl, benzyl, and phenyl;
15 or a pharmaceutically acceptable salt thereof.

[0011] Another aspect of the invention is a compound of formula I where R²⁰ and R²¹ are hydrogen.

[0012] Another aspect of the invention is a compound of formula I where
20 R¹ is R⁵R⁶N; (carboxy)alkenyl; (alkoxycarbonyl)alkenyl; (benzyloxycarbonyl)alkenyl; or phenyl where said phenyl is substituted with 1-2 substituents selected from the group consisting of cyano, alkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxyalkyloxy, alkoxyalkyloxy, haloalkyl, benzyloxy, carboxy, alkoxycarbonyl, alkylsulfonyl, (carboxy)alkenyl, (alkoxycarbonyl)alkenyl,
25 alkylcarboxamido, alkoxycarboxamido, alkylsulfamido, (alkylsulfamido)alkyl, tetrahydropyranyloxy, Ar⁵, SO₂NR¹⁵R¹⁶, and CONR⁷R⁸; and where said phenyl is also substituted with 0-1 substituents selected from the group consisting of halo; alkyl; hydroxyalkyl; alkoxyalkyl; hydroxyl; alkoxy; OR¹⁷; cycloalkoxy; amino; alkylamino; dialkylamino; alkylcarboxamido; alkoxyalkylcarboxamido; furanyl;
30 indolyl; isoquinolinyl; pyridinyl substituted with 0-2 halo, alkyl, hydroxy, or alkoxy substituents; pyrazolyl substituted with 0-2 alkyl substituents; and phenyl substituted with 0-2 halo, alkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxy,

carboxy, alkoxy carbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarboxamido, carboxyalkenyl, or phenyl substituents;

R^2 is hydrogen, nitro, or R^5R^6N ;

R^3 is cyano, alkoxy carbonyl, (cycloalkyl)oxy carbonyl,

5 (alkylsulfonyl)aminocarbonyl, $CONR^{11}R^{12}$, $(R^{11})(R^{12})NCONH$, triazolyl, thiazolyl, or tetrazolyl;





R^4 is phenyl substituted with 0-2 halo substituents;

R^5 is hydrogen, alkyl, or alkylsulfonyl;

R^6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or alkylsulfonyl;

10 R^7 is hydrogen, alkyl, alkenyl, alkynyl, cyanoalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, oxoalkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkyl)alkyl, cycloalkyl, (alkyl)cycloalkyl, (hydroxyalkyl)cycloalkyl, (tetrahydrofuranyl)alkyl, (tetrahydropyranyl)alkyl, (carboxy)alkyl, (alkoxy carbonyl)alkyl, (alkoxy carbonyl)hydroxyalkyl, $(CONR^{13}R^{14})$ alkyl,


15 (alkyl carbonyl)aminoalkyl, (phenyl)alkyl, (pyridinyl)alkyl, alkylsulfonyl,

phenylsulfonyl, Ar^2 , Ar^3 , , , , or ;

R^8 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;

or R^7R^8N taken together is azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or dihydroindolyl, and is substituted with 0-2 substituents selected from

20 alkyl, hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxy, carboxy, alkoxy carbonyl, dimethylcarboxamido, alkylcarbonylamino, alkoxy carbonylamino, pyridinyl, and phenyl where phenyl is substituted with 0-2 substituents selected from halo and alkyl;

or where R^7R^8N taken together is , (quinuclidinyl)(alkyl)amino, (methylpyrrolidinyl)(alkyl)amino, (alkylthiazolyl)amino,

25 ((carboxamido)cyclopentanylamino, ((halophenyl)cyclopentanylamino, or (hydroxyindanylamino;

R^9 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;

R^{10} is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;

or R^9 and R^{10} taken together is ethylene, propylene, butylene, or pentylene;

30 R^{11} is hydrogen, alkyl, or cycloalkyl;

- R¹² is hydrogen, alkyl, or cycloalkyl;
or R¹¹ and R¹² taken together with the nitrogen to which they are attached is
azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl;
R¹³ is hydrogen, alkyl, cyanoalkyl, alkenyl, or alkynyl;
5 R¹⁴ is hydrogen or alkyl;
R¹⁵ is hydrogen or alkyl;
R¹⁶ is hydrogen or alkyl;
R¹⁷ is haloalkyl, hydroxyalkyl, alkoxyalkyl, alkynyl, (R¹⁸)alkyl or (Ar⁴)alkyl;
R¹⁸ is CONH₂, dibenzylamino, amino, alkylamino, dialkylamino, azetidiny,
10 pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl where azetidiny, pyrrolidinyl,
piperidinyl, piperazinyl, or morpholinyl, and is substituted with 0-3 substituents
selected from alkyl and alkoxy carbonyl;
R¹⁹ is cyano, ((alkyl)pyrazolyl)amino, ((alkyl)isoxazolyl)amino
(thiadiazolyl)amino, or (triazinyl)amino;
15 R²⁰ and R²¹ are hydrogen;
Ar¹ is phenyl, naphthalenyl, pyridinyl, thienyl, thiazolyl, or pyrazinyl and is
substituted with 0-2 substituents selected from alkyl, halo, hydroxy, alkoxy, amino,
alkylamino, and dialkylamino;
Ar² is phenyl, biphenyl, or pyridinyl and is substituted with 0-2 substituents
20 selected from halo, alkyl, cyano, hydroxy, and alkoxy;
Ar³ is pyrazolyl isoxazolyl, thiazolyl, pyrimidinyl, or pyrizinyl and is
substituted with 0-2 substituents selected from alkyl and hydroxyalkyl;
Ar⁴ is pyrrolyl, imidazolyl, pyridinyl, indolyl, or phenyl and is substituted
with 0-2 substituents selected from halo, alkyl, hydroxyl, and alkoxy; and
25 Ar⁵ is pyrrolyl, imidazolyl, or oxadiazolyl and is substituted with 0-2
substituents selected from alkyl, carboxy, alkoxy carbonyl, benzyl, and phenyl;
or a pharmaceutically acceptable salt thereof.

- [0013] Another aspect of the invention is a compound of formula I where
30 R¹ is alkoxy; (alkoxy carbonylamino)alkoxy; (alkylphenyl)alkoxy;
(carboxy)alkenyl; ((N-dimethylbenzyl)aminocarbonyl)alkenyl; or phenyl where said
phenyl is substituted with 1-2 substituents selected from the group consisting of halo,

cyano, alkyl, haloalkyl, hydroxyalkyl, (carboxy)alkyl, alkoxy, hydroxyalkyloxy, tetrahydropyranyloxy, carboxy, alkoxycarbonyl, (carboxy)alkenyl, alkylcarboxamido, alkoxycarboxamido, (alkylsulfamido)alkyl, Ar^5 , $SO_2NR^{15}R^{16}$, and $CONR^7R^8$; and where said phenyl is also substituted with 0-2 substituents selected from the group consisting of halo; nitro; alkyl; cycloalkyl; haloalkyl; aminoalkyl; hydroxy; alkoxy; OR¹⁷; cycloalkoxy; amino; alkoxycarboxamido; furanyl, thienyl, or pyrazolyl substituted with 0-2 alkyl substituents; pyridinyl substituted with 0-2 halo, cyano, alkyl, hydroxy, alkoxy, amino, or alkylaminocarbonyl substituents; pyrimidinyl; pyrimidinedionyl; aminopyrimidinyl; indolyl; isoquinolinyl; and phenyl substituted with 0-2 substituents selected from halo, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, amino, carboxy, aminocarbonyl, alkylaminocarbonyl, alkylcarboxamido, and carboxyalkenyl;

R^2 is hydrogen, halo, nitro, amino, phenyl, or R^5R^6N ;


R^3 is $CONR^{11}R^{12}$;

R^4 is phenyl substituted with 0-2 halo substituents;

R^5 is hydrogen or alkylsulfonyl;


R^6 is hydrogen, alkyl, hydroxyalkyl, or alkylsulfonyl;


R^7 is hydrogen, alkyl, alkynyl, cyanoalkyl, haloalkyl, hydroxyalkyl, dihydroxyalkyl, alkoxyalkyl, oxoalkyl, (dialkylamino)alkyl, (cycloalkyl)alkyl, cycloalkyl, (alkyl)cycloalkyl, (hydroxyalkyl)cycloalkyl, (tetrahydrofuranyl)alkyl, (tetrahydropyranyl)alkyl, (carboxy)alkyl, (alkoxycarbonyl)alkyl, (alkenyloxycarbonyl)alkyl, (alkoxycarbonyl)hydroxyalkyl, $(CONR^{13}R^{14})alkyl$, $(CONR^{13}R^{14})(hydroxyalkyl)alkyl$, $(CONR^{13}R^{14})cycloalkyl$, (alkylcarbonyl)aminoalkyl, (phenyl)alkyl, alkylsulfonyl, phenylsulfonyl, Ar^2 , Ar^3 ,



R^8 is hydrogen, alkyl, or alkoxyalkyl;

or R^7R^8N taken together is azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, dihydroindolyl, or isoindolinyl, and is substituted with 0-2 substituents selected from alkyl, hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxycarbonyl, dialkylcarboxamido, alkylcarbonylamino, pyridinyl, and phenyl where said phenyl is substituted with 0-2 halo or alkyl substituents;

or where R⁷R⁸N taken together is , (quinuclidinyl)amino, (quinuclidinyl)(alkyl)amino, (methylpyrrolidinyl)(alkyl)amino, ((imidazolyl)alkyl)(hydroxyalkyl)amino, (alkylthiazolyl)amino, ((carboxamido)cyclopentanyl)amino, ((halophenyl)cyclopentanyl)amino, 3H-



- 5 spiro(isobenzofuranyl)piperidinyl, (hydroxyindanyl)amino, or
 R⁹ is hydrogen, alkyl, or hydroxyalkyl;
 R¹⁰ is hydrogen or alkyl;
 or R⁹ and R¹⁰ taken together is ethylene or propylene;
 R¹¹ is alkyl;
- 10 R¹² is hydrogen;
 R¹³ is hydrogen, alkyl, cyanoalkyl, haloalkyl, alkenyl, or thiazolyl;
 R¹⁴ is hydrogen or alkyl;
 R¹⁵ is alkyl, hydroxyalkyl, cycloalkyl, or benzyl;
 R¹⁶ is hydrogen;
- 15 or R¹⁵ and R¹⁶ taken together with the nitrogen to which they are attached is
 azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl;
 R¹⁷ is haloalkyl, cyanoalkyl, (cycloalkyl)alkyl, hydroxyalkyl, alkoxyalkyl,
 aminoalkyl, (R¹⁸)alkyl, (Ar⁴)alkyl, alkynyl, or aminocycloalkyl;
 R¹⁸ is CONH₂, H₂NCONH, dibenzylamino, phthalimido, amino,
- 20 dialkylamino, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl where azetidiny,
 pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl is substituted with 0-3 alkyl or
 alkoxycarbonyl substituents;
 R¹⁹ is cyano, hydroxyalkyl, morpholinylalkyl, carboxy, alkoxy carbonyl,
 cycloalkylsulfoxamido, ((alkyl)pyrazolyl)amino, ((alkyl)isoxazolyl)amino,
- 25 (thiadiazolyl)amino, (triazinyl)amino, or alkynylaminocarbonyl;
 R²⁰ and R²¹ are hydrogen;
 Ar¹ is phenyl, naphthalenyl, pyridinyl, furanyl, pyrazolyl, isoxazolyl,
 imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyrazinyl,

pyrimidinyl, or benzothiazolyl, and is substituted with 0-2 substituents selected from halo, alkyl, cycloalkyl, haloalkyl, alkoxyalkyl, hydroxy, alkoxy, amino, aminocarbonyl, pyridinyl, phenyl, halophenyl, alkylphenyl, and alkoxyphenyl;

Ar² is phenyl, biphenyl, or pyridinyl and is substituted with 0-2 substituents
5 selected from halo, alkyl, cyano, hydroxy, alkoxy, and carboxy;


Ar³ is pyrazolyl, isoxazolyl, thiazolyl, triazolyl, pyrimidinyl, or pyridinyl and is substituted with 0-2 substituents selected from hydroxy, alkyl, and CONR¹³R¹⁴;

Ar⁴ is furanyl, pyrrolyl, pyrazolyl, isoxazolyl, imidazolyl, oxadiazolyl, triazolyl, pyridinyl, indolyl, or phenyl and is substituted with 0-2 substituents selected
10 from halo, alkyl, haloalkyl, and hydroxy; and

Ar⁵ is pyrrolyl, imidazolyl, or oxadiazolyl and is substituted with 0-2 substituents selected from alkyl, alkoxycarbonyl, benzyl, and phenyl;

or a pharmaceutically acceptable salt thereof.

15 **[0014]** Another aspect of the invention is a compound of formula I where R¹ is phenyl substituted with 1 CONR⁷R⁸ substituent and also substituted with 0-2 halo, alkyl, or alkoxy substituents; R² is hydrogen, halo, or R⁵R⁶N; R³ CONR¹¹R¹²; R⁴ is

monofluorophenyl; R⁵ is alkylsulfonyl; R⁶ is hydroxyalkyl; R⁷ is ; R⁸ is hydrogen; R⁹ is alkyl; R¹⁰ is alkyl or R⁹ and R¹⁰ taken together is ethylene or

20 propylene; R¹¹ is alkyl; R¹² is hydrogen; R²⁰ and R²¹ are hydrogen; Ar¹ is phenyl, pyridinyl, pyrimidinyl, isoxazolyl, oxazolyl, or oxadiazolyl, and is substituted with 0-1 halo or alkyl substituents; or a pharmaceutically acceptable salt thereof.

[0015] Another aspect of the invention is a compound of formula I where R¹ is phenyl substituted with 1-2 substituents selected from the group consisting of halo, cyano, alkyl, haloalkyl, hydroxyalkyl, (carboxy)alkyl, alkoxy, hydroxyalkoxy, tetrahydropyranyloxy, carboxy, alkoxycarbonyl, (carboxy)alkenyl, alkylcarboxamido, alkoxycarboxamido, (alkylsulfamido)alkyl, Ar⁵, SO₂NR¹⁵R¹⁶, and CONR⁷R⁸; and where said phenyl is also substituted with 0-2 substituents selected from the group consisting of halo; nitro; alkyl; cycloalkyl; haloalkyl; aminoalkyl; hydroxy; alkoxy;
25 OR¹⁷; cycloalkoxy; amino; alkoxycarboxamido; furanyl, thienyl, or pyrazolyl substituted with 0-2 alkyl substituents; pyridinyl substituted with 0-2 halo, cyano,

alkyl, hydroxy, alkoxy, amino, or alkylaminocarbonyl substituents; pyrimidinyl; pyrimidinedionyl; aminopyrimidinyl; indolyl; isoquinolinyl; and phenyl substituted with 0-2 substituents selected from halo, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, amino, carboxy, aminocarbonyl, alkylaminocarbonyl, alkylcarboxamido, and
 5 carboxyalkenyl.

[0016] Another aspect of the invention is a compound of formula I where R^1 is phenyl substituted with 1 CONR^7R^8 substituent and also substituted with 0-2 halo, alkyl, or alkoxy substituents.

[0017] Another aspect of the invention is compound of formula I where R^7 is

10  and at least one of R^9 and R^{10} is not hydrogen.

[0018] Another aspect of the invention is compound of formula I where R^2 is $\text{R}^5\text{R}^6\text{N}$.

[0019] Another aspect of the invention is compound of formula I where R^3 is $\text{CONR}^{11}\text{R}^{12}$.

15 **[0020]** Another aspect of the invention is compound of formula I where R^4 is phenyl or monofluorophenyl.

[0021] Unless specified otherwise, these terms have the following meanings.


“Alkyl” means a straight or branched alkyl group composed of 1 to 6 carbons.

20 “Alkenyl” means a straight or branched alkyl group composed of 2 to 6 carbons with at least one double bond. “Cycloalkyl” means a monocyclic ring system composed of 3 to 7 carbons. “Hydroxyalkyl,” “alkoxy” and other terms with a substituted alkyl moiety include straight and branched isomers composed of 1 to 6 carbon atoms for the alkyl moiety. “Haloalkyl” and “haloalkoxy” include all halogenated isomers from
 25 monohalo substituted alkyl to perhalo substituted alkyl. “Aryl” includes carbocyclic and heterocyclic aromatic substituents. Parenthetical and multiparenthetical terms are intended to clarify bonding relationships to those skilled in the art. For example, a term such as ((R)alkyl) means an alkyl substituent further substituted with the substituent R.

30 **[0022]** Substituents which are illustrated by chemical drawing to bond at variable positions on a multiple ring system (for example a bicyclic ring system) are intended

to bond to the ring where they are drawn to append. For example, substituents R¹ and R² of formula I are intended to bond to the benzene ring of formula I and not to the furan ring.

[0023] Ethylene means ethanediyl or -CH₂CH₂-; propylene means propanediyl or -CH₂CH₂CH₂-; butylene means butanediyl or -CH₂CH₂CH₂CH₂-; pentylene means pentanediyl or -CH₂CH₂CH₂CH₂CH₂-.



[0024] Dioxothiazinyl means .

[0025] Any scope of any variable, including R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, Ar¹, Ar², Ar³, Ar⁴, or Ar⁵ can be used independently with the scope of any other instance of a variable.

[0026] The invention includes all pharmaceutically acceptable salt forms of the compounds. Pharmaceutically acceptable salts are those in which the counter ions do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. These salts can be made according to common organic techniques employing commercially available reagents. Some anionic salt forms include acetate, acistrate, besylate, bromide, chloride, citrate, fumarate, glucuronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xinofoate. Some cationic salt forms include ammonium, aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc.

[0027] Some of the compounds of the invention possess asymmetric carbon atoms. The invention includes all stereoisomeric forms, including enantiomers and diastereomers as well as mixtures of stereoisomers such as racemates. Some stereoisomers can be made using methods known in the art. Stereoisomeric mixtures of the compounds and related intermediates can be separated into individual isomers according to methods known in the art.

[0028] The invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number

but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include ^{13}C and ^{14}C . Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Such compounds may have a variety of potential uses, for example as standards and reagents in determining biological activity. In the case of stable isotopes, such compounds may have the potential to favorably modify biological, pharmacological, or pharmacokinetic properties.

SYNTHETIC METHODS

[0029] The compounds may be made by methods known in the art including those described below and including variations within the skill of the art. Some reagents and intermediates are known in the art. Other reagents and intermediates can be made by methods known in the art using readily available materials. The variables (*e.g.*, numbered “R” substituents) used to describe the synthesis of the compounds are intended only to illustrate how to make the compounds and are not to be confused with variables used in the claims or in other sections of the specification. The following methods are for illustrative purposes and are not intended to limit the scope of the invention.


[0030] Abbreviations used in the schemes generally follow conventions used in the art. Chemical abbreviations used in the specification and examples are defined as follows: “NaHMDS” for sodium bis(trimethylsilyl)amide; “DMF” for N,N-dimethylformamide; “MeOH” for methanol; “NBS” for N-bromosuccinimide; “Ar” for aryl; “TFA” for trifluoroacetic acid; “LAH” for lithium aluminum hydride; “BOC”, “DMSO” for dimethylsulfoxide; “h” for hours; “rt” for room temperature or retention time (context will dictate); “min” for minutes; “EtOAc” for ethyl acetate; “THF” for tetrahydrofuran; “EDTA” for ethylenediaminetetraacetic acid; “Et₂O” for diethyl ether; “DMAP” for 4-dimethylaminopyridine; “DCE” for 1,2-dichloroethane; “ACN” for acetonitrile; “DME” for 1,2-dimethoxyethane; “HOBt” for 1-

hydroxybenzotriazole hydrate; “DIEA” for diisopropylethylamine, “Nf” for $\text{CF}_3(\text{CF}_2)_3\text{SO}_2^-$; and “TMOF” for trimethylorthoformate.

[0031] As shown in Scheme 1, some compounds of the invention may be prepared by coupling a benzofuran triflate or halide to a substituted phenyl boronic acid that in some examples contains a carboxylic acid or carboxylic acid ester. Other coupling techniques and conditions are also known in the art as are other carbon-carbon bond forming reactions. Acids and esters may be converted to amides by methods known in the art.

10

Scheme 1




[0032] Scheme 2 depicts one specific example of Scheme 1.

15 [0033] As shown in Scheme 2, a nitro group on the benzofuran ring may be reduced and the resulting amino group may be functionalized using known chemistry. For example, the amine may be converted to a monosulfonamide via reaction with a

sulfonyl chloride or by preparation of a bis sulfonamide followed by selective hydrolysis. The monosulfonamide may be alkylated again with either a simple or functionalized alkyl. In Scheme 3, the hydroxyl ethyl group is unmasked via acidic removal of the silyl protecting group.

5


Scheme 2



[0034] Scheme 3 depicts the preparation of two intermediates labeled as common intermediate 1 and 2 which can be used to prepare some compounds of the invention. The isopropyl group is used to temporarily mask the C5 hydroxy group so the methyl amide can be constructed from the ethyl ester. The more advanced common intermediate 2 allows functionalization of the sulfonamide, acid deprotection and formation of some amide compounds after coupling of amines to the acid as described earlier.

15


Scheme 3



[0035] Scheme 4 depicts some conditions for preparing some of the compounds described and for accessing an alternate common intermediate 3 which allows amide formation prior to nitro reduction and amine functionalization.

5


Scheme 4



[0036] Scheme 5 illustrates a method for preparing some compounds by preparing 2-(4-fluorophenyl)-N-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzofuran-3-carboxamide in which the boron is attached to the benzofuran and then coupling to triflates or halogen containing aryl moieties.

5


Scheme 5



[0037] Scheme 6 shows a preparation of the functionalized benzofuran and


10 Scheme 7 shows one method for installation of nitrogen functionality which can then
functionalized as described in the previous schemes.

Scheme 6




15

Scheme 7




- [0038] Scheme 8 illustrates that a free phenolic OH group can be used to form some ether compounds. Scheme 9 provides an alkylation for forming ethers under mild or more extreme conditions depending on the reactivity of the alkylating reagent.

Scheme 8




Scheme 9



[0039] Scheme 10 shows how an ether with a protected amine can be attached,
 5 and after subsequent deprotection of the phthalimide, a free amine is liberated which
 can be either incorporated into compounds of the invention or derivatized further via
 standard chemistry to provide secondary or tertiary amines or amides or
 sulfonamides.

Scheme 10



BIOLOGICAL METHODS

- 5 **[0040]** The compounds demonstrated activity against HCV NS5B as determined in the following HCV RdRp assays.

HCV NS5B RdRp Cloning, Expression, and Purification

- [0041]** The cDNA encoding the NS5B protein of HCV, genotype 1b, was cloned into the pET21a expression vector. The protein was expressed with an 18 amino acid C-terminal truncation to enhance the solubility. The *E. coli* competent cell line BL21(DE3) was used for expression of the protein. Cultures were grown at 37 °C for ~ 4 hours until the cultures reached an optical density of 2.0 at 600 nm. The cultures were cooled to 20 °C and induced with 1 mM IPTG. Fresh ampicillin was added to a
- 10
- 15 final concentration of 50 µg/ml and the cells were grown overnight at 20 °C.
- [0042]** Cell pellets (3L) were lysed for purification to yield 15-24 mgs of purified NS5B. The lysis buffer consisted of 20 mM Tris-HCl, pH 7.4, 500 mM NaCl, 0.5%

triton X-100, 1 mM DTT, 1mM EDTA, 20% glycerol, 0.5 mg/ml lysozyme, 10 mM MgCl₂, 15 ug/ml deoxyribonuclease I, and Complete TM protease inhibitor tablets (Roche). After addition of the lysis buffer, frozen cell pellets were resuspended using a tissue homogenizer. To reduce the viscosity of the sample, aliquots of the lysate
5 were sonicated on ice using a microtip attached to a Branson sonicator. The sonicated lysate was centrifuged at 100,000 x g for 1hr at 4 °C and filtered through a 0.2 µm filter unit (CORNING®).

[0043] The protein was purified using three sequential chromatography steps: Heparin sepharose CL-6B, polyU sepharose 4B, and HITRAP® SP sepharose
10 (Pharmacia). The chromatography buffers were identical to the lysis buffer but contained no lysozyme, deoxyribonuclease I, MgCl₂ or protease inhibitor and the NaCl concentration of the buffer was adjusted according to the requirements for charging the protein onto the column. Each column was eluted with a NaCl gradient which varied in length from 5-50 column volumes depending on the column type.
15 After the final chromatography step, the resulting purity of the enzyme is >90% based on SDS-PAGE analysis. The enzyme was aliquoted and stored at -80 °C.\

Standard HCV NS5B RdRp Enzyme Assay

[0044] HCV RdRp genotype 1b assays were run in a final volume of 60 µl in 96
20 well plates (COSTAR® 3912). The assay buffer is composed of 20 mM Hepes, pH 7.5, 2.5 mM KCl, 2.5 mM MgCl₂, 1 mM DTT, 1.6 U RNase inhibitor (Promega N2515), 0.1 mg/ml BSA (Promega R3961), and 2 % glycerol. All compounds were serially diluted (3-fold) in DMSO and diluted further in water such that the final concentration of DMSO in the assay was 2%. HCV RdRp genotype 1b enzyme was
25 used at a final concentration of 28 nM. A polyA template was used at 6 nM, and a biotinylated oligo-dT12 primer was used at 180 nM final concentration. Template was obtained commercially (Amersham 27-4110). Biotinylated primer was prepared by Sigma Genosys. 3H-UTP was used at 0.6 µCi (0.29 µM total UTP). Reactions
30 by adding 25 µl of 50 mM EDTA containing SPA beads (4 µg/µl, Amersham RPNQ 0007). Plates were read on a Packard Top Count NXT after >1hr incubation at room temperature.

Modified HCV NS5B RdRp Enzyme Assay

[0045] A modified enzyme assay was performed essentially as described for the standard enzyme assay except for the following: The biotinylated oligo dT12 primer
5 was precaptured on streptavidin-coated SPA beads by mixing primer and beads in assay buffer and incubating at room temperature for one hour. Unbound primer was removed after centrifugation. The primer-bound beads were resuspended in 20 mM Hepes buffer, pH 7.5 and used in the assay at final concentrations of 20 nM primer and 0.67 µg/µl beads. Order of addition in the assay: enzyme (14 nM) was added to
10 diluted compound followed by the addition of a mixture of template (0.2 nM), 3H-UTP (0.6 µCi, 0.29 µM), and primer-bound beads, to initiate the reaction; concentrations given are final. Reactions were allowed to proceed for 4 hours at 30 °C.

[0046] IC₅₀ values for compounds were determined using seven different [I]. IC₅₀
15 values were calculated from the inhibition using the formula $y = A + ((B - A) / (1 + ((C/x)^D)))$.

FRET Assay Preparation

[0047] To perform the HCV FRET screening assay, 96-well cell culture plates
20 were used. The FRET peptide (Anaspec, Inc.) (Taliani et al., *Anal. Biochem.*, 240:60-67 (1996)) contains a fluorescence donor, EDANS, near one end of the peptide and an acceptor, DABCYL, near the other end. The fluorescence of the peptide is quenched by intermolecular resonance energy transfer (RET) between the donor and the acceptor, but as the NS3 protease cleaves the peptide the products are released from
25 RET quenching and the fluorescence of the donor becomes apparent. The assay reagent was made as follows: 5X cell Luciferase cell culture lysis reagent from Promega (#E153A) diluted to 1X with dH₂O, NaCl added to 150 mM final, the FRET peptide diluted to 20 µM final from a 2 mM stock.

[0048] To prepare plates, HCV replicon cells, with or without a Renilla luciferase
30 reporter gene, were trypsinized and placed into each well of a 96-well plate with titrated test compounds added in columns 3 through 12; columns 1 and 2 contained a

control compound (HCV protease inhibitor), and the bottom row contained cells without compound. The plates were then placed in a CO₂ incubator at 37 °C.

Assays

5 **[0049]** Subsequent to addition of the test compounds described above (FRET Assay Preparation), at various times the plate was removed and Alamar blue solution (Trek Diagnostics, #00-100) was added per well as a measure of cellular toxicity. After reading in a CYTOFLUOR® 4000 instrument (PE Biosystems), plates were rinsed with PBS and then used for FRET assay by the addition of 30 ul of the FRET
10 peptide assay reagent described above (FRET Assay Preparation) per well. The plate was then placed into the CYTOFLUOR® 4000 instrument which had been set to 340 excite/490 emission, automatic mode for 20 cycles and the plate read in a kinetic mode. Typically, the signal to noise using an endpoint analysis after the reads was at least three-fold. Alternatively, after Alamar blue reading, plates were rinsed with
15 PBS, 50 ul of DMEM (high glucose) without phenol red was added and plates were then used for luciferase assay using the Promega DUAL-GLO® Luciferase Assay System.

[0050] Compound analysis was determined by quantification of the relative HCV replicon inhibition and the relative cytotoxicity values. To calculate cytotoxicity
20 values, the average Alamar Blue fluorescence signals from the control wells were set as 100% non-toxic. The individual signals in each of the compound test wells were then divided by the average control signal and multiplied by 100% to determine percent cytotoxicity. To calculate the HCV replicon inhibition values, an average background value was obtained from the two wells containing the highest amount of
25 HCV protease inhibitor at the end of the assay period. These numbers were similar to those obtained from naïve Huh-7 cells.

[0051] The background numbers were then subtracted from the average signal obtained from the control wells and this number was used as 100% activity. The individual signals in each of the compound test wells were then divided by the
30 averaged control values after background subtraction and multiplied by 100% to determine percent activity. EC₅₀ values for a protease inhibitor titration were calculated as the concentration which caused a 50% reduction in FRET or luciferase






activity. The two numbers generated for the compound plate, percent cytotoxicity and percent activity were used to determine compounds of interest for further analysis.







HCV Replicon Luciferase Reporter Assay








- 5 **[0052]** The HCV replicon luciferase assay was developed to monitor the inhibitory effects of compounds described in the disclosure on HCV viral replication. Utilization of a replicon luciferase reporter assay was first described by Krieger et al (Krieger, N. et al., *J. Virol.*, 75(10):4614-4624 (2001)). HUH-7 cells, constitutively expressing the HCV replicon, were grown in Dulbecco's Modified Eagle Media
- 10 (DMEM) (Gibco-BRL) containing 10% Fetal calf serum (FCS) (Sigma) and 1 mg/ml G418 (Gibco-BRL). Compounds were serially diluted 3 folds in DMSO for a twenty-point titration and subsequently transferred to sterile 384-well tissue-culture treated plates (CORNING® cat # 3571). The plates were then seeded with 50 µl of cells at a density of 3.0×10^3 cells/well in DMEM containing 4 % FCS (final DMSO
- 15 concentration at 0.5 %). After 3 days incubation at 37 °C, cells were analyzed for Renilla Luciferase activity using the EnduRen as substrate (Promega cat #E6485). The EnduRen substrate was diluted in DMEM and then added to the plates to a final concentration of 7.5 µM. The plates were incubated for 2 hrs at 37 °C and then read immediately for 30 seconds with VIEWLUX® Imager (PerkinElmer) using a
- 20 luminescence program. To assess cytotoxicity of compounds, CC₅₀ values were generated by multiplexing the EnduRen-containing plates with CELLTITER-BLUE® (Promega, cat # G8082). 3 µl of CellTiter Blue was added to each well and incubated for 8 hrs at 37 °C. The fluorescence signal from each well was read, with an excitation wavelength at 525/10 nm and an emission wavelength of 598/10 nm, using
- 25 the VIEWLUX® Imager.








[0053] Representative data for compounds are reported in Tables 1a,1b, and 1c.








TABLE 1a








Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	A	A
	A	A








Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	B	A
	A	A
	A	A

Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	A	A
	A	A
	A	A
	A	A

Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	B	A
	A	A
	B	A
	A	A






Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	B	A
	A	A
	A	A
	A	A






Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	A	A
	A	A
	A	A
	A	A

Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	B	A
	A	A
	A	A
	A	A







Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
Chiral 	F	A
Chiral 	A	A
	A	A
	A	A







Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	B	A
	A	A
	A	A
	A	A
	B	A







Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	A	A
	A	A








Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	C	A
	A	A








Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	A	A
	A	A
	A	A
	A	A








Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	E	B
	E	F
	E	H
	E	F







Structure	IC ₅₀	EC ₅₀
	E	B
	C	B
	B	B
	A	A
	B	B
	A	B







Structure	IC ₅₀	EC ₅₀
	B	B
	B	B
	B	B
	A	B
	A	B
	B	B






Structure	IC ₅₀	EC ₅₀
	B	B
	C	B
	A	B
	A	B
	B	B
	A	B
	B	B

Structure	IC ₅₀	EC ₅₀
	A	B
	A	B
	A	B
	C	B
	E	B
	A	A
	B	B







Structure	IC ₅₀	EC ₅₀
	B	B
	A	B
	B	B
	B	B
	B	B
	B	B
	A	B






Structure	IC ₅₀	EC ₅₀
	G	B
	C	B
	A	B
	B	B
	B	B
	B	B







Structure	IC ₅₀	EC ₅₀
	B	B
	A	B
	C	B
	E	B
	E	B
	B	B







Structure	IC ₅₀	EC ₅₀
	B	B
	B	B
	B	B
	A	B
	B	B








Structure	IC ₅₀	EC ₅₀
	B	B
	B	B
	G	B
	B	B
	C	C
		C









Structure	IC ₅₀	EC ₅₀
		C
	C	C
	B	C
	C	C
	C	C
	C	C

Structure	IC ₅₀	EC ₅₀
	E	C
	C	C
	E	C
	E	C
	E	C








Structure	IC ₅₀	EC ₅₀
	E	C
	E	C
	C	C
	E	C
	B	C
	C	C

Structure	IC ₅₀	EC ₅₀
	C	C
	C	C
	C	C
	B	C
	C	C
	B	C







Structure	IC ₅₀	EC ₅₀
	C	C
	B	C
	C	C
	C	C
	C	C
	B	C
	B	C







Structure	IC ₅₀	EC ₅₀
	B	C
 Chiral	C	C
	C	C
	C	C
	C	C
	C	C
	E	C
	C	C








Structure	IC ₅₀	EC ₅₀
	C	C
	B	C
	C	C
 Chiral	B	C
	C	C
	B	C
	C	C








Structure	IC ₅₀	EC ₅₀
	C	C
	C	C
	C	C
	C	C
	E	C
	E	C
	E	C








Structure	IC ₅₀	EC ₅₀
	E	C
	E	C
	B	C
	C	C
	C	C
	C	C
Chiral 	A	C








Structure	IC ₅₀	EC ₅₀
 Chiral	C	C
 Chiral	A	C
 Chiral	B	C
	B	C
 Chiral	C	C
	C	C








Structure	IC ₅₀	EC ₅₀
 Chiral	B	C
 Chiral	B	C
 Chiral	B	C
	B	C
 Chiral	B	C
 Chiral	B	C

Structure	IC ₅₀	EC ₅₀
	C	C
	C	C
	F	C
	A	C
	A	C
	G	C
	C	C

Structure	IC ₅₀	EC ₅₀
	E	C
	E	C
	E	J
	E	K
	E	J
	E	K
	E	K







Structure	IC ₅₀	EC ₅₀
	E	K
	E	K
	E	K
	E	H
	C	J
	E	J
	E	J







Structure	IC ₅₀	EC ₅₀
	E	J
	C	E
	C	E
	E	E
	C	E
	E	E
	C	E






Structure	IC ₅₀	EC ₅₀
	C	E
	E	E
	E	E
	E	E
	C	E
	E	E
	C	E






Structure	IC ₅₀	EC ₅₀
	C	E
	E	E
	E	E
	C	E
	B	E
	C	E
	Chiral C	E








Structure	IC ₅₀	EC ₅₀
	E	E
	E	E
	E	E
	E	E
	C	E
 Chiral	E	E
	E	E







Structure	IC ₅₀	EC ₅₀
	C	E
	C	E
	E	E
	E	E
	E	E
	E	E

Structure	IC ₅₀	EC ₅₀
	E	E
	E	E
	C	E
	C	E
	C	E
	B	E

Structure	IC ₅₀	EC ₅₀
	B	E
Chiral 	C	E
	C	E
	B	E
	A	E

Structure	IC ₅₀	EC ₅₀
	C	E
 Chiral	C	E
	B	E
	B	E
 Chiral	A	E

Structure	IC ₅₀	EC ₅₀
	C	E
	A	E
	B	E
	B	E
	B	E
	E	E
	I	E

Structure	IC ₅₀	EC ₅₀
	E	E
	E	E
	E	E
	E	E
	C	E
	E	E

























Structure	IC ₅₀	EC ₅₀
	F	E






TABLE 1b







Structure	IC ₅₀	EC ₅₀
	B	A
	A	A
	E	C
	C	B





Structure	IC ₅₀	EC ₅₀
	E	C
		A
		
	A	A
		
	A	A
		A






Structure	IC ₅₀	EC ₅₀
	A	A
		A
	A	A
	B	A
	A	A
		E

Structure	IC ₅₀	EC ₅₀
	A	A
	A	B
		C
	B	A
		A
	A	A

Structure	IC ₅₀	EC ₅₀
	A	A
	B	C
		A
	B	A
	A	A






Structure	IC ₅₀	EC ₅₀
	A	A
		A
	E	B
	G	B
	E	A
	A	A

Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	B	A







Structure	IC ₅₀	EC ₅₀
	A	A
	C	C
	A	A
	A	A
	C	E






Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A





Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	A	A
	E	E
	B	A





Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	B	A
	A	A






Structure	IC ₅₀	EC ₅₀
	A	
	A	A
	A	A
	A	A




Structure	IC ₅₀	EC ₅₀
	A	A
	C	C
	A	A
	A	A
	A	A
	A	A






Structure	IC ₅₀	EC ₅₀
	B	B
	C	B
	E	E
	A	A
		

Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	A	A

Structure	IC ₅₀	EC ₅₀
	B	A
	B	A
	A	A
	E	E





Structure	IC ₅₀	EC ₅₀
	A	A
	C	B
	C	C
	B	A
	B	B

Structure	IC ₅₀	EC ₅₀
	A	A
		C
		A







Structure	IC ₅₀	EC ₅₀
		A
		A
		B
		C
		

Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	A	A
	C	C

[illegible]

Structure	IC ₅₀	EC ₅₀
	A	A
	E	C
	A	A
	A	B







Structure	IC ₅₀	EC ₅₀
	A	A
	B	B
	C	

Structure	IC ₅₀	EC ₅₀
	A	A
	A	
		
		
		
		






Structure	IC ₅₀	EC ₅₀
	E	E
	A	A
	A	B
	A	A







Structure	IC ₅₀	EC ₅₀
	A	A
	C	C
	A	A
	C	B
	A	A
	A	A
	A	A

Structure	IC ₅₀	EC ₅₀
	A	A
	A	C
	C	C
	A	A
	A	A
	A	A
	A	A







Structure	IC ₅₀	EC ₅₀
	A	C
	A	A
	C	E
	A	A
	A	A
	A	A







Structure	IC ₅₀	EC ₅₀
	A	A
		E
		E
	A	A







Structure	IC ₅₀	EC ₅₀
	E	E
	A	A
	A	A
	A	A
	E	E






Structure	IC ₅₀	EC ₅₀
	A	A
	A	E
	A	B
	A	A
	A	A
		A







Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	C	E
	B	E
	A	B
	A	A






Structure	IC ₅₀	EC ₅₀
		E
	B	A
	B	A
	A	A
	A	A
	A	A





Structure	IC ₅₀	EC ₅₀
	E	B
	A	
	A	
	B	A
	A	A
	A	A

Structure	IC ₅₀	EC ₅₀
	B	B
	E	C
	A	A
	A	A
	A	A
	L	A





Structure	IC ₅₀	EC ₅₀
	A	
	A	A
	A	B
	A	
	L	A






Structure	IC ₅₀	EC ₅₀
	B	
	A	
	B	
	A	
	A	B
	L	A






Structure	IC ₅₀	EC ₅₀
	B	
	B	
	A	B
	A	C
	A	A






Structure	IC ₅₀	EC ₅₀
	C	C
	A	M
	C	C
	E	B






Structure	IC ₅₀	EC ₅₀
	C	C
	C	C
	A	C
	E	C

Structure	IC ₅₀	EC ₅₀
	M	C
	M	C
	C	C
	Chiral C	C








Structure	IC ₅₀	EC ₅₀
	G	C
	C	C
	E	C
	A	C
	B	C

Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	A	A
	A	A

Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
	A	A
	A	A
	A	A

Structure	IC ₅₀	EC ₅₀
	B	E
		A
		A
	A	A
	A	A








Structure	IC ₅₀	EC ₅₀
		A
	A	A
	A	A
	A	A
	A	A
	A	A
	A	A
	B	A








Structure	IC ₅₀	EC ₅₀
	A	B
		A
	A	A
	A	A
		A
	A	A
	A	A


Structure	IC ₅₀	EC ₅₀
		A
		A
		A
	A	A
	A	A

Structure	IC ₅₀	EC ₅₀
	N	A
	A	A
	A	A
	A	A

Structure	IC ₅₀	EC ₅₀
	A	A
	A	A
		C
	N	A
	A	A
	A	A
	A	A

Structure	IC ₅₀	EC ₅₀
		A
	A	A
	N	A
	A	A
	A	A
	A	A
	A	A

Structure	IC ₅₀	EC ₅₀
	A	A
	C	E
	N	A
	B	A
	A	A
		A
		A




Structure	IC ₅₀	EC ₅₀
		A

[0054] A 0.002 or less to 0.25 μM ; B $>0.25 \mu\text{M} - <1.0 \mu\text{M}$; C $1.0 \mu\text{M} - 10.0 \mu\text{M}$; D $>0.67 \mu\text{M}$ but an exact value was not determined; E $>10.0 \mu\text{M}$; F $>0.4 \mu\text{M}$; but an exact value was not determined; G $>1.39 \mu\text{M}$ but an exact value was not determined;







5 H $>0.62 \mu\text{M}$ but an exact value was not determined; I $>4 \mu\text{M}$ but an exact value was not determined; J $>3.7 \mu\text{M}$ but an exact value was not determined; K $>1.23 \mu\text{M}$ but an exact value was not determined; L $<0.02 \mu\text{M}$ but an exact value was not determined; M >0.50 but an exact value was not determined. N <0.02 but an exact value was not determined.







10





TABLE 1c

Structure	IC ₅₀ (μM)	EC ₅₀ (μM)
	0.02	1.60E-03*
	<0.02	3.04E-04*
	0.01	4.25E-04*

Structure	IC ₅₀ (μM)	EC ₅₀ (μM)
	0.02	7.86E-04*
	7.20E-03	8.05E-04*
	3.95E-03	8.30E-04*
	9.95E-03	1.78E-03
	0.01	1.83E-03
	8.60E-03	1.95E-03
	5.45E-03	2.47E-03

Structure	IC ₅₀ (μM)	EC ₅₀ (μM)
	9.65E-03	3.04E-03
	0.02	3.57E-03
	5.90E-03	3.58E-03
	0.29	1.13
	> 12.50	1.13
Chiral 	0.80	1.25

Structure	IC ₅₀ (μM)	EC ₅₀ (μM)
 Chiral	0.60	1.26
	1.71	1.34
	0.80	1.38
 Chiral	1.15	1.39
	4.75	13.26
	> 12.50	13.66

Structure	IC ₅₀ (μM)	EC ₅₀ (μM)
	9.92	15.11
Chiral 	10.39	15.39
Chiral 	7.13	16.08
		5.68E-03*

* EC50 determined using 384 well plate method

PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT

[0055] The compounds demonstrate activity against HCV NS5B and can be useful in treating HCV and HCV infection. Therefore, another aspect of the invention is a composition comprising a compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0056] Another aspect of the invention is a composition further comprising a compound having anti-HCV activity.

[0057] Another aspect of the invention is a composition where the compound having anti-HCV activity is an interferon. Another aspect of the invention is where the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastoid interferon tau.

[0058] Another aspect of the invention is a composition where the compound having anti-HCV activity is a cyclosporin. Another aspect of the invention is where the cyclosporin is cyclosporin A.

[0059] Another aspect of the invention is a composition where the compound
5 having anti-HCV activity is selected from the group consisting of interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiquimod, ribavirin, an inosine 5'-monophosphate dehydrogenase inhibitor, amantadine, and rimantadine.

[0060] Another aspect of the invention is a composition where the compound
10 having anti-HCV activity is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH, and a nucleoside analog for the treatment of an HCV infection.

[0061] Another aspect of the invention is a composition comprising a compound,
15 or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, an interferon and ribavirin.

[0062] Another aspect of the invention is a method of inhibiting the function of the HCV replicon comprising contacting the HCV replicon with a compound of formula I or a pharmaceutically acceptable salt thereof.

20 [0063] Another aspect of the invention is a method of inhibiting the function of the HCV NS5B protein comprising contacting the HCV NS5B protein with a compound of formula I or a pharmaceutically acceptable salt thereof.

[0064] Another aspect of the invention is a method of treating an HCV infection in a patient comprising administering to the patient a therapeutically effective amount
25 of a compound or a pharmaceutically acceptable salt thereof. Another aspect of the invention is a method of inhibiting the function of the HCV replicon. Another aspect of the invention is a method of inhibiting the function of the HCV NS5B protein.

[0065] Another aspect of the invention is a method of treating an HCV infection in a patient comprising administering to the patient a therapeutically effective amount
30 of a compound, or a pharmaceutically acceptable salt thereof, in conjunction with (prior to, after, or concurrently) another compound having anti-HCV activity.

[0066] Another aspect of the invention is the method where the other compound having anti-HCV activity is an interferon.

[0067] Another aspect of the invention is the method where the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, 5 interferon alpha 2A, and lymphoblastoid interferon tau.

[0068] Another aspect of the invention is the method where the other compound having anti-HCV activity is a cyclosporin.

[0069] Another aspect of the invention is the method where the cyclosporin is cyclosporin A.

10 [0070] Another aspect of the invention is the method where the other compound having anti-HCV activity is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'-monophosphate dehydrogenase inhibitor, amantadine, and rimantadine.

15 [0071] Another aspect of the invention is the method where the other compound having anti-HCV activity is effective to inhibit the function of a target selected from the group consisting of HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH, and a nucleoside analog for the treatment of an 20 HCV infection.

[0072] Another aspect of the invention is the method where the other compound having anti-HCV activity is effective to inhibit the function of target in the HCV life cycle other than the HCV NS5B protein.

[0073] "Therapeutically effective" means the amount of agent required to provide 25 a meaningful patient benefit as understood by practitioners in the field of hepatitis and HCV infection.

[0074] "Patient" means a person infected with the HCV virus and suitable for therapy as understood by practitioners in the field of hepatitis and HCV infection.

[0075] "Treatment," "therapy," "regimen," "HCV infection," and related terms 30 are used as understood by practitioners in the field of hepatitis and HCV infection.

[0076] The compounds of this invention are generally given as pharmaceutical compositions comprised of a therapeutically effective amount of a compound or its

pharmaceutically acceptable salt and a pharmaceutically acceptable carrier and may contain conventional excipients. Pharmaceutically acceptable carriers are those conventionally known carriers having acceptable safety profiles. Compositions encompass all common solid and liquid forms including for example capsules, tablets, 5 lozenges, and powders as well as liquid suspensions, syrups, elixirs, and solutions. Compositions are made using common formulation techniques, and conventional excipients (such as binding and wetting agents) and vehicles (such as water and alcohols) are generally used for compositions. See, for example, *Remington's Pharmaceutical Sciences*, 17th edition, Mack Publishing Company, Easton, PA 10 (1985).

[0077] Solid compositions are normally formulated in dosage units and compositions providing from about 1 to 1000 mg of the active ingredient per dose are preferred. Some examples of dosages are 1 mg, 10 mg, 100 mg, 250 mg, 500 mg, and 1000 mg. Generally, other agents will be present in a unit range similar to agents of 15 that class used clinically. Typically, this is 0.25-1000 mg/unit.

[0078] Liquid compositions are usually in dosage unit ranges. Generally, the liquid composition will be in a unit dosage range of 1-100 mg/mL. Some examples of dosages are 1 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100 mg/mL. Generally, other agents will be present in a unit range similar to agents of that class used 20 clinically. Typically, this is 1-100 mg/mL.

[0079] The invention encompasses all conventional modes of administration; oral and parenteral methods are preferred. Generally, the dosing regimen will be similar to other agents used clinically. Typically, the daily dose will be 1-100 mg/kg body weight daily. Generally, more compound is required orally and less parenterally. 25 The specific dosing regime, however, will be determined by a physician using sound medical judgment.

[0080] The invention also encompasses methods where the compound is given in combination therapy. That is, the compound can be used in conjunction with, but separately from, other agents useful in treating hepatitis and HCV infection. In these 30 combination methods, the compound will generally be given in a daily dose of 1-100 mg/kg body weight daily in conjunction with other agents. The other agents

generally will be given in the amounts used therapeutically. The specific dosing regime, however, will be determined by a physician using sound medical judgment.

[0081] Some examples of compounds suitable for compositions and methods are listed in Table 2.

5

TABLE 2

Brand Name	Type of Inhibitor or Target	Source Company
Omega IFN	IFN- ω	Intarcia Therapeutics
BILN-2061	Serine protease inhibitor	Boehringer Ingelheim Pharma KG, Ingelheim, Germany
Summetrel	Antiviral	Endo Pharmaceuticals Holdings Inc., Chadds Ford, PA
Roferon A	IFN- α 2a	F. Hoffmann-La Roche Ltd., Basel, Switzerland
Pegasys	PEGylated IFN- α 2a	F. Hoffmann-La Roche Ltd., Basel, Switzerland
Pegasys and Ribavirin	PEGylated IFN- α 2a/ribavirin	F. Hoffmann-La Roche Ltd., Basel, Switzerland
CELLCEPT®	HCV IgG immunosuppressant	F. Hoffmann-La Roche Ltd., Basel, Switzerland
Wellferon	Lymphoblastoid IFN- α n1	GlaxoSmithKline plc, Uxbridge, UK
Albuferon - α	Albumin IFN- α 2b	Human Genome Sciences Inc., Rockville, MD
Levovirin	Ribavirin	ICN Pharmaceuticals, Costa Mesa, CA
IDN-6556	Caspase inhibitor	Idun Pharmaceuticals Inc., San Diego, CA

Brand Name	Type of Inhibitor or Target	Source Company
IP-501	Antifibrotic	Indevus Pharmaceuticals Inc., Lexington, MA
Actimmune	INF- γ	InterMune Inc., Brisbane, CA
Infergen A	IFN alfacon-1	InterMune Pharmaceuticals Inc., Brisbane, CA
ISIS 14803	Antisense	ISIS Pharmaceuticals Inc, Carlsbad, CA / Elan Pharmaceuticals Inc., New York, NY
JTK-003	RdRp inhibitor	Japan Tobacco Inc., Tokyo, Japan
Pegasys and Ceplene	PEGylated IFN- α 2a/ immune modulator	Maxim Pharmaceuticals Inc., San Diego, CA
Ceplene	Immune modulator	Maxim Pharmaceuticals Inc., San Diego, CA
Civacir	HCV IgG immunosuppressant	Nabi Biopharmaceuticals Inc., Boca Raton, FL
Intron A and Zadaxin	IFN- α 2b/ α 1-thymosin	RegeneRx Biopharmaceuticals Inc., Bethesda, MD / SciClone Pharmaceuticals Inc, San Mateo, CA
Levovirin	IMPDH inhibitor	Ribapharm Inc., Costa Mesa, CA
Viramidine	Ribavirin prodrug	Ribapharm Inc., Costa Mesa, CA
Heptazyme	Ribozyme	Ribozyme Pharmaceuticals Inc., Boulder, CO


Brand Name	Type of Inhibitor or Target	Source Company
Intron A	IFN- α 2b	Schering-Plough Corporation, Kenilworth, NJ
PEG-Intron	PEGylated IFN- α 2b	Schering-Plough Corporation, Kenilworth, NJ
Rebetron	IFN- α 2b/ribavirin	Schering-Plough Corporation, Kenilworth, NJ
Ribavirin	Ribavirin	Schering-Plough Corporation, Kenilworth, NJ
PEG-Intron / Ribavirin	PEGylated IFN- α 2b/ribavirin	Schering-Plough Corporation, Kenilworth, NJ
Zadazim	Immune modulator	SciClone Pharmaceuticals Inc., San Mateo, CA
Rebif	IFN- β 1a	Serono, Geneva, Switzerland
IFN- β and EMZ701	IFN- β and EMZ701	Transition Therapeutics Inc., Ontario, Canada
Batabulin (T67)	β -tubulin inhibitor	Tularik Inc., South San Francisco, CA
Merimepodib (VX-497)	IMPDH inhibitor	Vertex Pharmaceuticals Inc., Cambridge, MA
Telaprevir (VX-950, LY-570310)	NS3 serine protease inhibitor	Vertex Pharmaceuticals Inc., Cambridge, MA / Eli Lilly and Co. Inc., Indianapolis, IN

Brand Name	Type of Inhibitor or Target	Source Company
Omniferon	Natural IFN- α	Viragen Inc., Plantation, FL
XTL-6865 (XTL-002)	Monoclonal antibody	XTL Biopharmaceuticals Ltd., Rehovot, Israel
HCV-796	NS5B replicase inhibitor	Wyeth / Viropharma
NM-283	NS5B replicase inhibitor	Idenix / Novartis
GL-59728	NS5B replicase inhibitor	Gene Labs / Novartis
GL-60667	NS5B replicase inhibitor	Gene Labs / Novartis
2'C MeA	NS5B replicase inhibitor	Gilead
PSI 6130	NS5B replicase inhibitor	Roche
R1626	NS5B replicase inhibitor	Roche
SCH 503034	Serine protease inhibitor	Schering-Plough
NIM811	Cyclophilin Inhibitor	Novartis
Suvus	Methylene blue	Bioenvision
Multiferon	Long lasting IFN	Viragen / Valentis
Actilon (CPG10101)	TLR9 agonist	Coley
Interferon- β	Interferon- β -1a	Serono
Zadaxin	Immunomodulator	SciClone
Pyrazolopyrimidine compounds and salts From WO 2005/047288	HCV Inhibitors	Arrow Therapeutics Ltd.
2'C Methyl adenosine	NS5B replicase inhibitor	Merck
GS-9132 (ACH-806)	HCV inhibitor	Achillion / Gilead

DESCRIPTION OF SPECIFIC EMBODIMENTS

[0082] Abbreviations as used herein, are defined as follows: “1 x” for once, “2 x” for twice, “3 x” for thrice, “°C” for degrees Celsius, “eq” for equivalent or
5 equivalents, “g” for gram or grams, “mg” for milligram or milligrams, “L” for liter or liters, “mL” for milliliter or milliliters, “ μ L” for microliter or microliters, “N” for normal, “M” for molar, “mmol” for millimole or millimoles, “min” for minute or


minutes, “h” for hour or hours, “rt” for room temperature, “RT” for retention time, “atm” for atmosphere, “psi” for pounds per square inch, “conc.” for concentrate, “sat” or “sat’d” for saturated, “MW” for molecular weight, “mp” for melting point, “ee” for enantiomeric excess, “MS” or “Mass Spec” for mass spectrometry, “ESI” for electrospray ionization mass spectroscopy, “HR” for high resolution, “HRMS” for high resolution mass spectrometry, “LCMS” for liquid chromatography mass spectrometry, “HPLC” for high pressure liquid chromatography, “RP HPLC” for reverse phase HPLC, “TLC” or “tlc” for thin layer chromatography, “NMR” for nuclear magnetic resonance spectroscopy, “¹H” for proton, “δ” for delta, “s” for singlet, “d” for doublet, “t” for triplet, “q” for quartet, “m” for multiplet, “br” for broad, “Hz” for hertz, and “α”, “β”, “R”, “S”, “E”, and “Z” are stereochemical designations familiar to one skilled in the art.




2-(4-Fluorophenyl)-5-isopropoxy-6-(methylsulfonamido)benzofuran-3-carboxylic acid

[0083] Excess NaOH (10 mL, 1N aq) was added to a stirring solution of methyl 2-(4-fluorophenyl)-5-isopropoxy-6-(methylsulfonamido)benzofuran-3-carboxylate (3.0 g, 6.89 mmol) in EtOH (34 mL) and THF (34 mL). It was allowed to stir at 60 °C overnight. The mixture was then heated to 67 °C and allowed to stir for 4 more hours. The mixture was concentrated then diluted with EtOAc and washed with 1M HCl, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated to give the titled compound (2.7 g, 96%). ¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.31 - 1.38 (m, 6 H) 2.99 (s, 3 H) 4.63 - 4.73 (m, 1 H) 7.32 - 7.41 (m, 2 H) 8.00 - 8.08 (m, 2 H) 8.88 (s, 2 H) 13.05 (s, 1 H). LC-MS retention time: 1.03 min; m/z (MH⁻): 406. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5

ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was
 5 determined using a MICROMASS® Platform for LC in electrospray mode.




2-(4-Fluorophenyl)-5-isopropoxy-6-(methylsulfonamido)benzofuran-3-carboxamide
[0084] Ammonia (6.1 ml, 12.2 mmol, 2M in MeOH) was added to a stirring
 10 solution of HATU (1.1 g, 2.95 mmol) and 2-(4-fluorophenyl)-5-isopropoxy-6-(methylsulfonamido)benzofuran-3-carboxylic acid (1.0 g, 2.46 mmol) in DMF (20 ml) at 0 °C. It was allowed to warm to rt and stir for 1 hr. The mixture was diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated to give the title compound (925 mg,
 15 93%). ¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.30 - 1.37 (m, 6 H) 2.98 (s, 3 H) 4.64 - 4.77 (m, 1 H) 7.19 (s, 1 H) 7.30 - 7.41 (m, 2 H) 7.54 (s, 1 H) 7.63 - 7.71 (m, 1 H) 7.89 (s, 1 H) 7.93 - 8.02 (m, 2 H) 8.85 (s, 1 H). LC-MS retention time: 1.26 min; m/z (MH⁺) 407. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-
 20 Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data
 25 was determined using a MICROMASS® Platform for LC in electrospray mode.




N-(3-Cyano-2-(4-fluorophenyl)-5-isopropoxybenzofuran-6-yl)methanesulfonamide.

- [0085] Trifluoroacetic anhydride (375 μ L, 2.66 mmol) was added to a stirring solution of DIEA (928 μ L, 5.31 mmol), 2-(4-fluorophenyl)-5-isopropoxy-6
- 5 (methylsulfonamido) benzofuran-3-carboxamide (300 mg, 0.738 mmol) in CH_2Cl_2 (4 mL) and THF (4 mL) at 0 $^\circ\text{C}$ for 1 hour. The mixture was diluted with EtOAc and washed with sat NaHCO_3 , and sat NaCl . The organic phase was dried over Na_2SO_4 , filtered and concentrated. The crude residue was purified by on silica gel (BIOTAGE $^\circ$, gradient EtOAc/hexanes, fraction collection at $\lambda = 254$ nm) to give the
- 10 title compound (143 mg, 50%). ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ ppm 1.28 - 1.41 (m, 6 H) 3.01 (s, 3 H) 4.77 - 4.95 (m, 1 H) 7.35 (s, 1 H) 7.44 - 7.57 (m, 2 H) 7.68 (s, 1 H) 8.04 - 8.20 (m, 2 H) 9.01 (s, 1 H). LC-MS retention time: 1.65 min; m/z (MH $^-$): 387. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis
- 15 detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H_2O / 10 mM ammonium acetate and solvent B was 5% H_2O / 95% acetonitrile / 10 mM ammonium acetate. MS data
- 20 was determined using a MICROMASS $^\circ$ Platform for LC in electrospray mode.



3-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid

[0086] Cesium carbonate (3.5 g, 10.7 mmol) was added to Pd(Ph₃P)₄ (108 mg, 0.093 mmol), 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (3.0 g, 7.19 mmol), 3-boronobenzoic acid (1.97 g, 11.86 mmol). Dioxane (60 ml) and water (12 ml) was added at rt. The reaction was degassed 3x and then heated to 95 °C and allowed to stir overnight. It was allowed to cool to rt. The mixture was diluted with EtOAc and washed with 1M HCl, and sat NaCl. The precipitate that formed was filtered and dried overnight at 55 °C under vacuum. The remaining organic phase was concentrated and triturated with DCM, followed by hot DCE and finally hot MeOH to afford the titled compound which was combined with the previously collected precipitate (2.4 g, 87%). LC-MS retention time: 1.19 min; m/z (MH⁺): 390. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.



Ethyl 2-(4-fluorophenyl)-5-hydroxy-4-nitrobenzofuran-3-carboxylate and

Ethyl 2-(4-fluorophenyl)-5-hydroxy-6-nitrobenzofuran-3-carboxylate

[0087] Nitric acid (21 µL, 0.33 mmol) was added to a stirring solution of ethyl 2-(4-fluorophenyl)-5-hydroxybenzofuran-3-carboxylate (100 mg, 0.33 mmol) in chloroform (3.3 mL) at -20 °C. It was allowed to stir for 10 min. A 9:2 ratio of ethyl 2-(4-fluorophenyl)-5-hydroxy-4-nitrobenzofuran-3-carboxylate to ethyl 2-(4-fluorophenyl)-5-hydroxy-6-nitrobenzofuran-3-carboxylate was observed. The crude


reaction was purified on silica gel (BIOTAGE®, EtOAc/hexanes gradient, fraction collection at $\lambda = 254$ nm) to give the titled compounds:

Ethyl 2-(4-fluorophenyl)-5-hydroxy-6-nitrobenzofuran-3-carboxylate

- 5 **[0088]** ^1H NMR (500 MHz, DMSO- d_6) δ ppm 10.92 (1 H, s), 8.33 (1 H, s), 8.03 - 8.11 (2 H, m), 7.69 (1 H, s), 7.43 (2 H, t, $J=8.85$ Hz), 4.34 (2 H, q, $J=7.22$ Hz), 1.33 (3 H, t, $J=7.17$ Hz). LC-MS retention time: 1.79 min; m/z (MH $^-$): 344. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector
- 10 wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H $_2$ O / 10 mM ammonium acetate and solvent B was 5% H $_2$ O / 95% acetonitrile / 10 mM ammonium acetate. MS data was
- 15 determined using a MICROMASS® Platform for LC in electrospray mode.


Ethyl 2-(4-fluorophenyl)-5-hydroxy-4-nitrobenzofuran-3-carboxylate

- [0089]** ^1H NMR (500 MHz, DMSO- d_6) δ ppm 11.03 (1 H, s), 7.92 - 8.01 (2 H, m), 7.86 (1 H, d, $J=9.16$ Hz), 7.42 (2 H, t, $J=8.85$ Hz), 7.17 (1 H, d, $J=8.85$ Hz), 4.20
- 20 (2 H, q, $J=7.12$ Hz), 1.21 (3 H, t, $J=7.17$ Hz). LC-MS retention time: 1.56 min; m/z (MH $^-$): 344. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A /
- 25 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H $_2$ O / 10 mM ammonium acetate and solvent B was 5% H $_2$ O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.



Ethyl 2-(4-fluorophenyl)-4-nitro-5-(trifluoromethylsulfonyloxy)benzofuran-3-carboxylate

[0090] Triethylamine (91 μ L, 0.652 mmol) was added to a stirring solution of 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (116 mg, 0.326 mmol) and ethyl 2-(4-fluorophenyl)-5-hydroxy-4-nitrobenzofuran-3-carboxylate (75 mg, 0.217 mmol) in DCM (2.2 mL). The crude reaction was purified on silica gel (BIOTAGE®, EtOAc/hexanes gradient, fraction collection at $\lambda = 254$ nm) to give titled compound (78 mg, 75%). ^1H NMR (500 MHz, DMSO- d_6) δ ppm 11.03 (1 H, s), 7.92 - 8.01 (2 H, m), 7.86 (1 H, d, $J=9.16$ Hz), 7.42 (2 H, t, $J=8.85$ Hz), 7.17 (1 H, d, $J=8.85$ Hz), 4.20 (2 H, q, $J=7.12$ Hz), 1.21 (3 H, t, $J=7.17$ Hz). LC-MS retention time: 1.91 min; m/z (MH $^+$): no ion detected. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H $_2$ O / 10 mM ammonium acetate and solvent B was 5% H $_2$ O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.



Ethyl 2-(4-fluorophenyl)-4-nitro-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxylate

[0091] Step 1: Cesium carbonate (333 mg, 1.021 mmol) was added to Pd(Ph₃P)₄ (39 mg, 0.034 mmol), ethyl 2-(4-fluorophenyl)-4-nitro-5-

(trifluoromethylsulfonyloxy)benzofuran-3-carboxylate (325 mg, 0.681 mmol), 3-boronobenzoic acid (169 mg, 1.021 mmol). Dioxane (5.6 mL) and water (1.1 mL)

5 was added at rt. The reaction was degassed 3x and heated to 90 °C overnight. It was allowed to cool. The mixture was diluted with EtOAc and washed with 1M HCl, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated to give the *m*-acid.

[0092] Step 2: The crude *m*-acid was diluted with DMF (5 mL) and treated with

10 HATU (388 mg, 1.021 mmol), 2-phenylpropan-2-amine (138 mg, 1.021 mmol), and DIEA (357 μL, 2.043 mmol) and allowed to stir at rt for 1 hr. The mixture was


diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated to give the titled compound which

15 was purified on silica gel (BIOTAGE® 25+M column, EtOAc/hexanes gradient; R_f ~.2 for 20% EtOAc/hexanes; fraction collection at λ = 254 nm) to give a light yellow solid (294 mg, 76%). LC-MS retention time: 1.97 min; m/z (MH⁺): 567. LC data

was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a


20 gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.

25




Ethyl 2-(4-fluorophenyl)-6-nitro-5-(trifluoromethylsulfonyloxy)benzofuran-3-carboxylate

- [0093]** Triethylamine (121 μ L, 0.869 mmol) was added to a stirring solution of 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (155 mg, 0.434 mmol) and ethyl 2-(4-fluorophenyl)-5-hydroxy-6-nitrobenzofuran-3-carboxylate (100 mg, 0.290 mmol) in DCM (3 mL). It was allowed to stir overnight.
- 5 The mixture concentrated and was purified on silica gel (BIOTAGE®), EtOAc/hexanes gradient, fraction collection at $\lambda = 254$ nm) to give the titled compound (140 mg, 100%). ^1H NMR (300 MHz, DMSO- d_6) δ ppm 8.91 (1 H, s), 8.10 - 8.19 (3 H, m), 7.48 (2 H, t, $J=8.97$ Hz), 4.37 (2 H, q, $J=7.07$ Hz), 1.34 (3 H, t, $J=6.95$ Hz). LC-MS retention time: 1.91 min; m/z (MH $^+$): no ion detected. LC data
- 10 was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where
- 15 solvent A was 5% acetonitrile / 95% H $_2$ O / 10 mM ammonium acetate and solvent B was 5% H $_2$ O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.



- 20 2-(4-Fluorophenyl)-5-hydroxy-6-nitrobenzofuran-3-carboxylic acid
- [0094]** Excess NaOH (11 ml, 11.00 mmol, 1M aq) was added to a stirring solution of ethyl 2-(4-fluorophenyl)-5-hydroxy-6-nitrobenzofuran-3-carboxylate (1.9 g, 5.50 mmol) in EtOH (55 ml) and THF (55 ml) and was allowed to stir at 64 $^{\circ}$ C overnight. The mixture was concentrated and diluted with EtOAc and washed with 1M HCl, and
- 25 sat NaCl. The organic phase was dried over Na $_2$ SO $_4$, filtered and concentrated to give the titled compound (1.7 g, quant.). ^1H NMR (300 MHz, DMSO- d_6) δ ppm 7.31 - 7.48 (m, 2 H) 7.71 (s, 1 H) 8.00 - 8.14 (m, 2 H) 8.29 (s, 1 H) 10.80 (s, 1 H) 13.35 (s, 1 H). LC-MS retention time: 0.99 min; m/z (MH $^-$): 416. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18

4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.




20 2-(4-Fluorophenyl)-3-(methylcarbamoyl)-6-nitrobenzofuran-5-yl
trifluoromethanesulfonate.

[0095] Step 1: Methanamine (4.4 ml, 8.83 mmol) was added to a stirring solution of DIEA (3 ml, 17.65 mmol), BOP (2.9 g, 6.62 mmol), and 2-(4-fluorophenyl)-5-hydroxy-6-nitrobenzofuran-3-carboxylic acid (1.4 g, 4.41 mmol) in DMF (44 ml) at 15 °C. It was allowed to warm to rt and stir for 1 hr. The mixture was concentrated and diluted with EtOAc and washed with 1M HCl, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated to give a crude product which was triturated with MeOH to give the methyl amide, nitro phenol-hmpa adduct (1.7 g, 78%).

20 [0096] Step 2: The hmpa-adduct (100 mg, 0.203 mmol) was taken up in EtOH and treated with 1M NaOH (609 µL, 0.609 mmol) at 70 °C. It was allowed to stir overnight. The mixture was diluted with EtOAc and washed with 1M HCl, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated to give the nitro phenol (50 mg, 75%) as a brown solid. LC-MS retention time: 1.34 min; m/z
25 (MH⁺): 331. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time

of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.


[0097] Step 3: Triethylamine (422 μ L, 3.03 mmol) was added to a stirring solution of N-Phenylbis(trifluoromethane)sulfonimide (649 mg, 1.817 mmol) and 2-(4-fluorophenyl)-5-hydroxy-N-methyl-6-nitrobenzofuran-3-carboxamide (400 mg, 1.211 mmol) in DCM (24 mL) at rt. The slurry was allowed to stir overnight. The mixture was diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated to give a crude residue which was purified on silica gel (BIOTAGE®, EtOAc/hexanes gradient, R_f ~.2 in 30% EtOAc/hexanes, fraction collection at λ = 254 nm) to give the titled compound (375 mg, 67%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.83 (1 H, s), 8.55 - 8.65 (1 H, m), 7.98 - 8.05 (2 H, m), 7.95 (1 H, s), 7.47 (2 H, t, *J*=8.85 Hz), 2.84 (3 H, d, *J*=4.58 Hz). LC-MS retention time: 1.96 min; *m/z* (MH⁻): 461. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.



25 6-Amino-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl
 trifluoromethanesulfonate

[0098] Iron (211 mg, 3.79 mmol) was added to a stirring solution of 2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-nitrobenzofuran-5-yl trifluoromethanesulfonate (350 mg, 0.757 mmol) in EtOH (8.4 mL) and AcOH (8.4 mL) at rt and then was

heated to 100 °C for 10 min. The mixture was diluted with EtOAc and washed with 1M HCl, and sat NaCl followed by 1M NaOH and brine. The organic phase was dried over Na₂SO₄, filtered and concentrated to give a white solid which was 1:1 starting material:product. It was resubjected to the reaction conditions for 15 min and re-worked up to give the titled compound (275 mg, 84%). LC-MS retention time: 1.47 min; m/z (MH⁺): 433. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.




2-(4-Fluorophenyl)-3-(methylcarbamoyl)-6-(N-

(methylsulfonyl)methylsulfonamido)benzofuran-5-yl trifluoromethanesulfonate


[0099] Methanesulfonyl chloride (146 µL, 1.873 mmol) was added to a stirring solution of 6-amino-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (270 mg, 0.624 mmol) and DIEA (500 µL, 2.86 mmol) in DCM (6.3 mL) at 25 °C. It was allowed to stir for 1 hour and then diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated. It was purified on silica gel (BIOTAGE®, EtOAc/hexanes gradient, fraction collection at λ = 254 nm) to give the titled compound (300 mg, 82%). LC-MS retention time: 1.49 min; m/z (MH⁺): 589. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a

detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.




5-(3-(1H-Tetrazol-5-yl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00100] Azidotrimethylsilane (161 μ L, 1.215 mmol) was added to a stirring solution of 5-(3-cyanophenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (225 mg, 0.607 mmol) and dibutylstannanone (30 mg, 0.121 mmol) in toluene (6 mL) at rt. It was heated to 105 °C and allowed to stir overnight. The reaction, which remained a slurry, resulted in ~70% conversion. Additional equiv of reagents and solvents were added and the mixture was allowed to stir overnight at 105 °C. The reaction was allowed to cool and filtered to give the titled compound (205 mg, 82%). LC-MS retention time: 1.03 min; m/z (MH⁺): 414. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.



Methyl 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoate

[00101] Trimethylsilyldiazomethane (500 μ L, 1.00 mmol, 2M in diethyl ether) was added to a stirring solution of 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (100 mg, 0.257 mmol) in diethyl ether (2.5 mL) at 25 $^{\circ}$ C. It was allowed to stir for 2 hours. The mixture was concentrated to afford the titled compound (100 mg, 97%). LC-MS retention time: 2.46 min; m/z (MH^{+}) : 404. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters SunFire 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 3 min, a hold time of 1 min, and an analysis time of 4 min where solvent A was 10% acetonitrile / 90% H_2O / 0.1% trifluoroacetic acid and solvent B was 10% H_2O / 90% acetonitrile / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS[®] Platform for LC in electrospray mode.




2-(4-Fluorophenyl)-5-(3-formylphenyl)-N-methylbenzofuran-3-carboxamide

[00102] Cesium carbonate (176 mg, 0.539 mmol) was added to $Pd(Ph_3P)_4$ (20 mg, 0.018 mmol), 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (150 mg, 0.359 mmol), 3-formylphenylboronic acid (59 mg, 0.395 mmol). Dioxane (3 mL) and water (600 μ L) was added at rt. The reaction was heated to 90 $^{\circ}$ C overnight. The mixture was diluted with ethyl acetate and washed with sat $NaHCO_3$, and sat $NaCl$. The organic phase was dried over Na_2SO_4 , filtered and concentrated and triturated with DCM to give the titled compound (55

mg, 41%). LC-MS retention time: 1.49 min; m/z (MH^+): 374. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a
 5 gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H_2O / 10 mM ammonium acetate and solvent B was 5% H_2O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.


10



Ethyl 5-(3-(*tert*-butoxycarbonyl)phenyl)-2-(4-fluorophenyl)-6-nitrobenzofuran-3-carboxylate

[00103] Cesium carbonate (1.54 g, 4.71 mmol) was added to $Pd(Ph_3P)_4$ (182 mg, 0.157 mmol), ethyl 2-(4-fluorophenyl)-6-nitro-5-
 15 (trifluoromethylsulfonyloxy)benzofuran-3-carboxylate (1500 mg, 3.14 mmol), 3-(*tert*-butoxycarbonyl)phenylboronic acid (768 mg, 3.46 mmol). Dioxane (26 mL) and water (5 mL) was added at rt. The reaction was heated to 90 °C overnight. The reaction was allowed to cool was diluted with EtOAc and washed with sat $NaHCO_3$,
 20 and sat NaCl. The organic phase was dried over Na_2SO_4 , filtered and concentrated and purified on silica gel (BIOTAGE®, EtOAc/hexanes gradient, fraction collection at $\lambda = 254$ nm) to give to give the titled compound (1.10 g, 69%). ^1H NMR (300 MHz, $DMSO-d_6$) δ ppm 8.60 (1 H, s), 8.08 - 8.18 (2 H, m), 8.02 (1 H, s), 7.95 - 8.01 (1 H, m), 7.88 (1 H, s), 7.58 - 7.70 (2 H, m), 7.46 (2 H, t, $J=8.78$ Hz), 4.34 (2 H, q, $J=7.20$ Hz), 1.56 (9 H, s), 1.27 (3 H, t, $J=7.14$ Hz). LC-MS retention time: 2.13 min;
 25 m/z (MH^+): parent does not ionize. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column


using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.



10 Ethyl 6-amino-5-(3-(*tert*-butoxycarbonyl)phenyl)-2-(4-fluorophenyl)benzofuran-3-carboxylate

[00104] Iron (28 mg, 0.495 mmol) was added to a stirring solution of ethyl 5-(3-(*tert*-butoxycarbonyl)phenyl)-2-(4-fluorophenyl)-6-nitrobenzofuran-3-carboxylate (50 mg, 0.099 mmol) in EtOH (495 μ L) and AcOH (495 μ L) at 100 °C. It was allowed to stir for 1 hr. The mixture was diluted with EtOAc and washed with 1M HCl, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated to give the titled compound (45 mg, 96%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.99 - 8.06 (2 H, m), 7.89 - 7.96 (2 H, m), 7.65 - 7.72 (1 H, m), 7.61 (1 H, t, *J*=7.65 Hz), 7.55 (1 H, s), 7.31 - 7.40 (2 H, m), 7.00 (1 H, s), 5.10 (2 H, br. s.), 4.29 (2 H, q, *J*=7.03 Hz), 1.56 (9 H, s), 1.26 (3 H, t, *J*=7.15 Hz). LC-MS retention time: 2.03 min; *m/z* (MH⁺) : parent does not ionize. 420 (-tBu) was observed. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B

was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.




5 Ethyl 5-(3-(*tert*-butoxycarbonyl)phenyl)-2-(4-fluorophenyl)-6-(N-methylmethanesulfonamido)benzofuran-3-carboxylate

[00105] Step 1: Methanesulfonyl chloride (16 μ L, 0.208 mmol) was added to a stirring solution of ethyl 6-amino-5-(3-(*tert*-butoxycarbonyl)phenyl)-2-(4-fluorophenyl)benzofuran-3-carboxylate (90 mg, 0.189 mmol) in pyridine (2 mL) at rt.

10 It was allowed to stir for 6 hrs, then 8 μ L of MsCl was added and the reaction was allowed to stir overnight. The reaction was concentrated and diluted with ethyl acetate and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated to give the NH sulfonamide intermediate. LC-MS retention time: 1.93 min; m/z (MH⁻) : 552. LC data was recorded on a Shimadzu
 15 LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile /
 20 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.

[00106] Step 2: The crude residue was diluted with DMF (2mL) and treated with DIEA (99 μ L, 0.568 mmol) and Iodomethane (18 μ L, 0.284 mmol) followed by
 25 Na₂CO₃ (20 mg). The reaction was allowed to stir for 3 days. The mixture was diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase


was dried over Na₂SO₄, filtered and concentrated to give the titled compound (100 mg, 93%). LC-MS retention time: 1.96 min; m/z (MH⁺): the parent does not ionize. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.



3-(3-(Ethoxycarbonyl)-2-(4-fluorophenyl)-6-(N-methylmethanesulfonyl)benzofuran-5-yl)benzoic acid

[00107] TFA (2 mL, 26.0 mmol) was added to a stirring solution of ethyl 5-(3-(*tert*-butoxycarbonyl)phenyl)-2-(4-fluorophenyl)-6-(N-methylmethanesulfonyl)benzofuran-3-carboxylate (100 mg, 0.176 mmol) in DCE (9 mL) at 25 °C. It was allowed to stir for several hours then concentrated to give the titled compound (92 mg, quant). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.05 - 8.12 (3 H, m), 7.92 - 8.03 (3 H, m), 7.65 - 7.75 (1 H, m), 7.53 - 7.64 (1 H, m), 7.44 (2 H, t, *J*=8.91 Hz), 4.33 (2 H, q, *J*=7.03 Hz), 3.12 (3 H, s), 2.93 (3 H, s), 1.26 (3 H, t, *J*=7.15 Hz). LC-MS retention time: 1.17 min; m/z (MH⁻): 510. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5%

acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.




5

Ethyl 2-(4-fluorophenyl)-6-(N-methylmethanesulfonamido)-5-(3-(2-phenylpropan-2-yl)carbamoyl)phenylbenzofuran-3-carboxylate


[00108] DIEA (51 μ L, 0.293 mmol) was added to a stirring solution of 3-(3-(ethoxycarbonyl)-2-(4-fluorophenyl)-6-(N-methylmethanesulfonamido)benzofuran-5-yl)benzoic acid (50 mg, 0.098 mmol), 2-phenylpropan-2-amine (26 mg, 0.195 mmol), HATU (56 mg, 0.147 mmol) in DMF (1 mL) at 25 °C. It was allowed to stir for 1 hour. The mixture was diluted with EtOAc and washed with 1M HCl, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated to give the titled compound (50 mg, 81%). LC-MS retention time: 1.82 min; m/z (MH⁺) : 629. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.

20




2-(4-Fluorophenyl)-6-(N-methylmethanysulfonamido)-5-(3-(2-phenylpropan-2-ylcarbonyl)phenyl)benzofuran-3-carboxylic acid

[00109] NaOH (500 μ L, 0.500 mmol, 1M aq.) was added to a stirring solution of ethyl 2-(4-fluorophenyl)-6-(N-methylmethanysulfonamido)-5-(3-(2-phenylpropan-2-ylcarbonyl)phenyl)benzofuran-3-carboxylate (50 mg, 0.080 mmol) in ethanol (795 μ L) at 60 $^{\circ}$ C. The slurry was allowed to stir overnight. DMF (2 mL) was added along with additional portion of NaOH and the mixture was warmed to 70 $^{\circ}$ C and allowed to stir overnight. The mixture was diluted with EtOAc and washed with 1M HCl, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated to give the titled compound (49 mg, quant). LC-MS retention time: 2.36 min; m/z (MH⁺): 601. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters SunFire 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 3 min, a hold time of 1 min, and an analysis time of 4 min where solvent A was 10% acetonitrile / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% acetonitrile / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS[®] Platform for LC in electrospray mode.




Ethyl 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-nitrobenzofuran-5-yl)benzoate
[00110] Cesium carbonate (1.69 g, 5.19 mmol) was added to Pd(Ph₃P)₄ (250 mg, 0.216 mmol), 2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-nitrobenzofuran-5-yl trifluoromethanesulfonate (2.00 g, 4.33 mmol), 3-(ethoxycarbonyl)phenylboronic acid (1.01 g, 5.19 mmol). Dioxane (36 mL) and water (7 mL) was added at rt and the mixture was degassed 3x. The reaction was heated to 90 °C overnight. It was allowed to cool. The mixture was diluted with EtOAc and washed with 1M HCl, and sat NaCl. The organic phase was dried over Na₂SO₄, filter and concentrated. The crude solid was triturated with DCM to give the titled compound (1.70 g, 85%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.55 - 8.61 (1 H, m), 8.54 (1 H, s), 8.00 - 8.09 (3 H, m), 7.95 (1 H, s), 7.73 (1 H, s), 7.61 - 7.70 (2 H, m), 7.45 (2 H, t, *J*=8.91 Hz), 4.35 (2 H, q, *J*=7.19 Hz), 2.83 (3 H, d, *J*=4.52 Hz), 1.34 (3 H, t, *J*=7.03 Hz). LC-MS retention time: 1.62 min; *m/z* (MH⁺): 463. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.



Ethyl 3-(6-amino-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoate
[00111] Iron (1.03 g, 18.4 mmol) was added to a stirring solution of ethyl 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-nitrobenzofuran-5-yl)benzoate (1.70 g, 3.68 mmol) in EtOH (37 mL) and AcOH (37 mL) at 90 °C. The slurry was allowed to stir for 1 hour. The mixture was diluted with EtOAc and washed with 1M HCl, and sat


NaCl followed by 1M NaOH and sat. NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated to give the titled compound (1.40 g 88%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.25 - 8.34 (1 H, m), 8.00 - 8.03 (1 H, m), 7.87 - 7.99 (3 H, m), 7.69 - 7.75 (1 H, m), 7.63 (1 H, t, *J*=7.65 Hz), 7.26 - 7.37 (2 H, m), 7.20 (1 H, s), 6.98 (1 H, s), 5.07 (2 H, s), 4.35 (2 H, q, *J*=7.03 Hz), 2.78 (3 H, d, *J*=4.52 Hz), 1.34 (3 H, t, *J*=7.03 Hz). LC-MS retention time: 1.46 min; *m/z* (MH⁺): 433. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.



Ethyl 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(methylsulfonylamido)benzofuran-5-yl)benzoate

[00112] Methanesulfonyl chloride (303 μL, 3.88 mmol) was added to a stirring solution of ethyl 3-(6-amino-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoate (1.40 g, 3.24 mmol) in pyridine (32 mL) at 25 °C. It was allowed to stir overnight at rt. The reaction was concentrated and was purified on silica gel (BIOTAGE®, EtOAc/hexanes gradient, fraction collection at λ = 254 nm) to give the titled compound (1.01 g, 61%). LC-MS retention time: 1.53 min; *m/z* (MH⁺): 511. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5

ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was
 5 determined using a MICROMASS® Platform for LC in electrospray mode.




3-(2-(4-Fluorophenyl)-6-(N-(2-hydroxyethyl)methylsulfonamido)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid

10 **[00113]** Step 1: (2-Bromoethoxy)(*tert*-butyl)dimethylsilane (189 μ L, 0.881 mmol) was added to a stirring suspension of Na₂CO₃ (311 mg, 2.94 mmol) and ethyl 3-(6-(N-(2-(*tert*-butyldimethylsilyloxy)ethyl)methylsulfonamido)-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoate in DMF (6 mL) at 100 °C. It was allowed to stir for 5 hrs, and then allowed to cool to rt and stir overnight. The mixture
 15 was diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated. LC-MS retention time: 2.12 min; m/z (MH⁺): 669. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution
 20 conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for
 25 LC in electrospray mode.

[00114] Step 2: The residue was diluted with EtOH (10 mL) and treated with NaOH (2938 μ L, 2.94 mmol) and allowed to stir at 60 °C for 4 hours. The mixture

was diluted with EtOAc and washed with 1M HCl, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated.

[00115] Step 3: The crude residue was taken up in THF and treated with 1M HCl (making it 30% in THF). The reaction was allowed to stir for 1 hour. The mixture was diluted with EtOAc and washed with 1M HCl, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated to give the titled compound (300 mg, 97%). LC-MS retention time: 1.09 min; m/z (MH⁺): 527. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.



N-(2-(4-Fluorophenyl)-5-isopropoxy-3-(1H-1,2,4-triazol-5-yl)benzofuran-6-yl)methanesulfonamide, and

N-(2-(4-fluorophenyl)-5-isopropoxy-3-(1H-1,2,4-triazol-5-yl)benzofuran-6-yl)-N-methylmethanesulfonamide

[00116] N,N-Dimethylformamide dimethyl acetal (500 μ L, 3.76 mmol) and 2-(4-fluorophenyl)-5-isopropoxy-6-(methylsulfonamido)benzofuran-3-carboxamide (100 mg, 0.246 mmol) were combined and heated to 85 $^{\circ}$ C. DMF (1 mL) was added. It was allowed to stir for 1 hr. The mixture was concentrated and diluted with dioxane (200 μ l), acetic acid (1 ml) and treated with hydrazine (154 μ L, 4.92 mmol) and heated at 85 $^{\circ}$ C for several hours. The mixture was diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and

concentrated. The crude residue was purified by preparative reverse phase HPLC on a C18 column using a suitably buffered gradient, and concentrated to give to give N-(2-(4-fluorophenyl)-5-isopropoxy-3-(1H-1,2,4-triazol-5-yl)benzofuran-6-yl)methanesulfonamide (25 mg, 0.058 mmol) and N-(2-(4-fluorophenyl)-5-isopropoxy-3-(1H-1,2,4-triazol-5-yl)benzofuran-6-yl)-N-methylmethanesulfonamide (11 mg, 0.025 mmol).


N-(2-(4-Fluorophenyl)-5-isopropoxy-3-(1H-1,2,4-triazol-5-yl)benzofuran-6-yl)methanesulfonamide

10 **[00117]** ¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.30 - 1.42 (m, 6 H) 2.99 (s, 3 H) 4.57 - 4.73 (m, 1 H) 7.24 - 7.40 (m, 2 H) 7.57 (s, 1 H) 7.67 (s, 1 H) 8.06 - 8.22 (m, 2 H) 8.68 (s, 1 H). LC-MS retention time: 1.30 min; m/z (MH⁺): 431. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector
15 wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was
20 determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC were performed using a Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate =
25 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μm, R_t = 10.71 min, purity = 94%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μm, R_t = 9.74 min, purity = 97%.

N-(2-(4-Fluorophenyl)-5-isopropoxy-3-(1H-1,2,4-triazol-5-yl)benzofuran-6-yl)-N-methylmethanesulfonamide

30 **[00118]** ¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.29 - 1.41 (m, 6 H) 3.04 (s, 3 H) 3.19 - 3.24 (m, 3 H) 4.61 - 4.80 (m, 1 H) 7.28 - 7.39 (m, 2 H) 7.61 (s, 1 H) 7.76 (s, 1

- H) 8.08 - 8.27 (m, 2 H) 8.78 (s, 1 H) 14.34 (s, 1 H). LC-MS retention time: 1.36 min; m/z (MH⁺) 345. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μm, R_t = 11.30 min, purity = >95%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μm, R_t = 10.21 min, purity = >95%.




N-(2-(4-Fluorophenyl)-5-isopropoxy-3-(1H-1,2,4-triazol-5-yl)benzofuran-6-yl)methanesulfonamide

- [00119]** Azidotrimethylsilane (34.2 μL, 0.257 mmol) was added to a stirring solution of dibutyltin oxide (6.41 mg, 0.026 mmol) and N-(3-cyano-2-(4-fluorophenyl)-5-isopropoxybenzofuran-6-yl)methanesulfonamide (50 mg, 0.129 mmol) in dioxane (1.3 mL) at rt. It was subjected to microwave irradiation for 15 min at 150 °C. It was treated with additional equivalents of reagents and re-subjected for 30 min followed by 60 min. The mixture was concentrated and purified by preparative reverse phase HPLC on a C18 column using a suitably buffered gradient, and concentrated to give the titled compound (12 mg, 22%). ¹H NMR (300 MHz,

DMSO- d_6) δ ppm 1.29 - 1.39 (m, 6 H) 3.01 (s, 3 H) 4.62 - 4.81 (m, 1 H) 7.28 - 7.45 (m, 3 H) 7.65 (s, 1 H) 7.84 - 7.98 (m, 2 H) 8.92 (s, 1 H). LC-MS retention time: 1.04 min; m/z (MH⁺): 432. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μ m, R_t = 11.56 min, purity = 94%;
Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μ m, R_t = 10.55 min, purity = 96%.


General Procedure: *m*-Amide Coupling

[00120] DIEA (36 μ L, 0.205 mmol) was added to a stirring solution of HATU (59 mg, 0.154 mmol), the appropriate amine (0.164 mmol), and 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (40 mg, 0.103 mmol) in DMF (1 mL) at room temperature. It was allowed to stir overnight. The reaction was concentrated and purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the expected product. This general procedure was applied to Examples KP4 through KP14.



5-(3-(*tert*-Butyl(methyl)carbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00121] ¹H NMR (500 MHz, CD₃OD) δ ppm 1.54 - 1.57 (m, 9 H) 2.94 - 2.99 (m, 6 H) 7.25 (t, 2 H) 7.35 - 7.40 (m, 1 H) 7.53 (t, 1 H) 7.64 - 7.67 (m, 2 H) 7.67 - 7.68 (m, 1 H) 7.72 - 7.77 (m, 1 H) 7.88 - 7.90 (m, 1 H) 7.92 - 7.97 (m, 2 H). LC-MS retention time: 1.71 min; m/z (MH⁺): 459. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.




2-(4-Fluorophenyl)-5-(3-(1-(4-fluorophenyl)ethylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide

[00122] ¹H NMR (500 MHz, CD₃OD) δ ppm 8.10 - 8.15 (1 H, m), 7.90 - 7.99 (3 H, m), 7.84 (2 H, t, *J*=9.61 Hz), 7.63 - 7.72 (2 H, m), 7.56 (1 H, t, *J*=7.78 Hz), 7.40 - 7.47 (2 H, m), 7.22 - 7.29 (2 H, m), 7.03 - 7.10 (2 H, m), 5.24 - 5.30 (1 H, m), 2.97 (3 H, s), 1.59 (3 H, d, *J*=7.02 Hz). LC-MS retention time: 1.67 min; m/z (MH⁻): 509. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B

was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.

Additional HPLC method: Solvent A = 5% MeOH/95% H₂O/10 mM ammonium bicarbonate, Solvent B = 95% MeOH/5% H₂O/10 mM ammonium bicarbonate, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: PHENOMENEX® Gemini C1 C-18, 4.6 x 150 mm, 3 μm, R_t = 15.64 min, purity = 97%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μm, R_t = 15.63 min, purity = 98%.




(S)-2-(4-Fluorophenyl)-5-(3-(1-(4-fluorophenyl)ethylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide

[00123] ¹H NMR (500 MHz, CD₃OD) δ ppm 8.13 (1 H, s), 7.91 - 7.99 (3 H, m), 7.84 (2 H, t, *J*=9.31 Hz), 7.64 - 7.72 (2 H, m), 7.56 (1 H, t, *J*=7.78 Hz), 7.41 - 7.48 (2 H, m), 7.26 (2 H, t, *J*=8.85 Hz), 7.02 - 7.10 (2 H, m), 5.28 (1 H, q, *J*=7.22 Hz), 2.97 (3 H, s), 1.59 (3 H, d, *J*=7.02 Hz). LC-MS retention time: 1.67 min; *m/z* (MH⁻): 509. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5

ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.


15.55 min, purity = 99%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μ m, R_t = 15.34 min, purity = 98%.



5 (R)-2-(4-Fluorophenyl)-5-(3-(1-(4-fluorophenyl)ethylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide


[00124] ^1H NMR (500 MHz, CD_3OD) δ ppm 8.14 (1 H, s), 7.92 - 7.99 (3 H, m), 7.81 - 7.87 (2 H, m), 7.65 - 7.72 (2 H, m), 7.57 (1 H, t, $J=7.63$ Hz), 7.42 - 7.47 (2 H, m), 7.23 - 7.29 (2 H, m), 7.04 - 7.10 (2 H, m), 5.28 (1 H, q, $J=7.02$ Hz), 2.97 (3 H, s), 1.59 (3 H, d, $J=7.02$ Hz). LC-MS retention time: 1.66 min; m/z (MH $^-$): 509. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H_2O / 10 mM ammonium acetate and solvent B was 5% H_2O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% MeOH/95% H_2O /10 mM ammonium bicarbonate, Solvent B = 95% MeOH/5% H_2O /10 mM ammonium bicarbonate, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: PHENOMENEX® Gemini C1 C-18, 4.6 x 150 mm, 3 μ m, R_t = 15.56 min, purity = 99%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μ m, R_t = 15.33 min, purity = 97%.

25




2-(4-Fluorophenyl)-5-(3-(2-(4-fluorophenyl)propan-2-ylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide

- [00125] ^1H NMR (500 MHz, CD_3OD) δ ppm 8.04 - 8.10 (1 H, m), 7.89 - 7.99 (3 H, m), 7.76 - 7.86 (2 H, m), 7.63 - 7.73 (2 H, m), 7.56 (1 H, t, $J=7.78$ Hz), 7.42 - 7.51 (2 H, m), 7.26 (2 H, t, $J=8.70$ Hz), 6.98 - 7.06 (2 H, m), 2.98 (3 H, s), 1.78 (6 H, s). LC-MS retention time: 1.72 min; m/z (MH $^-$): 523. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H_2O / 10 mM ammonium acetate and solvent B was 5% H_2O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% MeOH/95% H_2O /10 mM ammonium bicarbonate, Solvent B = 95% MeOH/5% H_2O /10 mM ammonium bicarbonate, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: PHENOMENEX® Gemini C1 C-18, 4.6 x 150 mm, 3 μm , R_t = 15.73 min, purity = 99%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μm , R_t = 15.53 min, purity = 99%.



2-(4-Fluorophenyl)-N-methyl-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide


- [00126] ¹H NMR (500 MHz, CD₃OD) δ ppm 8.09 (1 H, s), 7.90 - 7.99 (3 H, m), 7.74 - 7.89 (1 H, m), 7.63 - 7.72 (2 H, m), 7.55 (1 H, t, *J*=7.63 Hz), 7.47 (2 H, d, *J*=7.32 Hz), 7.31 (2 H, t, *J*=7.78 Hz), 7.22 - 7.28 (2 H, m), 7.19 (1 H, t, *J*=7.32 Hz), 2.97 (3 H, s), 1.79 (6 H, s). LC-MS retention time: 1.71 min; *m/z* (MH⁻): 505. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.
- Additional HPLC method: Solvent A = 5% MeOH/95% H₂O/10 mM ammonium bicarbonate, Solvent B = 95% MeOH/5% H₂O/10 mM ammonium bicarbonate, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: PHENOMENEX® Gemini C1 C-18, 4.6 x 150 mm, 3 μm, *R*_t = 15.79 min, purity = 99%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μm, *R*_t = 15.53 min, purity = 98%.



2-(4-Fluorophenyl)-N-methyl-5-(3-(1-phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

- [00127] ¹H NMR (500 MHz, DMSO-d₆) δ ppm 9.35 (1 H, s), 8.48 - 8.56 (1 H, m), 8.24 (1 H, s), 7.96 - 8.04 (2 H, m), 7.87 - 7.96 (3 H, m), 7.75 - 7.82 (2 H, m), 7.59 (1 H, t, *J*=7.63 Hz), 7.40 (2 H, t, *J*=8.70 Hz), 7.21 - 7.29 (4 H, m), 7.16 (1 H, t, *J*=7.17 Hz), 2.86 (3 H, d, *J*=4.58 Hz), 1.25 - 1.35 (4 H, m). LC-MS retention time: 1.63 min;

m/z (MH⁺): 503. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% MeOH/95% H₂O/10 mM ammonium bicarbonate, Solvent B = 95% MeOH/5% H₂O/10 mM ammonium bicarbonate, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: PHENOMENEX® Gemini C1 C-18, 4.6 x 150 mm, 3 µm, R_t = 15.91 min, purity = 96%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 µm, R_t = 15.79 min, purity = 95%.




2-(4-Fluorophenyl)-N-methyl-5-(3-(1-phenylcyclobutylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00128] ¹H NMR (500 MHz, DMSO-d₆) δ ppm 9.18 (1 H, s), 8.53 (1 H, q, *J*=4.48 Hz), 8.20 (1 H, s), 8.01 (2 H, dd, *J*=8.85, 5.49 Hz), 7.92 (1 H, d, *J*=1.22 Hz), 7.87 (2 H, dd, *J*=7.63, 1.53 Hz), 7.73 - 7.83 (2 H, m), 7.57 (1 H, t, *J*=7.78 Hz), 7.52 (2 H, d, *J*=7.32 Hz), 7.40 (2 H, t, *J*=9.00 Hz), 7.33 (2 H, t, *J*=7.78 Hz), 7.20 (1 H, t, *J*=7.32 Hz), 2.87 (3 H, d), 2.61 - 2.71 (2 H, m), 2.54 - 2.58 (2 H, m), 2.01 - 2.11 (1 H, m), 1.82 - 1.92 (1 H, m). LC-MS retention time 2.42 min; m/z (MH⁺): 519. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 3 min, a hold time of 1 min, and an analysis time

of 4 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.

Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μm, R_t = 14.66 min, purity = 97%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μm, R_t = 13.13 min, purity = 97%.




N-(2-(4-Fluorophenyl)-5-isopropoxy-3-(1H-1,2,4-triazol-5-yl)benzofuran-6-yl)methanesulfonamide

[00129] ¹H NMR (500 MHz, DMSO-d₆) δ ppm 11.03 (1 H, s), 7.92 - 8.01 (2 H, m), 7.86 (1 H, d, J=9.16 Hz), 7.42 (2 H, t, J=8.85 Hz), 7.17 (1 H, d, J=8.85 Hz), 4.20 (2 H, q, J=7.12 Hz), 1.21 (3 H, t, J=7.17 Hz). LC-MS retention time: 1.70 min; m/z (MH⁺): 547. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μm, R_t = 14.86 min, purity = 99%; Additional HPLC method 2:


Solvent A = 5% MeOH/95% H₂O/10 mM ammonium bicarbonate, Solvent B = 95% MeOH/5% H₂O/10 mM ammonium bicarbonate, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: PHENOMENEX® Gemini C-18, 4.6 x 150 mm, 3 µm, R_t = 17.53 min, purity = 99%.

5




2-(4-Fluorophenyl)-N-methyl-5-(3-(pyridin-4-ylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00130] ¹H NMR (500 MHz, DMSO-d₆) δ ppm 11.15 (1 H, s), 8.64 (2 H, d, *J*=6.41 Hz), 8.48 - 8.55 (1 H, m), 8.30 (1 H, s), 8.05 - 8.08 (2 H, m), 7.97 - 8.03 (6 H, m), 7.76 - 7.85 (2 H, m), 7.71 (1 H, t, *J*=7.78 Hz), 7.41 (2 H, t, *J*=8.70 Hz), 2.83 - 2.92 (3 H, m). LC-MS retention time: 1.45 min; *m/z* (MH⁺): 466. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% MeOH/95% H₂O/10 mM ammonium bicarbonate, Solvent B = 95% MeOH/5% H₂O/10 mM ammonium bicarbonate, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: PHENOMENEX® Gemini C-18, 4.6 x 150 mm, 3 µm, R_t = 15.11 min, purity = 97%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 µm, R_t = 14.81 min, purity = 96%.



2-(4-Fluorophenyl)-5-(3-(isobutyl(methyl)carbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide

[00131] ^1H NMR (500 MHz, CD_3OD) δ ppm 7.93 - 7.98 (2 H, m), 7.88 - 7.91 (1 H, m), 7.74 - 7.81 (1 H, m), 7.63 - 7.70 (3 H, m), 7.51 - 7.60 (1 H, m), 7.32 - 7.41 (1 H, m), 7.25 (2 H, t), 3.43 (1 H, d), 3.21 (1 H, d), 3.10 (2 H, s), 3.03 (2 H, s), 2.96 (3 H, s), 2.10 - 2.21 (1 H, m), 1.92 - 2.07 (1 H, m), 1.01 (3 H, d), 0.78 (3 H, d). LC-MS retention time: 1.65 min; m/z (MH^+): 459. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H_2O / 10 mM ammonium acetate and solvent B was 5% H_2O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.




2-(4-Fluorophenyl)-N-methyl-4-nitro-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00132] Step1: Ethyl 2-(4-fluorophenyl)-4-nitro-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxylate (300 mg, 0.529 mmol) was diluted with EtOH (10 mL) and treated with NaOH (2.1 mL, 2.12 mmol, 1N aq.) and the mixture, which became a slurry, was allowed to stir overnight at 60 °C. The reaction

was diluted with EtOAc and washed with 1M HCl, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated.


[00133] Step 2: EDC (128 mg, 0.668 mmol) was added to a stirring solution of the crude 2-(4-fluorophenyl)-4-nitro-5-(3-(2-phenylpropan-2-

- 5 ylcabamoyl)phenyl)benzofuran-3-carboxylic acid (300 mg, 0.557 mmol), methanamine (306 μ L, 0.613 mmol), 1-hydroxy-7-azabenzotriazole (83 mg, 0.613 mmol), DIEA (204 μ L, 1.170 mmol) in DCM (5.5 mL) at rt. It was allowed to stir for 3 days. The slurry had gone into solution over that period of time. The mixture was concentrated and purified on silica gel (BIOTAGE®, EtOAc/hexanes gradient, 10 fraction collection at $\lambda = 254$ nm) to give the titled compound (220 mg, 95%). ¹H NMR (500 MHz, CD₃OD) δ ppm 7.90 - 7.99 (3 H, m), 7.85 - 7.90 (1 H, m), 7.82 - 7.84 (1 H, m), 7.49 - 7.56 (3 H, m), 7.45 (2 H, d, $J=7.32$ Hz), 7.27 - 7.34 (4 H, m), 7.19 (1 H, t, $J=7.32$ Hz), 2.87 (3 H, s), 1.76 (6 H, s). LC-MS retention time: 1.62 min; m/z (MH⁺): 552. LC data was recorded on a Shimadzu LC-10AS liquid 15 chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O 20 / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. 25 Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μ m, R_t = 13.60 min, purity = 94%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μ m, R_t = 12.66 min, purity = 96%.




4-Amino-2-(4-fluorophenyl)-N-methyl-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide

- [00134]** Iron (25 mg, 0.453 mmol) was added to a stirring solution of 2-(4-fluorophenyl)-N-methyl-4-nitro-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide (50 mg, 0.091 mmol) in ethanol (1 mL) and AcOH (1 mL) at rt. It was placed in a reaction block set to 100 °C. It was allowed to stir for 1 hr. The mixture was allowed to cool and was diluted with EtOAc and washed with 1M HCl, followed by 1N NaOH and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated and triturated with Et₂O to give the titled compound (28 mg, 56%). ¹H NMR (300 MHz, CD₃OD) δ ppm 7.83 - 7.89 (1 H, m), 7.73 - 7.81 (3 H, m), 7.52 - 7.64 (2 H, m), 7.42 - 7.49 (2 H, m), 7.10 - 7.35 (6 H, m), 6.98 (1 H, d, *J*=8.42 Hz), 2.87 (3 H, s), 1.76 (6 H, s). LC-MS retention time: 2.33 min; *m/z* (MH⁺): 522. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μm, *R*_t = 14.17 min, purity = 97%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μm, *R*_t = 12.84 min, purity = 98%.



4-Acetamido-2-(4-fluorophenyl)-N-methyl-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide

- [00135]** 4-Amino-2-(4-fluorophenyl)-N-methyl-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide (20 mg, 0.038 mmol) was diluted in pyridine (1 mL) and treated with excess acetyl chloride (10 μ L). The reaction was allowed to stir for 2 hours. The mixture was concentrated and diluted with MeOH (1mL). The product began to crash out, it was sonicated and filtered and washed with MeOH to afford the titled compound (8 mg, 34 %). ^1H NMR (500 MHz, DMSO- d_6) δ ppm 9.41 (1 H, s), 8.43 (1 H, s), 8.31 - 8.38 (1 H, m), 7.88 - 7.92 (1 H, m), 7.82 - 7.87 (2 H, m), 7.80 (1 H, d, $J=7.63$ Hz), 7.71 (1 H, d, $J=8.55$ Hz), 7.54 - 7.60 (1 H, m), 7.43 - 7.49 (2 H, m), 7.36 - 7.43 (5 H, m), 7.28 (2 H, t, $J=7.78$ Hz), 7.17 (1 H, t, $J=7.32$ Hz), 2.76 (3 H, d), 1.79 (3 H, s), 1.69 (6 H, s). LC-MS retention time 1.42 min; m/z 564 (MH^+). LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H_2O / 10 mM ammonium acetate and solvent B was 5% H_2O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH_3CN /95% H_2O /0.1% TFA, Solvent B = 95% CH_3CN /5% H_2O /0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min.
- Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μm , R_t = 12.00 min, purity = 96%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μm , R_t = 11.26 min, purity = 95%.




2-(4-Fluorophenyl)-N-methyl-6-nitro-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide

- [00136]** Step 1: Cesium carbonate (143 mg, 0.440 mmol) was added to Pd(Ph₃P)₄ (17 mg, 0.015 mmol), ethyl 2-(4-fluorophenyl)-6-nitro-5-(trifluoromethylsulfonyloxy)benzofuran-3-carboxylate (140 mg, 0.293 mmol), 3-boronobenzoic acid (73 mg, 0.440 mmol). Dioxane (2.5 mL) and water (500 µL) was added at rt. The reaction was degassed 3x and heated to 90 °C overnight. It was allowed to cool. The mixture was diluted with EtOAc and washed with 1M HCl, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated.
- [00137]** Step 2: The residue was diluted with DMF and treated with HATU (167 mg, 0.440 mmol), 2-phenylpropan-2-amine (60 mg, 0.440 mmol), and DIEA (154 µL, 0.880 mmol) and allowed to stir at rt overnight. The mixture was diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated and purified on silica gel (BIOTAGE®, EtOAc/hexanes gradient, fraction collection at λ = 254 nm) to give ethyl 2-(4-fluorophenyl)-6-nitro-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxylate. (LC-MS retention time: 1.97 min; m/z (MH⁺): 567. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode).


[00138] Step 3: This material was treated with NaOH (1 mL, 1.000 mmol) in ethanol (2.93 mL) at 60 °C for 2 hr then allowed to stir overnight while cooling to rt. The reaction was heated to 60 °C for 3 hrs. The mixture was diluted with EtOAc and washed with 1M HCl, and sat NaCl. The organic phase was dried over Na₂SO₄,
5 filtered and concentrated.

[00139] Step 4: EDC (58 mg, 0.301 mmol), methanamine (1 mL, 2.000 mmol), 1-hydroxy-7-azabenzotriazole (38 mg, 0.276 mmol), DIEA (92 µL, 0.526 mmol) was added to the residue in DCE (2.5 mL) at rt. It was allowed to stir for 3 days. The slurry had gone into solution over that period of time. The crude reaction was purified
10 on silica gel (BIOTAGE®, EtOAc/hexanes gradient, fraction collection at λ = 254 nm) to give the titled compound (112 mg, 81%). ¹H NMR (500 MHz, CD₃OD) δ ppm 8.32 (1 H, s), 7.97 - 8.06 (2 H, m), 7.82 - 7.90 (2 H, m), 7.75 (1 H, s), 7.47 - 7.56 (2 H, m), 7.45 (2 H, d, *J*=7.32 Hz), 7.31 (4 H, t, *J*=8.09 Hz), 7.18 (1 H, t, *J*=7.32 Hz), 2.94 (3 H, s), 1.77 (6 H, s). LC-MS retention time: 3.10 min; *m/z* (MH⁺): 552. LC
15 data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 3 min, a hold time of 1 min, and an analysis time
20 of 4 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time =
25 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 µm, *R*_t = 14.12 min, purity = 96%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 µm, *R*_t = 12.98 min, purity = 97%.



6-Amino-2-(4-fluorophenyl)-N-methyl-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide


[00140] Iron (68 mg, 1.22 mmol) was added to a stirring solution of 2-(4-fluorophenyl)-N-methyl-6-nitro-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide (112 mg, 0.203 mmol) in ethanol (2.3 mL) and AcOH (2.3 mL) at rt. It was placed in a reaction block set to 100 °C and allowed to stir for 1 hr. The mixture was allowed to cool and was diluted with EtOAc and washed with 1M HCl, followed by 1N NaOH and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated and triturated with Et₂O to give the titled compound (52 mg, 47%). ¹H NMR (500 MHz, CD₃OD) δ ppm 6.58 - 6.65 (3 H, m), 6.52 (1 H, d, *J*=7.63 Hz), 6.37 (1 H, d, *J*=7.93 Hz), 6.30 (1 H, t, *J*=7.63 Hz), 6.18 (2 H, d, *J*=7.32 Hz), 6.08 (1 H, s), 6.03 (2 H, t, *J*=7.78 Hz), 5.88 - 5.97 (3 H, m), 5.73 (1 H, s), 1.65 (3 H, s), 0.50 (6 H, s). LC-MS retention time 1.54 min; *m/z* (MH⁺): 520. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μm, *R*_t = 15.11 min, purity = 95%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μm, *R*_t = 11.11 min, purity = 94%.



2-(4-Fluorophenyl)-N-methyl-6-(methylsulfonylamino)-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide

- 5 **[00141]** Step 1: DIEA (134 μ L, 0.765 mmol) was added to $\text{Pd}(\text{Ph}_3\text{P})_4$ (30 mg, 0.025 mmol), 2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-(methylsulfonyl)methylsulfonylamino)benzofuran-5-yl trifluoromethanesulfonate (150 mg, 0.255 mmol), 3-(ethoxycarbonyl)phenylboronic acid (74 mg, 0.382 mmol). Dioxane (5 mL) and water (1 mL) was added at rt. The reaction was degassed 3x and
- 10 heated to 90 $^{\circ}\text{C}$ overnight. It was allowed to cool and left to stir for 3 days at rt.
- [00142]** Step 2: The mixture was concentrated and diluted with EtOH (5 mL) and treated with excess 1N NaOH (~1 mL) and allowed to stir at rt overnight to give the meta-acid. The mixture was diluted with EtOAc and washed with 1M HCl, and 1M HCl. The organic phase was dried over Na_2SO_4 , filtered and concentrated.
- 15 **[00143]** Step 3: The crude residue was diluted with DMF (5 mL) and treated with HATU (145 mg, 0.382 mmol), 2-phenylpropan-2-amine (52 mg, 0.382 mmol) and DIEA (134 μ L, 0.765 mmol) and allowed to stir at rt overnight. The mixture was concentrated and purified by preparative reverse phase HPLC on a C18 column using a suitably buffered gradient, and concentrated. The isolated titled compound was re-
- 20 purified on silica gel (BIOTAGE®, EtOAc/hexanes gradient, $R_f \sim 0.2$ 50% EtOAc/hexanes, fraction collection at $\lambda = 254$ nm) to give the titled compound (7 mg, 4%). ^1H NMR (500 MHz, CD_3OD) δ ppm 7.94 - 8.01 (2 H, m), 7.92 (1 H, s), 7.83 (1 H, d, $J=7.63$ Hz), 7.77 (1 H, s), 7.63 - 7.68 (2 H, m), 7.59 (1 H, t, $J=7.63$ Hz), 7.46 (2 H, d, $J=7.32$ Hz), 7.24 - 7.32 (4 H, m), 7.18 (1 H, t, $J=7.32$ Hz), 2.94 (3 H, s), 2.88 (3
- 25 H, s), 1.77 (6 H, s). LC-MS retention time: 2.25 min; m/z (MH^+): 600. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters

SunFire 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 3 min, a hold time of 1 min, and an analysis time of 4 min where
 5 solvent A was 5% acetonitrile / 95% H₂O / 0.1% TFA and solvent B was 5% H₂O / 95% acetonitrile / 0.1% TFA. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate =
 10 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 µm, R_t = 12.87 min, purity = 96%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 µm, R_t = 11.97 min, purity = 98%.




15 2-(4-Fluorophenyl)-6-(N-(2-hydroxyethyl)methylsulfonamido)-N-methyl-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00144] Step 1: Methanesulfonyl chloride (10 µL, 0.128 mmol) was added to a stirring solution of 6-amino-2-(4-fluorophenyl)-N-methyl-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide (50 mg, 0.096 mmol) in pyridine (1
 20 mL) at rt. It was allowed to stir for 2 hours and then concentrated and diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated.

[00145] Step 2: The crude residue was dissolved in DMF (1 mL) and treated with (2-bromoethoxy)(*tert*-butyl)dimethylsilane (102 µL, 0.479 mmol) and Na₂CO₃ (31
 25 mg, 0.288 mmol) at rt. It was heated to 100 °C for 4 hours and then diluted with


EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated.

[00146] Step 3: The crude residue was taken up in THF (2 mL) and treated with 2 mL of 1N HCl, and allowed to stir at rt for 1 hr. The mixture was diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated and triturated with Et₂O to give the titled compound (25 mg, 39%). ¹H NMR (500 MHz, CD₃OD) δ ppm 8.14 - 8.21 (1 H, m), 7.95 - 8.04 (2 H, m), 7.83 - 7.87 (1 H, m), 7.76 - 7.81 (1 H, m), 7.66 - 7.74 (2 H, m), 7.56 (1 H, t, *J*=7.63 Hz), 7.41 - 7.49 (2 H, m), 7.24 - 7.33 (4 H, m), 7.17 (1 H, t, *J*=7.32 Hz), 2.94 (3 H, s), 1.76 (6 H, s). LC-MS retention time 1.42 min; *m/z* (MH⁺): 644. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μm, *R*_t = 12.26 min, purity = 96%; Additional HPLC method: Solvent A = 5% MeOH/95% H₂O/10 mM ammonium bicarbonate, Solvent B = 95% MeOH/5% H₂O/10 mM ammonium bicarbonate, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: PHENOMENEX® Gemini C-18, 4.6 x 150 mm, 3 μm, *R*_t = 13.61 min, purity = 94%.



5-(3-Cyanophenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

- [00147] Cesium carbonate (187 mg, 0.575 mmol) was added to Pd(Ph₃P)₄ (22 mg, 0.019 mmol), 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (160 mg, 0.383 mmol), 3-cyanophenylboronic acid (85 mg, 0.575 mmol). Dioxane (3 mL) and water (600 µL) was added at rt. The reaction was
- 5 degassed 3x and heated to 90 °C overnight. It was allowed to cool. The mixture was diluted with EtOAc and washed with 1M HCl, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated. The crude residue was taken up in DCM. A white precipitate formed which was filtered to give the titled compound. The filtrate was purified on silica gel (BIOTAGE®, EtOAc/hexanes gradient, R_f ~.4: 50%
- 10 EtOAc/Hex, fraction collection at λ = 254 nm) to give the titled compound which was combined with the previously collected precipitate (85 mg, 60%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.46 - 8.53 (1 H, m), 8.24 (1 H, s), 8.09 (1 H, d, J=7.93 Hz), 7.99 - 8.05 (2 H, m), 7.96 (1 H, d, J=1.53 Hz), 7.85 (1 H, d, J=7.63 Hz), 7.74 - 7.82 (2 H, m), 7.70 (1 H, t, J=7.78 Hz), 7.40 (2 H, t, J=8.85 Hz), 2.87 (3 H, d, J=4.58 Hz).
- 15 LC-MS retention time: 2.17 min; m/z (MH⁺): 371. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a
- 20 gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5%
- 25 H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 µm, R_t = 13.59 min, purity = 99%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 µm, R_t = 12.29 min, purity = 99%.




2-(4-Fluorophenyl)-5-(3-(5-isopropyl-1,3,4-oxadiazol-2-yl)phenyl)-N-methylbenzofuran-3-carboxamide

[00148] Isobutyryl chloride (90 mg, 0.847 mmol) was added to a stirring solution of 5-(3-(1H-tetrazol-5-yl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (50 mg, 0.085 mmol) in pyridine (1 mL) at 100 °C. It was allowed to stir overnight. The reaction was concentrated and diluted with EtOH (3 mL) and treated with excess 1N NaOH (500 µL) and stirred at 60 °C for 2 hours to hydrolyze the acylated amide. The mixture was filtered and the filtrate was diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated and purified on silica gel (BIOTAGE®, EtOAc/hexanes gradient, fraction collection at λ = 254 nm) to give the titled compound (8 mg, 20%).


¹H NMR (500 MHz, CD₃OD) δ ppm 8.31 - 8.35 (1 H, m), 8.03 (1 H, d, J=7.94 Hz), 7.95 - 8.00 (3 H, m), 7.93 (1 H, d, J=7.93 Hz), 7.67 - 7.74 (3 H, m), 7.25 - 7.30 (2 H, m), 3.37 - 3.40 (1 H, m), 2.99 (3 H, s), 1.49 (6 H, d, J=7.02 Hz). LC-MS retention time: 2.28 min; m/z (MH⁺): 456. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 µm, R_t = 14.30 min, purity = 94%;

Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μ m, R_t = 12.50 min, purity = 93%.



- 5 2-(4-Fluorophenyl)-5-(1H-indol-4-yl)-N-methylbenzofuran-3-carboxamide
[00149] Cesium carbonate (176 mg, 0.539 mmol) was added to Pd(Ph₃P)₄ (20.77 mg, 0.018 mmol), 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (150 mg, 0.359 mmol), 1H-indol-4-ylboronic acid (87 mg, 0.539 mmol). Dioxane (3 mL) and water (600 μ L) was added at rt. The reaction was
 10 degassed 3x and then heated to 90 °C overnight. It was allowed to cool. The mixture was diluted with ethyl acetate and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated and purified on silica gel (BIOTAGE®, EtOAc/hexanes gradient, fraction collection at λ = 254 nm) to give the titled compound (66 mg, 46%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 11.28 (1
 15 H, br. s.), 8.48 - 8.57 (1 H, m), 7.98 - 8.07 (2 H, m), 7.86 (1 H, br. s.), 7.79 (1 H, d, J =8.24 Hz), 7.69 (1 H, d, J =7.93 Hz), 7.37 - 7.47 (4 H, m), 7.21 (1 H, t, J =7.63 Hz), 7.14 (1 H, d, J =7.02 Hz), 6.60 (1 H, br. s.), 2.84 (3 H, d, J =4.27 Hz). LC-MS retention time: 1.53 min; m/z (MH⁺): 385. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm
 20 column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile /
 25 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μ m, R_t = 13.46 min,

purity = 99%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μ m, R_t = 12.27 min, purity = 97%.




5 5-(3-(2-Benzyl-2H-tetrazol-5-yl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00150] Benzyl bromide (29 μ L, 0.242 mmol) was added to a stirring solution of 5-(3-(1H-tetrazol-5-yl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (50 mg, 0.121 mmol) and Na_2CO_3 (26 mg, 0.242 mmol) in DMF (1.2 mL) at 100 $^\circ\text{C}$.

- 10 It was allowed to stir overnight. The mixture was concentrated and purified by preparative reverse phase HPLC on a C18 column using a suitably buffered $\text{H}_2\text{O}/\text{CH}_3\text{CN}$ gradient, and concentrated to give the titled compound (12 mg, 19%).
- ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ ppm 8.48 - 8.56 (1 H, m), 8.30 - 8.35 (1 H, m), 8.06 (1 H, d, $J=7.63$ Hz), 7.98 - 8.03 (2 H, m), 7.90 - 7.93 (2 H, m), 7.78 - 7.83 (1 H, m), 7.72 - 7.77 (1 H, m), 7.69 (1 H, t, $J=7.78$ Hz), 7.36 - 7.46 (7 H, m), 6.04 (2 H, s),
- 15 2.86 (3 H, d, $J=4.58$ Hz). LC-MS retention time: 1.78 min; m/z (MH^+): 504. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a
- 20 gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H_2O / 10 mM ammonium acetate and solvent B was 5% H_2O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.
- 25 Additional HPLC method: Solvent A = 5% $\text{CH}_3\text{CN}/95\%$ $\text{H}_2\text{O}/0.1\%$ TFA, Solvent B = 95% $\text{CH}_3\text{CN}/5\%$ $\text{H}_2\text{O}/0.1\%$ TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18,

4.6 x 150 mm, 3.5 μ m, R_t = 15.69 min, purity = 97%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μ m, R_t = 13.95 min, purity = 98%.



5 (R)-2-(4-Fluorophenyl)-5-(3-(4-isopropyl-4,5-dihydrooxazol-2-yl)phenyl)-N-methylbenzofuran-3-carboxamide


[00151] Zinc chloride (8 mg, 0.054 mmol) was added to a stirring solution of 5-(3-cyanophenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (40 mg, 0.108 mmol) and (R)-2-amino-3-methylbutan-1-ol (111 mg, 1.08 mmol) in PhCl (3 mL) at
 10 rt. It was subjected for two interactions to microwave irradiation for 1 hr at 200 °C. The mixture was concentrated and purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (13 mg, 25%). ¹H NMR (500 MHz, CD₃OD) δ ppm 8.24 (1 H, s), 7.93 - 7.99 (2 H, m), 7.89 - 7.93 (2 H, m), 7.86 (1 H, d, J =7.63 Hz), 7.63 - 7.69 (2 H,
 15 m), 7.56 (1 H, t, J =7.78 Hz), 7.26 (2 H, t, J =8.55 Hz), 4.52 (1 H, t, J =9.31 Hz), 4.30 (1 H, t, J =8.09 Hz), 4.14 - 4.22 (1 H, m), 2.98 (3 H, s), 1.87 - 1.97 (1 H, m), 1.04 (3 H, d, J =7.02 Hz), 0.97 (3 H, d, J =6.71 Hz). LC-MS retention time 1.64 min; m/z (MH⁺): 457. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-
 20 10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic
 25 acid. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final

%B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min.

Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μ m, R_t = 10.13 min, purity = 95%;

Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μ m, R_t = 10.58 min, purity = 94%.


5



(S)-2-(4-Fluorophenyl)-5-(3-(4-isopropyl-4,5-dihydrooxazol-2-yl)phenyl)-N-methylbenzofuran-3-carboxamide

[00152] Zinc chloride (8 mg, 0.054 mmol) was added to a stirring solution of 5-(3-cyanophenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (40 mg, 0.108 mmol) and (S)-2-amino-3-methylbutan-1-ol (111 mg, 1.080 mmol) in PhCl (3 mL) at rt. It was subjected for two 1 hr iterations to microwave irradiation at 200 °C. The reaction was concentrated and purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (9 mg, 17%). ¹H NMR (500 MHz, CD₃OD) δ ppm 8.24 (1 H, s), 7.93 - 7.99 (2 H, m), 7.89 - 7.93 (2 H, m), 7.86 (1 H, d, J =7.63 Hz), 7.63 - 7.69 (2 H, m), 7.56 (1 H, t, J =7.78 Hz), 7.26 (2 H, t, J =8.70 Hz), 4.52 (1 H, t, J =9.31 Hz), 4.30 (1 H, t, J =8.09 Hz), 4.15 - 4.22 (1 H, m), 2.98 (3 H, s), 1.86 - 1.96 (1 H, m), 1.04 (3 H, d, J =6.71 Hz), 0.97 (3 H, d, J =6.71 Hz). LC-MS retention time: 1.63 min; m/z (MH⁺): 457. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.


Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μm, R_t = 10.06 min, purity = 95%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μm, R_t = 10.53 min, purity = 95%.



2-(4-Fluorophenyl)-5-(3-(2-isobutyl-2H-tetrazol-5-yl)phenyl)-N-methylbenzofuran-3-carboxamide

- 10 **[00153]** 1-Bromo-2-methylpropane (23 mg, 0.169 mmol) was added to a stirring solution of 5-(3-(1H-tetrazol-5-yl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (35 mg, 0.085 mmol) and Na₂CO₃ (18 mg, 0.169 mmol) in DMF (1 mL) at 100 °C. It was allowed to stir overnight. The mixture was concentrated and purified by preparative reverse phase HPLC on a C18 column using a suitably buffered
- 15 H₂O/CH₃CN gradient, and concentrated to give the titled compound (15 mg, 38%).
¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.49 - 8.56 (1 H, m), 8.34 (1 H, s), 8.08 (1 H, d, *J*=7.63 Hz), 7.99 - 8.04 (2 H, m), 7.87 - 7.94 (2 H, m), 7.79 - 7.84 (1 H, m), 7.73 - 7.78 (1 H, m), 7.70 (1 H, t, *J*=7.63 Hz), 7.41 (2 H, t, *J*=8.70 Hz), 4.62 (2 H, d, *J*=7.32 Hz), 2.87 (3 H, d, *J*=4.27 Hz), 2.31 - 2.39 (1 H, m), 0.95 (6 H, d, *J*=6.71 Hz). LC-MS
- 20 retention time: 2.09 min; *m/z* (MH⁺): 470. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min,
- 25 a hold time of 1 min, and an analysis time of 3 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS® Platform

for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μm, R_t = 16.08 min, purity = 99%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μm, R_t = 13.89 min, purity = 99%.




5-(3-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00154] Zinc chloride (1 mg) was added to a stirring solution of 5-(3-cyanophenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (40 mg, 0.108 mmol) and 2-amino-2-methylpropan-1-ol (10 mg, 0.108 mmol) in PhCl (3 mL) at 130 °C. It was allowed to stir for 7 days. ~20% conversion was observed. Additional amounts of ZnCl (8 mg) and 2-amino-2-methylpropan-1-ol (50 mg) were added and the reaction was heated in the microwave for 1 hr at 200 °C. The reaction had progressed ~ 50%. The mixture was concentrated and purified on silica gel (BIOTAGE®, EtOAc/hexanes gradient, R_f ~.2 in 50% EtOAc/hexanes; fraction collection at λ = 254 nm) followed by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (7 mg, 14%). ¹H NMR (500 MHz, CD₃OD) δ ppm 8.24 (1 H, s), 7.97 (2 H, dd, J=8.09, 5.65 Hz), 7.93 (1 H, s), 7.88 (2 H, dd, J=11.44, 8.39 Hz), 7.68 (2 H, s), 7.57 (1 H, t, J=7.78 Hz), 7.27 (2 H, t, J=8.55 Hz), 4.25 (2 H, s), 2.99 (3 H, s), 1.42 (6 H, s). LC-MS retention time 1.60 min; m/z (MH⁺): 443. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100%

solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a


- 5 MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μm, R_t = 12.24 min, purity = 95%; Column: Waters XBridge phenyl column 4.6 x 150
10 mm, 3.5 μm, R_t = 10.02 min, purity = 95%.



2-(4-Fluorophenyl)-5-(3-(2-isopropyl-2H-tetrazol-5-yl)phenyl)-N-methylbenzofuran-3-carboxamide

- 15 **[00155]** 2-Iodopropane (29 mg, 0.169 mmol) was added to a stirring solution of 5-(3-(1H-tetrazol-5-yl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (35 mg, 0.085 mmol) and Na₂CO₃ (18 mg, 0.169 mmol) in DMF (1 mL) at 100 °C. It was allowed to stir overnight. The mixture was concentrated and purified by
20 preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (12 mg, 30%).
¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.49 - 8.57 (1 H, m), 8.34 (1 H, s), 8.08 (1 H, d, J=7.32 Hz), 7.99 - 8.05 (2 H, m), 7.87 - 7.94 (2 H, m), 7.79 - 7.83 (1 H, m), 7.72 - 7.78 (1 H, m), 7.70 (1 H, t, J=7.78 Hz), 7.41 (2 H, t, J=8.70 Hz), 5.17 - 5.27 (1 H, m), 2.87 (3 H, d, J=4.58 Hz), 1.66 (6 H, d, J=6.71 Hz). LC-MS retention time: 2.02 min;
25 m/z (MH⁺): 456. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution


- conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μm, R_t = 15.35 min, purity = 96%;
- 10 Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μm, R_t = 13.39 min, purity = 97%.



- (R)-2-(4-Fluorophenyl)-N-methyl-5-(3-(4-phenyl-4,5-dihydrooxazol-2-yl)phenyl)benzofuran-3-carboxamide
- 15

- [00156]** Zinc chloride (8 mg, 0.054 mmol) was added to a stirring solution of 5-(3-cyanophenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (40 mg, 0.108 mmol) and (R)-2-amino-2-phenylethanol (148 mg, 1.080 mmol) in PhCl (3 mL) at rt. It was subjected to two interactions of microwave irradiation at 200 °C for 1 hr. The material was concentrated and purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (7 mg, 13%). ¹H NMR (500 MHz, CD₃OD) δ ppm 8.33 (1 H, s), 7.94 - 8.00 (4 H, m), 7.91 (1 H, d, *J*=7.94 Hz), 7.64 - 7.73 (2 H, m), 7.61 (1 H, t, *J*=7.78 Hz), 7.32 - 7.42 (6 H, m), 7.26 (2 H, t, *J*=8.55 Hz), 5.45 (1 H, t, *J*=9.16 Hz), 4.94 (1 H, t, *J*=9.31 Hz), 4.36 (1 H, t, *J*=8.24 Hz), 2.97 (3 H, s). LC-MS retention time 1.75 min; *m/z* (MH⁺): 491. LC data was recorded on a Shimadzu LC-10AS liquid
- 20
- 25


chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% MeOH/95% H₂O/10 mM ammonium bicarbonate, Solvent B = 95% MeOH/5% H₂O/10 mM ammonium bicarbonate, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: PHENOMENEX® Gemini C-18, 4.6 x 150 mm, 3 μm, R_t = 18.32 min, purity = 97%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μm, R_t = 18.11 min, purity = 97%.



(S)-2-(4-Fluorophenyl)-N-methyl-5-(3-(4-phenyl-4,5-dihydrooxazol-2-yl)phenyl)benzofuran-3-carboxamide

[00157] Zinc chloride (9 mg, 0.067 mmol) was added to a stirring solution of 5-(3-cyanophenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (50 mg, 0.135 mmol) and (S)-2-amino-2-phenylethanol (93 mg, 0.675 mmol) in PhCl (3 mL) rt. It was subjected to two interactions of microwave irradiation at 200 °C for 1 hr. The material was concentrated and purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (16 mg, 23%). ¹H NMR (500 MHz, CD₃OD) δ ppm 8.33 (1 H, s), 7.94 - 8.00 (4 H, m), 7.91 (1 H, d, *J*=7.94 Hz), 7.64 - 7.73 (2 H, m), 7.61 (1 H, t, *J*=7.78 Hz), 7.32 - 7.42 (6 H, m), 7.26 (2 H, t, *J*=8.55 Hz), 5.45 (1 H, t, *J*=9.16 Hz),

4.94 (1 H, t, $J=9.31$ Hz), 4.36 (1 H, t, $J=8.24$ Hz), 2.97 (3 H, s). LC-MS retention time 1.76 min; m/z (MH^+): 491. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H_2O / 10 mM ammonium acetate and solvent B was 5% H_2O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% MeOH/95% H_2O /10 mM ammonium bicarbonate, Solvent B = 95% MeOH/5% H_2O /10 mM ammonium bicarbonate, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: PHENOMENEX® Gemini C-18, 4.6 x 150 mm, 3 μ m, R_t = 18.32 min, purity = 99%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 μ m, R_t = 18.10 min, purity = 99%.




2-(4-Fluorophenyl)-N-methyl-5-(3-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)benzofuran-3-carboxamide

[00158] DIEA (50 μ L, 0.288 mmol) was added to $Pd(Ph_3P)_4$ (6 mg, 4.79 μ mol), - (4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (40 mg, 0.096 mmol), 3-(5-methyl-1,3,4-oxadiazol-2-yl)phenylboronic acid (29 mg, 0.144 mmol). Dioxane (1 mL) and water (200 μ L) was added at rt. The reaction was heated to 90 $^{\circ}C$ overnight. The mixture was cooled and purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H_2O/CH_3CN gradient, and concentrated to give the titled compound (16 mg, 37%). ^1H NMR (500 MHz, $DMSO-d_6$) δ ppm 8.49 - 8.56 (1 H, m), 8.24 (1 H, s), 7.98 - 8.05 (4 H, m), 7.93 (1 H, s), 7.79 - 7.83 (1 H, m), 7.68 - 7.76 (2 H, m), 7.41 (2 H, t, $J=8.70$ Hz), 2.87 (3

H, d, J=4.58 Hz), 2.62 (3 H, s). LC-MS retention time: 1.41 min; m/z (MH⁻): 426.
 LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with
 a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at
 a detector wave length of 220nm. The elution conditions employed a flow rate of 5
 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent
 B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where
 solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B
 was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was
 determined using a MICROMASS® Platform for LC in electrospray mode.

10 Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B
 = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time =
 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18,
 4.6 x 150 mm, 3.5 mm, Rt = 12.96 min, purity = 95% ; Column: Waters XBridge
 phenyl column 4.6 x 150 mm, 3.5 mm, Rt = 11.53 min, purity = 94%.

15




6-(Cyclopropanesulfonamido)-2-(4-fluorophenyl)-N-methyl-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00159] Cyclopropanesulfonyl chloride (8 μ L, 0.058 mmol) was added to a stirring
 20 solution of 6-amino-2-(4-fluorophenyl)-N-methyl-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide (20 mg, 0.038 mmol) in Pyridine (.5
 mL) at rt. It was allowed to stir for 2 hours. The mixture was concentrated purified by
 preparative reverse phase HPLC on a C18 column using a suitably buffered
 H₂O/CH₃CN gradient, and concentrated to give the titled compound (17 mg, 70%).

25 ¹H NMR (500 MHz, CD₃OD) δ ppm 8.41 (1 H, br. s.), 7.91 - 8.01 (3 H, m), 7.78 -


7.86 (2 H, m), 7.61 - 7.71 (2 H, m), 7.58 (1 H, t, J=7.63 Hz), 7.41 - 7.49 (2 H, m), 7.24 - 7.33 (4 H, m), 7.18 (1 H, t, J=6.87 Hz), 2.94 (3 H, s), 2.34 - 2.43 (1 H, m), 1.77 (6 H, s), 0.80 - 1.03 (4 H, m). LC-MS retention time: 1.53 min; m/z (MH⁺): 626. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, Rt = 15.40 min, purity = 99% ; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, Rt = 12.65 min, purity = 99%.



20 2-(4-Fluorophenyl)-N-methyl-5-(3-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)benzofuran-3-carboxamide

[00160] DIEA (50 μ L, 0.288 mmol) was added to Pd(Ph₃P)₄ (6 mg, 4.79 μ mol), 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (40 mg, 0.096 mmol), 3-(5-methyl-1,3,4-oxadiazol-2-yl)phenylboronic acid (29 mg, 0.144 mmol). Dioxane (799 μ L) and water (160 μ L) was added at rt. The reaction was heated to 90 $^{\circ}$ C overnight. The mixture was cooled and purified by prep HPLC to give the titled compound (16 mg, 37%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.49 - 8.56 (1 H, m), 8.24 (1 H, s), 7.98 - 8.05 (4 H, m), 7.93 (1 H, s), 7.79 - 7.83 (1 H, m),


7.68 - 7.76 (2 H, m), 7.41 (2 H, t, $J=8.70$ Hz), 2.87 (3 H, d, $J=4.58$ Hz), 2.62 (3 H, s).
 LC-MS retention time: 1.41 min; m/z (MH⁻): 426. LC data was recorded on a
 Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18
 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of
 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100%
 solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min,
 a hold time of 1 min, and an analysis time of 3 min where solvent A was 5%
 acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95%
 acetonitrile / 10 mM ammonium acetate. MS data was determined using a
 MICROMASS® Platform for LC in electrospray mode. Analytical HPLC method:
 Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5%
 H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time =
 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μ m,
 R_t = 12.96 min, purity = 95% ; Column: Waters XBridge phenyl column 4.6 x 150
 mm, 3.5 μ m, R_t = 11.53 min, purity = 94%.



2-(4-Fluorophenyl)-5-(3-(3-isopropyl-1,2,4-oxadiazol-5-yl)phenyl)-N-methylbenzofuran-3-carboxamide

[00161] Sodium methoxide (33 mg, 0.620 mmol) was added to a stirring slurry of
 methyl 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoate (50 mg,
 0.124 mmol) and (Z)-N'-hydroxyisobutyrimidamide (38 mg, 0.372 mmol) in EtOH
 (2.5 mL) at rt. The mixture was subjected to microwave irradiation for 5 min at 160
 °C. The mixture was concentrated and purified by preparative reverse phase HPLC on
 a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to
 give the titled compound (11 mg, 20%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.46 -
 8.54 (1 H, m), 8.35 (1 H, s), 8.11 (1 H, d, $J=7.78$ Hz), 7.97 - 8.08 (3 H, m), 7.92 -
 7.97 (1 H, m), 7.73 - 7.84 (3 H, m), 7.40 (2 H, t, $J=8.91$ Hz), 3.12 - 3.23 (1 H, m),
 2.87 (3 H, d, $J=4.52$ Hz), 1.36 (6 H, d, $J=7.03$ Hz). LC-MS retention time: 1.80 min;


m/z (MH⁺) : 456. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, R_t = 16.33 min, purity = 99% ; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, R_t = 13.72 min, purity = 99%.



2-(4-Fluorophenyl)-N-methyl-5-(3-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl)benzofuran-3-carboxamide

[00162] Sodium methoxide (33 mg, 0.620 mmol) was added to a stirring slurry of methyl 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoate (50 mg, 0.124 mmol) and (Z)-N'-hydroxybenzimidamide (51 mg, 0.372 mmol) in EtOH (2.5 mL) at rt. The mixture was subjected to microwave irradiation for 5 min at 160 °C. The mixture was concentrated and purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (8.7 mg, 14%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.49 - 8.56 (1 H, m), 8.44 - 8.49 (1 H, m), 8.19 - 8.25 (1 H, m), 8.13 - 8.18 (2 H, m), 8.07 - 8.12 (1 H, m), 8.00 - 8.07 (2 H, m), 7.98 (1 H, s), 7.76 - 7.86 (3 H, m), 7.59 - 7.68 (3 H, m), 7.41 (2 H, t, J=8.91 Hz), 2.88 (3 H, d, J=4.77 Hz). LC-MS retention time: 1.94 min; m/z (MH⁺) : 490. LC data was recorded on a Shimadzu LC-10AS liquid

chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, R_t = 17.39 min, purity = 99%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, R_t = 14.58 min, purity = 98%.




2-(4-Fluorophenyl)-N-methyl-5-(3-(4-phenyl-1H-imidazol-2-yl)phenyl)benzofuran-3-carboxamide

[00163] 2-Oxo-2-phenylacetaldehyde hydrate (10 mg, 0.066 mmol) in MeOH (1 mL) was added to a stirring solution of 2-(4-fluorophenyl)-5-(3-formylphenyl)-N-methylbenzofuran-3-carboxamide (20 mg, 0.054 mmol) and ammonium acetate (25 mg, 0.324 mmol) in MeOH (1 mL) at rt. It was allowed to stir overnight. The reaction was purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (6.5 mg, 24%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 12.82 (1 H, br. s.), 8.51 - 8.58 (1 H, m), 8.35 (1 H, br. s.), 7.98 - 8.07 (3 H, m), 7.93 - 7.97 (1 H, m), 7.76 - 7.90 (4 H, m), 7.72 (1 H, d, J=7.63 Hz), 7.60 (1 H, t, J=7.78 Hz), 7.36 - 7.45 (4 H, m), 7.19 - 7.29 (1 H,

m), 2.88 (3 H, d, $J=4.58$ Hz). LC-MS retention time: 1.57 min; m/z (MH^+) : 488.
 LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with
 a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis
 detector at a detector wave length of 220nm. The elution conditions employed a flow
 rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A /
 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time
 of 3 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and
 solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was
 determined using a MICROMASS® Platform for LC in electrospray mode.


Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B
 = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time =
 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18,
 4.6 x 150 mm, 3.5 mm, R_t = 9.54 min, purity = 96% ; Column: Waters XBridge
 phenyl column 4.6 x 150 mm, 3.5 mm, R_t = 10.41 min, purity = 97%.



5-(3-(1-(1,3,4-Thiadiazol-2-ylamino)-2-methyl-1-oxopropan-2-ylcarbamoyl)phenyl)-
 2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00164] DIEA (44 μ L, 0.253 mmol) was added to a stirring solution of 2-(3-(2-(4-
 fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzamido)-2-methylpropanoic
 acid (40 mg, 0.084 mmol), 1,3,4-thiadiazol-2-amine (17.05 mg, 0.169 mmol) in DMF
 (843 μ L) at rt. NaH (17 mg, 0.422 mmol) was added, and the slurry became a clear
 solution after 10 min. It was allowed to stir overnight. The reaction was purified by
 preparative reverse phase HPLC on a C18 column using a suitably buffered
 H₂O/CH₃CN gradient, and concentrated to give the titled compound (22 mg, 45%).


¹H NMR (500 MHz, DMSO-d₆) δ ppm 12.44 (1 H, br. s.), 9.14 (1 H, br. s.), 8.78 (1 H, br. s.), 8.47 - 8.57 (1 H, m), 8.30 (1 H, s), 7.97 - 8.04 (2 H, m), 7.88 - 7.95 (3 H, m), 7.75 - 7.84 (2 H, m), 7.61 (1 H, t, *J*=7.78 Hz), 7.41 (2 H, t), 2.86 (3 H, d, *J*=4.88 Hz), 1.57 (6 H, s). LC-MS retention time: 1.57 min; *m/z* (MH⁺): 488. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, *R*_t = 11.23 min, purity = 97% ; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, *R*_t = 10.56 min, purity = 96%.



20 5-(3-(1H-Pyrazol-5-yl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00165] Cesium carbonate (234 mg, 0.719 mmol) was added to Pd(Ph₃P)₄ (20.77 mg, 0.018 mmol), 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (150 mg, 0.359 mmol), 5-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (146 mg, 0.539 mmol). Dioxane (3 mL) and water (599 μL) was added at rt. The reaction was heated to 90 °C overnight. The mixture was diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated and purified by

trituration with Et₂O to give the titled compound (140 mg, 92%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 13.40 (1 H, br. s.), 12.91 (1 H, br. s.), 8.45 - 8.55 (1 H, m), 8.13 (1 H, s), 7.97 - 8.08 (2 H, m), 7.85 - 7.95 (1 H, m), 7.73 - 7.85 (4 H, m), 7.59 - 7.67 (1 H, m), 7.49 - 7.58 (1 H, m), 7.35 - 7.45 (2 H, m), 6.84 (1 H, br. s.), 2.87 (3 H, d, *J*=4.52 Hz). LC-MS retention time: 1.41 min; *m/z* (MH⁺) : 412. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, *R*_t = 11.86 min, purity = 97% ; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, *R*_t = 10.97 min, purity = 99%.




5-(3-(1-Benzyl-1H-pyrazol-5-yl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00166] (Bromomethyl)benzene (17 mg, 0.097 mmol) was added to a stirring solution of Na₂CO₃ (11 mg, 0.097 mmol) and 5-(3-(1H-pyrazol-5-yl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (20 mg, 0.049 mmol) in DMF (486 μL) at 100 °C. It was allowed to stir overnight, filtered and purified by preparative reverse phase HPLC on a C18 column using a suitably buffered


H₂O/CH₃CN gradient, and concentrated to give the titled compound (8.6 mg, 35%).
¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.49 - 8.57 (1 H, m), 8.06 - 8.11 (1 H, m),
 7.98 - 8.04 (2 H, m), 7.92 (1 H, d, *J*=2.44 Hz), 7.86 - 7.89 (1 H, m), 7.75 - 7.83 (2 H,
 m), 7.69 - 7.75 (1 H, m), 7.63 (1 H, d, *J*=8.24 Hz), 7.51 (1 H, t, *J*=7.63 Hz), 7.34 -
 5 7.43 (4 H, m), 7.27 - 7.32 (3 H, m), 6.89 (1 H, d, *J*=2.44 Hz), 5.41 (2 H, s), 2.86 (3 H,
 d, *J*=4.58 Hz). LC-MS retention time: 2.00 min; *m/z* (MH⁺) : 502. LC data was
 recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a
 PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis
 detector at a detector wave length of 220nm. The elution conditions employed a flow
 10 rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A /
 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time
 of 3 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and
 solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was
 determined using a MICROMASS® Platform for LC in electrospray mode.
 15 Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B
 = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time =
 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18,
 4.6 x 150 mm, 3.5 mm, *R*_t = 15.47 min, purity = 99% ; Column: Waters XBridge
 phenyl column 4.6 x 150 mm, 3.5 mm, *R*_t = 13.77 min, purity = 100%.

20




2-(4-Fluorophenyl)-N-methyl-5-(3-(2-methyl-1-(5-methyl-1H-pyrazol-3-ylamino)-1-
 oxopropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide
[00167] DIEA (28 μL, 0.158 mmol) was added to a stirring solution of 2-(3-(2-(4-
 25 fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzamido)-2-methylpropanoic

acid (25 mg, 0.053 mmol), 5-methyl-1H-pyrazol-3-amine (11 mg, 0.105 mmol) in DMF (527 μ L) at rt. It was allowed to stir for 30 min. NaH (11 mg, 0.263 mmol) was added and the reaction was allowed to stir overnight. The mixture was treated with a drop of MeOH and was purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (6.4 mg, 21%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 11.90 (1 H, br. s.), 9.84 (1 H, br. s.), 8.51 - 8.56 (1 H, m), 8.41 (1 H, br. s.), 8.23 - 8.28 (1 H, m), 7.98 - 8.03 (2 H, m), 7.86 - 7.93 (3 H, m), 7.76 - 7.83 (2 H, m), 7.59 (1 H, t, *J*=7.63 Hz), 7.37 - 7.43 (2 H, m), 6.28 (1 H, br. s.), 2.87 (3 H, d, *J*=4.88 Hz), 2.17 (3 H, s), 1.54 (6 H, s). LC-MS retention time: 1.56 min; *m/z* (MH⁺): 554. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wavelength of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, *R*_t = 10.47 min, purity = 97% ; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, *R*_t = 9.58 min, purity = 96%.



2-(4-Fluorophenyl)-N-methyl-5-(3-(2-methyl-1-(3-methylisoxazol-5-ylamino)-1-oxopropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide


- [00168] DIEA (28 μ L, 0.158 mmol) was added to a stirring solution of 2-(3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzamido)-2-methylpropanoic acid (25 mg, 0.053 mmol), 3-methylisoxazol-5-amine (11 mg, 0.105 mmol) in DMF (527 μ L) at rt. It was allowed to stir for 30 min. NaH (11 mg, 0.263 mmol) was added and the reaction was allowed to stir overnight. The mixture was treated with a drop of MeOH and was purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (3.3 mg, 11%). ¹H NMR (500 MHz, CD₃OD) δ ppm 8.18 - 8.24 (1 H, m), 7.93 - 8.00 (3 H, m), 7.84 - 7.91 (2 H, m), 7.65 - 7.74 (2 H, m), 7.58 (1 H, t, *J*=7.78 Hz), 7.23 - 7.31 (2 H, m), 2.98 (3 H, s), 2.24 (3 H, s), 1.65 (6 H, s). LC-MS retention time: 1.69 min; *m/z* (MH⁺) : 555. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, *R*_t = 12.09 min, purity = 100%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, *R*_t = 11.18 min, purity = 99%.



2-(4-Fluorophenyl)-N-methyl-5-(3-(2-methyl-1-(5-methylisoxazol-3-ylamino)-1-oxopropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00169] DIEA (28 μ L, 0.158 mmol) was added to a stirring solution of 2-(3-(2-(4-fluorophenyl)-3-(methylcarbonyl)benzofuran-5-yl)benzamido)-2-methylpropanoic acid (25 mg, 0.053 mmol), 5-methylisoxazol-3-amine (11 mg, 0.105 mmol) in DMF (527 μ L) at rt. It was allowed to stir for 30 min. NaH (11 mg, 0.263 mmol) was added and the reaction was allowed to stir overnight. The mixture was treated with a drop of MeOH and was purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (2.8 mg, 9%). ¹H NMR (500 MHz, CD₃OD) δ ppm 8.17 - 8.25 (1 H, m), 7.92 - 8.00 (3 H, m), 7.83 - 7.91 (2 H, m), 7.66 - 7.76 (2 H, m), 7.58 (1 H, t, *J*=7.78 Hz), 7.27 (2 H, t, *J*=8.85 Hz), 6.63 (1 H, s), 2.98 (3 H, s), 2.39 (3 H, s), 1.65 (6 H, s). LC-MS retention time: 1.69 min; *m/z* (MH⁺) : 555. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wavelength of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5

mm, R_t = 12.20 min, purity = 95% ; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, R_t = 11.30 min, purity = 90%.




- 5 5-(3-(1-(1,2,4-Triazin-3-ylamino)-2-methyl-1-oxopropan-2-ylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide
- [00170]** DIEA (28 μ L, 0.158 mmol) was added to a stirring solution of 2-(3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzamido)-2-methylpropanoic acid (25 mg, 0.053 mmol), 1,2,4-triazin-3-amine (11 mg, 0.105 mmol) in DMF (527
- 10 μ L) at rt. It was allowed to stir for 30 min. NaH (11 mg, 0.263 mmol) was added and the reaction was allowed to stir overnight. The mixture was treated with a drop of MeOH and was purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H_2O/CH_3CN gradient, and concentrated to give the titled compound (7.4 mg, 25%). ^1H NMR (500 MHz, CD_3OD) δ ppm 8.58 - 8.63 (1 H, m), 8.22 - 8.26
- 15 (1 H, m), 7.93 - 8.00 (3 H, m), 7.85 - 7.93 (2 H, m), 7.66 - 7.75 (2 H, m), 7.59 (1 H, t, $J=7.63$ Hz), 7.27 (2 H, t, $J=8.85$ Hz), 2.98 (3 H, s), 1.72 (6 H, s). LC-MS retention time: 1.56 min; m/z (MH^+): 553. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm.
- 20 The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 10% MeOH / 90% H_2O / 0.1% trifluoroacetic acid and solvent B was 10% H_2O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS® Platform for
- 25 LC in electrospray mode. Additional HPLC method: Solvent A = 5% $CH_3CN/95\%$

H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min.

Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, R_t = 9.65 min, purity = 97% ;

Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, R_t = 9.58 min,


5 purity = 97%.



2-(4-Fluorophenyl)-N-methyl-6-(N-methylmethananesulfonyl)-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide

- 10 **[00171]** Oxalyl chloride (22 μ L, 0.250 mmol) was added to a stirring solution of 2-(4-fluorophenyl)-6-(N-methylmethananesulfonyl)-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxylic acid (50 mg, 0.083 mmol) in DCE (832 μ L) at rt. DMF (3 μ L, 0.042 mmol) was added. The mixture was allowed to stir for 30 min, concentrated and diluted with THF. DIEA (59 μ L, 0.333 mmol) and
- 15 methanamine (208 μ L, 0.416 mmol, 2M in THF) was added. It was allowed to stir overnight. The mixture was diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated and was purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (11 mg,
- 20 20%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.46 - 8.56 (1 H, m), 8.36 (1 H, s), 7.97 - 8.05 (3 H, m), 7.94 (1 H, s), 7.86 (1 H, d, *J*=7.78 Hz), 7.59 - 7.67 (2 H, m), 7.53 (1 H, t, *J*=7.65 Hz), 7.35 - 7.42 (4 H, m), 7.29 (2 H, t, *J*=7.78 Hz), 7.17 (1 H, t, *J*=7.28 Hz), 3.06 (3 H, s), 3.01 (3 H, s), 2.82 (3 H, d, *J*=4.52 Hz), 1.69 (6 H, s). LC-MS retention time: 1.51 min; *m/z* (MH⁺) : 614. LC data was recorded on a Shimadzu
- 25 LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm.

The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, R_t = 12.89 min, purity = 92% ; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, R_t = 12.11 min, purity = 91%.




5-(3-(*tert*-Butylcarbamoyl)phenyl)-2-(4-fluorophenyl)-6-(N-(2-hydroxyethyl)methylsulfonamido)-N-methylbenzofuran-3-carboxamide
[00172] *tert*-Butylamine (21 μ L, 0.195 mmol) was added to a stirring solution of HATU (45 mg, 0.117 mmol), DIEA (41 μ L, 0.234 mmol), and 3-(6-(N-(2-(*tert*-butyldimethylsilyloxy)ethyl)methylsulfonamido)-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (50 mg, 0.078 mmol) in DMF (780 μ L) at rt. It was allowed to stir for 1 hour. The mixture was diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated and was purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (11 mg, 23%). ¹H NMR (500 MHz, CD₃OD) δ ppm 8.04 (1 H, br. s.), 7.94 - 8.02 (2 H, m), 7.77 - 7.86 (2 H, m), 7.66 - 7.73 (2 H, m), 7.49 - 7.59 (2 H, m), 7.24 - 7.34 (2 H, m), 3.56 - 3.66 (1 H, m), 3.35 - 3.43 (2 H, m), 3.27 (3 H, s),

2.94 (3 H, s), 2.78 - 2.87 (1 H, m), 1.47 (9 H, s). LC-MS retention time: 1.57 min; m/z (MH⁺): 582. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.

10 Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, R_t = 10.88 min, purity = 97% ; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, R_t = 10.27 min, purity = 96 %.

15




Ethyl 2-(3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)phenyl)-4-methyl-1H-imidazole-5-carboxylate

[00173] Cesium carbonate (234 mg, 0.719 mmol) was added to Pd(Ph₃P)₄ (27.7 mg, 0.024 mmol), 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (200 mg, 0.479 mmol), ethyl 4-methyl-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazole-5-carboxylate (171 mg, 0.479 mmol). Dioxane (4 mL) and water (800 µL) was added at rt. The reaction was heated to 90 °C overnight. The mixture was diluted with ethyl acetate and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated and was purified on silica gel (BIOTAGE®, EtOAc/hexanes gradient, fraction collection at λ = 254 nm) to give the titled compound (6.8 mg, 3%).

¹H NMR (500 MHz, DMSO-d₆) δ ppm 13.16 (0.34 H, s), 12.96 (0.66 H, s), 8.54 (1 H, q, *J*=4.48 Hz), 8.50 (0.32 H, s), 8.24 (0.68 H, s), 8.10 (0.31 H, d, *J*=7.93 Hz), 7.97 - 8.04 (2 H, m), 7.89 - 7.97 (2 H, m), 7.79 - 7.84 (1.35 H, m), 7.70 - 7.79 (2 H, m), 7.54 - 7.63 (1 H, m), 7.37 - 7.44 (2 H, m), 4.33 (0.65 H, q, *J*=7.22 Hz), 4.25 (1.42 H, q, *J*=7.22 Hz), 2.87 (3 H, d, *J*=4.88 Hz), 2.55 (2 H, s), 2.45 (1 H, s), 1.34 (1 H, t, *J*=7.02 Hz), 1.31 (2 H, t, *J*=7.17 Hz). LC-MS retention time: 1.46 min; *m/z* (MH⁺): 498. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.

Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, *R*_t = 9.90 min, purity = 99%.




20

2-(4-Fluorophenyl)-6-(N-(2-hydroxyethyl)methylsulfonamido)-N-methyl-5-(3-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00174] 1-(Pyridin-2-yl)cyclopropanamine dihydrochloride (24 mg, 0.114 mmol) was added to a stirring solution of HATU (54 mg, 0.142 mmol), DIEA (50 μL, 0.285 mmol), and 3-(2-(4-fluorophenyl)-6-(N-(2-hydroxyethyl)methylsulfonamido)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (50 mg, 0.095 mmol) in DMF (950


25

μL) at rt. It was allowed to stir for 1 hour. The mixture was diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated and was purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (20 mg, 32%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 9.20 (1 H, s), 8.49 - 8.57 (1 H, m), 8.45 (1 H, d, *J*=3.97 Hz), 7.97 - 8.05 (3 H, m), 7.96 (1 H, s), 7.94 (1 H, d, *J*=7.93 Hz), 7.80 (1 H, d, *J*=7.93 Hz), 7.64 - 7.69 (1 H, m), 7.63 (1 H, s), 7.56 (1 H, t, *J*=7.63 Hz), 7.37 - 7.47 (3 H, m), 7.15 (1 H, dd, *J*=6.41, 4.88 Hz), 4.91 (1 H, br. s.), 3.51 - 3.60 (1 H, m), 3.22 (3 H, s), 2.89 - 2.98 (3 H, m), 2.81 (3 H, d), 1.50 - 1.60 (2 H, m), 1.23 - 1.33 (2 H, m). LC-MS retention time: 1.37 min; *m/z* (MH⁺): 643. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, *R*_t = 7.17 min, purity = 98% ; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, *R*_t = 7.89 min, purity = 99%.



2-(4-Fluorophenyl)-6-(N-(2-hydroxyethyl)methylsulfonamido)-N-methyl-5-(3-(1-phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

- [00175]** 1-Phenylcyclopropanamine hydrochloride (16 mg, 0.091 mmol) was added to a stirring solution of HATU (43 mg, 0.114 mmol), DIEA (40 μ L, 0.228 mmol), and 3-(2-(4-fluorophenyl)-6-(N-(2-hydroxyethyl)methylsulfonamido)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (40 mg, 0.076 mmol) in DMF (760 μ L) at rt. It was allowed to stir for 1 hour. The mixture was diluted with EtOAc and washed with sat NaHCO_3 , and sat NaCl . The organic phase was dried over Na_2SO_4 , filtered and concentrated and was purified by preparative reverse phase HPLC on a C18 column using a suitably buffered $\text{H}_2\text{O}/\text{CH}_3\text{CN}$ gradient, and concentrated to give the titled compound (22 mg, 44%). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ ppm 9.12 (1 H, s), 8.49 - 8.56 (1 H, m), 7.97 - 8.05 (3 H, m), 7.95 (1 H, s), 7.90 (1 H, d, $J=7.93$ Hz), 7.78 (1 H, d, $J=7.93$ Hz), 7.62 (1 H, s), 7.54 (1 H, t, $J=7.78$ Hz), 7.37 - 7.46 (2 H, m), 7.28 (2 H, t, $J=7.63$ Hz), 7.19 - 7.24 (2 H, m), 7.15 (1 H, t, $J=7.32$ Hz), 4.90 (1 H, t, $J=5.19$ Hz), 3.50 - 3.58 (1 H, m), 3.25 - 3.28 (1 H, m), 3.21 (3 H, s), 2.88 - 2.96 (2 H, m), 2.82 (3 H, d, $J=4.58$ Hz), 1.22 - 1.32 (4 H, m). LC-MS retention time: 1.57 min; m/z (MH^+): 642. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H_2O / 10 mM ammonium acetate and solvent B was 5% H_2O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% $\text{CH}_3\text{CN}/95\%$ $\text{H}_2\text{O}/0.1\%$ TFA, Solvent B = 95% $\text{CH}_3\text{CN}/5\%$ $\text{H}_2\text{O}/0.1\%$ TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, R_t = 11.28 min, purity = 99%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, R_t = 10.86 min, purity = 98%.




2-(4-Fluorophenyl)-5-(3-(1-(4-fluorophenyl)cyclopropylcarbamoyl)phenyl)-6-(N-(2-hydroxyethyl)methylsulfonamido)-N-methylbenzofuran-3-carboxamide

- [00176]** 1-(4-Fluorophenyl)cyclopropanamine hydrochloride (22 mg, 0.114 mmol) was added to a stirring solution of HATU (54 mg, 0.142 mmol), DIEA (50 μ L, 0.285 mmol), and 3-(2-(4-fluorophenyl)-6-(N-(2-hydroxyethyl)methylsulfonamido)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (50 mg, 0.095 mmol) in DMF (950 μ L) at rt. It was allowed to stir for 1 hour. The mixture was diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated and was purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (30 mg, 47%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 9.14 (1 H, s), 8.49 - 8.55 (1 H, m), 7.99 - 8.04 (2 H, m), 7.97 - 7.98 (1 H, m), 7.95 (1 H, s), 7.88 (1 H, d, *J*=8.24 Hz), 7.78 (1 H, d, *J*=7.93 Hz), 7.61 (1 H, s), 7.53 (1 H, t, *J*=7.78 Hz), 7.39 - 7.45 (2 H, m), 7.22 - 7.32 (2 H, m), 7.05 - 7.13 (2 H, m), 4.90 (1 H, t, *J*=5.04 Hz), 3.50 - 3.58 (1 H, m), 3.24 - 3.28 (1 H, m), 3.20 (3 H, s), 2.93 (2 H, br. s.), 2.81 (3 H, d, *J*=4.58 Hz), 1.25 (4 H, d, *J*=9.77 Hz). LC-MS retention time: 1.60 min; *m/z* (MH⁺): 660. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B

= 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, R_t = 11.49 min, purity = 99% ; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, R_t = 11.04 min, purity = 99%.


5



2-(4-Fluorophenyl)-5-(3-(2-(4-fluorophenyl)propan-2-ylcarbamoyl)phenyl)-6-(N-(2-hydroxyethyl)methylsulfonamido)-N-methylbenzofuran-3-carboxamide

[00177] 2-(4-Fluorophenyl)propan-2-amine (18 mg, 0.114 mmol) was added to a stirring solution of HATU (54 mg, 0.142 mmol), DIEA (50 μ L, 0.285 mmol), and 2-(4-fluorophenyl)propan-2-amine (18 mg, 0.114 mmol) in DMF (950 μ L) at rt. It was allowed to stir for 1 hour. The mixture was diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated and was purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (18 mg, 28%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.50 - 8.56 (1 H, m), 8.31 (1 H, s), 7.98 - 8.05 (3 H, m), 7.96 (1 H, s), 7.83 (1 H, d, *J*=7.63 Hz), 7.73 (1 H, d, *J*=7.63 Hz), 7.62 (1 H, s), 7.53 (1 H, t, *J*=7.78 Hz), 7.38 - 7.47 (4 H, m), 7.09 (2 H, t, *J*=8.85 Hz), 4.90 (1 H, t, *J*=5.19 Hz), 3.50 - 3.58 (1 H, m), 3.26 - 3.29 (1 H, m), 3.23 (3 H, s), 2.87 - 2.93 (2 H, m), 2.82 (3 H, d, *J*=4.58 Hz), 1.67 (6 H, s). LC-MS retention time: 1.66 min; *m/z* (MH⁺): 662. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile /

95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, R_t = 12.11 min, purity = 99%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, R_t = 11.48 min, purity = 100%.




5-(3-(1-(4-Chlorophenyl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00178] 1-(4-Chlorophenyl)cyclopropanamine hydrochloride (25 mg, 0.123 mmol) was added to a stirring solution of HATU (59 mg, 0.154 mmol), DIEA (54 μ L, 0.308 mmol), and 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (40 mg, 0.103 mmol) in DMF (1 mL) at rt. It was allowed to stir for 1 hour. The mixture was diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated and was purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (8 mg, 14%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 9.37 (1 H, s), 8.46 - 8.55 (1 H, m), 8.22 (1 H, s), 7.95 - 8.05 (2 H, m), 7.86 - 7.95 (3 H, m), 7.74 - 7.83 (2 H, m), 7.59 (1 H, t, *J*=7.63 Hz), 7.38 - 7.44 (2 H, m), 7.30 - 7.36 (2 H, m), 7.20 - 7.28 (2 H, m), 2.86 (3 H, d, *J*=4.58 Hz), 1.26 - 1.36 (4 H, m). LC-MS retention time: 1.92 min; *m/z* (MH⁺): 539. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0% solvent B to 0% solvent A /

100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.

- 5 Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, R_t = 14.56 min, purity = 99%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, R_t = 13.20 min, purity = 97%.


10



5-(3-(2-(4-Chlorophenyl)propan-2-ylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

- [00179] 2-(4-Chlorophenyl)propan-2-amine (21 mg, 0.123 mmol) was added to a stirring solution of HATU (59 mg, 0.154 mmol), DIEA (54 μ L, 0.308 mmol), and 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (40 mg, 0.103 mmol) in DMF (1 mL) at rt. It was allowed to stir for 1 hour. The mixture was diluted with EtOAc and washed with sat NaHCO₃, and sat NaCl. The organic phase was dried over Na₂SO₄, filtered and concentrated and was purified by preparative reverse phase HPLC on a C18 column using a suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (32 mg, 57%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.64 (1 H, s), 8.47 - 8.55 (1 H, m), 8.14 (1 H, s), 7.99 - 8.04 (2 H, m), 7.92 (1 H, s), 7.74 - 7.89 (4 H, m), 7.57 (1 H, t, *J*=7.78 Hz), 7.37 - 7.45 (4 H, m), 7.34 (2 H, d, *J*=8.85 Hz), 2.87 (3 H, d, *J*=4.58 Hz), 1.69 (6 H, s). LC-MS retention time: 1.95 min; *m/z* (MH⁺): 541. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10u C18 3.0x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent A / 0%

- solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid. MS data was determined using a MICROMASS® Platform for
- 5 LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, R_t = 15.18 min, purity = 99% ; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, R_t = 13.66 min,
- 10 purity = 99%.




2-(4-Fluorophenyl)-N-methyl-5-(3-(2-(pyridin-4-yl)propan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide

- 15 **[00180]** 2-(Pyridin-4-yl)propan-2-amine dihydrochloride (26 mg, 0.123 mmol) was added to a stirring solution of HATU (59 mg, 0.154 mmol), DIEA (54 μ L, 0.308 mmol), and 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (40 mg, 0.103 mmol) in DMF (1 mL) at rt. It was allowed to stir for 1 hour. The reaction was purified by preparative reverse phase HPLC on a C18 column using a
- 20 suitably buffered H₂O/CH₃CN gradient, and concentrated to give the titled compound (15 mg, 27%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.73 (1 H, s), 8.50 - 8.55 (1 H, m), 8.48 (2 H, dd, *J*=4.58, 1.53 Hz), 8.16 (1 H, s), 7.97 - 8.04 (2 H, m), 7.91 - 7.94 (1 H, m), 7.88 (1 H, d, *J*=7.63 Hz), 7.85 (1 H, d, *J*=7.93 Hz), 7.75 - 7.82 (2 H, m), 7.58 (1 H, t, *J*=7.63 Hz), 7.36 - 7.43 (4 H, m), 2.86 (3 H, d, *J*=4.58 Hz), 1.68 (6 H, s). LC-
- 25 MS retention time: 1.59 min; *m/z* (MH⁺): 508. LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a Waters XBridge 5u C18 4.6x50mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220nm. The elution conditions employed a flow rate of 5 ml/min, a gradient of 100% solvent

A / 0% solvent B to 0% solvent A / 100% solvent B, a gradient time of 2 min, a hold time of 1 min, and an analysis time of 3 min where solvent A was 5% acetonitrile / 95% H₂O / 10 mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10 mM ammonium acetate. MS data was determined using a MICROMASS®


- 5 Platform for LC in electrospray mode. Additional HPLC method: Solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, Solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 mm, R_t = 8.60 min, purity = 95%; Column: Waters XBridge phenyl column 4.6 x 150 mm, 3.5 mm, R_t =
10 9.26 min, purity = 96%.



2-(4-Fluorophenyl)-5-isopropoxy-6-(methylsulfonamido)benzofuran-3-carbothioamide

- 15 **[00181]** The reaction was run in two batches and combined for workup. In the first batch, Lawesson's reagent (27 mg, 0.067 mmol) was added to a solution of 2-(4-fluorophenyl)-5-isopropoxy-6-(methylsulfonamido)benzofuran-3-carboxamide (35 mg, 0.086 mmol) in THF (1.2 mL). The reaction was stirred at r.t. for 2 h, at which point additional Lawesson's reagent (8 mg, 0.020 mmol) was added. In the second
20 batch, Lawesson's reagent (129 mg, 0.32 mmol) was added to a solution of 2-(4-fluorophenyl)-5-isopropoxy-6-(methylsulfonamido)benzofuran-3-carboxamide (125 mg, 0.31 mmol) in THF (3 mL) was stirred at r.t. for 1.5 h. The two batches were then combined and partitioned between EtOAc (50 mL) and water (10 mL). The organic phase was washed with sat'd NaHCO₃ and brine, dried over Na₂SO₄, filtered, and
25 concentrated to give a yellow oil. The residue was purified by silica gel chromatography (BIOTAGE® 25+S silica gel cartridge, gradient elution: 20% to 80% EtOAc/hexanes over 20 column volumes, fraction collection at λ = 320 nm) to give 48 mg (29% yield) of the title compound. ¹H NMR (300 MHz, CDCl₃) δ ppm 7.76 - 7.87 (m, 2 H) 7.71 (d, J = 5.86 Hz, 2 H) 7.53 (br. s., 1 H) 7.13 - 7.23 (m, 2 H)


6.97 (s, 1 H) 6.90 (br. s., 1 H) 4.74 (dt, $J = 12.08$, 6.04 Hz, 1 H) 2.93 (s, 3 H) 1.40 (d, $J = 6.22$ Hz, 6 H). LC/MS was performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. LC/MS method: solvent A = 5% CH₃CN/95% H₂O/0.1% NH₄OAc, solvent B = 95% CH₃CN/5%H₂O/0.1% NH₄OAc, start %B = 0, final %B = 100, gradient time = 2 min, stop time = 3 min, flow rate = 5 ml/min, column: XBridge C18 5 μ m 4.6 x 50 mm; HPLC R_t = 1.39 min, (ES+) m/z (MH⁺) = 423.



10 N-(2-(4-Fluorophenyl)-5-isopropoxy-3-(thiazol-2-yl)benzofuran-6-yl)methanesulfonamide

[00182] Chloroacetaldehyde (50% solution in water, 100 μ L, 0.79 mmol) was added to a stirred suspension of the intermediate 2-(4-fluorophenyl)-5-isopropoxy-6-(methylsulfonamido)benzofuran-3-carbothioamide (48 mg, 0.11 mmol) in ethanol (1.5 mL), and the reaction was brought to reflux (100 °C oil bath temp). After 4 h, additional chloroacetaldehyde solution (200 μ L, 1.6 mmol) was added and heating was continued overnight. The reaction was cooled to r.t., diluted with EtOAc (75 mL), washed with water (10 mL), sat'd NaHCO₃ (2 x 5 mL), and brine, dried over Na₂SO₄, filtered, and concentrated to give a brown oil. The residue was purified on silica gel (BIOTAGE® 12+M column, gradient elution 10% to 40% EtOAc/hexanes over 20 column volumes, fraction collection at $\lambda = 320$ nm) to give a colorless oil, 38 mg (75% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm 7.96 (d, $J = 3.29$ Hz, 1 H) 7.73 - 7.86 (m, 3 H) 7.56 (s, 1 H) 7.37 (d, $J = 3.29$ Hz, 1 H) 7.07 - 7.19 (m, 2 H) 6.98 (s, 1 H) 4.73 (spt, $J = 6.04$ Hz, 1 H) 2.96 (s, 3 H) 1.40 (d, $J = 5.86$ Hz, 7 H). An analytically pure sample was obtained by precipitation from Et₂O/hexanes to give a yellow ppt., which was triturated with Et₂O and air dried. LC/MS was performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. LC/MS method: solvent A = 5% CH₃CN/95% H₂O/0.1% NH₄OAc, solvent B = 95% CH₃CN/5%H₂O/0.1% NH₄OAc, start %B = 0, final %B = 100,

gradient time = 2 min, stop time = 3 min, flow rate = 5 ml/min, column: XBridge C18 5 μ m 4.6 x 50 mm; HPLC R_t = 1.69 min, (ES+) m/z (MH^+) = 447. Analytical HPLC were performed using a Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: solvent A = 5% CH_3CN /95% H_2O /0.1% TFA, solvent B = 95% CH_3CN /5% H_2O /0.1% TFA, start %B = 10, final %B = 100, gradient time = 15 min, stop time = 18 min, flow rate = 1 ml/min. Column: Waters Sunfire C-18, 4.6 x 150 mm, 3.5 μ m, R_t = 14.74 min, purity = 97%; column: Waters XBridge phenyl 4.6 x 150 mm, 3.5 μ m, R_t = 12.86 min, purity = 98%.




2-(4-Fluorophenyl)-N-methyl-5-(3-(methylsulfonylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00183] In a 1 dram vial with stir bar were combined 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (35 mg, 0.090 mmol), DMAP (33 mg, 0.27 mmol), EDC hydrochloride (26 mg, 0.14 mmol), and methanesulfonamide (25 mg, 0.26 mmol). DMF (0.5 mL) was added, the vial was capped, and the reaction was stirred at r.t. overnight. The reaction was filtered, purified by prep HPLC, and concentrated to give 30 mg (72% yield) of the title compound as a white powder. ^1H NMR (500 MHz, $DMSO-d_6$) δ ppm 12.36 (br. s., 1 H) 8.53 (d, J = 4.58 Hz, 1 H) 8.27 (s, 1 H) 7.97 - 8.05 (m, 2 H) 7.84 - 7.96 (m, 3 H) 7.77 - 7.82 (m, 1 H) 7.71 - 7.76 (m, 1 H) 7.56 (t, J = 7.78 Hz, 1 H) 7.40 (t, J = 8.85 Hz, 2 H) 3.17 (s, 3 H) 2.86 (d, J = 4.58 Hz, 3 H). LC/MS was performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. LC/MS method: solvent A = 10% CH_3CN /90% H_2O /0.1% TFA, solvent B = 90% CH_3CN /10% H_2O /0.1% TFA, start %B = 0, final %B = 100, gradient time = 2 min, stop time = 3 min, flow rate = 4 ml/min, column: Sunfire C18 5 μ m 4.6 x 50 mm; HPLC R_t = 1.56 min, (ES+) m/z (MH^+) = 467. Analytical HPLC were performed using a Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: solvent A = 5% CH_3OH /95% H_2O /10 mM NH_4HCO_3 , solvent B = 95% CH_3OH /5% H_2O /10 mM

NH₄HCO₃, start %B = 10, final %B = 100, gradient time = 15 min, stop time = 18 min, flow rate = 1 ml/min. Column: PHENOMENEX® Gemini C18, 4.6 mm, 3 μm, R_t = 11.93 min, purity = 100%; column: Waters XBridge phenyl 4.6 x 150 mm, 3.5 μm, R_t = 13.97 min, purity = 99%.


5



5-(3-(*tert*-Butylsulfonylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide


[00184] In a 1 dram vial with stir bar were combined 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (35 mg, 0.090 mmol), DMAP (33 mg, 0.27 mmol), EDC hydrochloride (26 mg, 0.14 mmol), and *tert*-butylsulfonamide (37 mg, 0.27 mmol). 1,2-Dichloroethane (1 mL) and DMF (0.3 mL) were added, the vial was capped, and the reaction was stirred at r.t. overnight. The reaction was concentrated, filtered, purified by prep HPLC, and concentrated on a SPEEDVAC® to give 14 mg (31% yield) of the title compound as a white powder. ¹H NMR (500 MHz, CDCl₃) δ ppm 8.12 (s, 1 H) 7.97 (s, 1 H) 7.91 (dd, *J* = 8.55, 5.19 Hz, 2 H) 7.84 (d, *J* = 7.63 Hz, 1 H) 7.79 (d, *J* = 7.32 Hz, 1 H) 7.46 - 7.59 (m, 3 H) 7.19 (t, *J* = 8.55 Hz, 2 H) 6.04 (br. s., 1 H) 2.99 (d, *J* = 4.58 Hz, 3 H) 1.54 (s, 9 H). LC/MS was performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. LC/MS method: solvent A = 10% CH₃CN/90% H₂O/0.1% TFA, solvent B = 90% CH₃CN/10%H₂O/0.1% TFA, start %B = 0, final %B = 100, gradient time = 2 min, stop time = 3 min, flow rate = 4 ml/min, column: Sunfire C18 5 μm 4.6 x 50 mm; HPLC R_t = 1.71 min, (ES+) *m/z* (MH⁺) = 509. Analytical HPLC were performed using a Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: solvent A = 5% CH₃OH/95% H₂O/10 mM NH₄HCO₃, solvent B = 95% CH₃OH/5% H₂O/10 mM NH₄HCO₃, start %B = 10, final %B = 100, gradient time = 15 min, stop time = 18 min, flow rate = 1 ml/min. Column: PHENOMENEX® Gemini C18, 4.6 mm, 3 μm, R_t = 16.49 min, purity =

100%; column: Waters XBridge phenyl 4.6 x 150 mm, 3.5 μ m, R_t = 15.35 min, purity = 100%.



5 2-(4-Fluorophenyl)-N-methyl-5-(3-(phenylsulfonylcarbamoyl)phenyl)benzofuran-3-carboxamide


[00185] In a 1 dram vial with stir bar were combined 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (35 mg, 0.090 mmol), DMAP (33 mg, 0.27 mmol), EDC hydrochloride (26 mg, 0.14 mmol), and benzenesulfonamide
 10 (43 mg, 0.27 mmol). 1,2-Dichloroethane (1 mL) and DMF (0.3 mL) were added, the vial was capped, and the suspension was stirred at r.t. overnight, over which time the solids dissolved. The reaction was concentrated, filtered, purified by prep HPLC, and concentrated to give 32 mg (67% yield) of the title compound as a white powder. ^1H NMR (500 MHz, DMSO- d_6) δ ppm 12.78 (br. s., 1 H) 8.52 (q, J = 4.48 Hz, 1 H) 8.24
 15 (s, 1 H) 7.97 - 8.06 (m, 4 H) 7.90 - 7.97 (m, 2 H) 7.85 (d, J = 7.94 Hz, 1 H) 7.74 - 7.81 (m, 2 H) 7.66 - 7.73 (m, 1 H) 7.63 (t, J = 7.63 Hz, 2 H) 7.58 (t, J = 7.63 Hz, 1 H) 7.40 (t, J = 8.85 Hz, 2 H) 2.87 (d, J = 4.58 Hz, 3 H). LC/MS was performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. LC/MS method: solvent A = 10% CH₃CN/90% H₂O/0.1% TFA, solvent B = 90%
 20 CH₃CN/10%H₂O/0.1% TFA, start %B = 0, final %B = 100, gradient time = 2 min, stop time = 3 min, flow rate = 4 ml/min, column: Sunfire C18 5 μ m 4.6 x 50 mm; HPLC R_t = 1.77 min, (ES+) m/z (MH^+) = 529. Analytical HPLC were performed using a Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: solvent A = 5% CH₃OH/95% H₂O/10 mM NH₄HCO₃,
 25 solvent B = 95% CH₃OH/5% H₂O/10 mM NH₄HCO₃, start %B = 10, final %B = 100, gradient time = 15 min, stop time = 18 min, flow rate = 1 ml/min. Column: PHENOMENEX® Gemini C18, 4.6 mm, 3 μ m, R_t = 15.70 min, purity = 100%; column: Waters XBridge phenyl 4.6 x 150 mm, 3.5 μ m, R_t = 14.90 min, purity = 99%.



2-(4-Fluorophenyl)-N-methyl-5-(3-


(methyl(phenylsulfonyl)carbamoyl)phenyl)benzofuran-3-carboxamide

- 5 **[00186]** In a 1 dram vial with stir bar were combined 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (35 mg, 0.090 mmol), DMAP (33 mg, 0.27 mmol), EDC hydrochloride (26 mg, 0.14 mmol), and *N*-methylbenzenesulfonamide (50 μ L, 0.26 mmol). 1,2-Dichloroethane (0.5 mL) and DMF (0.5 mL) were added, the vial was capped, and the reaction was stirred at r.t.
- 10 overnight. The reaction was filtered, purified by prep HPLC, and concentrated on a SPEEDVAC® to give 27 mg (55% yield) of the title compound as a white powder. ^1H NMR (500 MHz, CDCl_3) δ ppm 7.91 - 8.02 (m, 5 H) 7.75 - 7.82 (m, 2 H) 7.65 (t, J = 7.48 Hz, 1 H) 7.47 - 7.60 (m, 6 H) 7.15 - 7.24 (m, 2 H) 5.91 (d, J = 4.27 Hz, 1 H) 3.36 (s, 3 H) 3.04 (d, J = 4.88 Hz, 3 H). LC/MS was performed by using Shimadzu-
- 15 VP instrument with UV detection at 220 nm and Waters MICROMASS®. LC/MS method: solvent A = 10% $\text{CH}_3\text{CN}/90\%$ $\text{H}_2\text{O}/0.1\%$ TFA, Solvent B = 90% $\text{CH}_3\text{CN}/10\%\text{H}_2\text{O}/0.1\%$ TFA, start %B = 0, final %B = 100, gradient time = 2 min, stop time = 3 min, flow rate = 4 ml/min, column: Sunfire C18 5 μ m 4.6 x 50 mm; HPLC R_t = 1.89 min, (ES+) m/z (MH^+) = 543. Analytical HPLC were performed
- 20 using a Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: solvent A = 5% $\text{CH}_3\text{OH}/95\%$ $\text{H}_2\text{O}/10$ mM NH_4HCO_3 , solvent B = 95% $\text{CH}_3\text{OH}/5\%$ $\text{H}_2\text{O}/10$ mM NH_4HCO_3 , start %B = 10, final %B = 100, gradient time = 15 min, stop time = 18 min, flow rate = 1 ml/min. Column: PHENOMENEX® Gemini C18, 4.6 mm, 3 μ m, R_t = 17.42 min, purity = 92%;
- 25 column: Waters XBridge phenyl 4.6 x 150 mm, 3.5 μ m, R_t = 17.86 min, purity >90%.




5-(3-(1-(Cyclopropylsulfonylcarbamoyl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00187] In a 7 mL scintillation vial were combined 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (30 mg, 0.077 mmol), 1-amino-*N*-(cyclopropylsulfonyl)cyclopropanecarboxamide hydrochloride (20 mg, 0.083 mmol), and HATU (40 mg, 0.10 mmol). DMF (0.4 mL) and DIPEA (0.1 mL, 0.57 mmol) were added, the vial was capped, and the solution was stirred at r.t. for 45 min. The reaction was diluted with MeOH, filtered, purified by prep HPLC, and the collected fractions were concentrated on a SPEEDVAC® to afford the title compound (23 mg, 52% yield) as a white powder. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.99 (br. s., 1 H) 8.53 (q, *J* = 4.78 Hz, 1 H) 8.25 (br. s., 1 H) 8.00 (dd, *J* = 8.85, 5.49 Hz, 2 H) 7.93 (s, 1 H) 7.89 (t, *J* = 7.78 Hz, 2 H) 7.72 - 7.83 (m, 2 H) 7.58 (t, *J* = 7.48 Hz, 1 H) 7.40 (t, *J* = 8.85 Hz, 2 H) 7.07 (br. s., 1 H) 2.89 - 2.98 (m, 1 H) 2.87 (d, *J* = 4.58 Hz, 3 H) 1.35 - 1.56 (m, 2 H) 0.77 - 1.28 (m, 6 H). LC/MS was performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. LC/MS method: solvent A = 10% CH₃CN/90% H₂O/0.1% TFA, solvent B = 90% CH₃CN/10%H₂O/0.1% TFA, start %B = 0, final %B = 100, gradient time = 2 min, stop time = 3 min, flow rate = 4 ml/min, column: Sunfire C18 5 μm 4.6 x 50 mm; HPLC *R*_t = 1.59 min, (ES+) *m/z* (MH⁺) = 576. Analytical HPLC were performed using a Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: solvent A = 5% CH₃OH/95% H₂O/10 mM NH₄HCO₃, solvent B = 95% CH₃OH/5% H₂O/10 mM NH₄HCO₃, start %B = 10, final %B = 100, gradient time = 15 min, stop time = 18 min, flow rate = 1 ml/min. Column: PHENOMENEX® Gemini C18, 4.6 mm, 3 μm, *R*_t = 15.39 min, purity = 100%; column: Waters XBridge phenyl 4.6 x 150 mm, 3.5 μm, *R*_t = 14.50 min, purity = 100%.



5-(3-((1R,2S)-1-(Cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide


[00188] In a 7 mL scintillation vial were combined 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (30 mg, 0.077 mmol), (1R,2S)-1-amino-N-(cyclopropylsulfonyl)-2-vinylcyclopropanecarboxamide 4-methylbenzenesulfonate (30 mg, 0.075 mmol), and HATU (40 mg, 0.10 mmol). DMF (0.4 mL) and DIPEA (0.1 mL, 0.57 mmol) were added, the vial was capped, and the solution was stirred at r.t. for 45 min. The reaction was diluted with MeOH, filtered, purified by prep HPLC, and the collected fractions were concentrated on a SPEEDVAC® to afford the title compound (25 mg, 54% yield) as a white powder. ¹H NMR (500 MHz, CDCl₃) δ ppm 8.01 (s, 1 H) 7.97 (s, 1 H) 7.88 (dd, *J* = 8.85, 5.19 Hz, 2 H) 7.80 (d, *J* = 7.63 Hz, 1 H) 7.74 (d, *J* = 7.63 Hz, 1 H) 7.59 (br. s., 1 H) 7.52 (s, 2 H) 7.48 (t, *J* = 7.63 Hz, 1 H) 7.18 (t, *J* = 8.55 Hz, 2 H) 6.00 (d, *J* = 3.97 Hz, 1 H) 5.61 - 5.73 (m, 1 H) 5.39 (d, *J* = 17.09 Hz, 1 H) 5.20 (d, *J* = 10.99 Hz, 1 H) 3.02 (d, *J* = 4.88 Hz, 3 H) 2.91 - 2.99 (m, 1 H) 2.34 (q, *J* = 8.44 Hz, 1 H) 2.05 - 2.09 (m, 1 H) 1.49 (dd, *J* = 9.31, 5.95 Hz, 1 H) 1.41 (dd, *J* = 5.80, 4.58 Hz, 1 H) 1.30 - 1.35 (m, 1 H) 1.22 - 1.30 (m, 1 H) 1.04 - 1.12 (m, 1 H) 0.96 - 1.04 (m, 1 H). LC/MS was performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. LC/MS method: solvent A = 10% CH₃CN/90% H₂O/0.1% TFA, solvent B = 90% CH₃CN/10%H₂O/0.1% TFA, start %B = 0, final %B = 100, gradient time = 2 min, stop time = 3 min, flow rate = 4 ml/min, column: Sunfire C18 5 μm 4.6 x 50 mm; HPLC *R*_t = 1.73 min, (ES⁺) *m/z* (MH⁺) = 602. Analytical HPLC were performed using a Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: solvent A = 5% CH₃OH/95% H₂O/10 mM NH₄HCO₃, solvent B = 95% CH₃OH/5% H₂O/10 mM NH₄HCO₃, start %B = 10, final %B = 100, gradient time = 15 min, stop time = 18 min, flow rate = 1 ml/min. Column: PHENOMENEX® Gemini C18, 4.6 mm, 3 μm, *R*_t = 16.26 min, purity = 100%; column: Waters XBridge phenyl 4.6 x 150 mm, 3.5 μm, *R*_t = 15.28 min, purity = 100%.



2-(3-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzamido)-2-methylpropanoic acid

- [00189] HATU (450 mg, 1.18 mmol) was added to a suspension of 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (400 mg, 1.03 mmol), methyl 2-amino-2-methylpropanoate hydrochloride (180 mg, 1.17 mmol), and DIPEA (0.6 mL, 3.4 mmol) in DCE (10 mL). After 5 min, the solids had not dissolved. Add DMF (0.5 mL) and continue stirring the suspension at r.t. overnight. The reaction was then concentrated to give a thick suspension (DMF remained after concentration). Water and Et₂O were added and the flask swirled until a fine grey suspension was formed. The ppt. was collected by filtration, rinsed with 1 N HCl, water, and ether, and air dried to afford 550 mg (110% yield) of the title compound as a grey solid. LC/MS was performed on a Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. LC/MS method: solvent A = 5% CH₃CN/95% H₂O/10 mM NH₄OAc, solvent B = 95% CH₃CN/5% H₂O/10 mM NH₄OAc, start %B = 0, sin² %B = 100, gradient time = 2 min, stop time = 3 min, flow rate = 5 ml/min, column: XBridge C18 5 μm 4.6 x 50 mm; HPLC R_t = 1.49 min, (ES⁺) m/z (MH⁺) = 489. To a suspension of the crude ester from above (~0.1 mmol) in MeOH (7 mL)/H₂O (2.1 mL) in a 20 mL scintillation vial with stir bar was added 10 N NaOH soln. (0.4 mL, 4.00 mmol). The vial was capped, stirred at r.t. overnight, then quenched by pouring into 8 mL of 1 N HCl. A white ppt. formed. The suspension was extracted with EtOAc, and the insoluble grey solid was collected by filtration and air dried (61 mg). The organic phase was washed with brine, dried over Na₂SO₄, filtered, and concentrated to give a white powder. This was triturated with Et₂O and collected by filtration to give 360 mg of the white powder. Both crops of ppt. were identical by LC/MS and were combined to give 421 mg (86% over two steps) of the title compound as an off-white powder. ¹H NMR (300 MHz, CD₃OD) δ ppm 8.59 (s, 1 H) 8.50 (d, *J* = 3.29 Hz, 1 H) 8.10 - 8.16 (m, 1 H) 7.91 - 8.01 (m, 3 H) 7.83 (dd, *J* = 12.99, 7.87 Hz, 2 H) 7.64 - 7.74 (m, 2 H) 7.56 (t, *J* = 7.68 Hz, 1 H) 7.27

(t, $J = 8.78$ Hz, 2 H) 2.95 - 3.02 (m, 3 H) 1.62 (s, 6 H). LC/MS was performed on a Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. LC/MS method: solvent A = 5% CH₃CN/95% H₂O/10 mM NH₄OAc, solvent B = 95% CH₃CN/5%H₂O/10 mM NH₄OAc, start %B = 0, final %B = 100, gradient time = 2 min, stop time = 3 min, flow rate = 5 ml/min, column: XBridge C18 5 μ m 4.6 x 50 mm; HPLC R_t = 1.06 min, (ES+) m/z (MH^+) = 475. Analytical HPLC were performed using a Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, start %B = 10, final %B = 100, gradient time = 15 min, stop time = 18 min, flow rate = 1 ml/min. Column: Waters Sunfire C-18, 3.5 μ m 4.6 x 150 mm, R_t = 10.91 min, purity = 98%; column: Waters XBridge phenyl 3.5 μ m 4.6 x 150 mm, R_t = 10.21 min, purity = 98%.




5-(3-(1-(Dimethylamino)-2-methyl-1-oxopropan-2-ylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00190] A solution of dimethylamine in THF (2 molar, 0.10 mL, 0.20 mmol) was added to 2-(3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzamido)-2-methylpropanoic acid (17 mg, 0.036 mmol) and HATU (15 mg, 0.039 mmol) in a 1 dram vial. DMF (0.3 mL) was added, the vial was capped, and the homogeneous solution was stirred at r.t. for 1 h, at which point DIPEA (50 μ L, 0.29 mmol) was added. Stirring was continued for 3 h, at which point the reaction was filtered and purified directly by prep HPLC. Concentration of the collected fractions afforded the title compound as a white solid (13 mg, 71% yield). ¹H NMR (500 MHz, CD₃OD) δ ppm 8.09 - 8.17 (m, 1 H) 7.90 - 7.98 (m, 3 H) 7.86 (d, $J = 7.94$ Hz, 1 H) 7.79 - 7.84 (m, 1 H) 7.63 - 7.72 (m, 2 H) 7.57 (t, $J = 7.63$ Hz, 1 H) 7.20 - 7.32 (m, 2 H) 3.14 (br. s., 3 H) 2.98 (s, 6 H) 1.61 (s, 6 H). LC/MS was performed on a Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. LC/MS method: solvent A = 5% CH₃CN/95% H₂O/10 mM NH₄OAc, solvent B = 95%

CH₃CN/5% H₂O/10 mM NH₄OAc, start %B = 0, final %B = 100, gradient time = 2 min, stop time = 3 min, flow rate = 5 ml/min, column: XBridge C18 5 μm 4.6 x 50 mm; HPLC R_t = 1.29 min, (ES+) m/z (MH⁺) = 502. Analytical HPLC method: solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, solvent B = 95% CH₃CN/5%

- 5 H₂O/0.1% TFA, start %B = 10, final %B = 100, gradient time = 15 min, stop time = 18 min, flow rate = 1 ml/min. Column: Waters Sunfire C-18, 3.5 μm 4.6 x 150 mm, R_t = 14.80 min, purity = 100%; column: Waters XBridge phenyl 3.5 μm 4.6 x 150 mm, R_t = 10.37 min, purity = 100%.




10

5-(3-((Cis)-2-(4-chlorophenyl)cyclopentylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

- [00191]** In a 1 dram vial were combined 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (20 mg, 0.051 mmol), *cis*-2-(4-chlorophenyl)cyclopentanamine (14 mg, 0.072 mmol), and HATU (31 mg, 0.082 mmol). DMF (0.4 mL) and DIPEA (50 μL, 0.29 mmol) were added, and the vial was capped and stirred at r.t. for 2 h, then diluted with MeOH, filtered, and purify directly by prep HPLC. Concentration afforded the title compound (15 mg, 52% yield) as a fluffy white solid. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.47 - 8.59 (m, 1 H) 8.06 (d, *J* = 8.85 Hz, 1 H) 7.97 - 8.03 (m, 2 H) 7.86 (d, *J* = 1.83 Hz, 1 H) 7.75 - 7.82 (m, 2 H) 7.68 (s, 1 H) 7.65 (dd, *J* = 8.55, 1.83 Hz, 1 H) 7.45 - 7.53 (m, 2 H) 7.40 (t, *J* = 8.85 Hz, 2 H) 7.27 (s, 4 H) 4.60 - 4.71 (m, *J* = 7.67, 7.67, 7.55, 7.32 Hz, 1 H) 3.33 - 3.41 (m, 1 H) 2.87 (d, *J* = 4.58 Hz, 3 H) 1.99 - 2.15 (m, 3 H) 1.89 - 1.98 (m, 1 H) 1.72 - 1.82 (m, 1 H) 1.57 - 1.71 (m, 1 H). LC/MS was performed on a Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. LC/MS method: solvent A = 10% CH₃CN/90% H₂O/0.1% TFA, solvent B = 90% CH₃CN/10% H₂O/0.1% TFA, start %B = 0, final %B = 100, gradient time = 2 min, stop time = 3 min, flow rate = 4 ml/min, column: Sunfire C18 5 μm 4.6 x 50 mm;


HPLC R_t = 2.02 min, (ES+) m/z (MH^+) = 567. Analytical HPLC method: solvent A = 5% CH_3CN /95% H_2O /0.1% TFA, solvent B = 95% CH_3CN /5% H_2O /0.1% TFA, start %B = 10, final %B = 100, gradient time = 15 min, stop time = 18 min, flow rate = 1 ml/min. Column: Waters Sunfire C-18, 3.5 μm 4.6 x 150 mm, R_t = 15.42 min, purity = 98%; column: Waters XBridge phenyl 3.5 μm 4.6 x 150 mm, R_t = 13.74 min, purity = 97%.



5-(3-(Biphenyl-2-ylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide


[00192] In a 1 dram vial were combined 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (30 mg, 0.077 mmol), biphenyl-2-amine (17 mg, 0.10 mmol), and HATU (40 mg, 0.105 mmol). DMF (0.4 mL) and DIPEA (50 μL , 0.29 mmol) were added, and the vial was capped and stirred at r.t. for overnight, then diluted with MeOH, filtered, and purified directly by prep HPLC. Concentration afforded the title compound (17 mg, 41% yield) as a fluffy white solid. ^1H NMR (500 MHz, $DMSO-d_6$) δ ppm 9.96 (s, 1 H) 8.53 (q, J = 4.58 Hz, 1 H) 7.96 - 8.06 (m, 3 H) 7.85 - 7.91 (m, 2 H) 7.80 (d, J = 8.55 Hz, 1 H) 7.77 (d, J = 7.32 Hz, 1 H) 7.70 (dd, J = 8.55, 1.83 Hz, 1 H) 7.57 - 7.61 (m, 1 H) 7.56 (d, J = 6.10 Hz, 1 H) 7.48 (d, J = 7.32 Hz, 2 H) 7.36 - 7.46 (m, 7 H) 7.31 (t, J = 7.48 Hz, 1 H) 2.87 (d, J = 4.88 Hz, 3 H). LC/MS was performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. LC/MS method: solvent A = 10% CH_3CN /90% H_2O /0.1% TFA, solvent B = 90% CH_3CN /10% H_2O /0.1% TFA, start %B = 0, final %B = 100, gradient time = 2 min, stop time = 3 min, flow rate = 4 ml/min, column: Sunfire C18 5 μm 4.6 x 50 mm; HPLC R_t = 2.02 min, (ES+) m/z (MH^+) = 541. Analytical HPLC method: solvent A = 5% CH_3CN /95% H_2O /0.1% TFA, solvent B = 95% CH_3CN /5% H_2O /0.1% TFA, start %B = 10, final %B = 100, gradient time = 15 min, stop time = 18 min, flow rate = 1 ml/min. Column: Waters

Sunfire C-18, 3.5 μ m 4.6 x 150 mm, R_t = 15.37 min, purity = 100%; column: Waters XBridge phenyl 3.5 μ m 4.6 x 150 mm, R_t = 13.75 min, purity = 100%.




5 5-(3-(Benzyl(methyl)carbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00193] DIPEA (50 μ L, 0.29 mmol) and *N*-methylbenzylamine (20 μ L, 0.16 mmol) were added to a stirred suspension of 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (20 mg, 0.051 mmol) and HATU (25 mg, 0.066 mmol) in DMF (0.5 mL) and the reaction was stirred at r.t. overnight. The reaction was then diluted with MeOH, filtered, purified by prep HPLC, and concentrated to give the title compound as a tan powder (12 mg, 47% yield). ^1H NMR (500 MHz, DMSO- d_6) δ ppm 8.50 (br. s., 1 H) 8.01 (dd, J = 8.39, 5.65 Hz, 2 H) 7.66 - 7.93 (m, 5 H) 7.58 (br. s., 1 H) 7.42 - 7.50 (m, 1 H) 7.35 - 7.42 (m, 4 H) 7.31 (d, J = 5.80 Hz, 1 H) 7.23 (d, J = 4.58 Hz, 1 H) 4.72 (br. s., 1 H) 4.54 (br. s., 1 H) 2.83 - 3.00 (m, 6 H). LC/MS was performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. LC/MS method: solvent A = 10% CH₃CN/90% H₂O/0.1% TFA, solvent B = 90% CH₃CN/10% H₂O/0.1% TFA, start %B = 0, final %B = 100, gradient time = 2 min, stop time = 3 min, flow rate = 4 ml/min, column: Sunfire C18 5 μ m 4.6 x 50 mm; HPLC R_t = 1.85 min, (ES+) m/z (MH⁺) = 493. Analytical HPLC method: solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, start %B = 10, final %B = 100, gradient time = 15 min, stop time = 18 min, flow rate = 1 ml/min. Column: Waters Sunfire C-18, 3.5 μ m 4.6 x 150 mm, R_t = 16.26 min, purity = 99%; column: Waters XBridge phenyl 3.5 μ m 4.6 x 150 mm, R_t = 12.81 min, purity = 98%.



2-(4-Fluorophenyl)-5-(3-(isoindoline-2-carbonyl)phenyl)-N-methylbenzofuran-3-carboxamide


[00194] Isoindoline (20 μ L, 0.18 mmol) was added to a stirred suspension of 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (20 mg, 0.051 mmol), HATU (25 mg, 0.066 mmol), and DIPEA (50 μ L, 0.29 mmol) in DMF (0.5 mL). The reaction was stirred at r.t. overnight. The reaction was then diluted with MeOH and an off-white ppt. formed. The ppt. was collected by filtration, triturated with MeOH, and air dried to afford the title compound (17 mg, 68% yield). ^1H NMR (500 MHz, DMSO- d_6) δ ppm 8.50 (q, J = 4.58 Hz, 1 H) 7.99 - 8.05 (m, 2 H) 7.90 - 7.95 (m, 2 H) 7.85 (dt, J = 6.10, 2.44 Hz, 1 H) 7.77 - 7.81 (m, 1 H) 7.73 - 7.77 (m, 1 H) 7.58 - 7.64 (m, 2 H) 7.36 - 7.45 (m, 3 H) 7.30 - 7.34 (m, 1 H) 7.29 (s, 2 H) 4.91 (s, 2 H) 4.84 (s, 2 H) 2.86 (d, J = 4.88 Hz, 3 H). LC/MS was performed on a Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. LC/MS method: solvent A = 10% CH_3CN /90% H_2O /0.1% TFA, solvent B = 90% CH_3CN /10% H_2O /0.1% TFA, start %B = 0, final %B = 100, gradient time = 3 min, stop time = 4 min, flow rate = 4 ml/min, column: Sunfire C18 5 μ m 4.6 x 50 mm; HPLC R_t = 2.48 min, (ES+) m/z (MH^+) = 491. Analytical HPLC method: solvent A = 5% CH_3CN /95% H_2O /0.1% TFA, solvent B = 95% CH_3CN /5% H_2O /0.1% TFA, start %B = 10, final %B = 100, gradient time = 15 min, stop time = 18 min, flow rate = 1 ml/min. Column: Waters Sunfire C-18, 3.5 μ m 4.6 x 150 mm, R_t = 13.81 min, purity = 100%; column: Waters XBridge phenyl 3.5 μ m 4.6 x 150 mm, R_t = 13.81 min, purity = 100%.



2-(4-Fluorophenyl)-N-methyl-5-(3-(2-phenylpyrrolidine-1-carbonyl)phenyl)benzofuran-3-carboxamide

[00195] 2-Phenylpyrrolidine (20 mg, 0.14 mmol) was added to a stirred suspension of 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (20 mg, 0.051 mmol), HATU (25 mg, 0.066 mmol), and DIPEA (50 μ L, 0.29 mmol) in DMF (0.5 mL). The reaction was stirred at r.t. overnight. The reaction was then diluted with MeOH, filtered, and purified by prep HPLC. Concentration afforded the title compound (21 mg, 78% yield) as a light pink solid. ^1H NMR ($\sim$ 3:2 ratio of amide rotamers, 500 MHz, DMSO- d_6) δ ppm 8.44 - 8.56 (m, 1 H) 7.96 - 8.07 (m, 2 H) 7.74 - 7.89 (m, 3 H) 7.56 - 7.67 (m, 2 H) 7.30 - 7.45 (m, 5.4 H) 7.16 - 7.29 (m, 2.6 H) 7.09 (d, J = 7.02 Hz, 1 H) 5.19 (t, J = 6.71 Hz, 0.6 H) 4.98 (d, J = 6.41 Hz, 0.4 H) 3.75 - 3.92 (m, 1.4 H) 3.53 - 3.64 (m, 0.6 H) 2.87 (m, 3 H) 2.40 (dd, J = 12.36, 6.56 Hz, 0.6 H) 2.30 - 2.38 (m, 0.4 H) 1.73 - 1.92 (m, 3 H). LC/MS was performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS[®]. LC/MS method: solvent A = 10% CH₃CN/90% H₂O/0.1% TFA, solvent B = 90% CH₃CN/10% H₂O/0.1% TFA, start %B = 0, final %B = 100, gradient time = 3 min, stop time = 4 min, flow rate = 4 ml/min, column: Sunfire C18 5 μ m 4.6 x 50 mm; HPLC R_t = 1.86 min, (ES+) m/z (MH^+) = 519. Analytical HPLC method: solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, start %B = 10, final %B = 100, gradient time = 15 min, stop time = 18 min, flow rate = 1 ml/min. Column: Waters Sunfire C-18, 3.5 μ m 4.6 x 150 mm, R_t = 14.38 min, purity = 99%; column: Waters XBridge phenyl column 3.5 μ m 4.6 x 150 mm, R_t = 13.01 min, purity = 99%.


25



2-(4-Fluorophenyl)-5-(3-(3-(4-fluorophenyl)pyrrolidine-1-carbonyl)phenyl)-N-methylbenzofuran-3-carboxamide


[00196] 3-(4-Fluorophenyl)pyrrolidine hydrochloride (25 mg, 0.12 mmol) was added to a stirred suspension of 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (20 mg, 0.051 mmol), HATU (25 mg, 0.066 mmol), and DIPEA (50 μ L, 0.29 mmol) in DMF (0.5 mL). The reaction was stirred at r.t. overnight, then diluted with MeOH, filtered, and purified by prep HPLC. Concentration afforded the title compound (22 mg, 79% yield) as a pink solid.

¹H NMR (~1:1 ratio of amide rotamers, 500 MHz, DMSO-d₆) δ ppm 8.44 - 8.54 (m, 1 H) 7.98 - 8.06 (m, 2 H) 7.66 - 7.91 (m, 5 H) 7.52 - 7.61 (m, 2 H) 7.36 - 7.44 (m, 3 H) 7.33 (dd, J = 8.55, 5.49 Hz, 1 H) 7.18 (t, J = 8.85 Hz, 1 H) 7.12 (t, J = 8.85 Hz, 1 H) 4.01 (dd, J = 11.14, 7.17 Hz, 0.5 H) 3.72 - 3.82 (m, 1.5 H) 3.56 - 3.69 (m, 1.5 H) 3.36 - 3.55 (m, 1.5 H) 2.87 (d, J = 4.58 Hz, 1.5 H) 2.84 (d, J = 4.58 Hz, 1.5 H) 2.27 - 2.34 (m, 0.5 H) 2.24 (dd, J = 6.56, 3.51 Hz, 0.5 H) 2.04 - 2.12 (m, 0.5 H) 2.00 (dd, J = 19.84, 10.38 Hz, 0.5 H). LC/MS was performed on a Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. LC/MS method: solvent A = 10% CH₃CN/90% H₂O/0.1% TFA, solvent B = 90% CH₃CN/10% H₂O/0.1% TFA, start %B = 0, final %B = 100, gradient time = 3 min, stop time = 4 min, flow rate = 4 ml/min, column: Sunfire C18 5 μ m 4.6 x 50 mm; HPLC R_t = 1.89 min, (ES+) m/z (MH⁺) = 537. Analytical HPLC method: solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, start %B = 10, final %B = 100, gradient time = 15 min, stop time = 18 min, flow rate = 1 ml/min. Column: Waters Sunfire C-18, 3.5 μ m 4.6 x 150 mm, R_t = 14.43 min, purity = 99%; column: Waters XBridge phenyl 3.5 μ m 4.6 x 150 mm, R_t = 13.18 min, purity = 99%.




5-(3-(*tert*-Butylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00197] DIEA (50 μ L, 0.29 mmol) was added to a suspension of 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (50 mg, 0.13 mmol) and HATU (60 mg, 0.16 mmol) in DMF (0.5 mL). The solids dissolved over 5 min, at which point *tert*-butylamine (20 μ L, 0.19 mmol) was added. The solution was stirred at r.t. for 1 h, then diluted with CH₃CN (1 mL), filtered, purified by prep HPLC, concentrated, and dried in a vacuum oven over the weekend at 40 °C to give the title compound (39 mg, 69% yield) as a white powder. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.53 (q, J = 4.37 Hz, 1 H) 8.08 (s, 1 H) 8.01 (dd, J = 8.24, 5.80 Hz, 2 H) 7.92 (d, J = 7.93 Hz, 2 H) 7.84 (d, J = 7.63 Hz, 1 H) 7.77 - 7.82 (m, 2 H) 7.73 - 7.77 (m, 1 H) 7.55 (t, J = 7.63 Hz, 1 H) 7.40 (t, J = 8.85 Hz, 2 H) 2.87 (d, J = 4.58 Hz, 3 H) 1.42 (s, 9 H). ¹³C NMR (125 MHz, DMSO-d₆) δ ppm 166.20 (s) 163.22 (s) 162.66 (d, J = 246 Hz) 152.56 (s) 152.52 (s) 140.06 (s) 136.53 (s) 135.76 (s) 129.38 (d, J = 12 Hz) 129.36 (s) 128.70 (s) 127.86 (s) 126.27 (s) 125.86 (s) 125.70 (d, J = 2.5 Hz) 124.83 (s) 118.90 (s) 115.93 (d, J = 20 Hz) 113.88 (s) 111.60 (s) 50.85 (s) 28.60 (s) 26.19 (s). LC/MS method: solvent A = 5% CH₃CN/95% H₂O/10 mM NH₄OAc, solvent B = 95% CH₃CN/5%H₂O/10 mM NH₄OAc, start %B = 0, final %B = 100, gradient time = 2 min, stop time = 3 min, flow rate = 5 ml/min, column: XBridge C18 5 μ m 4.6 x 50 mm; HPLC R_t = 1.57, (ES-) m/z (M^+) = 443. Analytical HPLC method: solvent A = 5% CH₃CN/95% H₂O/0.1% TFA, solvent B = 95% CH₃CN/5% H₂O/0.1% TFA, start %B = 10, final %B = 100, gradient time = 15 min, stop time = 18 min, flow rate = 1 ml/min. column: Waters Sunfire C-18, 3.5 μ m 4.6 x 150 mm, R_t = 11.71 min, purity = 100%; column: Waters XBridge phenyl column 3.5 μ m 4.6 x 150 mm, R_t = 9.53 min, purity = 100%.



2-(4-Fluorophenyl)-5-hydroxy-N-methyl-6-nitrobenzofuran-3-carboxamide

[00198] To a mixture of 2-(4-fluorophenyl)-5-isopropoxy-N-methyl-6-nitrobenzofuran-3-carboxamide (210.5 mg, 0.565 mmol) in CH₂Cl₂ (14 mL) at 0 °C under N₂ was added trichloroborane (1.70 mL, 1.7 mmol) (1M solution in CH₂Cl₂). The mixture was then stirred at r.t. for 17 hr. The mixture was evaporated. The reddish orange residue was added 7 ml H₂O, and then 3.5 ml 1N HCl, and left standing until the solid turned yellow. The yellow solid product was then filtered and washed with 3 x 3 ml H₂O and dried (182 mg, 93%). ¹H NMR (500 MHz, DMSO-d₆) δ 10.18 (broad s, 1H), 8.53 (m, 1H), 8.31 (s, 1H), 7.98 (apparent dd, *J* = 8.85, 5.49, 2H), 7.43 (apparent t, *J* = 8.85, 2H), 7.28 (s, 1H), 2.84 (appeared as d, *J* = 4.58, 3H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) *m/z* (M+H)⁺ = 331.21, HPLC *R*_t = 1.442 min.




20 2-(4-Fluorophenyl)-3-(methanecarbonyl)-6-nitrobenzofuran-5-yl
trifluoromethanesulfonate


[00199] To a mixture of 2-(4-fluorophenyl)-5-hydroxy-N-methyl-6-nitrobenzofuran-3-carboxamide (100 mg, 0.303 mmol) in CH₂Cl₂ (4 mL) at r.t. under N₂ was added triethylamine (0.084 mL, 0.606 mmol). The mixture was then cooled to 0 °C, and then added 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (162 mg, 0.454 mmol). The orange suspension was then stirred at r.t. for 23 hr. The mixture was evaporated. The

grayish-green residue was added 3 ml H₂O, the solid product filtered and washed with 3 x 3 ml H₂O and dried (130.8 mg, 89%). ¹H NMR (500 MHz, DMSO-d₆) δ 8.84 (s, 1H), 8.62 (broad s, 1H), 8.02 (td, *J* = 5.65, 2.44, 2H), 7.96 (s, 1H), 7.48 (td, *J* = 8.77, 2.59, 2H), 2.85 (appeared as d, *J* = 3.97, 3H). LC/MS were performed by using
 5 Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μm, C18, 3.0 x 50 mm; (ES+) *m/z* (M+H)⁺ = 463.25, HPLC *R*_t = 1.700 min.

10




[00200] General procedure: A mixture of 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (or the 6-nitro analog) (0.3 mmol, 1 equiv.), 3-boronobenzoic acid (1.5 equiv.), cesium carbonate (1.7
 15 equiv.) and Pd(PPh₃)₄ (0.1 equiv.) in a mixture of H₂O (0.6 mL)/1,4-dioxane (3.00 mL) under N₂ was stirred at 90 °C for about 1.5 to 5 hr. The mixture was cooled to r.t. and diluted with 3 ml 1,4-dioxane. The mixture was filtered through a Whatman PTFE 4.5 μm disk, and concentrated. The mixture was added 4 ml 1N HCl, diluted with 5 ml H₂O. The precipitates were filtered and washed with 3 x 4 ml H₂O, and
 20 dried. The crude material was purified as indicated or used for the amide coupling step without further purification. To a mixture of 3-(benzofuran-5-yl)benzoic acid derivative obtained from above (0.074 mmol, 1 equiv.), amine (1.5 equiv.) and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethylisouronium tetrafluoroborate (2 equiv.) in DMF (1 mL) at r.t. under N₂ was added N,N-diisopropylethylamine (3
 25 equiv.). The mixture was stirred at r.t. for about 23 hr. The mixture was diluted with MeOH and purified as indicated, *e.g.*, by Shimadzu-VP preparative reverse phase HPLC.



4-Fluoro-3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid.


[00201] ^1H NMR (500 MHz, DMSO- d_6) δ 13.17 (s, 1H), 8.51 (q, J = 4.27, 1H), 8.13 (dd, J = 7.78, 1.98, 1H), 8.01 (apparent dd, J = 8.70, 5.34, 3H), 7.81 (d, J = 8.54, 1H), 7.80 (s, 1H), 7.61 (d, J = 8.54, 1H), 7.49 (dd, J = 10.07, 8.85, 1H), 7.41 (apparent t, J = 8.85, 2H), 2.85 (appeared as d, J = 4.58, 3H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μm , C18, 3.0 x 50 mm; (ES+) m/z ($M+H$)⁺ = 408.29, HPLC R_t = 1.693 min.



15 5-(2-Fluoro-5-(1-phenylcyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide


[00202] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 8.79 - 9.35 min. (UV detection at 220 nm). ^1H NMR (500 MHz, DMSO- d_6) δ 9.33 (s, 1H), 8.51 (q, J = 4.58, 1H), 8.15 (dd, J = 7.48, 2.29, 1H), 8.00 (dd, J = 9.00, 5.34, 2H), 7.97 (m, 1H), 7.83 (s, 1H), 7.82 (d, J = 8.60, 1H), 7.64 (d, J = 8.55, 1H), 7.46 (dd, J = 10.22, 8.70, 1H), 7.41 (t, J = 9.00, 2H), 7.29 (t, J = 7.63, 1H), 7.28 (d, J = 7.32, 1H), 7.23 (apparent d, J = 7.10, 2H), 7.17 (t, J = 7.17, 1H), 2.85 (appeared as d, J = 4.58, 3H), 1.30 (appeared as d, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and

Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 523.44, HPLC R_t = 1.803 min.




5-(2-Fluoro-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

- 10 **[00203]** Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 8.47 - 9.09 min. (UV detection at 220 nm). ¹H NMR
- 15 (500 MHz, CD₃OD, appeared as a mixture of two isomers) δ 8.06-8.04 (m, 1H), 8.00-7.97 (m, 2H), 7.90-7.87 (m, 2H), 7.70 (d, *J* = 8.50, major) and 7.69 (d, *J* = 8.50, minor) (1H), 7.63-7.62 (m, 1H), 7.36-7.27 (overlapping m, 3H), 3.23 (d, *J* = 7.02, major) and 3.23-3.22 (d, minor) (2H), 2.98 (s, major) and 2.97 (s, minor) (3H), 1.97 (m, 1H), 1.00 (d, *J* = 6.71, major) and 0.99 (d, *J* = 6.71, minor) (6H). LC/MS were
- 20 performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 463.38, HPLC R_t =
- 25 1.772 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 um, 4.6 x 150 mm, R_t = 8.85 min; Column:
- 30 XBridge phenyl 3.5 um, 4.6 x 150 mm, R_t = 6.44 min.




5-(2-Chloro-5-(1-phenylcyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

- 5 **[00204]** Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 9.28 - 9.85 min. (UV detection at 220 nm). ¹H NMR
- 10 (500 MHz, CD₃OD, appeared as a mixture of two isomers) δ 9.36 (broad s, 1H), 7.98-7.94 (overlapping m, 3H), 7.85 (dd, *J* = 8.39, 2.29, major) and 7.86-7.83 (dd, minor) (1H), 7.75 (d, *J* = 1.83, major) and 7.75-7.74 (d, minor) (1H), 7.66 (d, *J* = 8.55, major) and 7.66-7.64 (d, minor) (1H), 7.633 (d, *J* = 8.00, major) and 7.626 (d, *J* = 8.50, minor) (1H), 7.48 (dd, *J* = 8.55, 1.83, major) and 7.49-7.47 (dd, minor) (1H),
- 15 7.29-7.25 (overlapping m, 6H), 7.17 (m, 1H), 2.95 (s, major) and 2.94 (s, minor) (3H), 1.36-1.34 (appeared as d, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time
- 20 = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) *m/z* (M+H)⁺ = 539.37, 541.38, HPLC *R*_t = 1.868 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time =
- 25 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, *R*_t = 10.84 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, *R*_t = 8.37 min.



5-(2-Chloro-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide


[00205] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 9.01 - 9.47 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD, appeared as a mixture of two isomers) δ 7.98 (major) and 7.97 (minor) (dd, 2H), 7.91 (d, J = 2.14, major) and 7.91-7.90 (d, minor) (1H), 7.82 (dd, J = 8.24, 2.14, major) and 7.82 -7.80 (dd, minor) (1H), 7.75 (m, 1H), 7.65 (dd, J = 16, 8.39, major) and 7.64 (dd, J = 16.5, 8.55, minor) (2H), 7.49 (dd, J = 8.24, 1.83, major) and 7.49-7.47 (dd, minor) (1H), 7.27 (t, J = 8.85, major) and 7.29-7.25 (apparent m, minor) (2H), 3.22 (d, J = 7.02, major) and 3.21 (d, J = 7.02, major) (2H), 2.96 (s, major) and 2.95 (s, minor) (3H), 1.95 (m, 1H), 0.98 (d, J = 6.71, major) and 0.97 (d, J = 6.71, minor) (6H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 479.33, 481.36, HPLC R_t = 1.830 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 9.66 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 7.19 min.



3-(2-(4-Fluorophenyl)-3-(methoxycarbonyl)-6-nitrobenzofuran-5-yl)-4-methoxybenzoic acid

[00206] LC/MS were performed by using Shimadzu-VP instrument with UV
 5 detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES⁺) m/z (M+H)⁺ = 465.31, HPLC R_t = 1.568 min.


10



2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-methoxyphenyl)-N-methyl-6-nitrobenzofuran-3-carboxamide

[00207] Purification by Shimadzu-VP preparative reverse phase HPLC using the
 15 separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.79 - 8.36 min. (UV detection at 220 nm). ¹H NMR (500 MHz, DMSO-d₆) δ 8.62 (q, J = 4.48, 1H), 8.48 (s, 1H), 8.46 (t, J = 5.80, 1H),
 20 8.05 (dd, J = 9.00, 5.34, 2H), 7.96 (dd, 1H), 7.95 (apparent s, 1H), 7.68 (s, 1H), 7.46 (t, J = 8.85, 2H), 7.14 (d, J = 8.55, 1H), 3.69 (s, 3H), 3.11 (broad d, 2H), 2.83 (appeared as d, J = 4.58, 3H), 1.87 (m, 1H), 0.91 (d, J = 6.71, 6H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1%
 25 TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column:


XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 520.40, HPLC R_t = 1.688 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 7.93 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 6.30 min.



10 3-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)-6-nitrobenzofuran-5-yl)benzoic acid.

[00208] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 6.98 - 7.51 min. (UV detection at 220 nm). ¹H NMR (500 MHz, DMSO-d₆) δ 13.17 (s, 1H), 8.60 (m, 1H), 8.54 (s, 1H), 8.08-8.05 (overlapping m, 2H), 8.02 (d, J = 7.63, 1H), 7.95 (s, 1H), 7.74 (s, 1H), 7.67-7.61 (overlapping m, 2H), 7.46 (apparent t, J = 8.85, 2H), 2.84 (appeared as d, J = 4.58, 3H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 435.27, HPLC R_t = 1.588 min.

25




2-(4-Fluorophenyl)-N-methyl-6-nitro-5-(3-(1-phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00209] 2-(4-Fluorophenyl)-N-methyl-6-nitro-5-(3-(1-

phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide was prepared as

5 described in the general procedure. The reaction mixture was concentrated, and then added excess water. The off white precipitates of the product were filtered, washed with 3 times of water and dried. ¹H NMR (500 MHz, DMSO-d₆) δ 9.31 (s, 1H), 8.60 (m, 1H), 8.55 (s, 1H), 8.05 (m, 2H), 7.99-7.97 (overlapping m, 2H), 7.75 (s, 1H), 7.59-7.53 (overlapping m, 2H), 7.46 (t, *J* = 8.70, 2H), 7.29 (t, *J* = 7.02, 2H), 7.24 (s, 1H), 7.23 (d, *J* = 7.02, 1H), 7.17 (t, *J* = 6.71, 1H), 2.83 (s, 3H), 1.29 (appeared as d, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, 10 15 Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) *m/z* (M+H)⁺ = 550.45, HPLC R_t = 1.738 min.



6-Amino-2-(4-fluorophenyl)-N-methyl-5-(3-(1-

phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide


[00210] 2-(4-Fluorophenyl)-N-methyl-6-nitro-5-(3-(1-

phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide (83.3 mg, 0.152

mmol) under N₂ at r.t. was dissolved in DMF (2 ml) and then added ethyl acetate (10 mL). The mixture remained as a clear light brown solution. The mixture was added

25 palladium (97 mg, 0.045 mmol, 5%/C), flushed with H₂ using a balloon, and the mixture stirred under H₂ for about 8 hr. The mixture was diluted with EtOAc, and filtered through a Whatman PTFE 45 uM disk. The filtrate was evaporated. The residue was titrated with 3 x 1 ml Et₂O (the Et₂O solution was removed by using a pipette), and the light orange solid product dried (64.4 mg, 82%). ¹H NMR (500


MHz, DMSO-d₆) δ 9.26 (s, 1H), 8.32 (q, J = 4.17, 1H), 7.94-7.89 (overlapping m, 3H), 7.97 (s, 1H), 7.62 (d, J = 6.8, 1H), 7.58 (q, 1H), 7.34 (t, J = 8.70, 2H), 7.29 (t, 1H), 7.28 (d, J = 7.50, 1H), 7.23 (s, 2H), 7.227 (d, J = 8.00, 1H), 7.17 (t, J = 7.17, 1H), 6.99 (s, 1H), 5.09 (s, 2H), 2.79 (appeared as d, J = 3.97, 3H), 1.29 (appeared as d, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 520.39, HPLC R_t = 1.497 min.



2-(4-Fluorophenyl)-6-(2-methoxyacetamido)-N-methyl-5-(3-(1-phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide


[00211] To a mixture of 2-methoxyacetic acid (10.40 mg, 0.115 mmol) in THF (3 mL) at r.t. under N₂ was added 1,1'-carbonyldiimidazole (CDI) (28.1 mg, 0.173 mmol). The mixture was stirred at 55 °C for 1 hr. The mixture was then transferred to a flask containing 6-amino-2-(4-fluorophenyl)-N-methyl-5-(3-(1-phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide (30 mg, 0.058 mmol) at r.t. under N₂. 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) (0.035 mL, 0.231 mmol) was then added and the mixture was stirred at 55 °C for 2 hr 35 min. The mixture was then left standing at r.t. overnight. The mixture was re-stirred at 55 °C for 3 hr. The mixture was cooled to r.t., diluted with MeOH and purified by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.28 - 7.84 min. (UV detection at 220 nm). ¹H NMR (500 MHz, DMSO-

- d₆) δ 9.29 (s, 1H), 9.04 (s, 1H), 8.49 (q, *J* = 4.58, 1H), 8.31 (s, 1H), 8.03-8.00 (overlapping m, 3H), 7.98 (m, 1H), 7.59 (s, 1H), 7.63 (s, 1H), 7.625 (d, *J* = 2.44, 1H), 7.40 (t, *J* = 9.00, 2H), 7.28 (apparent t, *J* = 7.63, 2H), 7.23 (apparent d, 2H), 7.17 (t, *J* = 7.17, 1H), 3.90 (s, 2H), 3.18 (s, 3H), 2.83 (appeared as d, *J* = 4.58, 3H), 1.28 (s, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μm, C18, 3.0 x 50 mm; (ES⁺) *m/z* (M+H)⁺ = 592.49, HPLC *R*_t = 1.652 min.



3-(*tert*-Butoxycarbonylamino)-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid


- [00212] LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μm, C18, 3.0 x 50 mm; (ES⁺) *m/z* (M - Me₂CCH₂ + H)⁺ = 449.35, HPLC *R*_t = 1.808 min.



tert-Butyl 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-5-(isobutylcarbamoyl)phenylcarbamate

- [00213] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90%

MeOH-10% H₂O-0.1% TFA, Start %B = 70, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.13 - 7.93 min. (UV detection at 220 nm). ¹H NMR (500 MHz, DMSO-d₆) δ 9.57 (s, 1H), 8.55 (dt, *J* = 10.38, 5.19, 1H), 8.50 (broad s, 1H), 8.01-7.98 (m, 3H), 7.89 (s, 1H), 7.86-7.85 (m, 1H), 7.81 (apparent d, 1H), 7.75 (s, 1H), 7.70 (dd, *J* = 8.55, 1.83, 1H), 7.41 (apparent t, *J* = 8.85, 2H), 3.11 (t, *J* = 6.41, 2H), 2.87 (appeared as d, *J* = 4.58, 3H), 1.88 (ddd, *J* = 13.50, 6.64, 6.41, 1H), 1.55 (s) and 1.51 (s) (9H), 0.92 (d, *J* = 6.50, major) and 0.91 (d, *J* = 6.50, minor) (6H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) *m/z* (M+H)⁺ = 560.40, HPLC *R*_t = 1.898 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 70, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 um, 4.6 x 150 mm, *R*_t = 5.77 min; Column: XBridge phenyl 3.5 um, 4.6 x 150 mm, *R*_t = 3.70 min.




2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)phenyl)-N-methyl-6-nitrobenzofuran-3-carboxamide

[00214] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.89 - 8.57 min. (UV detection at 220 nm). ¹H NMR (500 MHz, DMSO-d₆) δ 8.59 (m, 2H), 8.54 (s, 1H), 8.05 (m, 2H), 7.93 (d, *J* = 7.63,

1H), 7.90 (s, 1H), 7.75 (s, 1H), 7.57 (apparent t, $J = 7.63$, 1H), 7.54 (apparent t, 1H), 7.46 (apparent t, $J = 8.85$, 2H), 3.11 (t, $J = 6.41$, 2H), 2.84 (appeared as d, $J = 4.58$, 3H), 1.87 (m, 1H), 0.91 (d, $J = 6.71$, 6H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®.

- 5 HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 490.41, HPLC R_t = 1.693 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254
- 10 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 70, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 8.09 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 6.38 min.


15



2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

- [00215] Purification by Shimadzu-VP preparative reverse phase HPLC using the
- 20 separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 8.92 - 9.62 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 7.97 (dd, $J = 8.85$, 5.49, 2H), 7.79 (m, 2H), 7.65-7.64 (d
- 25 overlapping s, 1H), 7.64 (s, 1H), 7.42 (m, 1H), 7.37 (dd, $J = 8.24$, 1.83, 1H), 7.29-7.26 (overlapping m, 6H), 7.16 (m, 1H), 2.95 (s, 3H), 2.34 (s, 3H), 1.36-1.33 (appeared as d, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA,
- 30 Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate


= 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 519.40, HPLC R_t = 1.832 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 9.93 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 7.64 min.



10 5-(3-Fluoro-5-(propylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide


[00216] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 8.32 - 8.96 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 8.00-7.97 (overlapping m, 4H), 7.74-7.69 (overlapping m, 2H), 7.65-7.62 (m, 1H), 7.58-7.55 (m, 1H), 7.29 (t, J = 8.70, 2H), 3.39 (t, J = 7.00, 2H), 3.00 (s, 3H), 1.69 (m, 2H), 1.02 (t, J = 7.48, 3H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 449.40, HPLC R_t = 1.752 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6

x 150 mm, R_t = 8.08 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 5.87 min.



5 5-(3-(*tert*-Butylcarbamoyl)-4-fluorophenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide


[00217] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 8.48 - 9.02 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 7.97-7.94 (overlapping m, 2H), 7.90 (dd, J = 6.87, 2.59, 1H), 7.88 (s, 1H), 7.78 (ddd, J = 8.47, 4.65, 2.44, 1H), 7.64 (m, 2H), 7.30-7.25 (overlapping m, 3H), 2.99 (s, 3H), 1.50 (2, 9H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES⁺) m/z (M+H)⁺ = 463.36, HPLC R_t = 1.788 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 9.97 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 6.81 min.



5-(3-Amino-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00218] Obtained as a hydrochloride salt from the deprotection of *tert*-Butyl 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-5-


- 5 (isobutylcarbamoyl)phenylcarbamate using 4 M HCl in 1,4-dioxane (r.t.). ¹H NMR (500 MHz, CD₃OD) δ 8.26 (s, 1H), 8.02 (s, 1H), 7.97 (dd, *J* = 7.63, 5.49, 2H), 7.87 (s, 2H), 7.75 (s, 2H), 7.30 (t, *J* = 8.39, 2H), 3.28 (d, *J* = 7.02, 2H), 2.99 (s, 3H), 2.00 (m, 1H), 1.02 (d, *J* = 6.71, 6H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μm, C18, 3.0 x 50 mm; (ES+) *m/z* (M+H)⁺ = 460.42, HPLC *R*_t = 1.510 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm, 4.6 x 150 mm, *R*_t = 8.96 min; Column: XBridge phenyl 3.5 μm, 4.6 x 150 mm, *R*_t = 9.23 min.



3-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxybenzoic acid

- [00219]** Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.02 - 7.76 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 8.00-7.97 (overlapping m, 2H), 7.84 (d, *J* = 1.53, 1H), 7.81 (dd, *J* = 7.63, 1.83, 1H), 7.67 (d, *J* = 8.50, 1H), 7.63-7.60 (overlapping m, 2H), 7.32-


- 7.26 (overlapping m, 3H), 3.50 (s, 3H), 2.97 (s, 3H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 420.27, HPLC R_t = 1.623 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 um, 4.6 x 150 mm, R_t = 6.08 min; Column: XBridge phenyl 3.5 um, 4.6 x 150 mm, R_t = 4.83 min.



- 2-(4-Fluorophenyl)-5-(2-methoxy-3-(1-phenylcyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide


- [00220]** Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 8.65 - 9.45 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 7.99-7.96 (overlapping m, 2H), 7.87 (d, *J* = 1.83, 1H), 7.69-7.63 (overlapping m, 3H), 7.57 (dd, *J* = 7.48, 1.68, 1H), 7.40 (d, *J* = 7.63, 1H), 7.39 (s, 1H), 7.34-7.27 (overlapping m, 5H), 7.20 (t, *J* = 7.17, 1H), 3.41 (s, 3H), 2.97 (s, 3H), 1.40-1.37 (appeared as d, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 535.45, HPLC R_t = 1.833 min. Analytical HPLC were

performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 9.93 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 7.75 min.



5-(2-Chloro-5-(1-(2-chlorophenyl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-
N-methylbenzofuran-3-carboxamide


[00221] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 80, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 5.53 - 6.33 min. (¹H NMR (500 MHz, CD₃OD) δ 7.99-7.96 (overlapping m, 2H), 7.84 (d, *J* = 2.14, 1H), 7.79 (dd, *J* = 7.17, 1.98, 1H), 7.74 (dd, *J* = 8.39, 2.29, 1H), 7.72 (d, *J* = 1.53, 1H), 7.65 (d, *J* = 8.55, 1H), 7.58 (d, *J* = 8.54, 1H), 7.45 (dd, *J* = 8.55, 1.83, 1H), 7.37 (dd, *J* = 7.25, 1.75, 1H), 7.30-7.23 (overlapping m, 4H), 2.95 (s, 3H), 1.34-1.24 (appeared as d, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) *m/z* (M+H)⁺ = 573.38, HPLC R_t = 1.945 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 12.00 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 8.98 min.



5-(2-Chloro-5-(3-phenylpentan-3-ylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide


- 5 **[00222]** Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 80, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 6.08 - 6.89 min. (UV detection at 220 nm). ¹H NMR
- 10 (500 MHz, CD₃OD) δ 8.00-7.97 (overlapping m, 2H), 7.87 (d, *J* = 2.14, 1H), 7.80 (dd, *J* = 8.24, 2.14, 1H), 7.76 (d, *J* = 1.53, 1H), 7.68 (d, *J* = 8.54, 1H), 7.64 (d, *J* = 8.00, 1H), 7.50 (dd, *J* = 8.55, 1.53, 1H), 7.42 (d, *J* = 7.32, 2H), 7.34-7.27 (overlapping m, 4H), 7.20 (d, *J* = 7.32, 1H), 2.96 (s, 3H), 2.35 (m, 2H), 2.08 (m, 2H), 0.80 (t, *J* = 7.32, 6H). LC/MS were performed by using Shimadzu-VP instrument with UV
- 15 detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μm, C18, 3.0 x 50 mm; (ES⁺) *m/z* (M+H)⁺ = 569.47, HPLC *R*_t = 1.972 min. Analytical HPLC were performed by using
- 20 Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm, 4.6 x 150 mm, *R*_t = 13.37 min; Column: XBridge phenyl 3.5 μm, 4.6 x 150 mm, *R*_t = 10.24 min.

25



6-Acetamido-2-(4-fluorophenyl)-N-methyl-5-(3-(1-phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide


[00223] Prepared from 6-amino-2-(4-fluorophenyl)-N-methyl-5-(3-(1-phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide in a similar manner as described. ¹H NMR (500 MHz, DMSO-d₆) δ 9.34 (s, 1H), 9.28 (s, 1H), 8.48 (m, 1H), 8.03-8.00 (overlapping m, 3H), 7.93 (m, 1H), 7.89 (s, 1H), 7.58-7.56 (overlapping m, 3H), 7.40 (t, *J* = 8.85, 2H), 7.30-7.27 (overlapping m, 2H), 7.23-7.21 (overlapping m, 2H), 7.17 (t, *J* = 7.32, 1H), 2.83 (appeared as d, *J* = 4.58, 3H), 1.92 (s, 3H), 1.29 (appeared as s, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES⁺) *m/z* (M+H)⁺ = 562.42, HPLC *R*_t = 1.547 min.



6-Amino-2-(4-fluorophenyl)-5-(3-(isobutylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide


[00224] Obtained from the reduction of 2-(4-fluorophenyl)-5-(3-(isobutylcarbamoyl)phenyl)-N-methyl-6-nitrobenzofuran-3-carboxamide using H₂ with 5% Pd/C as catalyst (1:6 DMF/EtOAc, r.t.) in a similar manner as described. ¹H NMR (500 MHz, DMSO-d₆) δ 8.54 (t, *J* = 5.95, 1H), 8.33 (q, *J* = 4.58, 1H), 7.94-7.91 (overlapping m, 3H), 7.85 (d, *J* = 7.32, 1H), 7.61-7.55 (overlapping m, 2H), 7.34 (t, *J* = 8.70, 2H), 7.23 (s, 1H), 6.99 (s, 1H), 5.05 (s, 2H), 3.11 (d, *J* = 7.02, 2H), 2.80-2.79 (appeared as d, 3H), 1.87 (m, 1H), 0.91 (d, *J* = 6.71, 6H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column:

XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 460.38, HPLC R_t = 1.407 min.




5 5-(2-Fluoro-5-(1-phenylcyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methyl-6-nitrobenzofuran-3-carboxamide

[00225] ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.33 (s, 1H), 8.64 (s, 2H), 8.12 (dd, J = 7.32, 2.14, 1H), 8.08-8.05 (overlapping m, 3H), 7.83 (s, 1H), 7.47 (t, J = 8.85, 2H), 7.42 (t, J = 9.30, 1H), 7.31-7.28 (overlapping m, 2H), 7.25-7.23 (overlapping m, 2H), 7.17 (t, J = 7.17, 1H), 2.84 (appeared as d, J = 4.58, 3H), 1.31-1.28 (appeared as d, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, 15 Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 568.39, HPLC R_t = 1.768 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, 20 Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 9.28 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 7.82 min.



25 6-Amino-5-(2-fluoro-5-(1-phenylcyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide


[00226] Obtained from the reduction of 5-(2-fluoro-5-(1-phenylcyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methyl-6-nitrobenzofuran-3-carboxamide using H₂ with 5% Pd/C as catalyst (1:5 DMF/EtOAc, r.t.) in a similar manner as described. LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 538.41, HPLC R_t = 1.510 min.



6-Amino-5-(2-fluoro-5-(1-phenylpropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00227] Obtained as a side product from the over-reduction of 5-(2-fluoro-5-(1-phenylcyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methyl-6-nitrobenzofuran-3-carboxamide under the conditions using H₂ with 5% Pd/C as catalyst (1:5 DMF/EtOAc, r.t.). The product was obtained as a TFA salt after purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 6.52 - 7.08 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 7.98 (m, 1H), 7.93-7.91 (overlapping m, 3H), 7.51 (s, 1H), 7.40-7.38 (overlapping m, 2H), 7.34 (d, J = 7.60, 1H), 7.33 (t, J = 7.78, 2H), 7.27-7.23 (overlapping m, 4H), 4.99 (t, J = 7.48, 1H), 2.92 (s, 3H), 1.94 (m, 2H), 0.99 (t, J = 7.32, 3H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4

- ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 540.45, HPLC R_t = 1.587 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 6.56 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 5.42 min.




- 10 5-(2-Fluoro-5-(1-phenylcyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methyl-6-(methanesulfonamido)benzofuran-3-carboxamide

[00228] Prepared from the coupling between 6-amino-5-(2-fluoro-5-(1-phenylcyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide and methanesulfonyl chloride (*N,N*-diisopropylethylamine,

- 15 ClCH₂CH₂Cl, r.t.), followed by hydrolysis of the intermediate N-(methanesulfonyl)methanesulfonamide (Cs₂CO₃, 1:5 H₂O/1,4-dioxane, 90 °C). Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop
20 time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 6.70 - 7.25 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 8.00-7.95 (overlapping m, 4H), 7.83 (s, 1H), 7.66 (s, 1H), 7.35 (t, *J* = 9.00, 1H), 7.30-7.27 (overlapping m, 6H), 7.18 (m, 1H), 2.94 (s, 3H), 2.88 (s, 3H), 1.37-1.35 (appeared as d, 4H). LC/MS were performed by using Shimadzu-VP instrument
25 with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ =

616.48, HPLC R_t = 1.563 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 6.57 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 5.80 min.




5-(2-Fluoro-5-(1-phenylpropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methyl-6-(methylsulfonamido)benzofuran-3-carboxamide

[00229] Prepared in a similar manner as 5-(2-fluoro-5-(1-phenylcyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methyl-6-(methylsulfonamido)benzofuran-3-carboxamide. Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.35 - 7.81 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 8.00-7.93 (overlapping m, 4H), 7.83 (s, 1H), 7.66 (s, 1H), 7.41 (d overlapping with s, J = 8.00, 1H), 7.40 (s, 1H), 7.35-7.32 (overlapping m, 3H), 7.29 (t, J = 8.10, 2H), 7.25 (t, J = 7.93, 1H), 4.99 (t, J = 7.48, 1H), 2.94 (s, 3H), 2.89 (s, 3H), 1.94 (m, 2H), 1.00 (t, J = 7.17, 3H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES⁺) m/z (M+H)⁺ = 618.48, HPLC R_t = 1.637 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical

HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 7.76 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 6.37 min.

5




Methyl 2-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yloxy)acetate


[00230] To a 50 mL round-bottomed flask was added 2-(4-fluorophenyl)-5-hydroxy-N-methylbenzofuran-3-carboxamide (285 mg, 1 mmol), potassium carbonate (207 mg, 1.500 mmol), and methyl bromoacetate (0.101 ml, 1.1 mmol) in DMF (3 mL) to give a yellow suspension. The mixture was stirred at room temperature under nitrogen overnight. The crude product was diluted with 100 mL of dichloromethane, washed with water, then brine and dried over magnesium sulfate. The residue was purified using a BIOTAGE® Horizon employing a gradient of 0 to 30% methanol in dichloromethane and a 40+M silica gel column. The product was then triturated with cold ethyl acetate to give a 73% yield (259 mgs) of product, a white amorphous solid after drying under vacuum.

[00231] The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® 10 μ m C18, 4.6 x 30mm column, with a gradient of 0-100%B (B = 90% HPLC grade methanol/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade methanol), in 2 minutes with a 1 minute hold at a rate of 5 mL/minute. The NMR spectra was recorded at room temperature using a Bruker DRX300 spectrometer. Chemical shifts were reported in ppm relative to the deuterated solvent used. Coupling constants were reported in hertz. Peak multiplicity was reported using the following abbreviations: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), m (multiplet), br (broad). ¹H NMR (300 MHz, CD₃OD) δ ppm 2.93 (s, 3 H), 3.79 (s, 3 H), 4.75 (s, 2 H), 7.01 (dd, *J* = 8.97, 2.38 Hz, 1 H), 7.15 (d, *J* = 2.38 Hz, 1 H), 7.22 (t,

$J = 8.78$ Hz, 2 H), 7.46 (d, $J = 8.97$ Hz, 1 H), 7.88 (m, 2 H). LCMS m/z 358.27 (M+H), R_t 1.553 min., 97.4 % purity.




- 5 2-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yloxy)acetic acid
- [00232] To a 50mL round-bottomed flask was added methyl 2-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yloxy)acetate (132.3 mg, 0.370 mmol) and 2 equivalents of potassium trimethylsilanolate (95 mg, 0.740 mmol) along with a 1:1 solution of tetrahydrofuran/dichloromethane (10 ml) to give a yellow heterogeneous
- 10 mixture. The mixture was stirred at room temperature overnight. The crude product was then cooled to 0°C, diluted further with dichloromethane, and acidified with 1 N HCl. The product was extracted, washed with water then brine, and dried over magnesium sulfate. After solvent evaporation, the product was triturated with hexane to give a 91% yield (115 mgs), a white amorphous solid after drying under vacuum.
- 15 The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® 10µm C18, 4.6 x 30mm column, with a gradient of 0-100%B (B = 90% HPLC grade methanol/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade methanol), in 2
- 20 minutes with a 1 minute hold at a rate of 5 mL/minute. The NMR spectra was recorded at room temperature using a Bruker DRX300 spectrometer. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 2.82 (d, $J = 4.39$ Hz, 3 H), 4.72 (s, 2 H), 7.00 (dd, $J = 8.78$, 2.56 Hz, 1 H), 7.08 (d, $J = 2.56$ Hz, 1 H), 7.35 (t, $J = 8.97$ Hz, 2 H), 7.57 (d, $J = 8.78$ Hz, 1 H), 7.92 (dd, $J = 8.78$, 5.49 Hz, 2 H), 8.34 (m, 1 H). LCMS m/z 344.27 (M+H),
- 25 R_t 1.450 min., 96.0 % purity.



2-Chloro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid


[00233] To a 250mL sealed tube was added 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (3.55 g, 8.5 mmol), dioxane (50 mL), water (10 mL), Tetrakis(triphenylphosphine)palladium(0) (0.196 g, 0.170 mmol), 5-borono-2-chlorobenzoic acid (2.55 g, 12.75 mmol), and cesium carbonate (4.15 g, 12.75 mmol). The tube was sealed and heated in an oil bath overnight at 85 °C. The reaction mixture was then cooled, diluted with 300mL of cold 0.5M HCl and stirred for 30minutes. The resulting solid was washed with 0.5 N HCl then with water and allowed to dry under vacuum giving a quantitative yield of 2-Chloro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid which was used without further purification. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. LCMS *m/z* 424.77 (M+H), *Rt* 2.150 min., 90 % purity.



3-Chloro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid

[00234] To a 250mL sealed tube was added 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (3.55 g, 8.5 mmol), dioxane (50 mL), water (10 mL), Tetrakis(triphenylphosphine)palladium(0) (0.196 g, 0.170 mmol), 5-borono-3-chlorobenzoic acid (2.55 g, 12.75 mmol), and cesium carbonate (4.15 g, 12.75 mmol). The tube was sealed and heated in an oil bath overnight at 85 °C. The reaction mixture was then cooled, diluted with 300mL of cold 0.5M HCl and stirred for 30minutes. The resulting solid was washed with 0.5 N HCl then with water and allowed to dry under vacuum giving a quantitative yield of 3-Chloro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid which was used without further purification. The LC/MS data was obtained on a


Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. LCMS *m/z* 424.09 (M+H), *R_f* 2.658 min., 88 % purity.



4-Chloro-3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid

10 **[00235]** To a 250mL sealed tube was added 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (3.55 g, 8.5 mmol), dioxane (50 mL), water (10 mL), Tetrakis(triphenylphosphine)palladium(0) (0.196 g, 0.170 mmol), 3-borono-4-chlorobenzoic acid (2.55 g, 12.75 mmol), and cesium carbonate (4.15 g, 12.75 mmol). The tube was sealed and heated in an oil bath overnight at 85 °C. The reaction mixture was then cooled, diluted with 300mL of cold 0.5M HCl and stirred for 30minutes. The resulting solid was washed with 0.5 N HCl then with water and allowed to dry under vacuum giving a quantitative yield of 4-Chloro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid which was used without further purification. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 220nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then

confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5 μ m 4.6 x 150mm column employing water/methanol/ 10 mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water),
 5 (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (500 MHz, DMF-d₇) δ ppm 2.95 (d, J = 4.58 Hz, 3 H), 7.39 - 7.47 (m, 2 H), 7.57 (dd, J = 8.55, 1.83 Hz, 1 H), 7.81 (dd, J = 15.72, 8.39 Hz, 2 H), 7.87 (d, J = 1.83 Hz, 1 H), 8.04 - 8.14 (m, 4 H), 8.40 (d, J = 4.58 Hz, 1 H). LCMS m/z 424.90 (M+H), R_t 2.287
 10 min. HPLC R_t 9.749min. (Sunfire C18) and 10.518min. (XBridge phenyl C18), 94 % purity.



5-(4-Chloro-3-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-
 15 3-carboxamide

[00236] To a 250mL RBF was added 2-chloro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (3.62 g, 8.55 mmol), 2-methylpropan-1-amine (1.274 mL, 12.83 mmol), *N*-ethyl-*N,N*-diisopropylamine (2.98 mL, 17.10 mmol), and 3 eq. of HATU, (2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (9.75 g, 25.7 mmol)) along
 20 with 114mL of DMF. The mixture was stirred overnight at room temperature. The crude reaction mixture was transferred to a separatory funnel, diluted with 300mL of dichloromethane and washed with 100mL of 1 N HCl, water, and brine. After drying over magnesium sulfate the crude residue was pushed through a plug of silica gel and
 25 evaporated to a tan solid. The solid was triturated with diethyl ether then cold acetonitrile to give a 48% yield of 5-(4-chloro-3-(isobutylcarbamoyl) phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide, as a light yellow powder. The NMR spectrum was recorded at room temperature using a Bruker DRX500 spectrometer. The LC/MS data was obtained on a Shimadzu analytical LC /
 30 MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions:


Waters Sunfire 5 μ m C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was

5 determined using a Shimadzu analytical LC at 220nm and 256nm with a Waters Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1

10 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5 μ m 4.6 x 150mm column employing water/methanol/ 0.1% ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water /

15 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (500 MHz, acetone-d₆) δ ppm 1.02 (d, *J*=6.71 Hz, 6 H), 1.92 - 2.01 (m, 1 H), 2.99 (d, *J* = 4.88 Hz, 3 H), 3.28 (t, *J* = 6.41 Hz, 2 H), 7.33 (t, *J* = 8.70 Hz, 2 H), 7.56 (d, *J* = 8.24 Hz, 1 H), 7.61 (br. s., 1 H), 7.66 (br. s., 1 H), 7.68 - 7.74 (m, 2 H), 7.74 - 7.82 (m, 2 H), 8.01 - 8.06 (m, 1 H), 8.13 (dd, *J*=8.70, 5.34 Hz, 2 H). LCMS *m/z* 479.06 (M+H), *R_t* 2.367 min. HPLC *R_t* 10.263min. (Sunfire C18) and 11.753min. (XBridge phenyl C18), 93 % purity.

20




25 5-(4-Chloro-3-(2-phenylpropan-2-ylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00237] To a 2 dram vial was added 2-chloro-5-(2-(4-fluorophenyl)-3-(methylecarbamoyl)benzofuran-5-yl)benzoic acid (42.4 mg, 0.1 mmol) in DMF (2 mL) along with cumylamine (0.029 mL, 0.200 mmol), *N,N*-Diisopropylethylamine (0.035 mL, 0.200 mmol) and HATU (114 mg, 0.300 mmol) to give a yellow solution. The

30 vial was shaken at room temperature overnight. The crude reaction mixture was then

evacuated to near dryness, taken up in 2 mL of methanol and purified using a Shimadzu preparative HPLC employing methanol/water/0.1%TFA where solvent A was 10% MeOH / 90% H₂O / 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% MeOH / 0.1% trifluoroacetic acid with a PHENOMENEX® Luna 10µm C18 30x100mm column at a gradient of 30-100% B and a flow rate of 40 mL/min. over 10 minutes with a 10 minute hold. The tubes containing purified product were evaporated overnight in a Savant/Thermo SPEEDVAC® to give a 45% yield of 5-(4-chloro-3-(2-phenylpropan-2-ylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide as a white powder. The NMR spectrum was recorded at room temperature using a Bruker DRX300 spectrometer. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 220nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5µm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (300 MHz, chloroform-d) δ ppm 1.87 (s, 6 H), 3.02 (d, *J* = 4.76 Hz, 3 H), 6.03 (d, *J* = 4.76 Hz, 1 H), 6.62 (s, 1 H), 7.13 - 7.23 (m, 2 H), 7.24 - 7.31 (m, 1 H), 7.33 - 7.42 (m, 2 H), 7.45 (d, *J* = 8.42 Hz, 1 H), 7.48 - 7.63 (m, 5 H), 7.83 - 8.00 (m, 4 H). LCMS *m/z* 542.90 (M+H), *Rt* 2.608 min. HPLC *Rt* 11.069min. (Sunfire C18) and 12.111min. (XBridge phenyl C18), 97.8 % purity.




2-(4-Fluorophenyl)-N-methyl-5-(2-(2-phenylpropan-2-ylcarbamoyl)biphenyl-4-yl)benzofuran-3-carboxamide

- 5 **[00238]** To a 2mL microwave vial was added dioxane (2 mL), water (0.200 mL), (S-Phos) dicyclohexyl (2',6'-dimethoxybiphenyl-2-yl)phosphine, (1.912 mg, 4.66 μ mol), 5-(4-chloro-3-(2-phenylpropan-2-ylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (0.0126 g, 0.023 mmol), potassium phosphate tribasic (0.020 g, 0.093 mmol), palladium(II) acetate (1.046 mg, 4.66 μ mol), and
- 10 phenylboronic acid (8.52 mg, 0.070 mmol). The vial was capped, degassed, flushed with N₂ and heated in the microwave for 10 minutes at 150°C. The crude product was taken up in a 1:1 solution of DMF/acetonitrile and purified by a Shimadzu preparative HPLC employing acetonitrile/0.1% TFA/water where solvent A was 10% acetonitrile / 90% H₂O/ 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90%
- 15 acetonitrile/ 0.1% trifluoroacetic acid with a Waters-Atlantis OBD 19 x 100mm 5 μ m column at a gradient of 50-100% B and a flow rate of 25 mL/min. over 10 minutes with a 10 minute hold. The purified product was evaporated to dryness overnight in a Savant Thermo SPEEDVAC® to give a 73% yield of 2-(4-fluorophenyl)-N-methyl-5-(2-(2-phenylpropan-2-ylcarbamoyl)biphenyl-4-yl) benzofuran-3-carboxamide. The
- 20 NMR spectrum was recorded at room temperature using a Bruker DRX500 spectrometer. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5 μ m C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A =
- 25 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 220nm and 256nm with a Waters Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic

acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18
 5 3.5 μ m 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (500 MHz, CD₃OD) δ ppm 1.54 (s, 6
 10 H), 3.01 (s, 3 H), 7.15 - 7.20 (m, 1 H), 7.21 - 7.33 (m, 6 H), 7.43 - 7.50 (m, 3 H), 7.51 - 7.55 (m, 3 H), 7.69 - 7.72 (m, 1 H), 7.72 - 7.76 (m, 1 H), 7.80 (d, *J* = 1.53 Hz, 1 H), 7.84 (dd, *J* = 7.93, 1.83 Hz, 1 H), 7.96 - 8.02 (m, 3 H), 8.10 (br. s., 1 H). LCMS *m/z* 583.03 (M+H), *R_t* 2.811 min. HPLC *R_t* 11.683min. (Sunfire C18) and 12.609min. (XBridge phenyl C18), 99 % purity.


15



5-(3-Chloro-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide


[00239] To a 250mL round-bottomed flask was added 3-chloro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (3.62 g, 8.55
 20 mmol), 2-methylpropan-1-amine (1.274 mL, 12.83 mmol), *N*-ethyl-*N*,*N*-diisopropylamine (2.98 mL, 17.10 mmol), and 3 eq. of HATU (2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (9.75 g, 25.7 mmol)) along with 114mL of DMF. The mixture was
 25 stirred overnight at room temperature. The crude reaction mixture was transferred to a separatory funnel, diluted with 300mL of dichloromethane and washed with 100mL of 1 N HCl, water, and brine. After drying over magnesium sulfate the crude residue was pushed through a plug of silica gel and evaporated to a tan solid. The solid was triturated with diethyl ether then cold acetonitrile to give a 52% yield of 5-(4-chloro-

3-(isobutylcarbamoyl) phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide, as a light yellow powder. The NMR spectrum was recorded at room temperature using a Bruker DRX500 spectrometer. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 220nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5µm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 0.94 (d, *J* = 6.41 Hz, 6 H), 1.72 - 1.97 (m, 1 H), 2.87 (d, *J* = 4.58 Hz, 3 H), 3.10 (t, *J* = 6.26 Hz, 2 H), 7.40 (t, *J* = 8.85 Hz, 2 H), 7.59 (d, *J* = 8.55 Hz, 1 H), 7.69 - 7.75 (m, 2 H), 7.76 - 7.82 (m, 2 H), 7.90 (br. s., 1 H), 7.97 - 8.07 (m, 2 H), 8.55 (br. s., 2 H). LCMS *m/z* 479.04 (M+H), *R_t* 2.658 min. HPLC *R_t* 10.810min. (Sunfire C18) and 12.154min. (XBridge phenyl C18), 92 % purity.




3-(2-(4-Fluorophenyl)-3-(methoxycarbonyl)benzofuran-5-yl)-4-methoxybenzoic acid

- [00240] To a 150mL sealed tube was added 2-(4-fluorophenyl)-3-(methoxycarbonyl)benzofuran-5-yl trifluoromethanesulfonate (1.252 g, 3 mmol), 3-borono-4-methoxybenzoic acid (0.882 g, 4.50 mmol), cesium carbonate (1.466 g, 4.50 mmol), tetrakis(triphenyl phosphine)palladium(0) (0.069 g, 0.060 mmol),
- 5 dioxane (18 mL) and water (3.60 mL). The vial was sealed and heated in an oil bath over night at 85°C. The reaction mixture was then filtered through CELITE® and concentrated *in vacuo*. Cold 0.5N HCl was then added and the heterogeneous mixture was stirred for 30 minutes. The resulting product, a white solid was filtered, washed with water and dried overnight to give a quantitative yield of 3-(2-(4-
- 10 fluorophenyl)-3-(methoxycarbonyl)benzofuran-5-yl)-4-methoxy benzoic acid which was carried on without further purification. LCMS *m/z* 420.88 (M+H), *Rt* 2.002 min., 88 % purity.




- 15 5-(2-(4-Fluorophenyl)-3-(methoxycarbonyl)benzofuran-5-yl)-2-methoxybenzoic acid
- [00241] To a 150mL sealed tube was added 2-(4-fluorophenyl)-3-(methoxycarbonyl)benzofuran-5-yl trifluoromethanesulfonate (1.252 g, 3 mmol), 5-borono-2-methoxybenzoic acid (0.882 g, 4.50 mmol), cesium carbonate (1.466 g, 4.50 mmol), tetrakis(triphenyl phosphine)palladium(0) (0.069 g, 0.060 mmol),
- 20 dioxane (18 mL) and water (3.60 mL). The vial was sealed and heated in an oil bath over night at 85°C. The reaction mixture was then filtered through CELITE® and concentrated *in vacuo*. Cold 0.5N HCl was then added and the heterogeneous mixture was stirred for 30 minutes. The resulting product, a white solid was filtered, washed with water and dried overnight to give a quantitative yield of 5-(2-(4-
- 25 fluorophenyl)-3-(methoxycarbonyl)benzofuran-5-yl)-2-methoxy benzoic acid which was carried on without further purification. LCMS *m/z* 420.92 (M+H), *Rt* 2.003 min., 87 % purity.



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-4-methoxyphenyl)-N-methylbenzofuran-3-carboxamide

- [00242]** To a vial containing (5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxybenzoic acid (378.5 mg, 0.902 mmol)) was added DMF (5 mL), *N*,-ethyl-*N,N*-diisopropylamine (0.786 mL, 4.51 mmol), 2-methylpropan-1-amine (0.448 mL, 4.51 mmol), and HATU, (2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (1029 mg, 2.71 mmol)). The vial was capped and the solution shaken overnight at room temperature. The crude product was diluted with ethyl acetate, washed with 0.5M HCl, and extracted. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated. The crude reaction mixture was taken up in acetonitrile, filtered and purified using a Shimadzu preparative HPLC employing acetonitrile/water/TFA where solvent A was 10% acetonitrile / 90% H₂O/ 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% acetonitrile/ 0.1% trifluoroacetic acid with a PHENOMENEX® Luna 10µm C18 30x100mm at a gradient of 40-100% B and a flow rate of 25 mL/min. over 10 minutes with a 10 minute hold. The purified product was concentrated *in vacuo* to give a 38% yield of 2-(4-fluorophenyl)-5-(3-(isobutylcarbamoyl)-4-methoxyphenyl)-N-methylbenzo- furan-3-carboxamide as a white solid. The NMR spectrum was recorded at room temperature using a Bruker DRX500 spectrometer. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 220nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B

(B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5 μ m 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (500 MHz, acetone-d₆) δ ppm 1.00 (d, *J* = 6.41 Hz, 6 H), 1.92 - 1.96 (m, 1 H), 3.01 (d, *J* = 4.27 Hz, 3 H), 3.30 (t, *J* = 6.26 Hz, 2 H), 4.09 (s, 3 H), 7.23 - 7.39 (m, 3 H), 7.61 (br. s., 1 H), 7.69 (s, 2 H), 7.84 (dd, *J* = 8.39, 1.98 Hz, 1 H), 7.99 (s, 1 H), 8.13 (dd, *J* = 7.93, 5.49 Hz, 3 H), 8.39 (d, *J* = 2.14 Hz, 1 H). LCMS *m/z* 475.15 (M+H), *R_t* 2.452 min. HPLC *R_t* 10.648min. (Sunfire C18) and 12.301min. (XBridge phenyl C18), 100 % purity.




2-(4-Fluorophenyl)-5-(4-methoxy-3-(2-phenylpropan-2-ylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide

[00243] To a vial containing (5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxybenzoic acid (61 mg, 0.145 mmol)) was added DMF (2 mL), *N*,-ethyl-*N,N*-diisopropylamine (0.050 mL, 0.29 mmol), cumylamine (39.3mg, 0.291 mmol), and finally TBTU, *o*-Benzotriazol-1-yl-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (140 mg, 0.436 mmol)). The vial was capped and the solution shaken overnight at room temperature. The crude product was diluted with ethyl acetate, washed with 1M HCl, and extracted. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated. The crude reaction mixture was taken up in acetonitrile, filtered and purified using a Shimadzu preparative HPLC employing acetonitrile/water/TFA

where solvent A was 10% acetonitrile / 90% H₂O/ 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% acetonitrile/ 0.1% trifluoroacetic acid with a PHENOMENEX® Luna 10µm C18 30x100mm at a gradient of 40-100% B and a flow rate of 25 mL/min. over 10 minutes with a 10 minute hold. The purified product was concentrated *in vacuo* to give a 42% yield of 2-(4-fluorophenyl)-5-(4-methoxy-3-(2-phenylpropan-2-ylcarbonyl)phenyl)-N-methylbenzofuran-3-carboxamide as a white solid. The NMR spectrum was recorded at room temperature using a Bruker DRX500 spectrometer. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions:

Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 220nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5µm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (500 MHz, CD₃OD) δ ppm 1.69 - 1.88 (m, 6 H), 2.99 (s, 3 H), 4.09 (s, 3 H), 7.20 - 7.32 (m, 4 H), 7.36 (t, *J* = 7.63 Hz, 2 H), 7.52 (d, *J* = 8.24 Hz, 2 H), 7.57 - 7.64 (m, 2 H), 7.79 - 7.89 (m, 2 H), 7.96 (t, *J* = 6.10 Hz, 2 H), 8.12 (br. s., 1 H). LCMS *m/z* 537.13 (M+H), *R_t* 2.705 min. HPLC *R_t* 11.563min. (Sunfire C18) and 12.876min. (XBridge phenyl C18), 93 % purity.


30



2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-methoxyphenyl)-N-methylbenzofuran-3-carboxamide

[00244] To a 100mL round-bottomed flask was added 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methoxybenzoic acid (1258 mg, 3 mmol), DMF (40mL), 2-methylpropan-1-amine (447 μ L, 4.50 mmol), *N*-ethyl-*N,N*-diisopropylamine (1.1 mL, 6.00 mmol), and finally HATU (2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (3422 mg, 9.00 mmol)). The mixture was stirred over night at room temperature. The crude product was diluted with ethyl acetate, washed with 1M HCl, and extracted. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated. The crude residue was loaded onto 40M BIOTAGE® column and purified using a BIOTAGE® Horizon with 2200mL of 0-6% methanol in DCM). The product was concentrated *in vacuo* then triturated with cold acetonitrile to give a 60% yield of 2-(4-fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-methoxyphenyl)-N-methylbenzofuran-3-carboxamide as a light yellow solid. The NMR spectrum was recorded at room temperature using a Bruker DRX500 spectrometer. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5 μ m C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 220nm and 256nm with a Waters Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column


using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5 μ m 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (500 MHz, CD₃OD) δ ppm 0.89 - 1.07 (m, 6 H), 1.96 (dt, *J* = 13.43, 6.71 Hz, 1 H), 2.97 (s, 3 H), 3.22 (d, *J* = 6.10 Hz, 2 H), 3.80 - 3.98 (m, 3 H), 7.19 (d, *J* = 9.46 Hz, 1 H), 7.24 - 7.33 (m, 2 H), 7.52 - 7.57 (m, 1 H), 7.57 - 7.65 (m, 1 H), 7.80 (s, 1 H), 7.84 - 7.92 (m, 2 H), 7.96 - 8.02 (m, 2 H), 8.46 (br. s., 1 H). LCMS *m/z* 475.02 (M+H), *R_t* 2.290 min. HPLC *R_t* 14.374min. (Sunfire C18) and 15.689min. (XBridge phenyl C18), 95 % purity.



2-(4-Fluorophenyl)-5-(2-hydroxy-5-(isobutylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide


[00245] To a 250mL sealed tube was added toluene (150 mL) 2-(4-fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-methoxyphenyl)-N-methylbenzofuran-3-carboxamide (1.187 g, 2.50 mmol) and finally, under a steady stream of N₂ Boron tribromide-methyl sulfide complex (8.76 g, 28.0 mmol) was quickly added. The tube was sealed and heated to 100 °C in an oil bath for 30 hours. The crude reaction mixture was cooled to room temperature, filtered, washed with wet hexane, then diethyl ether and dried overnight under vacuum to give a 96% yield of a tan solid. The NMR spectrum was recorded at room temperature using a Bruker DRX500 spectrometer. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5 μ m C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 220nm and 256nm with a Waters Sunfire C18 3.5 μ m 4.6 x

150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5 μ m 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (500 MHz, DMF-d₇) δ ppm 0.92 (d, *J* = 6.71 Hz, 6 H), 1.86 - 1.97 (m, 1 H), 2.94 - 2.98 (m, 3 H), 3.17 - 3.23 (m, 2 H), 7.19 (d, *J* = 8.55 Hz, 1 H), 7.42 (t, *J* = 9.00 Hz, 2 H), 7.66 - 7.75 (m, 2 H), 7.88 (dd, *J* = 8.39, 2.29 Hz, 1 H), 8.06 - 8.14 (m, 3 H), 8.37 - 8.46 (m, 2 H). LCMS *m/z* 461.95 (M+H), *R_t* 2.033 min. HPLC *R_t* 8.929min. (Sunfire C18) and 11.454min. (XBridge phenyl C18), 96 % purity.



[00246] General procedure: To a 2 dram vial was added 2-(4-fluorophenyl)-5-(2-hydroxy-5-(isobutylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide (46.0 mg, 0.1 mmol), DMF (2 mL), and 1.5 equivalents (0.15mmol) of either triethyl amine or potassium carbonate and 1.5 equivalents (0.15mmol) of alkyl bromide. The vials were sealed and shaken at 22-70 °C in a dry bath. Upon reaction completion the crude products were concentrated, diluted with 2mL of acetonitrile and purified using a Shimadzu preparative HPLC employing acetonitrile/water/0.1%TFA where solvent A was 10% acetonitrile / 90% H₂O/ 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 5 μ m C18 4.6 x 100mm column at a gradient of 30-100% B and a flow rate of 40 mL/min. over 8

minutes with a 10 minute hold. The desired products were evaporated to dryness in a Savant SPEEDVAC® overnight obtaining 25-60% yield of the desired ethers as white powders.




5

2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-isopropoxyphenyl)-N-methylbenzofuran-3-carboxamide

[00247] ^1H NMR (500 MHz, CD_3OD) δ ppm 1.00 (d, $J = 6.71$ Hz, 6 H), 1.32 (d, $J = 6.10$ Hz, 6 H), 1.87 - 2.05 (m, 1 H), 2.98 (s, 3 H), 3.22 (d, $J = 7.02$ Hz, 2 H), 4.64 - 4.79 (m, 1 H), 7.18 (d, $J = 8.55$ Hz, 1 H), 7.24 - 7.36 (m, 2 H), 7.57 - 7.67 (m, 2 H), 7.85 (dd, $J = 8.55, 2.44$ Hz, 1 H), 7.87 (s, 1 H), 7.90 (d, $J = 2.44$ Hz, 1 H), 7.95 - 8.01 (m, 2 H). LCMS m/z 503.12 (M+H), R_t 2.368 min. HPLC R_t 10.789min. (Sunfire C18) and 12.428min. (XBridge phenyl C18), 98.7 % purity.

10




15

5-(2-(Cyclobutyloxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00248] ^1H NMR (500 MHz, CD_3OD) δ ppm 0.99 (d, $J = 6.41$ Hz, 6 H), 1.71 - 1.81 (m, 1 H), 1.83 - 1.91 (m, 1 H), 1.92 - 2.00 (m, 1 H), 2.08 - 2.20 (m, 2 H), 2.45 - 2.56 (m, 2 H), 2.99 (s, 3 H), 3.22 (d, $J = 6.71$ Hz, 2 H), 4.80 - 4.84 (m, 1 H), 7.01 (d, $J = 8.55$ Hz, 1 H), 7.28 (t, $J = 8.55$ Hz, 2 H), 7.58 - 7.66 (m, 2 H), 7.83 (d, $J = 8.24$ Hz, 1 H), 7.86 - 7.92 (m, 2 H), 7.96 - 8.03 (m, 2 H). LCMS m/z 515.21 (M+H), R_t 2.613


20

min. HPLC *Rt* 11.161min. (Sunfire C18) and 12.693min. (XBridge phenyl C18), 97 % purity.




5 5-(2-(Cyclopentyloxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00249] ¹H NMR (400 MHz, CD₃OD) δ ppm 1.04 (d, *J* = 6.78 Hz, 6 H), 1.63 - 1.82 (m, 4 H), 1.83 - 2.08 (m, 5 H), 3.02 (s, 3 H), 3.27 (d, *J* = 7.03 Hz, 2 H), 5.02 (ddd, *J* = 5.21, 2.89, 2.70 Hz, 1 H), 7.21 (d, *J* = 8.78 Hz, 1 H), 7.28 - 7.36 (m, 2 H),
10 7.58 - 7.69 (m, 2 H), 7.88 (dd, *J* = 8.53, 2.51 Hz, 1 H), 7.91 (d, *J* = 1.25 Hz, 1 H), 7.95 (d, *J* = 2.26 Hz, 1 H), 7.99 - 8.06 (m, 2 H). LCMS *m/z* 529.16 (M+H), *Rt* 2.685 min. HPLC *Rt* 12.879min. (XBridge phenyl C18), 100 % purity.



15 2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-propoxyphenyl)-N-methylbenzofuran-3-carboxamide


[00250] ¹H NMR (400 MHz, CD₃OD) δ ppm 1.04 (m, 9 H), 1.75 - 1.90 (m, 2 H), 1.93 - 2.10 (m, 1 H), 3.02 (s, 3 H), 3.27 (d, *J* = 7.03 Hz, 2 H), 4.11 (t, *J* = 6.15 Hz, 2 H), 7.21 (d, *J* = 8.53 Hz, 1 H), 7.32 (t, *J* = 8.78 Hz, 2 H), 7.59 - 7.72 (m, 2 H), 7.88 -
20 7.98 (m, 3 H), 7.98 - 8.08 (m, 2 H). LCMS *m/z* 503.14 (M+H), *Rt* 2.548 min. HPLC *Rt* 12.554min. (XBridge phenyl C18), 100 % purity.



2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(isopentyloxy)phenyl)-N-methylbenzofuran-3-carboxamide

[00251] ^1H NMR (400 MHz, CD_3OD) δ ppm 0.93 - 1.01 (m, 6 H), 1.04 (d, $J = 6.78$ Hz, 6 H), 1.69 (q, $J = 6.53$ Hz, 2 H), 1.83 (ddd, $J = 13.61, 6.71, 6.53$ Hz, 1 H), 2.01 (dt, $J = 13.74, 6.81$ Hz, 1 H), 3.03 (s, 3 H), 3.27 (d, $J = 7.03$ Hz, 2 H), 4.18 (t, $J = 6.27$ Hz, 2 H), 7.22 (d, $J = 8.78$ Hz, 1 H), 7.28 - 7.39 (m, 2 H), 7.56 - 7.72 (m, 2 H), 7.86 - 7.98 (m, 3 H), 7.99 - 8.09 (m, 2 H). LCMS m/z 531.16 (M+H), R_t 2.791 min. HPLC R_t 13.122min. (XBridge phenyl C18), 100 % purity.


10



2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-ethoxyphenyl)-N-methylbenzofuran-3-carboxamide

[00252] ^1H NMR (400 MHz, CD_3OD) δ ppm 1.04 (d, $J = 6.53$ Hz, 6 H), 1.42 (t, $J = 6.78$ Hz, 3 H), 1.90 - 2.11 (m, 1 H), 3.02 (s, 3 H), 3.27 (d, $J = 7.03$ Hz, 2 H), 4.22 (q, $J = 6.78$ Hz, 2 H), 7.18 - 7.24 (m, 1 H), 7.29 - 7.38 (m, 2 H), 7.64 - 7.67 (m, 2 H), 7.87 - 7.93 (m, 2 H), 7.93 - 7.96 (m, 1 H), 8.00 - 8.08 (m, 2 H). LCMS m/z 489.15 (M+H), R_t 2.432 min. HPLC R_t 10.571min. (Sunfire C18) and 12.193min. (XBridge phenyl C18), 93 % purity.

20




2-(4-Fluorophenyl)-5-(2-methoxy-5-(2-phenylpropan-2-ylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide

- [00253]** To a 50mL RBF was added 3-(2-(4-fluorophenyl)-3-
- 5 (methylcarbamoyl)benzofuran-5-yl)-4-methoxybenzoic acid (433.9 mg, 1.035 mmol), DMF (15 mL), 2-phenylpropan-2-amine (210 mg, 1.552 mmol), N-ethyl-N-isopropylpropan-2-amine (0.360 mL, 2.069 mmol), and finally HATU, 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (1180 mg, 3.10 mmol)). The mixture was stirred over night
- 10 at room temperature. The resulting mixture was diluted with dichloromethane, washed with 0.5M HCl, then brine and dried over MgSO₄. The solution was concentrated to give a tan oil. The crude product was taken up in 10mL of acetonitrile and purified using a Shimadzu preparative HPLC employing acetonitrile/water/0.1%TFA where solvent A was 10% acetonitrile / 90% H₂O/ 0.1%
- 15 trifluoroacetic acid and solvent B was 10% H₂O / 90% acetonitrile/ 0.1% trifluoroacetic acid with a PHENOMENEX® Luna 10µm C18 30 x 100mm column at a gradient of 40-100% B and a flow rate of 40 mL/min. over 8 minutes with a 12 minute hold to give a 80% yield of product as a white powder. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at
- 20 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu
- 25 analytical LC at 220nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A

= 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile),
 in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was
 then confirmed with an orthogonal solvent system and column using a Shimadzu
 analytical LC with a Waters XBridge phenyl C18 3.5 μ m 4.6 x 150mm column
 5 employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-
 100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC
 grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5%
 HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1
 mL/minute. All NMR spectra were recorded at room temperature using a Bruker
 10 DRX400 spectrometer. LCMS m/z 537.18 (M+H), R_t 2.492 min. HPLC R_t 10.694
 min. (Sunfire C18), 99.6% purity and 12.230 min. (XBridge phenyl C18), 99.6 %
 purity. ^1H NMR (400 MHz, CD_3OD) δ ppm 1.82 (s, 6 H), 3.01 (s, 3 H), 3.94 (s, 3 H),
 7.18 - 7.27 (m, 2 H), 7.28 - 7.40 (m, 4 H), 7.50 (d, J = 7.53 Hz, 2 H), 7.57 - 7.67 (m, 2
 H), 7.85 (d, J = 1.00 Hz, 1 H), 7.89 - 7.95 (m, 2 H), 7.98 - 8.09 (m, 2 H).

15




2-(4-Fluorophenyl)-5-(2-methoxy-5-(1-phenylcyclopropylcarbamoyl)phenyl)-N-
 methylbenzofuran-3-carboxamide


[00254] To a 50mL RBF was added 3-(2-(4-fluorophenyl)-3-
 20 (methylcarbamoyl)benzofuran-5-yl)-4-methoxybenzoic acid (433.9 mg, 1.035 mmol),
 DMF (15 mL), 1-phenylcyclopropan- amine, HCl (214 mg, 1.259 mmol), N-ethyl-N-
 isopropylpropan-2-amine (0.438 mL, 2.52 mmol), and finally HATU, 2-(3H-
 [1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium
 hexafluorophosphate(V) (1180 mg, 3.10 mmol)). The mixture was stirred over night
 25 at room temperature. The reaction mixture was diluted with dichloromethane,
 washed with 0.5M HCl, then brine and dried over MgSO_4 . The solution was
 concentrated to give a tan oil. The crude product was taken up in 10mL of

acetonitrile and purified using a Shimadzu preparative HPLC employing acetonitrile/water/0.1%TFA where solvent A was 10% acetonitrile / 90% H₂O/ 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% acetonitrile/ 0.1% trifluoroacetic acid with a PHENOMENEX® Luna 10µm C18 30 x 100mm column at a gradient of 40-100% B and a flow rate of 40 mL/min. over 8 minutes with a 12 minute hold to give a 77% yield of product as a white powder. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 220nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5µm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. All NMR spectra were recorded at room temperature using a Bruker DRX400 spectrometer. LCMS *m/z* 535.16 (M+H), *R_t* 2.373 min. HPLC *R_t* 10.314 min. (Sunfire C18), 95.78% purity and 12.230 min. (XBridge phenyl C18), 99.6 % purity. ¹H NMR (400 MHz, CD₃OD) δ ppm 1.40 (dd, *J* = 7.03, 2.01 Hz, 4 H), 3.01 (s, 3 H), 3.94 (s, 3 H), 7.18 - 7.26 (m, 2 H), 7.28 - 7.38 (m, 6 H), 7.56 - 7.62 (m, 1 H), 7.62 - 7.67 (m, 1 H), 7.85 (d, *J* = 1.51 Hz, 1 H), 7.94 - 8.05 (m, 4 H).

30




[00255] General procedure: To a BIOTAGE® microwave vial (2-5 mL) was added 5-(4-chloro-3-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (0.075 mmol, 1 eq.) in dry 1,4-Dioxane (1 mL) along with the desired boronic acid (0.150 mmol, 2 eq.), potassium phosphate, tribasic (0.300 mmol, 52.3 mg) in water (0.2 mL), dicyclohexyl(2',6'-dimethoxybiphenyl-3-yl)phosphine (S-Phos) (6.16 mg, 0.015 mmol), and finally palladium (II) acetate (3.37 mg, 0.015 mmol) in 1,4-dioxane (0.5 mL). The vial was flushed with nitrogen then capped and placed into a BIOTAGE® microwave for 10 minutes at 150 °C. The solvent was removed in a Thermo/Savant SPEEDVAC® and the crude products were dissolved in DMF (1.8 mL) and purified by preparative HPLC employing a DIONEX® Prep HPLC system equipped with an ELS (Evaporative Light Scattering) detector. A PHENOMENEX® Gemini 5µm C18 21.2 x 250mm column was used with acetonitrile/HPLC grade water/20mM ammonium acetate where solvent A was HPLC grade water with 20mM ammonium acetate and solvent B was 100% acetonitrile at a gradient of 30-95% B in 23.5 minutes with a 2.5 minute hold at 20mL/minute. HPLC purity was determined using a Waters ZQ with ESCi mass spectrometer with a SUPELCO® Ascentis 2.7 µm C18 4.6 x 50mm column employing acetonitrile/HPLC grade water/0.1% trifluoroacetic acid where solvent A was 5% acetonitrile, 95% HPLC grade water with 0.1% trifluoroacetic acid and solvent B was 95% acetonitrile, 5% HPLC grade water with 0.1% trifluoroacetic acid at a gradient of 10-95% B in 8 minutes with a 1 minute hold at 2mL/minute. The NMR spectra were recorded at room temperature using a Varian 400MHz flow spectrometer. Chemical shifts were reported in ppm relative to the DMSO-d₆/CDCl₃ solvent used.



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-4-(pyridin-3-yl)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00256] LCMS m/z 522.19 (M+H), R_t 3.21 min., 100 % purity.


5



2-(4-Fluorophenyl)-5-(3'-(hydroxymethyl)-2-(isobutylcarbamoyl)biphenyl-4-yl)-*N*-methylbenzofuran-3-carboxamide

[00257] ^1H NMR δ ppm 0.76 (d, J = 6.74 Hz, 6 H), 1.68 (m, 1 H), 2.29 (s, 3 H), 2.81 - 3.00 (m, 4 H), 7.07 - 7.18 (m, 1 H), 7.22 (t, J = 7.47 Hz, 1 H), 7.26 - 7.37 (m, 2 H), 7.39 (s, 1 H), 7.48 (d, J = 7.91 Hz, 1 H), 7.72 (br. s., 2 H), 7.80 (d, J = 8.20 Hz, 1 H), 7.92 (s, 1 H), 8.01 (dd, J = 7.47, 5.42 Hz, 2 H), 8.22 (s, 2 H), 8.46 (br. s., 1 H).
LCMS m/z 551.23 (M+H), R_t 4.23 min., 100 % purity.


10



5-(3'-Ethoxy-2-(isobutylcarbamoyl)biphenyl-4-yl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide


[00258] LCMS m/z 565.24 (M+H), R_t 5.28 min., 93.4 % purity.

15




2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-
N-methylbenzofuran-3-carboxamide

[00259] ^1H NMR δ ppm 0.93 (d, $J = 6.74$ Hz, 6 H), 1.82 - 1.99 (m, 1 H), 2.37 (s, 3 H), 2.89 - 3.00 (m, 2 H), 3.94 (s, 3 H), 7.15 - 7.25 (m, 1 H), 7.25 - 7.33 (m, 1 H), 7.39 (t, $J = 8.20$ Hz, 1 H), 7.62 - 7.82 (m, 5 H), 7.93 (d, $J = 12.89$ Hz, 1 H), 8.02 - 8.12 (m, 1 H), 8.36 - 8.45 (m, 1 H), 8.53 (d, 1 H). LCMS m/z 525.21 (M+H), R_t 4.00 min., 100 % purity.




2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-4-(isoquinolin-4-yl)phenyl)-N-
methylbenzofuran-3-carboxamide

[00260] ^1H NMR δ ppm 0.64 (d, $J = 6.44$ Hz, 6 H), 1.38 - 1.48 (m, 1 H), 2.37 (s, 3 H), 2.93 - 3.02 (m, 2 H), 7.14 - 7.24 (m, 2 H), 7.25 - 7.33 (m, 2 H), 7.40 (t, $J = 8.79$ Hz, 1 H), 7.57 (d, $J = 7.32$ Hz, 1 H), 7.75 (br. s., 2 H), 7.81 - 7.90 (m, 1 H), 7.95 - 8.03 (m, 2 H), 8.08 (br. s., 2 H), 8.18 - 8.25 (m, 1 H), 8.31 - 8.37 (m, 1 H), 8.48 (s, 1 H), 8.55 (br. s., 1 H). LCMS m/z 572.22 (M+H), R_t 3.49 min., 100 % purity.




2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-4-(2-methoxypyridin-3-yl)phenyl)-N-
methylbenzo-furan-3-carboxamide

[00261] ^1H NMR δ ppm 0.88 (d, $J = 6.74$ Hz, 6 H), 1.68 - 1.83 (m, 1 H), 2.37 (s, 3 H), 2.96 (d, $J = 4.69$ Hz, 2 H), 3.86 (s, 3 H), 7.04 - 7.13 (m, 1 H), 7.21 (d, $J = 7.32$ Hz, 1 H), 7.28 (d, $J = 7.03$ Hz, 1 H), 7.39 (t, $J = 8.05$ Hz, 1 H), 7.48 (d, $J = 8.49$ Hz, 1 H), 7.67 (d, $J = 7.03$ Hz, 1 H), 7.82 (s, 2 H), 7.88 (br. s., 2 H), 8.04 (s, 1 H), 8.06 - 8.12 (m, 1 H), 8.18 (d, $J = 4.98$ Hz, 1 H), 8.54 (br. s., 1 H). LCMS m/z 552.21 (M+H), R_t 4.56 min., 90.5 % purity.




2-(4-Fluorophenyl)-5-(2-(isobutylcarbamoyl)-4'-isopentylbiphenyl-4-yl)-N-methylbenzofuran-3-carboxamide

[00262] ^1H NMR δ ppm 0.99 (dd, $J = 12.74, 6.59$ Hz, 9 H), 1.23 - 1.37 (m, 3 H), 1.59 - 1.70 (m, 1 H), 1.88 - 2.00 (m, 1 H), 2.37 (s, 3 H), 2.76 - 2.87 (m, 2 H), 2.91 - 2.99 (m, 2 H), 3.10 - 3.20 (m, 2 H), 7.14 - 7.25 (m, 1 H), 7.29 (t, $J = 7.32$ Hz, 1 H), 7.38 (t, $J = 8.05$ Hz, 2 H), 7.64 (s, 1 H), 7.72 (dd, $J = 16.26, 8.05$ Hz, 2 H), 7.93 (s, 1 H), 8.01 - 8.11 (m, 2 H), 8.44 (br. s., 1 H), 8.52 (br. s., 1 H). LCMS m/z 515.26 (M+H), R_t 5.63 min., 100 % purity.




2-(4-Fluorophenyl)-5-(2-(isobutylcarbamoyl)-2'-methoxybiphenyl-4-yl)-N-methylbenzofuran-3-carboxamide

[00263] ^1H NMR δ ppm 0.85 (d, $J = 6.74$ Hz, 6 H), 1.63 - 1.77 (m, 1 H), 2.37 (s, 3 H), 2.96 (d, $J = 4.39$ Hz, 2 H), 3.77 (s, 3 H), 6.99 - 7.09 (m, 1 H), 7.21 (d, $J = 7.62$ Hz, 1 H), 7.29 (t, $J = 7.62$ Hz, 2 H), 7.34 - 7.46 (m, 3 H), 7.76 - 7.88 (m, 3 H), 7.92 - 7.98 (m, 1 H), 8.02 (s, 1 H), 8.09 (dd, $J = 7.76, 6.00$ Hz, 2 H), 8.54 (br. s., 1 H). LCMS m/z 551.22 (M+H), R_t 5.07 min., 93.7 % purity.



(*E*)-3-(4'-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2'-(isobutylcarbamoyl)biphenyl-3-yl)acrylic acid


- 5 **[00264]** ^1H NMR δ ppm 0.81 (d, $J = 6.44$ Hz, 6 H), 1.65 - 1.77 (m, 1 H), 2.37 (s, 3 H), 2.96 (d, $J = 4.39$ Hz, 2 H), 6.55 (d, $J = 15.82$ Hz, 1 H), 7.14 - 7.25 (m, 2 H), 7.25 - 7.33 (m, 1 H), 7.40 (t, $J = 8.49$ Hz, 2 H), 7.47 - 7.56 (m, 1 H), 7.61 (d, $J = 8.20$ Hz, 1 H), 7.67 (br. s., 1 H), 7.73 (br. s., 1 H), 7.80 (br. s., 2 H), 7.90 (d, $J = 7.91$ Hz, 1 H), 8.01 (s, 1 H), 8.04 - 8.13 (m, 1 H), 8.36 (br. s., 1 H), 8.53 (br. s., 1 H). LCMS m/z
- 10 591.23 (M+H), R_t 4.37 min., 100 % purity.



4'-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2'-(isobutylcarbamoyl)biphenyl-3-carboxylic acid

- 15 **[00265]** ^1H NMR δ ppm 0.80 (d, $J = 6.74$ Hz, 6 H), 1.67 - 1.79 (m, 1 H), 2.37 (s, 3 H), 2.96 (d, $J = 4.69$ Hz, 2 H), 7.16 - 7.25 (m, 2 H), 7.26 - 7.32 (m, 1 H), 7.33 - 7.44 (m, 2 H), 7.50 - 7.62 (m, 2 H), 7.66 - 7.73 (m, 1 H), 7.76 - 7.84 (m, 2 H), 7.90 (d, $J = 7.91$ Hz, 1 H), 7.95 - 8.02 (m, 1 H), 8.04 - 8.14 (m, 2 H), 8.32 - 8.37 (m, 1 H), 8.55 (br. s., 1 H). LCMS m/z 565.22 (M+H), R_t 4.22 min., 100 % purity.


20



5-(4-(1*H*-Indol-6-yl)-3-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

[00266] LCMS m/z 560.23 (M+H), R_t 4.90 min., 97.2 % purity.


5



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-4-(1-propyl-1*H*-pyrazol-4-yl)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00267] LCMS m/z 553.25 (M+H), R_t 4.49 min., 96 % purity.


10



5-(2'-Chloro-2-(isobutylcarbamoyl)biphenyl-4-yl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide


[00268] ^1H NMR δ ppm 0.85 (d, J = 6.44 Hz, 6 H), 1.65 - 1.80 (m, 1 H), 2.37 (s, 3 H), 2.93 - 2.97 (m, 2 H), 7.06 (br. s., 1 H), 7.15 - 7.24 (m, 2 H), 7.25 - 7.35 (m, 2 H), 7.35 - 7.47 (m, 4 H), 7.49 - 7.55 (m, 1 H), 7.79 - 7.86 (m, 1 H), 7.87 - 7.93 (m, 1 H), 7.98 - 8.13 (m, 2 H), 8.21 - 8.27 (m, 1 H), 8.53 (br. s., 1 H). LCMS m/z 556.19 (M+H), R_t 5.28 min., 100 % purity.

15




4-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-N2-isobutylbiphenyl-2,2'-dicarboxamide

[00269] ^1H NMR δ ppm 0.69 (d, $J = 6.44$ Hz, 6 H), 1.42 - 1.54 (m, 1 H), 2.37 (s, 3 H), 2.92 - 2.97 (m, 2 H), 7.13 - 7.23 (m, 2 H), 7.23 - 7.33 (m, 2 H), 7.39 (t, $J = 8.64$ Hz, 1 H), 7.43 - 7.51 (m, 2 H), 7.61 (d, $J = 4.69$ Hz, 1 H), 7.75 - 7.82 (m, 2 H), 7.86 (s, 1 H), 7.96 - 8.03 (m, 1 H), 8.08 (d, $J = 5.27$ Hz, 1 H), 8.13 - 8.18 (m, 1 H), 8.51 (br. s., 1 H), 8.65 (br. s., 1 H). LCMS m/z 564.24 (M+H), R_t 4.07 min., 98.9 % purity.




5-(2'-(Acetamido)-2-(isobutylcarbamoyl)biphenyl-4-yl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00270] ^1H NMR δ ppm 0.50 - 0.73 (m, 6 H), 1.33 - 1.50 (m, 1 H), 1.90 (s, 3 H), 2.37 (s, 3 H), 2.92 - 2.97 (m, 2 H), 7.20 (t, $J = 7.91$ Hz, 3 H), 7.25 - 7.44 (m, 6 H), 7.75 - 7.82 (m, 2 H), 7.91 (s, 1 H), 7.96 - 8.03 (m, 1 H), 8.04 - 8.11 (m, 1 H), 8.24 (br. s., 1 H), 8.52 (br. s., 1 H), 9.89 - 9.96 (m, 1 H). LCMS m/z 578.24 (M+H), R_t 4.26 min., 93.5 % purity.




2-(4-Fluorophenyl)-5-(2'-(hydroxymethyl)-2-(isobutylcarbamoyl)biphenyl-4-yl)-*N*-methylbenzofuran-3-carboxamide

[00271] ^1H NMR δ ppm 0.71 (d, $J = 5.27$ Hz, 6 H), 1.45 - 1.57 (m, 1 H), 2.37 (s, 3 H), 2.90 (br. s., 2 H), 2.96 (d, $J = 4.69$ Hz, 2 H), 7.13 - 7.25 (m, 2 H), 7.25 - 7.35 (m, 1 H), 7.35 - 7.44 (m, 3 H), 7.56 (d, $J = 7.32$ Hz, 1 H), 7.81 (s, 2 H), 7.83 - 7.89 (m, 2 H), 8.01 (s, 1 H), 8.09 (dd, $J = 8.64, 5.42$ Hz, 2 H), 8.52 (br. s., 1 H). LCMS m/z 551.22 (M+H), R_t 4.58 min., 96 % purity.



10 2-(4-Fluorophenyl)-5-(2-(isobutylcarbamoyl)-2'-(methoxymethyl)biphenyl-4-yl)-*N*-methylbenzofuran-3-carboxamide


[00272] ^1H NMR δ ppm 0.64 - 0.79 (m, 6 H), 1.47 - 1.59 (m, 1 H), 2.37 (s, 3 H), 2.86 - 2.93 (m, 2 H), 2.93 - 2.99 (m, 2 H), 3.25 (s, 3 H), 7.15 - 7.25 (m, 2 H), 7.26 - 7.32 (m, 1 H), 7.33 - 7.44 (m, 4 H), 7.49 - 7.55 (m, 1 H), 7.81 (s, 2 H), 7.87 (br. s., 2 H), 8.02 (br. s., 1 H), 8.05 - 8.12 (m, 1 H), 8.53 (br. s., 1 H). LCMS m/z 565.22 (M+H), R_t 5.30 min., 100 % purity.



20 5-(3'-(Cyanomethyl)-2-(isobutylcarbamoyl)biphenyl-4-yl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide


[00273] ^1H NMR δ ppm 0.83 (d, $J = 6.44$ Hz, 6 H), 1.67 - 1.81 (m, 1 H), 2.37 (s, 3 H), 2.96 (d, $J = 4.39$ Hz, 2 H), 4.08 (s, 2 H), 7.14 - 7.25 (m, 2 H), 7.26 - 7.32 (m, 1 H), 7.35 - 7.44 (m, 2 H), 7.48 (d, $J = 5.27$ Hz, 2 H), 7.56 (d, $J = 7.91$ Hz, 1 H), 7.80 (br. s., 2 H), 7.90 (d, $J = 7.62$ Hz, 1 H), 8.00 (s, 1 H), 8.04 - 8.13 (m, 2 H), 8.35 (br. s.,

1 H), 8.54 (d, $J = 3.81$ Hz, 1 H). LCMS m/z 560.23 (M+H), R_t 4.67 min., 91.5 % purity.




- 5 *N*3'-Ethyl-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-*N*2-isobutylbiphenyl-2,3'-dicarboxamide

[00274] LCMS m/z 592.26 (M+H), R_t 4.28 min., 94.1 % purity.




- 10 2-(4-Fluorophenyl)-5-(4-(furan-3-yl)-3-(isobutylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00275] ^1H NMR δ ppm 0.86 - 1.03 (m, 6 H), 1.80 - 1.94 (m, 1 H), 2.37 (s, 3 H), 2.92 - 3.00 (m, 2 H), 6.79 (s, 1 H), 7.15 - 7.24 (m, 2 H), 7.28 (d, $J = 7.03$ Hz, 2 H), 7.35 - 7.42 (m, 1 H), 7.69 (t, $J = 7.91$ Hz, 2 H), 7.73 - 7.85 (m, 3 H), 7.94 (d, $J =$
15 19.33 Hz, 1 H), 8.04 - 8.12 (m, 1 H), 8.41 - 8.48 (m, 1 H), 8.53 (d, 1 H). LCMS m/z 511.17 (M+H), R_t 4.69 min., 86.5 % purity.




3'-Phenyl-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-N2-isobutylbiphenyl-2,3'-dicarboxamide

[00276] ^1H NMR δ ppm 0.75 (d, J = 6.74 Hz, 6 H), 1.59 - 1.72 (m, 1 H), 2.37 (s, 3 H), 2.94 - 2.98 (m, 2 H), 7.15 - 7.24 (m, 3 H), 7.25 - 7.33 (m, 2 H), 7.34 - 7.47 (m, 4 H), 7.49 - 7.58 (m, 2 H), 7.63 - 7.74 (m, 2 H), 7.75 - 7.83 (m, 3 H), 7.89 (br. s., 1 H), 8.00 (s, 1 H), 8.07 (br. s., 1 H), 8.54 (br. s., 1 H). LCMS m/z 597.27 (M+H), R_t 5.74 min., 80 % purity.




10 [00277] The general procedures (for amide formations) below pertain to the experimental procedures. Some of the compounds were made with different scales of the acids. The acid (0.075 mmol, 1 eq.) was dissolved in dried DMF and followed by adding HATU (0.090 mmol, 1.2 eq.) and DIPEA (0.225 mmol, 3.0 eq.). The solution was stirred for 2 minutes and added into amine (0.090 mmol, 1.2 eq.) at room
15 temperature. The mixture was stirred 14 h and purified by prep-HPLC.




2-(4-Fluorophenyl)-N-methyl-5-(3-(3-methylbenzylcarbamoyl)phenyl)benzofuran-3-carboxamide

20 [00278] ^1H NMR (600 MHz, DMSO- d_6 -CDCl $_3$) δ ppm 9.15 (1 H, t, J =5.86 Hz), 8.48 (1 H, d, J =4.69 Hz), 8.27 (2 H, d, J =4.69 Hz), 8.00 - 8.08 (1 H, m), 7.92 - 7.97 (2 H, m), 7.89 (1 H, d, J =7.62 Hz), 7.77 (2 H, s), 7.61 (1 H, t, J =7.62 Hz), 7.37 (2 H, t, J =8.50 Hz), 7.24 (1 H, t, J =7.32 Hz), 7.14 - 7.22 (2 H, m), 7.08 (1 H, d, J =7.03 Hz), 4.54 (2 H, d, J =5.86 Hz), 2.92 (3 H, d, J =4.10 Hz), 2.34 (3 H, s).



2-(4-Fluorophenyl)-N-methyl-5-(3-(neopentylcarbamoyl)phenyl)benzofuran-3-carboxamide

- 5 **[00279]** ^1H NMR (600 MHz, DMSO- d_6 -CDCl $_3$) δ ppm 8.44 - 8.51 (m, 2 H), 8.27 (s, 1 H), 8.20 (s, 1 H), 8.02 - 8.07 (m, 1 H), 7.96 (s, 1 H), 7.88 (t, J =7.32 Hz, 2 H), 7.77 (s, 2 H), 7.59 (t, J =7.62 Hz, 1 H), 7.37 (t, J =8.50 Hz, 2 H), 3.20 (d, J =6.44 Hz, 2 H), 2.92 (d, J =4.69 Hz, 3 H), 0.98 (s, 9 H).



10

2-(4-Fluorophenyl)-N-methyl-5-(3-(4-methylbenzylcarbamoyl)phenyl)benzofuran-3-carboxamide

- [00280]** ^1H NMR (600 MHz, DMSO- d_6 -CDCl $_3$) δ ppm 9.14 (t, J =5.86 Hz, 1 H), 8.48 (d, J =4.69 Hz, 1 H), 8.27 (s, 1 H), 8.25 (s, 1 H), 8.01 - 8.06 (m, 1 H), 7.95 (s, 1 H), 7.93 (d, J =7.62 Hz, 1 H), 7.89 (d, J =7.62 Hz, 1 H), 7.77 (s, 2 H), 7.61 (t, J =7.62 Hz, 1 H), 7.37 (t, J =8.50 Hz, 2 H), 7.27 (d, J =7.62 Hz, 2 H), 7.16 (d, J =7.62 Hz, 2 H), 4.52 (d, J =5.86 Hz, 2 H), 2.92 (d, J =4.10 Hz, 3 H), 2.30 - 2.35 (m, 3 H).
- 15

- [00281]** HPLC purity was determined using a Waters LCT Mass Spectrometer with four way MUX source analytical LC at 220nm with employing acetonitrile and water or Waters ZQ with ESCi mass spectrometer. A = 5:95 CH $_3$ CN:Water; B = 95:5 CH $_3$ CN :Water; Modifier = 10 mM NH $_4$ OAc. Retention time was recorded in minutes.
- 20

Analytical Method A:

Column Waters XTERRA® 2.1x50mm 5 um C18

Time	B%	Flow
0.00	0	1.0
4.00	100	1.0
5.00	100	1.0

Analytical Method B:

5 Column: Waters XBridge 2.1x50mm 5 um C18

Time	B%	Flow
0.00	0	1.0
4.00	100	1.0
5.00	100	1.0
5.05	100	1.0
6.00	0	1.0

Analytical Method C:

Column: Waters XBridge 4.6x50mm 5 um C18

Time	B%	Flow
0.00	0	2.0
8.00	100	2.0
9.00	100	2.0

10 Analytical Method D:

Column: Waters XBridge 4.6x50mm 5 um C18

Time	B%	Flow
0.00	0	1.0
8.00	100	1.0
9.00	100	1.0
9.10	100	1.0

Time	B%	Flow
1.00	0	10

Analytical Method E:

Waters ZQ with ESCi mass spectrometer

Column: SUPELCO® Ascentis 4.6x50mm 2.7 um C18

Time	B%	Flow
0.00	10	3.00
5.30	95	3.00
6.00	95	3.00
6.20	10	3.00
7.00	10	3.00


5

Analytical Method F:









Waters ZQ with ESCi mass spectrometer








Column: PHENOMENEX® Gemini 4.6x150mm 3 um C18








Time	B%	Flow
0.00	10	1.0
10.00	95	1.0
13.00	95	1.0
13.50	10	1.0
15.00	10	1.0








Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	2.81	100	458.93	Method A








Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	2.75	100	494.89	Method A
	2.38	100	468.9	Method A
	2.22	100	472.91	Method A
	2.46	100	482.9	Method A
	2.68	95.0177	493.92	Method A
	2.5	98.5972	494.9	Method A
	2.42	100	460.91	Method A
	2.34	100	494.9	Method A

Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	3.05	100	472.96	Method A
	2.48	100	426.91	Method A
	2.86	100	513.92	Method A
	2.89	100	513.91	Method A
	2.69	100	456.95	Method A
	2.8	100	495.94	Method A
	2.84	100	513.93	Method A
	2.85	100	498.9	Method A








Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	2.56	100	486.94	Method A
Chiral 	2.1	100	458.91	Method A
	2.93	100	509.94	Method A
	2.53	100	504.9	Method A
	2.23	100	485.92	Method A
	2.11	100	473.91	Method A
	2.51	100	460.92	Method A








Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	2.89	100	458.94	Method A
	2.62	100	459.94	Method A
	2.85	100	475.95	Method A
	2.72	100	444.94	Method A
	2.91	100	475.95	Method A
	2.97	100	509.93	Method A
	2	100	473.92	Method A








Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	2.89	100	475.95	Method A
	2.43	100	486.93	Method A
	2.44	100	485.85	Method A
	2.39	100	856.65	Method B
	2.81	96.6226	494.8	Method B
	2.75	100	940.66	Method B
	2.89	99.0179	988.56	Method B









Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	2.7	100	1056.6	Method B
	2.94	89.8624	968.67	Method B
	2.75	100	984.61	Method B
	2.29	100	455.82	Method B
	2.92	98.0936	980.59	Method B
	2.32	98.0376	479.8	Method B
	2.35	100	472.83	Method B








Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	2.56	100	972.64	Method B
	2.26	100	472.83	Method B
	2.06	98.6458	892.65	Method B
	2.43	100	884.66	Method B
	2.81	100	940.69	Method B
	2.82	100	940.7	Method B
	2.93	100	968.72	Method B








Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	2.95	100	968.7	Method B
	2.6	100	884.67	Method B
	2.35	100	856.66	Method B
	2.34	96.8795	958.6	Method B
	2.26	100	479.81	Method B
	2.82	100	806.66	Method B
	2.75	100	970.55	Method B








Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	2.48	100	480.8	Method B
	2.77	100	479.81	Method B
	2.7	98.233	480.8	Method B
	2.57	100	465.64	Method B
	2.85	97.8741	958.25	Method B
	2.64	100	930.26	Method B
	2.24	100	972.33	Method B







Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	5.21	100	444.95	Method C
	4.95	100	444.96	Method C
Chiral 	3.74	100	499.93	Method C
	4.54	100	507.94	Method C
	4.37	100	507.93	Method C
	4.32	100	460.91	Method C
	3.68	100	485.94	Method C







Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	5.31	100	510.91	Method C
	3.78	100	432.93	Method C
	4.68	93.1925	466.91	Method D
	5.72	96.6697	464.93	Method D
	5.57	96.8314	489.9	Method D
	5.72	94.0943	478.93	Method D
	4.93	94.4826	455.9	Method D
	5.26	88.6355	469.92	Method D

Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	4.7	100	466.92	Method D
	5.59	97.7461	494.92	Method D
	4.06	100	497.98	Method D
	5.05	97.6492	502.96	Method D
Chiral 	4.7	100	474.95	Method D
	4.7	100	501.98	Method D
Chiral 	3.74	100	512.96	Method D







Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	5.2	97.5131	486.97	Method D
Chiral 	5.05	100	488.95	Method D
Chiral 	4.74	100	508.95	Method D
	4.79	100	482.96	Method D
	4.18	100	490.94	Method D
Chiral 	4.8	100	474.98	Method D
Chiral 	4.43	100	499.97	Method D






Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	4.04	95.8428	481.93	Method D
Chiral 	4.5	93.8873	487.97	Method D
Chiral 	4.26	100	490.94	Method D
	4.88	100	488.93	Method D
Chiral 	5.11	100	488.97	Method D
	4.81	100	522.93	Method D
Chiral 	5.06	100	520.93	Method D



Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	5.74	100	516.94	Method D
Chiral 	4.26	100	473.94	Method D
Chiral 	5.85	100	504.94	Method D
Chiral 	4.69	100	474.96	Method D
	4.74	100	479.92	Method D
	4.71	100	493.93	Method D


Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
Chiral 	4.19	100	513.95	Method D
Chiral 	5.04	100	488.97	Method D
Chiral 	4.97	100	488.96	Method D
	4.7	98.2446	519.93	Method D
Chiral 	5.64	100	522.94	Method D
	5.97	100	487	Method D

Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	6.1	100	520.96	Method D
	3.168	100	455.14	Method E
	2.754	100	461.15	Method E
	3.53	95.5615	499.12	Method E
	4.061	100	501.23	Method E
	3.539	98.8021	459.19	Method E
	3.496	100	523.18	Method E


Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	3.008	100	506.17	Method E
	3.896	98.8111	539.22	Method E
	3.608	100	537.21	Method E
	3.868	98.488	557.22	Method E
	3.179	100	472.1	Method E
	2.536	100	488.16	Method E

Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	2.718	100	502.19	Method E
	3.025	100	557.15	Method E
	2.664	100	513.16	Method E
	2.835	100	514.17	Method E
	2.87	100	538.16	Method E

Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	8.435	100	423.19	Method F
	8.778	100	490.13	Method F




- [00282]** The general procedures below pertain to the experimental procedures. Some of the compounds were made with different scales. 2-(4-fluorophenyl)-3-
- 5 (methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (0.100 mmol, 1 eq.) was dissolved in dried 1,4-Dioxane (1 mL) and added into BIOTAGE® microwave vial (0.5-2 mL) containing boronic acid (0.340 mmol, 3.4 eq.). Then Cs₂CO₃ (0.300 mmol, 3 eq.) was added as a solid and following by adding water (0.25 mL). The vial
- 10 was flushed with nitrogen and Pd(PPh₃)₄ was added. After the vial was re-flushed with nitrogen and capped, it was heated in a BIOTAGE® microwave reactor at 150 °C for 15 minutes. The mixture was filtered with a 0.45 um filter and dried with a SPEEDVAC®. The sample was dissolved in DMF (1.6 mL) and purified by prep-HPLC.




5-(3-Acetamidophenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00283] ^1H NMR (600 MHz, DMSO- d_6 -CDCl $_3$) δ ppm 10.03 (br. s., 1 H), 8.49 (d, $J=4.69$ Hz, 1 H), 8.28 (s, 1 H), 8.03 (dd, $J=8.79$, 5.27 Hz, 2 H), 7.93 (br. s., 1 H), 7.84 (s, 1 H), 7.75 (d, $J=8.20$ Hz, 1 H), 7.64 (d, $J=6.44$ Hz, 2 H), 7.29 - 7.45 (m, 3 H), 2.92 (s, 3 H), 2.12 (s, 3 H).



5-(2-(Benzyloxy)-4-fluorophenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

10 **[00284]** ^1H NMR (600 MHz, DMSO- d_6 -CDCl $_3$) δ ppm 8.41 (d, $J=4.69$ Hz, 1 H), 8.28 (s, 1 H), 8.03 (dd, $J=8.79$, 5.27 Hz, 2 H), 7.82 (s, 1 H), 7.67 (d, $J=8.20$ Hz, 1 H), 7.55 (d, $J=7.03$ Hz, 1 H), 7.34 - 7.47 (m, 7 H), 7.13 (d, $J=9.37$ Hz, 1 H), 6.83 - 6.94 (m, 1 H), 5.19 (s, 2 H), 2.88 (d, $J=4.10$ Hz, 3 H).



2-(4-Fluorophenyl)-5-(4-isobutoxyphenyl)-N-methylbenzofuran-3-carboxamide

15 **[00285]** ^1H NMR (600 MHz, DMSO- d_6 -CDCl $_3$) δ ppm 8.46 (d, $J=4.69$ Hz, 1 H), 8.28 (s, 1 H), 8.04 (dd, $J=8.50$, 5.57 Hz, 1 H), 7.81 (s, 1 H), 7.67 - 7.73 (m, 1 H), 7.60 - 7.67 (m, 2 H), 7.36 (t, $J=8.79$ Hz, 1 H), 7.05 (d, $J=8.79$ Hz, 2 H), 3.83 (d, $J=6.44$ Hz, 2 H), 2.91 (d, $J=4.69$ Hz, 3 H), 2.09 (ddd, $J=13.33$, 6.59, 6.44 Hz, 1 H), 1.05 (d, $J=7.03$ Hz, 6 H).

20

[00286] HPLC purity was determined using a Waters LCT Mass Spectrometer with four way MUX source analytical LC at 220nm with employing acetonitrile and water or Waters ZQ with ESCi mass spectrometer. A = 5:95 CH₃CN :Water; B = 95:5

- 5 CH₃CN :Water; Modifier = 10 mM NH₄OAc. Retention time was recorded in minutes.

Analytical Method A:

Column Waters XTERRA® 2.1x50mm 5 um C18

Time	B%	Flow
0.00	0	1.0
4.00	100	1.0
5.00	100	1.0

10

Analytical Method B:

Column: Waters XBridge 2.1x50mm 5 um C18

Time	B%	Flow
0.00	0	1.0
4.00	100	1.0
5.00	100	1.0
5.05	100	1.0
6.00	0	1.0

Analytical Method F:






- 15 Waters ZQ with ESCi mass spectrometer






Column: PHENOMENEX® Gemini 4.6x150mm 3 um C18






Time	B%	Flow
0.00	10	1.0
10.00	95	1.0
13.00	95	1.0





Time	B%	Flow
13.50	10	1.0
15.00	10	1.0






Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	7.23	100	390.16	Method F
	3.842	100	460.23	Method F
	7.666	100	416.18	Method F
	7.018	100	403.2	Method F
	5.322	100	336.23	Method F
	7.091	100	396.13	Method F



Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	12.982	100	470.3	Method F
	13.755	100	418.33	Method F
	12.669	100	446.26	Method F
	10.775	100	395.28	Method F
	8.933	100	439.24	Method F


Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	10.716	100	395.31	Method F
	11.858	100	461.33	Method F
	10.916	100	399.21	Method F
	2.49	100	443.06	Method B
	2.56	100	410	Method B

Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	2.36	100	376.05	Method B
	2.75	90.0925	457.45	Method B
	2.36	95.5596	447.39	Method B
	3.34	100	446.41	Method B
	2.43	100	417.4	Method B


Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	2.67	97.2446	445.4	Method B
	2.37	100	417.33	Method B
	2.02	100	416.3	Method B
	2.92	100	471.37	Method B

Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	2.76	100	445.37	Method B
	2.71	100	457.35	Method B
	2.52	100	431.35	Method B
	2.725	94.4043	445.36	Method B
	2.38	95.3608	442.32	Method B

Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	2.56	100	431.34	Method B
	2.76	97.5284	445.38	Method B



- [00287]** The general procedures below pertain to the experimental procedures. 2-(4-fluorophenyl)-5-hydroxy-N-methylbenzofuran-3-carboxamide (0.120 mmol, 1 eq.)
- 5 in THF (2.3 mL) was added into BIOTAGE® microwave vial(5 mL) containing ROH (2.28 eq.) and PPh₃ (1.4 eq.). Then DEAD (1.4 eq.) was added as neat. The vial was flushed with nitrogen, capped and heated at 140 °C for 20 minutes in a BIOTAGE® microwave reactor. The mixture was dried with SPEEDVAC®, dissolved in DMF (1.6 mL) and purified by prep-HPLC.



5-(2-(4-*tert*-Butylphenoxy)ethoxy)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide



[00288] ¹H NMR (600 MHz, DMSO-*d*₆-CDCl₃) δ ppm 8.36 (d, J=4.69 Hz, 1 H),
 5 8.27 (s, 1 H), 7.99 (dd, J=8.50, 5.57 Hz, 1 H), 7.56 (d, J=8.79 Hz, 1 H), 7.28 - 7.39 (m, 3 H), 7.21 (d, J=2.34 Hz, 1 H), 7.05 (dd, J=9.37, 2.34 Hz, 1 H), 6.94 (d, J=8.79 Hz, 3 H), 4.28 - 4.45 (m, 4 H), 2.89 (d, J=4.69 Hz, 3 H), 1.30 (s, 9 H).


[00289] HPLC purity was determined using a Waters LCT Mass Spectrometer with
 10 four way MUX source analytical LC at 220nm with employing acetonitrile and water.
 A = 5:95 CH₃CN :Water; B = 95:5 CH₃CN :Water; Modifier = 10 mM NH₄OAc.
 Retention. Time was recorded in minutes.

Analytical Method B:

15 Column: Waters XBridge 2.1x50mm 5 um C18

Time	B%	Flow
0.00	0	1.0
4.00	100	1.0
5.00	100	1.0
5.05	100	1.0
6.00	0	1.0

Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	3.63	100	461.8073	Method B
	2.81	100	442.825	Method B



- [00290] The general procedures below pertain to the experimental procedures. 4-[2-(4-fluorophenyl)-3-(methanocarbamoyl)benzofuran-5-yl]-2-
- 5 (isobutylcarbamoyl)phenyl trifluoromethanesulfonate (0.076 mmol, 45 mg), dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (S-Phos) (6.24 mg, 0.02 mmol), boronic acid (0.175 mmol) and potassium phosphate (0.190 mmol, 40.2 mg) were added into BIOTAGE® microwave vial (5mL), and followed by adding dioxane (3 mL) and water (0.3 mL). The vial was flushed with nitrogen and Pd(OAc)₂ (0.076
- 10 mmol, 1.7 mg) was added. The vial was heated in a BIOTAGE® Initiator at 110 °C for 10 minutes and dried with a SPEEDVAC®-250 at 40 °C overnight. The samples were dissolved in DMF-MeOH, filtered via a plate with filters, and purified by prep-

HPLC. Prep-HPLC: DIONEX® APS-30000, UV 220nm, Column: Waters XBridge 19 x 200 mm, 5 μ m, C18. Solvents: A = Water, 20 mM NH₄OH, B = Acetonitrile).

Analytical Method A:

- 5 Waters LCT mass spectrometer with 4 way MUX source.

LC Conditions:




Column: Ascentis 4.6x50mm 5 μ m C18


Mobile Phase: A = 5:95 MeCN:Water; B = 95:5 MeCN:Water; Modifier = 10 mM

- 10 NH₄OAc


Retention Time Rt was recorded in minutes.

Time	B%	Flow
0.00'	0	2.0
8.00'	100	2.0
9.00'	100	2.0

Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	5.77	96	569.286	Method A
	4.86	95	536.2426	Method A
	5.20	97	536.26428	Method A

Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	5.93	100	557.2553	Method A


[00291] The following examples/intermediates were prepared by the Suzuki coupling of the corresponding benzofuran-5-yl trifluoromethanesulfonate with 3-boronic acid (or ester) of the corresponding benzoic acid, and the acid intermediate
 5 obtained was coupled to cyclopropylamine as described before.



3-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoic acid

[00292] LC/MS were performed by using Shimadzu-VP instrument with UV
 10 detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 404.04, HPLC R_t = 1.728 min.


15



2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide


[00293] The product was obtained as a TFA salt after purification by Shimadzu-VP
 20 preparative reverse phase HPLC first using the separation method: Solvent A = 10%

MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 8.80 - 9.26 min. (UV detection at 220 nm). The desired fractions collected were evaporated and the white solid obtained was purified again by the same method except with Start %B = 50, Final %B = 100, Fraction Collection: 5.34 - 6.15 min. ¹H NMR (500 MHz, CD₃OD) δ 8.61 (d, *J* = 5.80, 1H), 8.44 (t, *J* = 7.32, 1H), 7.97 (dd, *J* = 8.85, 5.19, 2H), 7.87 (s, 1H), 7.85 (d, *J* = 6.71, 1H), 7.83-7.81 (m, 2H), 7.67 (d, *J* = 8.24, 1H), 7.64 (d, *J* = 0.92, 1H), 7.47 (d, *J* = 8.55, 1H), 7.38 (dd, *J* = 8.39, 1.68, 1H), 7.29 (t, *J* = 8.85, 2H), 2.95 (s, 3H), 2.36 (s, 3H), 1.82 (m, 2H), 1.75 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μm, C18, 3.0 x 50 mm; (ES⁺) *m/z* (M+H)⁺ = 520.41, HPLC *R*_t = 1.513 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm, 4.6 x 150 mm, *R*_t = 8.90 min; Column: XBridge phenyl 3.5 μm, 4.6 x 150 mm, *R*_t = 9.43 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl, *R*_t = 13.20 min.



2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyridin-4-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide


[00294] The product was obtained as a TFA salt after purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 5.07 - 5.88 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 8.68 (d, *J* = 7.32, 1H), 7.97 (dd, *J* = 8.85, 5.19, 2H), 7.87 (d, *J* = 2.14, 1H), 7.86 (m overlapped with d, 1H), 7.81 (d, *J* = 7.02, 1H), 7.67 (d, *J* = 8.55, 1H), 7.65 (d, *J* = 1.22, 1H), 7.48 (d, *J* = 8.55, 1H), 7.39 (dd, *J* = 8.39, 1.68, 1H), 7.28 (t, *J* = 8.85, 2H), 2.95 (s, 3H), 2.37 (s, 3H), 1.83 (appeared as d, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) *m/z* (M+H)⁺ = 520.15, HPLC *R*_t = 1.435 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm, 4.6 x 150 mm, *R*_t = 8.03 min; Column: XBridge phenyl 3.5 μm, 4.6 x 150 mm (Start %B = 10, Final %B = 100), *R*_t = 14.09 min.



25 2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyridin-3-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00295] The product was obtained as a TFA salt after purification by Shimadzu-VP preparative reverse phase HPLC first using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate =


25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 5.05 - 5.76 min. (UV detection at 220 nm). The desired fractions collected were evaporated and the residue obtained was purified again by the same method except with Start %B = 10, Final %B = 100, Fraction Collection: 8.74 - 9.27 min. ¹H NMR (500 MHz, CD₃OD) δ 8.76 (d, *J* = 2.44, 1H), 8.71 (dd, *J* = 5.80, 0.92, 1H), 8.50 (ddd, *J* = 8.32, 2.21, 1.37, 1H), 8.04 (dd, *J* = 8.39, 5.65, 1H), 7.96 (dd, *J* = 9.00, 5.34, 2H), 7.83 (d, *J* = 1.53, 1H), 7.82 (m overlapped with d, 1H), 7.66 (d, *J* = 8.24, 1H), 7.64 (d, *J* = 1.83, 1H), 7.45 (d, *J* = 8.55, 1H), 7.28 (t, *J* = 8.70, 2H), 2.95 (s, 3H), 2.35 (s, 3H), 1.60 (appeared as td, *J* = 4.20, 2.59, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) *m/z* (M+H)⁺ = 520.08, HPLC *R*_t = 1.482 min.




2-(4-Fluorophenyl)-5-(5-(1-(4-fluorophenyl)cyclopropylcarbamoyl)-2-methylphenyl)-N-methylbenzofuran-3-carboxamide

[00296] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 9.08 - 9.63 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 7.97 (dd, *J* = 8.85, 5.19, 2H), 7.78 - 7.77 (overlapping m, 2H), 7.65 (d, *J* = 8.55, 1H), 7.63 (d, *J* = 1.22, 1H), 7.41 (d, *J* = 8.55, 1H), 7.37 - 7.33 (overlapping m, 3H), 7.28 (t, *J* = 8.85, 2H), 7.01 (t, *J* = 8.85, 2H), 2.95 (s, 3H), 2.33 (s, 3H), 1.32 (m, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA,

- Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 537.08, HPLC R_t = 1.840 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical
- 5 HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 10.20 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm (Start %B = 10, Final %B = 100), R_t = 8.16 min. Analytical HPLC method: Solvent A = 5% MeOH-
- 10 95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5%H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 14.20 min.




- 15 4-Chloro-3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid
[00297] LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4
- 20 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 424.26, 426.25, HPLC R_t = 1.763 min.



- 25 5-(2-Chloro-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide
[00298] The product was obtained as a TFA salt after purification by Shimadzu-VP preparative reverse phase HPLC first using the separation method: Solvent A = 10%


MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 6.02 - 6.54 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 8.62 (dd, *J* = 5.80, 0.61, 1H), 8.44 (td, *J* = 7.93, 1.53 1H), 8.04 (d, *J* = 2.44, 1H), 7.96 (dd, *J* = 8.85, 5.19, 2H), 7.93 (dd, *J* = 8.39, 2.29 1H), 7.84 - 7.81 (overlapping m, 2H), 7.76 (d, *J* = 1.83, 1H), 7.69 (d, *J* = 2.44, 1H), 7.67 (d, *J* = 2.75, 1H), 7.50 (dd, *J* = 8.55, 1.53, 1H), 7.28 (t, *J* = 8.70, 2H), 2.95 (s, 3H), 1.83 (m, 2H), 1.76 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μm, C18, 3.0 x 50 mm; (ES+) *m/z* (M+H)⁺ = 540.33, 542.33, HPLC *R*_t = 1.568 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm, 4.6 x 150 mm, *R*_t = 9.19 min; Column: XBridge phenyl 3.5 μm, 4.6 x 150 mm, *R*_t = 9.89 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl, *R*_t = 16.19 min.



5-(2-Chloro-5-(1-(3-methoxyphenyl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00299] Purification by Shimadzu-VP preparative reverse phase HPLC first using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B =


- 90% MeOH-10% H₂O-0.1% TFA, Start %B = 70, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 6.61 - 7.41 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 7.97 (dd, *J* = 8.70, 5.34, 2H), 7.94 (d, *J* = 2.14, 1H), 7.85 (dd, *J* = 8.39, 1.98, 1H), 7.76 (s, 1H), 7.65 (dd, *J* = 12.51, 8.55, 2H), 7.49 (dd, *J* = 8.55, 1.53, 1H), 7.28 (t, *J* = 8.70, 2H), 7.20 (t, *J* = 7.93, 1H), 6.87 (s, 1H), 6.85 (m overlapped with s, 1H), 6.75 (dd, *J* = 8.70, 1.68, 1H), 3.77 (s, 3H), 2.95 (s, 3H), 1.34 (appeared as d, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μm, C18, 3.0 x 50 mm; (ES⁺) *m/z* (M+H)⁺ = 569.39, HPLC *R*_t = 1.858 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm, 4.6 x 150 mm, *R*_t = 10.33 min; Column: XBridge phenyl 3.5 μm, 4.6 x 150 mm, *R*_t = 7.96 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3, *R*_t = 14.80 min.



- 5-(2-Chloro-5-(3H-spiro[isobenzofuran-1,4'-piperidine]-1'-yl)carbonyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00300] Purification by Shimadzu-VP preparative reverse phase HPLC first using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B =


90% MeOH-10% H₂O-0.1% TFA, Start %B = 70, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.88 - 8.49 min. (UV detection at 220 nm). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 595.39, HPLC R_t = 1.952 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 um, 4.6 x 150 mm, R_t = 11.75 min; Column: XBridge phenyl 3.5 um, 4.6 x 150 mm, R_t = 8.68 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3, R_t = 15.85 min.



5-(5-Amino-2-methylphenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00301] The Suzuki coupling with 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline was performed by using: dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (S-Phos), Pd(OAc)₂, K₂CO₃, (1:2 H₂O/1,4-dioxane, 90 °C). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4


ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 375.22, HPLC R_t = 1.362 min.



5 2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-phenylcyclopropanecarboxamido)phenyl)benzofuran-3-carboxamide


[00302] Purification by Shimadzu-VP preparative reverse phase HPLC first using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 10.05 - 10.51 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 7.97 (dd, J = 8.85, 5.49, 2H), 7.60 (d, J = 8.55, 1H), 7.55 (d, J = 1.53, 1H), 7.52 (dd overlapped with s, 1H), 7.51 (s, 1H), 7.44 (t, J = 7.48, 2H), 7.36 (m, 1H), 7.30 (dd overlapped with m, J = 1.53, 1H), 7.29 – 7.27 (overlapping m, 3H), 7.25 (d, J = 2.14, 1H), 7.21 (appeared as d, 1H), 2.95 (s, 3H), 2.21 (s, 3H), 1.60 (m, 2H), 1.19 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+Na)⁺ = 541.36, HPLC R_t = 1.952 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 12.49 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 9.11 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100,

Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column:
XBridge phenyl 3, R_t = 15.98 min.



5 4-Chloro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxybenzoic acid

[00303] LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start
10 %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES⁺) m/z (M+H)⁺ = 453.93, HPLC R_t = 1.757 min.




15 5-(2-Chloro-4-methoxy-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00304] The product was obtained as a TFA salt after purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start
20 %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 6.00 - 6.58 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 8.61 (d, J = 5.80, 1H), 8.42 (td, J = 8.01, 1.68, 1H), 7.99 (s, 1H), 7.96 (m, J = 8.85, 5.19, 2H), 7.87 (d, J = 8.24, 1H), 7.79 (ddd, J = 7.40, 6.03, 0.92, 1H), 7.69 (d, J = 1.83, 1H),
25 7.64 (d, J = 8.55, 1H), 7.44 (dd, J = 8.55, 1.83, 1H), 7.40 (s, 1H), 7.27 (t, J = 8.85, 2H), 4.10 (s, 3H), 2.95 (s, 3H), 1.84 (m, 2H), 1.75 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters

MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 569.90, 570.79,

- 5 571.82, HPLC R_t = 1.592 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 um, 4.6 x 150
- 10 mm, R_t = 9.56 min; Column: XBridge phenyl 3.5 um, 4.6 x 150 mm, R_t = 9.97 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5%H₂O-10 mM NH₄HCO₃, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 um, 4.6 x 150 mm, R_t = 16.35 min.


15



Methyl 1-(4-chloro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxybenzamido)cyclopropanecarboxylate


- [00305] LC/MS were performed by using Shimadzu-VP instrument with UV
- 20 detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 551.02, HPLC R_t = 1.753 min.

25



4-Chloro-2-fluoro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid

[00306] LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 441.91, HPLC R_t = 1.803 min.




5-(2-Chloro-4-fluoro-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00307] The product was obtained as a TFA salt after purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 5.63 - 6.40 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 8.60 (d, *J* = 5.49, 1H), 8.34 (td, *J* = 7.93, 1.83, 1H), 7.97 (m, *J* = 8.85, 5.19, 2H), 7.90 (d, *J* = 7.63, 1H), 7.83 (d, *J* = 8.24, 1H), 7.73 (overlapping, 2H), 7.68 (d, *J* = 8.54, 1H), 7.56 (d, *J* = 10.38, 1H), 7.47 (dd, *J* = 8.55, 1.83, 1H), 7.29 (t, *J* = 8.70, 2H), 2.95 (s, 3H), 1.82 (m, 2H), 1.70 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 558.04, HPLC R_t = 1.558 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95%


MeCN-5% H_2O -0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm , 4.6 x 150 mm, R_t = 3.10 min; Column: XBridge phenyl 3.5 μm , 4.6 x 150 mm, R_t = 3.60 min.

Analytical HPLC method: Solvent A = 5% MeOH-95% H_2O -10 mM NH_4HCO_3 ,

- 5 Solvent B = 95% MeOH-5% H_2O -10 mM NH_4HCO_3 , Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μm , 4.6 x 150 mm, R_t = 13.24 min.




- 10 **[00308]** 5-(5-(*tert*-Butylcarbamoyl)-2-methylphenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide. Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H_2O -0.1% TFA, Solvent B = 90% MeOH-10% H_2O -0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column:
- 15 Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 8.62 - 9.21 min. (UV detection at 220 nm). ^1H NMR (500 MHz, CD_3OD) δ 7.98 (m, J = 8.85, 5.49, 2H), 7.67 (d overlapping with s, 1H), 7.67 (s, 1H), 7.65 (d, J = 8.55, 1H), 7.63 (d, J = 1.22, 1H), 7.38 (d overlapping with dd, 1H), 7.37 (dd, J = 1.53, 1H), 7.28 (t, J = 8.70, 2H), 2.96 (s, 3H), 2.32 (s, 3H), 1.47 (s, 9H). LC/MS were performed by using Shimadzu-VP
- 20 instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H_2O -0.1% TFA, Solvent B = 90% MeOH-10% H_2O -0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μm , C18, 3.0 x 50 mm; (ES+) m/z ($\text{M}+\text{H}$) $^+$ = 459.31, HPLC R_t = 1.763 min. Analytical HPLC were
- 25 performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H_2O -0.1% TFA, Solvent B = 95% MeCN-5% H_2O -0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm , 4.6 x 150 mm, R_t = 17.08 min; XBridge phenyl 3.5 μm , 4.6 x 150 mm, R_t = 14.81 min.




5-(5-(1-Cyanocyclopropylcarbamoyl)-2-methylphenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

- 5 [00309] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.13 - 7.85 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 7.98 (m, *J* = 8.70, 5.34, 2H), 7.77 (d overlapping with s, 1H), 7.76 (s, 1H), 7.66 (d, *J* = 8.24, 1H), 7.63 (d, *J* = 1.53, 1H), 7.44 (d, *J* = 8.24, 1H), 7.37 (dd, *J* = 8.39, 1.68, 1H), 7.28 (t, *J* = 8.85, 2H), 2.95 (s, 3H), 2.34 (s, 3H), 1.59 (m, 2H), 1.36 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES⁺) *m/z* (M+H)⁺ = 468.28, HPLC *R*_t = 1.633 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, *R*_t = 14.21 min; XBridge phenyl 3.5 μ m, 4.6 x 150 mm, *R*_t = 12.79 min.



Methyl 1-(3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzamido)cyclopropanecarboxylate


[00310] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.26 - 7.97 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 7.98 (m, *J* = 8.85, 5.19, 2H), 7.77 (dd, *J* = 4.27, 2.14, 2H), 7.66 (d, *J* = 8.55, 1H), 7.63 (d, *J* = 1.22, 1H), 7.42 (d, *J* = 8.55, 1H), 7.37 (dd, *J* = 8.39, 1.68, 1H), 7.28 (t, *J* = 8.85, 2H), 3.71 (s, 3H), 2.96 (s, 3H), 2.34 (s, 3H), 1.59 (m, 2H), 1.26 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) *m/z* (M+H)⁺ = 501.23, HPLC *R*_t = 1.657 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 um, 4.6 x 150 mm, *R*_t = 6.81 min; XBridge phenyl 3.5 um, 4.6 x 150 mm, *R*_t = 5.58 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3, *R*_t = 12.48 min.



2-(4-Fluorophenyl)-5-(5-(1-(hydroxymethyl)cyclopropylcarbamoyl)-2-methylphenyl)-N-methylbenzofuran-3-carboxamide


[00311] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10

min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 8.78 - 9.06 min. (UV detection at 220 nm). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 473.33, HPLC R_t = 1.827 min.




2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(prop-2-ynylcarbamoyl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00312] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.43 - 7.91 min. (UV detection at 220 nm). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 524.21, HPLC R_t = 1.642 min.




2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(2-methyl-1-morpholinopropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00313] The product was obtained as a TFA salt after purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 20, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.64 - 8.27 min. (UV detection at 220 nm). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 544.38, HPLC R_t = 1.503 min.




5-(5-(2-Cyclopropylpropan-2-ylcarbamoyl)-2-methylphenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00314] The product was obtained as a TFA salt after purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 9.21 - 9.86 min. (UV detection at 220 nm). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 485.34, HPLC R_t = 1.842 min.




5-(2-Cyclopropyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

- [00315]** The product was obtained as a TFA salt after purification by Shimadzu-VP
- 5 preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 6.26 - 6.59 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 8.54 (d, *J* = 5.19, 1H), 8.17 (m, 1H), 7.98 (m, *J* = 8.85, 5.19, 2H), 7.87 - 7.86 (overlapped m, 2H), 7.77 (d, *J* = 1.53, 1H), 7.69 (d overlapped with d, 1H), 7.68 (d, *J* = 8.24, 1H), 7.58 (m, 1H), 7.50 (dd, *J* = 8.55, 1.83, 1H), 7.29 (t, *J* = 8.85, 2H), 7.11 (d, *J* = 8.55, 1H), 2.96 (s, 3H), 1.98 (m, 1H), 1.77 (m, 2H), 1.61 (m, 2H), 0.96 (m, 2H), 0.82 (m, 2H).
- 10 LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) *m/z* (M+H)⁺ = 546.04, HPLC *R*_t = 1.603 min. Analytical HPLC were performed by using Shimadzu-VP instrument with
- 15 UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, *R*_t = 9.71 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, *R*_t = 10.26 min. Analytical HPLC method:
- 20 Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, *R*_t = 13.95 min.



Ethyl 2-(4-fluorophenyl)-5-(2-methyl-5-(1-phenylcyclopropylcarbamoyl)phenyl)-6-nitrobenzofuran-3-carboxylate

[00316] LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 579.41, HPLC R_t = 2.032 min.




2-(4-Fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide

[00317] A mixture of 5-(2-chloro-4-methoxy-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (62.7 mg, 0.11 mmol, crude), dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (52.4 mg, 0.11 mmol), MeBF₃K (20.12 mg, 0.165 mmol), diacetoxypalladium (12.35 mg, 0.055 mmol) and potassium carbonate (76 mg, 0.550 mmol) in a mixture of H₂O (0.2 mL)/THF (2 mL) was stirred at 90 °C under N₂ for 6 hours 30 min. The mixture was left standing at r.t. overnight, and then diluted with MeOH and filtered through a Whatman 0.45 um PVDF with GMF disk. The filtrate was purified by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 70, Final %B = 90, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 2.26 - 2.77 min. (UV detection at 220 nm) to obtain the product as a TFA salt. ¹H NMR (500 MHz, CD₃OD) δ 8.60 (d, J = 5.80, 1H), 8.41 (m, 1H),

- 7.96 (m, $J = 9.00$, 5.34, 2H), 7.87 (s, 1H), 7.85 (d, $J = 9.00$, 1H), 7.79 (t, $J = 6.56$, 1H), 7.64 (d, $J = 8.24$, 1H), 7.58 (d, $J = 1.53$, 1H), 7.33 (dd, $J = 8.55$, 1.83, 1H), 7.17 (s, 1H), 7.28 (t, $J = 8.85$, 2H), 4.09 (s, 3H), 2.95 (s, 3H), 2.38 (s, 3H), 1.84 (m, 2H), 1.75 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV
- 5 detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 550.00, HPLC R_t = 1.588 min. Analytical HPLC were performed by using
- 10 Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 9.12 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 9.82 min.
- 15 Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 13.46 min.

20




5-(4-Fluoro-2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

- [00318] The product was obtained as a TFA salt after purification by Shimadzu-VP preparative reverse phase HPLC twice using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start
- 25 %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 5.58 - 5.94 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 8.57 (d, $J = 5.49$, 1H), 8.26 (td, $J = 7.93$, 1.53, 1H), 7.97 (m, $J = 9.16$, 5.19, 2H), 7.79 (d, $J = 8.24$,

- 1H), 7.73 (d, $J = 7.63$, 1H), 7.67 (d, $J = 8.55$, 1H), 7.65 (m overlapping with d, 1H), 7.62 (d, $J = 1.83$, 1H), 7.35 (dd, $J = 8.39$, 1.68, 1H), 7.29 (t, $J = 8.85$, 2H), 7.25 (d, $J = 11.90$, 1H), 2.95 (s, 3H), 2.35 (s, 3H), 1.80 (m, 2H), 1.66 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and
- 5 Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 538.04, HPLC R_t = 1.497 min. Analytical HPLC were performed by using Shimadzu-VP instrument with
- 10 UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 9.46 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 9.66 min. Analytical HPLC method:
- 15 Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 12.95 min.


20



5-(4-Fluoro-2-hydroxy-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

- [00319] 5-(4-Fluoro-2-hydroxy-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide was obtained as a side
- 25 product during the synthesis of 5-(4-fluoro-2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide. The product was obtained as a TFA salt after purification by Shimadzu-VP preparative reverse phase HPLC twice using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-


- 0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 4.16 - 4.55 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 8.55 (broad d, *J* = 3.66, 1H), 8.19 (t, *J* = 7.78, 1H), 7.97 (m, *J* = 8.85, 5.19, 2H), 7.86 (d, *J* = 8.54, 1H), 7.82 (s, 1H), 7.74 (d, *J* = 8.24, 1H), 7.61 (t overlapping with dd, 1H), 7.58 (dd, 2H), 7.28 (t, *J* = 8.70, 2H), 6.79 (d, *J* = 12.51, 1H), 2.97 (s, 3H), 1.78 (appeared as s, 2H), 1.63 (appeared as s, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) *m/z* (M+H)⁺ = 540.07, HPLC *R*_t = 1.342 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm, 4.6 x 150 mm, *R*_t = 8.06 min; Column: XBridge phenyl 3.5 μm, 4.6 x 150 mm, *R*_t = 8.56 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μm, 4.6 x 150 mm, *R*_t = 13.91 min.



- 25 2-(4-Fluorophenyl)-5-(2-hydroxy-5-(1-phenylcyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide

[00320] 2-(4-Fluorophenyl)-5-(2-hydroxy-5-(1-phenylcyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide was obtained as a side product from a similar reaction. Purification by Shimadzu-VP

- preparative reverse phase HPLC twice using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.79 - 8.24 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 7.98 (m, *J* = 9.00, 5.34, 2H), 7.91 (d, *J* = 2.14, 1H), 7.88 (d, *J* = 1.53, 1H), 7.76 (dd, *J* = 8.55, 2.14, 1H), 7.65 - 7.61 (overlapping m, 2H), 7.29 - 7.27 (overlapping m, 6H), 7.16 (m, 1H), 7.00 (d, *J* = 8.55, 1H), 2.97 (s, 3H), 1.35 (m, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®.
- 10 HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μm, C18, 3.0 x 50 mm; (ES⁺) *m/z* (M+H)⁺ = 521.28, HPLC *R*_t = 1.695 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254
- 15 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm, 4.6 x 150 mm, *R*_t = 6.84 min; Column: XBridge phenyl 3.5 μm, 4.6 x 150 mm, *R*_t = 5.71 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM
- 20 NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl, *R*_t = 12.68 min.




- 25 Methyl 1-(5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxy-4-methylbenzamido)cyclopropanecarboxylate

[00321] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10


30 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100

mm S5, Fraction Collection: 8.07 - 8.45 min. (UV detection at 220 nm). ^1H NMR (500 MHz, CD_3OD) δ 7.98 (m, 2H), 7.85 (s, 1H), 7.63 (d, $J = 8.55$, 1H), 7.58 (d, $J = 1.22$, 1H), 7.33 (dd, $J = 8.55$, 1.83, 1H), 7.27 (t, $J = 8.85$, 2H), 7.11 (s, 1H), 4.03 (s, 3H), 3.71 (s, 3H), 2.96 (s, 3H), 2.35 (s, 3H), 1.61 (m, 2H), 1.28 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H_2O -0.1% TFA, Solvent B = 90% MeOH-10% H_2O -0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z ($\text{M}+\text{H}$) $^+$ = 531.23, HPLC R_t = 1.715 min.




4-Cyclopropyl-3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid

[00322] 4-Cyclopropyl-3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid was prepared in a similar manner as described by using potassium cyclopropyltrifluoroborate. LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H_2O -0.1% TFA, Solvent B = 90% MeOH-10% H_2O -0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μm , C18, 3.0 x 50 mm; (ES+) m/z ($\text{M}+\text{H}$) $^+$ = 430.07, HPLC R_t = 1.802 min.



2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide


- [00323]** A mixture of methyl 1-(3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzamido)cyclopropanecarboxylate (25.3 mg, 0.051 mmol), N'-hydroxyacetimidamide (11.23 mg, 0.152 mmol) and K₂CO₃ (41.9 mg, 0.303 mmol) in toluene (1 mL) under N₂ in a re-usable sealed tube was stirred at 150 °C for two hours. The mixture was evaporated, diluted with MeOH and purified by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.54 - 8.08 min. (UV detection at 220 nm), to give the product as a white solid (19.9 mg, 75%). ¹H NMR (500 MHz, CD₃OD) δ 7.98 (m, *J* = 9.00, 5.34, 2H), 7.82 (d, *J* = 2.14, 1H), 7.81 (overlapping m, 1H), 7.66 (d, *J* = 8.55, 1H), 7.65 (d, *J* = 1.50, 1H), 7.44 (d, *J* = 8.55, 1H), 7.38 (dd, *J* = 8.24, 1.83, 1H), 7.28 (m, *J* = 8.85, 2H), 2.95 (s, 3H), 2.36 (s, 3H), 2.31 (s, 3H), 1.75 (m, 2H), 1.58 (m, 2H).
- LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) *m/z* (M+H)⁺ = 525.12, HPLC *R*_t = 1.700 min.



5-(5-(1-(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)cyclopropylcarbamoyl)-2-methylphenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

- [00324]** Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 8.32 - 8.92 min. (UV detection at 220 nm). ¹H NMR


(500 MHz, CD₃OD) δ 7.98 (m, J = 8.85, 5.49, 2H), 7.81 (d, J = 1.83, 1H), 7.80 (broad s overlapping with d, 1H), 7.66 (d overlapping with d, 1H), 7.64 (d, J = 1.53, 1H), 7.44 (d, J = 8.55, 1H), 7.38 (dd, J = 8.39, 1.68, 1H), 7.28 (m, J = 8.85, 2H), 2.95 (s, 3H), 2.35 (s, 3H), 2.02 (m, 1H), 1.72 (m, 2H), 1.54 (m, 2H), 1.04 (m, 2H), 0.95 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 551.09, HPLC R_t = 1.763 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 8.73 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 6.96 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 13.22 min.



2-(4-Fluorophenyl)-5-(5-(1-(3-(methoxymethyl)-1,2,4-oxadiazol-5-yl)cyclopropylcarbamoyl)-2-methylphenyl)-N-methylbenzofuran-3-carboxamide
[00325] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.92 - 8.52 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 7.98 (m, J = 9.00, 5.34, 2H), 7.82 (d, J = 2.14, 1H), 7.81 (t

- overlapped with d, 1H), 7.66 (d overlapped with d, 1H), 7.65 (d, $J = 1.83$, 1H), 7.45 (d, $J = 8.55$, 1H), 7.38 (dd, $J = 8.55$, 1.83, 1H), 7.28 (t, $J = 8.70$, 2H), 4.51 (s, 2H), 3.42 (s, 3H), 2.95 (s, 3H), 2.36 (s, 3H), 1.79 (m, 2H), 1.60 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and
- 5 Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 555.23, HPLC R_t = 1.700 min. Analytical HPLC were performed by using Shimadzu-VP instrument with
- 10 UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 7.11 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 5.57 min. Analytical HPLC method:
- 15 Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 12.51 min.


20



2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

- [00326] The product was obtained as a TFA salt after Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate =
- 25 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.83 - 8.56 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 8.71 (d, $J = 4.88$, 1H), 8.19 (d, $J = 7.93$, 1H), 8.08 (td, $J = 7.78$, 1.53, 1H), 7.97(m, $J = 9.00$, 5.34,


- 2H), 7.85 (s, 1H), 7.84 (m overlapping with s, 1H), 7.66 -7.63 (overlapping m, 3H), 7.45 (d, $J = 8.55$, 1H), 7.38 (dd, $J = 8.55$, 1.83, 1H), 7.28 (m, $J = 8.85$, 2H), 2.95 (s, 3H), 2.36 (s, 3H), 1.91 (m, 2H), 1.67 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®.
- 5 HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 588.07, HPLC R_t = 1.728 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and
- 10 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 6.96 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 5.83 min. Analytical HPLC method: Solvent A = 5% MeOH-95%
- 15 H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5%H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 13.15 min.



- 20 2-(4-Fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide
- [00327]** Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10
- 25 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.80 - 8.36 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 7.98 (m, $J = 9.00$, 5.34, 2H), 7.86 (s, 1H), 7.63 (d, $J = 8.55$, 1H), 7.59 (d, $J = 1.83$, 1H), 7.33 (dd, $J = 8.24$, 1.83, 1H), 7.27 (t, $J = 8.85$, 2H), 7.13 (s, 1H), 4.06 (s, 3H), 2.96 (s, 3H), 2.36 (s, 3H), 2.31 (s, 3H), 1.77 (m, 2H), 1.60 (m,

- 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min,
- 5 Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 555.10, HPLC R_t = 1.723 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min,
- 10 Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μm, 4.6 x 150 mm, R_t = 5.98 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μm, 4.6 x 150 mm, R_t = 12.98 min.

15




5-(2-Chloro-4-methoxy-5-(1-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

- 20 **[00328]** Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 8.06 - 8.56 min. (UV detection at 220 nm). ¹H NMR
- 25 (500 MHz, CD₃OD) δ 7.99-7.96 (m overlapping with s, 2H), 7.97 (s, 1H), 7.71 (d, J = 1.53, 1H), 7.64 (d, J = 8.55, 1H), 7.45 (dd, J = 8.55, 1.83, 1H), 7.37 (s, 1H), 7.27 (t, J = 8.85, 2H), 4.06 (s, 3H), 2.96 (s, 3H), 2.32 (s, 3H), 1.78 (m, 2H), 1.61 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90%

- H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 575.08, HPLC R_t = 1.752 min. Analytical HPLC were performed by using Shimadzu-VP instrument with
- 5 UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm, 4.6 x 150 mm, R_t = 8.23 min; Column: XBridge phenyl 3.5 μm, 4.6 x 150 mm, R_t = 6.39 min. Analytical HPLC method:
- 10 Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μm, 4.6 x 150 mm, R_t = 13.49 min.

15




2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(5-methyl-4H-1,2,4-triazol-3-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00329] A mixture of 5-(5-(1-cyanocyclopropylcarbamoyl)-2-methylphenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (33.8 mg, 0.072 mmol),

- 20 acetohydrazide (16.07 mg, 0.217 mmol) and K₂CO₃ (9.99 mg, 0.072 mmol) in n-BuOH (1 mL) under N₂ in a re-usable sealed tube was stirred at 150 °C for four hours. The mixture was diluted with MeOH and purified by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate =
- 25 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 5.93 - 6.53 min. (UV detection at 220 nm) to obtain the product as a TFA solvate. ¹H NMR (500 MHz, CD₃OD) δ 7.97 (m, J = 8.85, 5.49, 2H), 7.85 (s, 1H), 7.85 (m overlapped with s, J = 1.83, 1H), 7.66 (d, J = 8.55, 1H), 7.64 (d, J = 1.22, 1H), 7.45 (d, J = 7.63, 1H), 7.38 (dd, J = 8.39, 1.68, 1H), 7.29 (t, J = 8.70, 2H), 2.95 (s, 3H), 2.56 (s, 3H),
- 30

2.36 (s, 3H), 1.68 (m, 2H), 1.57 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 524.23, HPLC R_t = 1.545 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 11.80 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 12.13 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3, R_t = 11.87 min.




5-(5-(1-(5-Cyclopropyl-4H-1,2,4-triazol-3-yl)cyclopropylcarbamoyl)-2-methylphenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00330] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 8.05 - 8.58 min. (UV detection at 220 nm) to obtain the product as a TFA solvate. ¹H NMR (500 MHz, CD₃OD) δ 7.97 (m, *J* = 8.85, 5.19, 2H), 7.85 (s, 1H), 7.84 (dd overlapping with s, *J* = 1.83, 1H), 7.67 (d, *J* = 8.24, 1H), 7.64 (d, *J* = 1.53, 1H), 7.45 (d, *J* = 7.63, 1H), 7.38 (dd, *J* = 8.39, 1.68, 1H), 7.29 (t, *J* = 8.85, 2H), 2.95 (s, 3H), 2.36 (s, 3H), 2.15 (m, 1H), 1.66 (m, 2H), 1.55 (m, 2H), 1.23 (m, 2H), 1.11 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A

= 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 500.00, HPLC R_t = 1.598 min. Analytical HPLC were performed by using

- 5 Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 9.45 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 9.81 min.
- 10 Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5%H₂O-10 mM NH₄HCO₃, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl, R_t = 15.29 min.




15

2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(5-phenyl-4H-1,2,4-triazol-3-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00331] Purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90%


- 20 MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 6.48 - 7.03 min. (UV detection at 220 nm) to obtain the product as a TFA solvate. ¹H NMR (500 MHz, CD₃OD) δ 7.99 - 7.95 (overlapping m, 4H), 7.88 - 7.85 (overlapping m, 2H), 7.67 - 7.65 (overlapping m, 2H), 7.49 - 7.45 (overlapping m, 3H), 7.44 (d, *J* = 7.93, 1H), 7.39 (dd, *J* = 8.55, 1.53, 1H), 7.28 (t, *J* = 8.70, 2H), 2.95 (s, 3H), 2.35 (s, 3H), 1.72 (m, 2H), 1.48 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100,
- 30 Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column:

XTERRA® MS 7 μm , C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 585.89, HPLC R_t = 1.765 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm , 4.6 x 150 mm, R_t = 6.85 min; Column: XBridge phenyl 3.5 μm , 4.6 x 150 mm, R_t = 5.81 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5%H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl, R_t = 13.04 min.



2-(4-Fluorophenyl)-5-(5-(1-(N-hydroxycarbamimidoyl)cyclopropylcarbamoyl)-2-methylphenyl)-N-methylbenzofuran-3-carboxamide

[00332] To a mixture of 5-(5-(1-cyanocyclopropylcarbamoyl)-2-methylphenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (43.5 mg, 0.093 mmol) in ethanol (1.5 mL) at r.t. under N₂ was added hydroxylamine hydrochloride (12.93 mg, 0.186 mmol), followed by Et₃N (0.039 mL, 0.279 mmol). The mixture was stirred at reflux (115 °C) for about 4 hours. The mixture was cooled to r.t. and evaporated. The residue was used for the next step without further purification. LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 501.13, HPLC R_t = 1.385 min.




2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(5-methyl-1,2,4-oxadiazol-3-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

- [00333]** To a mixture of 2-(4-fluorophenyl)-5-(5-(1-(N-hydroxycarbamimidoyl)cyclopropylcarbamoyl)-2-methylphenyl)-N-methylbenzofuran-3-carboxamide (46.5 mg, 0.093 mmol, crude) in pyridine (0.5 mL, 6.18 mmol) at r.t. under N₂ was added acetyl chloride (0.020 mL, 0.279 mmol). The mixture was stirred at 115 °C for 2 hours. The mixture was cooled to r.t., diluted with MeOH and purified by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.64 - 7.95 min. (UV detection at 220 nm). The residue obtained after evaporation of the combined fractions was further purified by preparative TLC, 10% MeOH/CH₂Cl₂, two 20 cm x 20 cm x 0.5 mm plates. R_f about 0.67 (10% MeOH/CH₂Cl₂). ¹H NMR (500 MHz, CD₃OD) δ 7.98 (m, *J* = 9.00, 5.34, 2H), 7.81 (s, 1H), 7.80 ((m overlapped with s, *J* = 2.14, 1H), 7.66 (d, *J* = 8.55, 1H), 7.65 (d, *J* = 1.22, 1H), 7.43 (d, *J* = 8.55, 1H), 7.36 (dd, *J* = 8.55, 1.83, 1H), 7.28 (m, *J* = 8.70, 2H), 2.96 (s, 3H), 2.54 (s, 3H), 2.35 (s, 3H), 1.59 (m, 2H), 1.43 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) *m/z* (M+H)⁺ = 525.07, HPLC R_t = 1.682 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 um, 4.6 x 150 mm, R_t = 6.67 min; Column: XBridge phenyl 3.5 um, 4.6 x 150 mm, R_t = 5.22 min. Analytical HPLC method:


Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 12.36 min.

5




1-(3-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzamido)cyclopropanecarboxylic acid

- [00334] ¹H NMR (500 MHz, CD₃OD) δ 7.98 (m, *J* = 9.00, 5.34, 2H), 7.78 (s, 1H), 7.77 (m overlapping with s, 1H), 7.66 (d, *J* = 8.55, 1H), 7.64 (d, *J* = 1.22, 1H), 7.42 (d, *J* = 8.55, 1H), 7.38 (dd, *J* = 8.55, 1.83, 1H), 7.28 (t, *J* = 8.70, 2H), 2.96 (s, 3H), 2.34 (s, 3H), 1.60 (m, 2H), 1.25 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) *m/z* (M+H)⁺ = 487.27, HPLC R_t = 1.625 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 5.38 min; XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 4.43 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3, R_t = 10.67 min.



tert-Butyl 2-(1-(3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzamido)cyclopropanecarbonyl)hydrazinecarboxylate

- [00335]** To a mixture of 1-(3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzamido)cyclopropanecarboxylic acid (41.6 mg, 0.086 mmol), *tert*-butyl hydrazinecarboxylate (16.95 mg, 0.128 mmol) and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethylisouronium tetrafluoroborate (54.9 mg, 0.171 mmol) in DMF (1 mL) at r.t under N₂ was added N, N-diisopropylethylamine (0.060 mL, 0.342 mmol). The mixture was stirred at r.t. for 19 hours. The mixture was added 5 ml H₂O. The white precipitates were filtered, washed with 3 x 2 ml H₂O and dried (33.1 mg), and was used without further purification. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; HPLC R_t = 1.750 min.




2-(4-Fluorophenyl)-5-(5-(1-(hydrazinecarbonyl)cyclopropylcarbamoyl)-2-methylphenyl)-N-methylbenzofuran-3-carboxamide

- [00336]** To *tert*-butyl 2-(1-(3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzamido)cyclopropanecarbonyl)hydrazinecarboxylate (33.1 mg, 0.055 mmol) in a round-bottom flask at r.t. under N₂ was added HCl (1 ml, 4.00 mmol, 4 M in 1,4-dioxane). The mixture was stirred at r.t. for four hours. The mixture was evaporated, and the crude hydrochloride salt used without further purification. LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90%

H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 501.06, HPLC R_t = 1.483 min.

5




5-(5-(1-(5-Amino-1,3,4-oxadiazol-2-yl)cyclopropylcarbamoyl)-2-methylphenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00337] To a mixture of 2-(4-fluorophenyl)-5-(5-(1-

- 10 (hydrazinecarbonyl)cyclopropylcarbamoyl)-2-methylphenyl)-N-methylbenzofuran-3-carboxamide, hydrochloride (29.5 mg, 0.055 mmol, crude) in 1,4-dioxane (1 ml) at r.t. was added a solution of cyanic bromide (58.3 mg, 0.550 mmol) in acetonitrile (0.5 mL), and then sat. aq. NaHCO₃ (0.1 ml). The mixture was stirred at r.t. for about 5 hours. The mixture was added 0.3 ml 1N HCl, diluted with MeOH and purified by
- 15 Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 6.53 - 7.18 min. (UV detection at 220 nm) to obtain the product as a TFA
- 20 salt. ¹H NMR (500 MHz, CD₃OD) δ 7.97 (dd, *J* = 8.55, 5.19, 2H), 7.80 (s, 1H), 7.80 ((m overlapped with s, 1H), 7.66 (d, *J* = 8.55, 1H), 7.63 (s, 1H), 7.44 (d, *J* = 8.55, 1H), 7.37 (dd, *J* = 8.24, 1.22, 1H), 7.29 (t, *J* = 8.70, 2H), 2.95 (s, 3H), 2.35 (s, 3H), 1.64 (m, 2H), 1.49 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC
- 25 method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 526.05, HPLC R_t = 1.577 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254

nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 um, 4.6 x 150 mm, R_t = 3.23 min; Column: XBridge phenyl 3.5 um, 4.6 x 150 mm, R_t = 3.39 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5%H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 um, 4.6 x 150 mm, R_t = 11.04 min.




5-(5-(1-(1H-Tetrazol-5-yl)cyclopropylcarbamoyl)-2-methylphenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00338] To a mixture of 5-(5-(1-cyanocyclopropylcarbamoyl)-2-methylphenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (25.1 mg, 0.054 mmol) in DMF (1 mL) at r.t. under N₂ was added ammonium chloride (8.62 mg, 0.161 mmol), and then sodium azide (6.98 mg, 0.107 mmol). The mixture was stirred at 120 °C for about 4 hours. The mixture was cooled to r.t., and added with another 18 mg of NH₄Cl and then 14 mg of NaN₃. The mixture was stirred at 120 °C for 14.5 hours. The mixture was cooled to r.t., and added with another 26 mg of NH₄Cl, followed by 21 mg of NaN₃. The mixture was re-stirred at 120 °C for 24 hours. The mixture was cooled to r.t., and diluted with MeOH and purified by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 6.82 - 7.27 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 7.97 (m, *J* = 9.00, 5.34, 2H), 7.85 (d, *J* = 1.22, 1H), 7.84 (dd overlapping with d, *J* = 1.83, 1H), 7.67 (d, *J* = 8.24, 1H), 7.65 (d, *J* = 1.22, 1H), 7.45 (d, *J* = 7.63, 1H), 7.39 (dd, *J* = 8.55, 1.83, 1H), 7.29 (t, *J* = 8.85, 2H), 2.95 (s, 3H), 2.36 (s, 3H), 1.70 (m, 2H), 1.58 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and

Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column:

XTERRA® MS 7 µm, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 511.28, HPLC R_t =

- 5 1.595 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 µm, 4.6 x 150 mm, R_t = 5.10 min; XBridge phenyl
- 10 3.5 µm, 4.6 x 150 mm, R_t = 4.23 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5%H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3, R_t = 10.58 min.



15

2-(4-Fluorophenyl)-5-(2-methyl-5-(1-phenylcyclopropylcarbamoyl)phenyl)-6-nitrobenzofuran-3-carboxylic acid


[00339] Prepared by the hydrolysis of ethyl 2-(4-fluorophenyl)-5-(2-methyl-5-(1-phenylcyclopropylcarbamoyl)phenyl)-6-nitrobenzofuran-3-carboxylate. LC/MS were

20 performed by using Shimadzu-VP instrument with UV detection at 220 nm and

Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column:


XTERRA® MS 7 µm, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 551.34, HPLC R_t =

- 25 1.895 min.




2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-phenylcyclopropylcarbamoyl)phenyl)-6-nitrobenzofuran-3-carboxamide

- [00340] Prepared by the coupling of 2-(4-fluorophenyl)-5-(2-methyl-5-(1-phenylcyclopropylcarbamoyl)phenyl)-6-nitrobenzofuran-3-carboxylic acid with methylamine hydrochloride under the conditions as described. LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 564.36, HPLC R_t = 1.768 min.



- 6-Amino-2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-(1-phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide
- [00341] Obtained as a TFA salt from the reduction of 2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-(1-phenylcyclopropylcarbamoyl)phenyl)-6-nitrobenzofuran-3-carboxamide using H₂ with 5% Pd/C as catalyst (2:5 DMF/EtOAc, r.t.) after purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 6.17 - 6.79 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 7.94 (m, J = 8.85, 5.19, 2H), 7.87 (dd, J = 8.09, 1.98, 1H), 7.74 (d, J = 1.83, 1H), 7.50 (d, J = 7.93, 1H), 7.44 (s, 1H), 7.38 (s, 1H), 7.17 (m, 1H), 7.29 (s, 1H), 7.29 - 7.25 (overlapping m, 5H), 2.92 (s, 3H), 2.24 (s, 3H), 1.35 (m, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final

- %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 534.26, HPLC R_t = 1.563 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 11.58 min; XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 4.96 min (Start %B = 50). Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5%H₂O-10 mM NH₄HCO₃, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl, R_t = 15.09 min.




- 15 2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-phenylcyclopropylcarbamoyl)phenyl)-6-(methylsulfonamido)benzofuran-3-carboxamide

- [00342] To a mixture of 6-amino-2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-(1-phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide (53.3 mg, 0.100 mmol) (crude) in ClCH₂CH₂Cl (1 ml) at r.t. under N₂ was added pyridine (0.024 mL, 0.300 mmol). The mixture was then added a solution of methanesulfonyl chloride (22.88 mg, 0.200 mmol) in ClCH₂CH₂Cl (0.3 ml), and stirred for about 22 hours. The mixture was diluted with MeOH and purified by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 6.75 - 7.37 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 7.98 (m, J = 8.85, 5.19, 2H), 7.85 (dd, J


= 8.09, 1.98, 1H), 7.79 (s, 1H), 7.75 (d, $J = 1.53$, 1H), 7.51 (s, 1H), 7.47 (d, $J = 7.93$, 1H), 7.17 (m, 1H), 7.30 - 7.26 (overlapping m, 5H), 7.29 (s, 1H), 2.93 (s, 3H), 2.88 (s, 3H), 2.23 (s, 3H), 1.35 (appeared as d, 4H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®.

- 5 HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 μ m, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 612.34, HPLC R_t = 1.583 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254
- 10 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 7.48 min; XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 6.24 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃,
- 15 Solvent B = 95% MeOH-5%H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl, R_t = 11.46 min.



- 20 2-(4-Fluorophenyl)-6-(N-(2-hydroxyethyl)methylsulfonamido)-N-methyl-5-(2-methyl-5-(1-phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide
- [00343]** 2-(4-Fluorophenyl)-6-(N-(2-hydroxyethyl)methylsulfonamido)-N-methyl-5-(2-methyl-5-(1-phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide was prepared from the alkylation of 2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-phenylcyclopropylcarbamoyl)phenyl)-6-(methylsulfonamido)benzofuran-3-
- 25 carboxamide using (2-bromoethoxy)(*tert*-butyl)dimethylsilane (K₂CO₃, DMF 55 °C) followed by deprotection using HCl in 1,4-dioxane at r.t. Purification was performed by Shimadzu-VP preparative reverse phase HPLC using the separation method:


Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 6.32 - 6.81 min. (UV detection at 220 nm). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 mL/min, Column: XTERRA® MS 7 µm, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 656.06, HPLC R_t = 1.563 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 mL/min, Column: Sunfire C18, 3.5 µm, 4.6 x 150 mm, R_t = 6.05 min; XBridge phenyl 3.5 µm, 4.6 x 150 mm, R_t = 5.38 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 mL/min, Column: XBridge phenyl 3.5 µm, 4.6 x 150 mm, R_t = 11.42 min.



5-(2-Fluoro-5-(1-phenylcyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-6-(N-(2-hydroxyethyl)methylsulfonamido)-N-methylbenzofuran-3-carboxamide


[00344] Purification was performed by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 30, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 8.06 - 8.30 min. (UV detection

at 220 nm). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: XTERRA® MS 7 um, C18, 3.0 x 50 mm; (ES+) m/z (M+H)⁺ = 660.50, HPLC R_t = 1.530 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 um, 4.6 x 150 mm, R_t = 5.68 min; XBridge phenyl 3.5 um, 4.6 x 150 mm, R_t = 5.18 min.



[00345] General procedure: To a BIOTAGE® microwave vial (2-5 mL) was added either 5-(4-chloro-3-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (0.075 mmol, 1 eq.) or 4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-(isobutylcarbamoyl)phenyl trifluoromethane sulfonate (0.075 mmol, 1 eq.) in dry 1,4-Dioxane (1 mL) along with the desired boronic acid (0.150 mmol, 2 eq.), potassium phosphate, tribasic (0.300 mmol, 52.3 mg) in water (0.2 mL), dicyclohexyl(2',6'-dimethoxybiphenyl-3-yl)phosphine (S-Phos) (6.16 mg, 0.015 mmol), and finally palladium (II) acetate (3.37 mg, 0.015 mmol) in 1,4-dioxane (0.5 mL). The vial was flushed with nitrogen then capped and placed into the BIOTAGE® microwave for 10 minutes at 150 °C. The solvent was removed in a Thermo/Savant SPEEDVAC® and the crude products were dissolved in DMF (1.8 mL) and purified by preparative HPLC using a Shimadzu Prep HPLC employing acetonitrile/water/0.1%TFA where solvent A was 10% acetonitrile / 90% H₂O/ 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 5µm C18 30x100mm column at a gradient of 30-100% B and a flow rate of 40 mL/min. over 8 minutes with a 10 minute hold. The tubes with desired product were evaporated overnight in a Thermo/Savant


SPEEDVAC®. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% TFA/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% TFA/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/ 0.1%TFA with a gradient of 20-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a PHENOMENEX® Gemini C18 3µm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 20-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. Rt represents the LC retention time in minutes. All NMR spectra were recorded at room temperature using deuterated NMR solvents.



5-(4-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-(isobutylcarbamoyl)phenyl)-N-methylpicolinamide

[00346] ¹H NMR (400 MHz, THF-d₈) δ ppm 0.75 (d, *J*=7 Hz, 6 H), 1.63 - 1.71 (m, 1 H), 2.93 (d, *J*=5 Hz, 6 H), 3.00 (t, *J*=6 Hz, 2 H), 7.23 (t, *J*=9 Hz, 2 H), 7.37 (t, *J*=6 Hz, 1 H), 7.44 - 7.51 (m, 1 H), 7.53 (d, *J*=8 Hz, 1 H), 7.60 - 7.66 (m, 1 H), 7.67 - 7.73 (m, 1 H), 7.80 - 7.88 (m, 2 H), 7.98 (dd, *J*=8, 2 Hz, 1 H), 8.05 (s, 1 H), 8.08 -

8.18 (m, 3 H), 8.30 (d, $J=5$ Hz, 1 H), 8.66 (d, $J=2$ Hz, 1 H). LCMS Rt 2.125 min., m/z 579.32 (M+H), HPLC Rt 8.594 min. (Sunfire C18), 98.7 % purity and 11.276 min. (Gemini C18), 100 % purity.




5

4-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-N2-isobutylbiphenyl-2,4'-dicarboxamide

[00347] ^1H NMR (400 MHz, DMF- d_7) δ ppm 0.81 (d, $J=6.78$ Hz, 6 H), 1.71 - 1.82 (m, 1 H), 3.00 (d, $J=4.77$ Hz, 3 H), 3.06 (t, $J=6.40$ Hz, 2 H), 7.42 - 7.48 (m, 2 H), 7.57 (d, $J=8.28$ Hz, 1 H), 7.62 (m, 2 H), 7.78 (d, $J=8.28$ Hz, 1 H), 7.84 (m, 2 H), 7.94 (d, $J=8.03$ Hz, 1 H), 8.00 (d, $J=8.28$ Hz, 2 H), 8.06 - 8.08 (m, 1 H), 8.10 - 8.14 (m, 2 H), 8.20 (t, $J=5.77$ Hz, 1 H), 8.40 (d, $J=4.52$ Hz, 1 H). LCMS Rt 2.020 min, m/z 564.25 (M+H). HPLC Rt 8.224 min. (Sunfire C18), 98.2 % purity and 11.098 min. (Gemini C18), 98.3 % purity.

15




5-(4-(5-Cyanopyridin-3-yl)-3-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00348] ^1H NMR (400 MHz, THF- d_8) δ ppm 0.82 (d, $J=6.78$ Hz, 6 H), 1.74 - 1.80 (m, 1 H), 2.93 (d, $J=4.52$ Hz, 3 H), 3.01 - 3.11 (m, 2 H), 7.18 - 7.30 (m, 2 H), 7.42 - 7.51 (m, 1 H), 7.55 (d, $J=7.78$ Hz, 1 H), 7.56 - 7.61 (m, 1 H), 7.62 - 7.67 (m, 1 H), 7.68 - 7.75 (m, 1 H), 7.83 - 7.92 (m, 2 H), 8.04 - 8.15 (m, 3 H), 8.20 (t, $J=2.13$ Hz, 1

H), 8.85 (dd, $J=13.93$, 2.13 Hz, 2 H). LCMS Rt 2.278 min, m/z 547.23 (M+H). HPLC Rt 9.246 min. (Sunfire C18), 96.0 % purity and 11.343 min. (Gemini C18), 98.6 % purity.


[00349] An alternative approach to the coupling. To a small sized microwave vial
 5 was added 5-(4-chloro-3-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (47.9 mg, 0.1 mmol), BuOH (2 mL), boronic acid/ester (0.150 mmol), dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (19.07 mg, 0.040 mmol), potassium phosphate, tribasic (85 mg, 0.400 mmol) and finally Tris(dibenzylideneacetone) dipalladium(0) (18.31 mg, 0.020 mmol). The vial
 10 was capped and subjected to microwave heating (130 °C) for 12 minutes. Butanol was removed under a stream of nitrogen and the crude products were dissolved in DMF (1.8 mL) and purified by preparative HPLC employing a DIONEX® Prep HPLC system equipped with an ELS (Evaporative Light Scattering) detector. A Waters XBridge 19x200mm 5 μ m C18 column was used with acetonitrile/HPLC
 15 grade water/10mM ammonium acetate where solvent A was HPLC grade water with 10mM ammonium acetate and solvent B was 100% acetonitrile at a gradient of 30-95% B in 30 minutes with a flow rate of 25mL/minute. LCMS was run using a Waters ZQ with ESCi mass spectrometer with a SUPELCO® Ascentis Express 3 μ m C18 4.5 x 50mm column employing acetonitrile/HPLC grade water/10mM
 20 ammonium acetate where solvent A was 5% acetonitrile, 95% HPLC grade water with 10mM ammonium acetate and solvent B was 95% acetonitrile, 5% HPLC grade water with 10mM ammonium acetate at a gradient of 0-100% B in 8 minutes with a 1 minute hold at 2mL/minute.



25


2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-4-(2-methylpyridin-3-yl)phenyl)-N-methylbenzofuran-3-carboxamide

[00350] LCMS m/z 535.90 (M+H), Rt 4.89 min., 100 % purity.




5 5-(4-(5-Aminopyridin-3-yl)-3-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

[00351] LCMS m/z 536.96 (M+H), Rt 4.37 min., 100 % purity.




10 5-(4-(2,4-Dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

[00352] LCMS m/z 554.94 (M+H), Rt 3.88 min., 100 % purity.



15 5-(4-(2-Aminopyridin-4-yl)-3-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide


[00353] LCMS m/z 536.97 (M+H), Rt 4.55 min., 100 % purity.



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-4-(5-methoxypyridin-3-yl)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00354] LCMS m/z 551.96 (M+H), Rt 4.97 min., 89 % purity.


5



5-(4-(2-Aminopyrimidin-5-yl)-3-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

[00355] LCMS m/z 537.97 (M+H), Rt 4.23 min., 96 % purity.


10



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-4-(5-methylpyridin-3-yl)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00356] LCMS m/z 535.95 (M+H), Rt 4.99 min., 100 % purity.


15



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-4-(thiophen-3-yl)phenyl)-N-methylbenzofuran-3-carboxamide

[00357] LCMS m/z 526.96 (M+H), Rt 5.83 min., 74 % purity.


5



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-4-(pyrimidin-5-yl)phenyl)-N-methylbenzofuran-3-carboxamide

- [00358] Purification by using a Shimadzu preparative HPLC employing
- 10 CH₃CN/water/TFA where solvent A was 10% acetonitrile / 90% H₂O/ 0.1% trifluoroacetic acid and solvent B was 10% H₂O / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 5u C18 30x100mm column at a gradient of 30-100% B and a flow rate of 40 mL/min. over 10 minutes with a 10 minute hold. Post purification LC/MS data was obtained on a Shimadzu analytical LC /
- 15 MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5μm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% TFA/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% TFA/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a
- 20 Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5μm 4.6 x 150mm column employing water/acetonitrile/ 0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade

acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a PHENOMENEX® Gemini C18 3µm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a
 5 gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.76 (d, *J*=6.78 Hz, 6 H), 1.61 - 1.74 (m, 1 H), 2.87 (d, *J*=4.52 Hz, 3 H), 2.96 (t, *J*=6.27 Hz, 2 H),
 10 7.39 (t, *J*=8.91 Hz, 2 H), 7.64 (d, *J*=8.03 Hz, 1 H), 7.77 - 7.87 (m, 3 H), 7.91 - 8.07 (m, 4 H), 8.47 - 8.60 (m, 2 H), 8.81 (s, 2 H), 9.16 (s, 1 H). LCMS *m/z* 523.22 (M+H), Rt 2.052 min. HPLC Rt 8.908 min. (Sunfire C18), 96.0 % purity and 11.353 min. (Gemini C18), 98.6 % purity.



15 2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(2-methoxyethoxy)phenyl)-N-methylbenzofuran-3-carboxamide

[00359] To a small microwave vial was added 2-(4-fluorophenyl)-5-(2-hydroxy-5-(isobutylcarbamoyl) phenyl)-N-methylbenzofuran-3-carboxamide (33 mg, 0.072
 20 mmol), tetrahydrofuran (2 mL), triphenylphosphine (37.6 mg, 0.143 mmol), 2-methoxyethanol (0.011 mL, 0.139 mmol), and di-*tert*-butyl azodicarboxylate (33.0 mg, 0.143 mmol). The vial was crimped and heated to 100 °C for 10 minutes. After returning to room temperature tetrahydrofuran was removed under a stream of nitrogen. The crude product was taken up in 2mL of acetonitrile and purified using a
 25 Shimadzu preparative HPLC employing acetonitrile/water/0.1%TFA where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 5µm

C18 30 x 100mm column at a gradient of 40-100% B and a flow rate of 40 mL/min. over 8 minutes with a 10 minute hold. The desired material was concentrated to dryness. The resulting white solid (41% yield) was placed under high vacuum prior to final analysis. The LC/MS data was obtained on a Shimadzu analytical LC /

5 MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was

10 determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1


15 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5µm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water /

20 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The NMR spectrum was recorded at room temperature using a Bruker DRX400 spectrometer. Chemical shifts were reported in ppm relative to the deuterated solvent used. Coupling constants were reported in hertz. Peak multiplicity was reported using the following abbreviations: s (singlet), d

25 (doublet), dd (doublet of doublets), t (triplet), m (multiplet), br (broad). ¹H NMR (400 MHz, CD₃OD) δ ppm 1.04 (d, *J* = 6.53 Hz, 6 H), 1.35 - 1.40 (m, 3 H), 1.96 - 2.08 (m, 1 H), 2.97 - 3.10 (m, 3 H), 3.24 - 3.32 (m, 2 H), 3.73 - 3.82 (m, 2 H), 4.25 - 4.34 (m, 2 H), 7.24 (d, *J* = 8.53 Hz, 1 H), 7.29 - 7.38 (m, 2 H), 7.63 - 7.72 (m, 2 H), 7.91 (dd, *J* = 8.53, 2.26 Hz, 1 H), 7.94 - 7.99 (m, 2 H), 8.00 - 8.09 (m, 2 H), 8.48 (br. s., 1 H).

30 LCMS *m/z* 519.25 (M+H), Rt 2.292 min. HPLC (Sunfire C18) Rt 10.054 min, 96% purity and (XBridge phenyl C18) Rt 11.846 min., 97 % purity.

[00360] Additional examples of ether linked compounds are shown below. The compounds were synthesized in the same manner as above. The solvent (tetrahydrofuran) was removed under a stream of nitrogen and the crude products were dissolved in DMF (1.8 mL) and purified by preparative HPLC employing a DIONEX® Prep HPLC system equipped with an ELS (Evaporative Light Scattering) detector. A SUPELCO® Ascentis 5 μ m C18 21.2 x 250mm column was used with acetonitrile/HPLC grade water/10mM ammonium acetate where solvent A was 99.9% HPLC grade water with 10mM ammonium acetate and solvent B was 100% acetonitrile at a gradient of 30-95% B in 20 minutes with a 2.5 minute hold at 20mL/minute. LCMS was run using a Waters ZQ with ESCi mass spectrometer with a SUPELCO® Ascentis Express 3 μ m C18 4.5 x 50mm column employing acetonitrile/HPLC grade water/10mM ammonium acetate where solvent A was 5% acetonitrile, 95% HPLC grade water with 10mM ammonium acetate and solvent B was 95% acetonitrile, 5% HPLC grade water with 10mM ammonium acetate at a gradient of 0-100% B in 8 minutes with a 1 minute hold at 2mL/minute. The NMR spectra were recorded at room temperature using a Varian 600MHz flow spectrometer. Chemical shifts were reported in ppm relative to the 75% DMSO-d₆/25% CDCl₃ (v/v) solvent used.




2-(4-Fluorophenyl)-5-(2-(4-hydroxyphenethoxy))-5-(isobutylcarbamoyl)phenyl-*N*-methylbenzofuran-3-carboxamide

[00361] ¹H NMR (600 MHz, DMSO-d₆/CDCl₃) δ ppm 0.88 (d, *J*=7.03 Hz, 6 H), 1.85 (ddd, *J*=13.33, 6.59, 6.44 Hz, 1 H), 2.77 - 2.94 (m, 5 H), 3.08 (t, *J*=6.15 Hz, 2 H), 4.20 (t, *J*=6.44 Hz, 2 H), 6.59 - 6.68 (m, 2 H), 6.98 (d, *J*=8.20 Hz, 2 H), 7.13 (d,

$J=8.79$ Hz, 1 H), 7.32 (t, $J=8.79$ Hz, 1 H), 7.41 (d, $J=8.79$ Hz, 1 H), 7.59 (d, $J=8.20$ Hz, 1 H), 7.75 (s, 1 H), 7.81 - 7.91 (m, 2 H), 8.00 (dd, $J=8.20$, 5.27 Hz, 1 H), 8.33 (t, $J=5.57$ Hz, 1 H), 8.39 (d, $J=4.10$ Hz, 1 H). LCMS m/z 581.48 (M+H), Rt 5.30 min., 90 % purity.


5



5-(2-(3-(1*H*-Pyrrol-1-yl)propoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

[00362] ^1H NMR (600 MHz, DMSO- d_6 /CDCl $_3$) δ ppm 0.89 (d, $J=6.44$ Hz, 6 H),
 10 1.80 - 1.91 (m, 1 H), 2.07 (m, 2 H), 2.79 (d, $J=4.10$ Hz, 3 H), 3.09 (t, $J=6.44$ Hz, 2
 H), 3.90 - 4.01 (m, 4 H), 5.94 (s, 2 H), 6.61 (s, 2 H), 7.08 (d, $J=8.79$ Hz, 1 H), 7.32 (t,
 $J=8.50$ Hz, 2 H), 7.58 (d, $J=8.20$ Hz, 1 H), 7.70 (d, $J=8.79$ Hz, 1 H), 7.79 - 7.87 (m, 2
 H), 7.92 (s, 1 H), 7.97 (dd, $J=8.50$, 5.57 Hz, 2 H), 8.32 - 8.42 (m, 2 H). LCMS m/z
 568.47 (M+H), Rt 5.98 min., 100 % purity.

15




2-(4-Fluorophenyl)-5-(2-(4-chlorophenoxy)-5-(isobutylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00363] ^1H NMR (600 MHz, DMSO- d_6 /CDCl $_3$) δ ppm 0.88 (d, $J=7.03$ Hz, 6 H),
 20 1.80 - 1.90 (m, 1 H), 2.84 (d, $J=4.69$ Hz, 3 H), 2.96 (t, $J=6.15$ Hz, 2 H), 3.08 (t,

$J=6.15$ Hz, 2 H), 4.26 (t, $J=6.44$ Hz, 2 H), 7.14 (d, $J=8.79$ Hz, 1 H), 7.19 (d, $J=8.20$ Hz, 2 H), 7.23 - 7.27 (m, 2 H), 7.29 - 7.39 (m, 3 H), 7.58 (d, $J=8.79$ Hz, 1 H), 7.73 (s, 1 H), 7.83 - 7.89 (m, 2 H), 8.00 (dd, $J=8.50, 5.57$ Hz, 2 H), 8.33 (t, $J=5.27$ Hz, 1 H), 8.38 (d, $J=4.10$ Hz, 1 H). LCMS m/z 599.47 (M+H), Rt 6.52 min., 92 % purity.


5



2-(4-Fluorophenyl)-5-(2-((6-(hydroxymethyl)pyridin-2-yl)methoxy)-5-(isobutylcarbamoyl) phenyl)-N-methylbenzofuran-3-carboxamide

[00364] ^1H NMR (600 MHz, DMSO- d_6 /CDCl $_3$) δ ppm 0.89 (d, $J=6.44$ Hz, 6 H), 1.79 - 1.91 (m, 1 H), 2.82 (d, $J=4.10$ Hz, 3 H), 3.09 (t, $J=6.44$ Hz, 2 H), 4.56 (s, 2 H), 5.23 (s, 2 H), 7.24 (t, $J=9.37$ Hz, 2 H), 7.32 (t, $J=8.79$ Hz, 2 H), 7.37 (d, $J=8.20$ Hz, 1 H), 7.60 - 7.65 (m, 1 H), 7.66 - 7.70 (m, 1 H), 7.75 (t, $J=7.62$ Hz, 1 H), 7.84 - 7.90 (m, 2 H), 7.93 (s, 1 H), 7.96 - 8.03 (m, 2 H), 8.36 (t, $J=5.57$ Hz, 1 H), 8.40 (d, 1 H). LCMS m/z 582.48 (M+H), Rt 4.57 min., 93 % purity.

15




2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(3-morpholinopropoxy)phenyl)-N-methylbenzofuran-3-carboxamide

[00365] ^1H NMR (600 MHz, DMSO- d_6 /CDCl $_3$) δ ppm 0.89 (d, $J=7.03$ Hz, 6 H), 1.77 - 1.91 (m, 3 H), 2.23 - 2.43 (m, 6 H), 2.84 (d, $J=4.10$ Hz, 3 H), 3.08 (t, $J=6.44$

20

Hz, 2 H), 3.53 (br. s., 4 H), 4.09 (t, $J=5.86$ Hz, 2 H), 7.14 (d, $J=8.20$ Hz, 1 H), 7.32 (t, $J=8.79$ Hz, 2 H), 7.53 (d, $J=9.37$ Hz, 1 H), 7.65 (d, $J=8.79$ Hz, 1 H), 7.78 (s, 1 H), 7.84 - 7.92 (m, 2 H), 7.98 (dd, $J=7.91, 5.57$ Hz, 2 H), 8.31 - 8.43 (m, 2 H). LCMS m/z 588.40 (M+H), Rt 4.05 min., 98.7 % purity.


5



2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(2-morpholinoethoxy)phenyl)-N-methylbenzofuran-3-carboxamide

[00366] ^1H NMR (600 MHz, DMSO- d_6 /CDCl $_3$) δ ppm 0.89 (d, $J=6.44$ Hz, 6 H), 1.79 - 1.91 (m, 1 H), 2.38 (br. s., 4 H), 2.64 (t, $J=5.57$ Hz, 2 H), 2.84 (d, $J=4.10$ Hz, 3 H), 3.08 (t, $J=6.15$ Hz, 2 H), 3.52 (t, $J=4.39$ Hz, 4 H), 4.17 (t, $J=5.57$ Hz, 2 H), 7.16 (d, $J=8.79$ Hz, 1 H), 7.32 (t, $J=8.79$ Hz, 2 H), 7.56 - 7.61 (m, 1 H), 7.61 - 7.66 (m, 1 H), 7.75 (s, 1 H), 7.83 - 7.91 (m, 2 H), 7.98 (dd, $J=8.20, 5.86$ Hz, 2 H), 8.35 (t, $J=5.27$ Hz, 1 H), 8.38 (d, 1 H). LCMS m/z 574.35 (M+H), Rt 3.95 min., 100 % purity.


15



2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(pyridin-2-ylmethoxy)phenyl)-N-methylbenzofuran-3-carboxamide

[00367] ^1H NMR (600 MHz, DMSO- d_6 /CDCl $_3$) δ ppm 0.89 (d, $J=7.03$ Hz, 6 H), 1.82 - 1.91 (m, 1 H), 2.79 - 2.86 (m, 3 H), 3.09 (t, $J=6.44$ Hz, 2 H), 5.27 (s, 2 H), 7.22 - 7.30 (m, 2 H), 7.33 (t, $J=8.50$ Hz, 2 H), 7.40 (d, $J=7.62$ Hz, 1 H), 7.62 (d, $J=8.79$


Hz, 1 H), 7.66 - 7.71 (m, 1 H), 7.76 (t, $J=7.62$ Hz, 1 H), 7.84 - 7.91 (m, 2 H), 7.94 (s, 1 H), 7.99 (dd, $J=8.50, 5.57$ Hz, 2 H), 8.35 - 8.44 (m, 2 H), 8.53 (d, $J=4.69$ Hz, 1 H).
LCMS m/z 552.29 (M+H), Rt 4.29 min., 100 % purity.



5

2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-
N-methylbenzofuran-3-carboxamide

[00368] ^1H NMR (600 MHz, DMSO- d_6 /CDCl $_3$) δ ppm 0.89 (d, $J=6.44$ Hz, 6 H),
1.64 (br. s., 4 H), 1.80 - 1.91 (m, 1 H), 2.47 (br. s., 4 H), 2.75 - 2.82 (m, 2 H), 2.84 (d,
10 $J=4.10$ Hz, 3 H), 3.08 (t, $J=6.44$ Hz, 2 H), 4.16 (t, $J=5.27$ Hz, 2 H), 7.16 (d, 1 H), 7.32
(t, $J=8.79$ Hz, 2 H), 7.56 - 7.61 (m, 1 H), 7.61 - 7.66 (m, 1 H), 7.78 (s, 1 H), 7.86 (d,
 $J=8.20$ Hz, 1 H), 7.89 (s, 1 H), 7.98 (dd, $J=8.20, 5.27$ Hz, 2 H), 8.31 - 8.43 (m, 2 H).
LCMS m/z 558.37 (M+H), Rt 3.52 min., 100 % purity.




15

2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(2-(piperidin-1-yl)ethoxy)phenyl)-*N*-
methylbenzofuran-3-carboxamide

[00369] ^1H NMR (600 MHz, DMSO- d_6 /CDCl $_3$) δ ppm 0.89 (d, $J=6.44$ Hz, 6 H),
1.32 - 1.38 (m, 2 H), 1.38 - 1.43 (m, 2 H), 1.44 - 1.52 (m, 2 H), 1.79 - 1.93 (m, 1 H),
20 2.32 - 2.45 (m, 4 H), 2.57 - 2.68 (m, 2 H), 2.84 (d, $J=4.10$ Hz, 3 H), 3.08 (t, $J=6.15$
Hz, 2 H), 4.10 - 4.20 (m, 2 H), 7.16 (d, $J=8.79$ Hz, 1 H), 7.32 (t, $J=8.79$ Hz, 2 H),

7.61 (q, $J=8.79$ Hz, 2 H), 7.76 (s, 1 H), 7.86 (d, $J=8.20$ Hz, 1 H), 7.89 (s, 1 H), 7.98 (dd, $J=8.20, 5.86$ Hz, 2 H), 8.31 - 8.44 (m, 2 H). LCMS m/z 572.37 (M+H), Rt 3.89 min., 95.4 % purity.




5

2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(2-(pyridin-2-yl)ethoxy)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00370] ^1H NMR (600 MHz, DMSO- d_6 /CDCl $_3$) δ ppm 0.88 (d, $J=6.44$ Hz, 6 H), 1.79 - 1.91 (m, 1 H), 2.84 (d, $J=4.69$ Hz, 3 H), 3.08 (t, $J=6.15$ Hz, 2 H), 3.21 (t, $J=6.15$ Hz, 2 H), 4.47 (t, $J=6.15$ Hz, 2 H), 7.20 (dd, $J=19.92, 8.20$ Hz, 2 H), 7.29 - 7.41 (m, 4 H), 7.50 (d, $J=8.79$ Hz, 1 H), 7.67 (s, 1 H), 7.79 - 7.91 (m, 3 H), 8.00 (dd, $J=8.50, 5.57$ Hz, 2 H), 8.34 (t, $J=5.57$ Hz, 1 H), 8.45 (d, $J=4.10$ Hz, 1 H), 8.51 (d, $J=4.69$ Hz, 1 H). LCMS m/z 566.34 (M+H), Rt 4.32 min., 100 % purity.

10




15

2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-((2-methyl-1*H*-imidazol-4-yl)methoxy)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00371] ^1H NMR (600 MHz, DMSO- d_6 /CDCl $_3$) δ ppm 0.89 (d, $J=6.44$ Hz, 6 H), 1.85 (dd, $J=12.01, 6.74$ Hz, 1 H), 2.14 - 2.38 (m, 3 H), 2.81 - 2.88 (m, 3 H), 3.04 - 3.12 (m, 2 H), 5.00 (s, 1 H), 6.91 - 7.03 (m, 1 H), 7.32 (t, $J=9.08$ Hz, 2 H), 7.50 - 7.68 (m, 2 H), 7.70 (d, $J=6.44$ Hz, 1 H), 7.79 (d, $J=4.10$ Hz, 2 H), 7.86 (d, $J=11.72$ Hz, 1


20

H), 7.94 (s, 1 H), 7.96 - 8.04 (m, 1 H), 8.34 (t, $J=5.57$ Hz, 1 H), 8.40 (d, $J=4.69$ Hz, 1 H). LCMS m/z 555.34 (M+H), Rt 3.57 min., 93.3 % purity.




- 5 2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-((5-(trifluoromethyl)pyridin-2-yl)methoxy) phenyl)-*N*-methylbenzofuran-3-carboxamide

[00372] ^1H NMR (600 MHz, DMSO- d_6 /CDCl $_3$) δ ppm 0.90 (d, $J=7.03$ Hz, 6 H), 1.82 - 1.92 (m, 1 H), 2.79 (d, $J=4.69$ Hz, 3 H), 3.09 (t, $J=6.15$ Hz, 2 H), 5.39 (s, 2 H), 7.27 (d, $J=8.79$ Hz, 1 H), 7.34 (t, $J=8.50$ Hz, 2 H), 7.62 (t, $J=8.50$ Hz, 2 H), 7.71 (d, $J=8.20$ Hz, 1 H), 7.89 (d, $J=8.20$ Hz, 1 H), 7.92 (s, 1 H), 7.95 - 8.02 (m, 3 H), 8.16 (d, $J=8.20$ Hz, 1 H), 8.39 (t, $J=5.57$ Hz, 1 H), 8.44 (d, $J=4.69$ Hz, 1 H), 8.90 (s, 1 H).
 10 LCMS m/z 620.32 (M+H), Rt 5.09 min., 97.9 % purity.




- 15 5-(2-((1*H*-Imidazol-4-yl)methoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide
- [00373] LCMS m/z 541.29 (M+H), Rt 3.51 min., 100 % purity.



2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-((1-methyl-1H-imidazol-4-yl)methoxy)phenyl)-N-methylbenzofuran-3-carboxamide

[00374] ^1H NMR (600 MHz, DMSO- d_6 /CDCl $_3$) δ ppm 0.88 (d, J =6.44 Hz, 6 H),
 1.83 (dt, J =13.48, 6.74 Hz, 1 H), 2.84 (d, J =4.69 Hz, 3 H), 3.06 (t, J =6.44 Hz, 2 H),
 3.63 (s, 3 H), 3.88 (s, 2 H), 7.00 (s, 1 H), 7.32 (t, J =8.79 Hz, 2 H), 7.55 (d, J =8.20 Hz,
 1 H), 7.63 - 7.70 (m, 3 H), 7.74 (d, J =14.65 Hz, 2 H), 7.94 (s, 1 H), 7.99 (dd, J =8.20,
 5.27 Hz, 2 H), 8.23 (s, 1 H), 8.39 (d, J =4.10 Hz, 1 H). LCMS m/z 555.35 (M+H), Rt
 4.11 min., 100 % purity.


10



2-(4-Fluorophenyl)-5-(2-(hex-2-ynyloxy)-5-(isobutylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide

[00375] ^1H NMR (600 MHz, DMSO- d_6 /CDCl $_3$) δ ppm 0.83 - 0.97 (m, 9 H), 1.36 -
 1.48 (m, 2 H), 1.82 - 1.90 (m, 1 H), 2.16 (t, J =6.74 Hz, 2 H), 2.84 (d, J =4.69 Hz, 3
 H), 3.09 (t, J =6.44 Hz, 2 H), 4.82 (br. s., 2 H), 7.23 (d, J =8.20 Hz, 1 H), 7.29 - 7.33
 (m, 2 H), 7.51 (d, J =8.79 Hz, 1 H), 7.65 (d, J =8.20 Hz, 1 H), 7.72 (s, 1 H), 7.84 - 7.91
 (m, 2 H), 7.99 (dd, J =8.20, 5.27 Hz, 2 H), 8.36 (t, J =5.57 Hz, 1 H), 8.40 (d, J =4.10
 Hz, 1 H). LCMS m/z 541.35 (M+H), Rt 5.20 min., 95.3 % purity.


20



5-(2-(2,2-Difluoroethoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

[00376] ¹H NMR (600 MHz, DMSO-d₆/CDCl₃) δ ppm 0.89 (d, *J*=6.44 Hz, 6 H),
 5 1.86 (dt, *J*=13.48, 6.74 Hz, 1 H), 2.84 (d, *J*=4.10 Hz, 3 H), 3.09 (t, *J*=6.44 Hz, 2 H),
 4.39 (td, *J*=14.35, 2.93 Hz, 2 H), 6.15 - 6.40 (m, 1 H), 7.23 (d, *J*=8.79 Hz, 1 H), 7.32
 (t, *J*=8.79 Hz, 2 H), 7.56 (d, *J*=8.79 Hz, 1 H), 7.66 (d, *J*=8.20 Hz, 1 H), 7.79 (s, 1 H),
 7.89 (d, *J*=8.79 Hz, 1 H), 7.93 (s, 1 H), 7.99 (dd, *J*=8.20, 5.27 Hz, 2 H), 8.35 - 8.44
 (m, 2 H). LCMS *m/z* 525.27 (M+H), Rt 4.44 min., 97.4 % purity.


10



5-(2-((2-Bromopyridin-4-yl)methoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide


[00377] ¹H NMR (600 MHz, DMSO-d₆/CDCl₃) δ ppm 0.89 (d, *J*=6.44 Hz, 6 H),
 15 1.81 - 1.91 (m, 1 H), 2.82 (d, *J*=4.69 Hz, 3 H), 3.09 (t, *J*=6.15 Hz, 2 H), 5.27 (s, 2 H),
 7.21 (d, *J*=8.79 Hz, 1 H), 7.33 (t, *J*=8.50 Hz, 2 H), 7.37 (d, *J*=4.69 Hz, 1 H), 7.54 (s, 1
 H), 7.61 (d, *J*=8.79 Hz, 1 H), 7.70 (d, *J*=8.79 Hz, 1 H), 7.83 (s, 1 H), 7.89 (d, *J*=8.79
 Hz, 1 H), 7.94 (s, 1 H), 7.99 (dd, *J*=8.20, 5.27 Hz, 2 H), 8.32 (d, *J*=5.27 Hz, 1 H),
 8.38 (d, *J*=4.69 Hz, 2 H). LCMS *m/z* 630.26 (M+H), Rt 4.71 min., 98.4 % purity.

20



5-(2-(2-(Dibenzylamino)ethoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-
N-methylbenzofuran-3-carboxamide

- [00378]** Post purification LC/MS data was obtained on a Shimadzu analytical LC /
 5 MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions:
 Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90%
 HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A =
 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in
 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was
 10 determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters
 XBridge phenyl C18 3.5µm 4.6 x 150mm column employing water/methanol/ 10mM
 ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade
 methanol / 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC
 grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10
 15 minutes with a 10 minute hold at a rate of 1 mL/minute. The NMR spectrum was
 recorded at room temperature using a Bruker DRX400 spectrometer. ¹H NMR (400
 MHz, CD₃OD) δ ppm 0.96 (d, *J* = 6.53 Hz, 6 H), 1.83 - 2.07 (m, 1 H), 2.81 (t, *J* =
 5.40 Hz, 2 H), 2.90 (s, 3 H), 3.19 (d, *J* = 7.03 Hz, 2 H), 3.53 (s, 4 H), 4.10 (t, *J* = 5.40
 Hz, 2 H), 6.99 (d, *J* = 8.53 Hz, 1 H), 7.14 (dd, *J* = 5.52, 3.01 Hz, 2 H), 7.17 - 7.23 (m,
 20 8 H), 7.23 - 7.29 (m, 2 H), 7.41 - 7.47 (m, 1 H), 7.48 - 7.55 (m, 1 H), 7.75 - 7.82 (m, 2
 H), 7.84 (d, *J* = 2.26 Hz, 1 H), 7.92 (dd, *J* = 8.66, 5.40 Hz, 2 H). LCMS *m/z* 684.40
 (M+H), Rt = 1.897min. HPLC Rt 14.159 min. (XBridge phenyl C18), 100 % purity.




5-(2-(3-Aminocyclopentyloxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

[00379] Post purification LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+/-) at 220nm using the following set of conditions: Luna 10µm C18, 3.0 x 50mm column, with a gradient of 0-100%B (B = 95% HPLC grade acetonitrile/ 10mM ammonium acetate/ 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium acetate/ 5% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 5 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Gemini C18 3.0µm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The NMR spectrum was recorded at room temperature using a Bruker DRX400 spectrometer. ¹H NMR (400 MHz, THF-d₈) δ ppm 0.93 (d, *J* = 6.78 Hz, 6 H), 1.77 - 1.97 (m, 3 H), 2.04 - 2.19 (m, 2 H), 2.19 - 2.32 (m, 2 H), 2.90 (d, *J* = 4.52 Hz, 3 H), 3.17 (t, *J* = 6.40 Hz, 2 H), 3.69 - 3.82 (m, 2 H), 7.04 (d, *J* = 8.53 Hz, 1 H), 7.21 (t, *J* = 8.78 Hz, 2 H), 7.41 - 7.50 (m, 1 H), 7.50 - 7.56 (m, 1 H), 7.60 - 7.72 (m, 2 H), 7.81 (dd, *J* = 8.66, 2.13 Hz, 1 H), 7.85 (d, *J* = 1.25 Hz, 1 H), 7.90 (d, *J* = 2.01 Hz, 1 H), 7.99 - 8.10 (m, 2 H), 8.42 (br. s., 2 H). LCMS Rt 1.937min., *m/z* 542.34 (M-H) and *m/z* 544.29 (M+H). HPLC Rt 6.870 min. (Sunfire C18), 99.1 % purity and 11.133 min. (Gemini C18), 98.9 % purity.


[00380] An alternative synthesis to these ether linked analogs was carried out using phenol template in DMF with alkyl bromides and DBU. To a 2 dram vial was added 2-(4-fluorophenyl)-5-(2-hydroxy-5-(isobutylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide (46.0 mg, 0.1 mmol), DMF (2 mL), 4.0 equivalents of DBU, 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.4mmol) and 3.0 equivalents

(0.3mmol) of alkyl bromide. The vials were sealed and shaken at 75 °C in a dry bath. Upon reaction completion the crude products were concentrated, diluted with 2mL of acetonitrile and purified using a Shimadzu preparative HPLC employing acetonitrile/water/0.1%TFA where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 5µm C18 4.6 x 100mm column at a gradient of 30-100% B and a flow rate of 40 mL/min. over 8 minutes with a 10 minute hold. The desired products were evaporated to dryness in a Savant SPEEDVAC® overnight obtaining 25-60% yield of the desired ethers as powders. The NMR spectrum was recorded at room temperature using a Bruker DRX400 spectrometer. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5µm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute.




5-(2-(2-Amino-2-oxoethoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

[00381] ¹H NMR (400 MHz, THF-d₈) δ ppm 0.86 - 1.02 (m, 6 H), 1.81 - 1.99 (m, 1
 5 H), 2.91 (d, *J* = 4.77 Hz, 3 H), 3.06 - 3.29 (m, 2 H), 4.46 (s, 2 H), 6.43 (br. s., 1 H),
 6.69 (br. s., 1 H), 7.08 (d, *J* = 8.78 Hz, 1 H), 7.16 - 7.27 (m, 2 H), 7.53 (br. s., 1 H),
 7.56 - 7.62 (m, 2 H), 7.86 (dd, *J* = 8.53, 2.26 Hz, 1 H), 7.93 (d, *J* = 2.26 Hz, 1 H),
 7.97 (s, 1 H), 8.09 - 8.19 (m, 2 H). LCMS *m/z* 518.36 (M+H), Rt 1.880 min. HPLC
 (Sunfire C18) Rt 8.209min, 100% purity and (XBridge phenyl C18) Rt 11.254 min.,
 10 99.8 % purity.




5-(2-(2-(1*H*-Indol-3-yl)ethoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

15 [00382] ¹H NMR (500 MHz, CD₃OD) δ ppm 0.92 - 1.04 (m, 6 H), 1.87 - 2.03 (m,
 1 H), 2.95 (s, 3 H), 3.15 - 3.24 (m, 4 H), 4.37 (t, *J* = 6.71 Hz, 2 H), 6.94 (t, *J* = 7.48
 Hz, 1 H), 6.98 (s, 1 H), 7.07 (t, *J* = 7.63 Hz, 1 H), 7.18 (d, *J* = 8.55 Hz, 1 H), 7.24 -
 7.36 (m, 3 H), 7.44 - 7.50 (m, 2 H), 7.51 - 7.56 (m, 1 H), 7.84 (td, *J* = 4.27, 2.44 Hz, 2
 H), 7.88 (d, *J* = 2.14 Hz, 1 H), 7.94 - 8.03 (m, 2 H). LCMS *m/z* 604.31 (M+H), Rt
 20 2.621 min. HPLC Rt 11.054 min. (Sunfire C18), 98.1 % purity and 12.561 min.
 (XBridge phenyl C18), 97.8 % purity.




5-(2-(2-(1*H*-Indol-3-yl)ethoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

- 5 **[00383]** ^1H NMR (500 MHz, CD_3OD) δ ppm 0.87 - 1.03 (m, 6 H), 1.83 - 2.00 (m, 1 H), 2.17 (dd, $J = 9.77, 5.49$ Hz, 2 H), 2.81 - 2.90 (s, 3 H), 2.90 - 3.00 (s, 3 H), 3.12 - 3.25 (m, 4 H), 3.42 (br. s., 8 H), 4.21 (t, $J = 5.65$ Hz, 2 H), 7.17 (d, $J = 8.85$ Hz, 1 H), 7.22 - 7.33 (m, 2 H), 7.53 (dd, $J = 8.55, 1.83$ Hz, 1 H), 7.65 (d, $J = 8.24$ Hz, 1 H), 7.86 (td, $J = 8.47, 2.29$ Hz, 3 H), 7.89 - 7.96 (m, 2 H). LCMS m/z 601.36 ($\text{M}+\text{H}$), Rt 1.375 min. HPLC Rt 6.010 min. (Sunfire C18), 99.3% purity and 11.793 min. (XBridge phenyl C18), 98.4% purity.




- 15 5-(2-(2-(3,5-Dimethyl-1*H*-pyrazol-4-yl)ethoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide
- [00384]** ^1H NMR (500 MHz, CD_3OD) δ ppm 0.89 - 1.01 (m, 6 H), 1.86 - 1.98 (m, 1 H), 2.02 (s, 6 H), 2.90 (t, $J = 5.95$ Hz, 2 H), 2.95 (s, 3 H), 3.14 - 3.22 (m, 2 H), 4.24 (t, $J = 5.95$ Hz, 2 H), 7.18 (d, $J = 8.55$ Hz, 1 H), 7.24 - 7.33 (m, 2 H), 7.37 (dd, $J = 8.39, 1.68$ Hz, 1 H), 7.59 (d, $J = 8.55$ Hz, 1 H), 7.68 (d, $J = 1.83$ Hz, 1 H), 7.80 (d, $J = 2.44$ Hz, 1 H), 7.85 (dd, $J = 8.70, 2.29$ Hz, 1 H), 7.93 - 8.02 (m, 2 H). LCMS m/z 583.32
- 20

(M+H), Rt 1.698 min. HPLC Rt 7.270 min. (Sunfire C18), 92.6 % purity and 11.994 min. (XBridge phenyl C18), 92.0 % purity.




5 2-(4-Fluorophenyl)-5-(2-(2-hydroxybutoxy))-5-(isobutylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00385] ¹H NMR (400 MHz, CD₃OD) δ ppm 0.93 - 1.15 (m, 9 H), 1.45 - 1.61 (m, 1 H), 1.61 - 1.77 (m, 1 H), 2.01 (dt, *J*=13.55, 6.78 Hz, 1 H), 3.03 (s, 3 H), 3.27 (d, *J*=7.03 Hz, 2 H), 3.81 - 3.90 (m, 1 H), 4.10 (d, *J*=5.02 Hz, 2 H), 7.24 (d, *J*=8.78 Hz, 1 H), 7.28 - 7.38 (m, 2 H), 7.62 - 7.72 (m, 2 H), 7.91 (dd, *J*=8.53, 2.26 Hz, 1 H), 7.96 (d, *J*=2.01 Hz, 2 H), 8.00 - 8.08 (m, 2 H). LCMS *m/z* 533.30 (M+H), Rt 2.238 min. HPLC Rt 11.383 min. (Sunfire C18), 95.4 % purity and 11.896 min. (XBridge phenyl C18), 98.5% purity.




15 2-(4-Fluorophenyl)-5-(2-(2-hydroxypropoxy))-5-(isobutylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00386] ¹H NMR (400 MHz, CD₃OD) δ ppm 1.04 (d, *J*=6.53 Hz, 6 H), 1.27 (d, *J*=6.27 Hz, 3 H), 1.93 - 2.08 (m, 1 H), 3.03 (s, 3 H), 3.27 (d, *J*=7.03 Hz, 2 H), 3.97 - 4.15 (m, 3 H), 7.23 (d, *J*=8.53 Hz, 1 H), 7.32 (t, *J*=8.91 Hz, 2 H), 7.67 (d, *J*=1.00 Hz, 2 H), 7.86 - 7.93 (m, 1 H), 7.96 (d, *J*=2.26 Hz, 2 H), 8.03 (dd, *J*=9.04, 5.27 Hz, 2 H). LCMS *m/z* 519.28 (M+H), Rt 2.100 min. HPLC Rt 9.279 min. (Sunfire C18), 98.4 % purity and 11.674 min. (XBridge phenyl C18), 98.8% purity.




2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(2-(piperidin-2-yl)ethoxy)phenyl)-*N*-methylbenzofuran-3-carboxamide

- 5 **[00387]** ^1H NMR (500 MHz, CD_3OD) δ ppm 0.92 - 1.04 (m, 6 H), 1.32 - 1.48 (m, 2 H), 1.59 (d, $J=14.34$ Hz, 1 H), 1.78 (br. s., 2 H), 1.88 - 2.06 (m, 3 H), 2.11 - 2.25 (m, 1 H), 2.85 (m, 1 H), 2.96 (s, 3 H), 3.11 - 3.27 (m, 4 H), 4.17 - 4.37 (m, 2 H), 7.23 (d, $J=8.85$ Hz, 1 H), 7.26 - 7.36 (m, 2 H), 7.55 (dd, $J=8.55$, 1.83 Hz, 1 H), 7.70 (d, $J=8.55$ Hz, 1 H), 7.83 - 8.01 (m, 5 H). LCMS m/z 572.33 ($\text{M}+\text{H}$), Rt 1.663 min.
- 10 HPLC Rt 7.638 min. (Sunfire C18), 98.8 % purity and 12.003 min. (XBridge phenyl C18), 97.3 % purity.




2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(pyridin-4-ylmethoxy)phenyl)-*N*-methylbenzofuran-3-carboxamide

- 15 **[00388]** ^1H NMR (500 MHz, CD_3OD) δ ppm 0.98 (d, $J=6.71$ Hz, 6 H), 1.83 - 2.07 (m, 1 H), 2.92 (s, 3 H), 3.22 (d, $J=7.02$ Hz, 2 H), 5.54 (s, 2 H), 7.19 - 7.39 (m, 3 H), 7.62 (dd, $J=8.55$, 1.53 Hz, 1 H), 7.65 - 7.72 (m, 1 H), 7.88 - 7.99 (m, 5 H), 8.01 (d, $J=6.41$ Hz, 2 H), 8.79 (d, $J=6.71$ Hz, 2 H). LCMS m/z 552.28 ($\text{M}+\text{H}$), Rt 1.600 min.
- 20 HPLC Rt 6.831 min. (Sunfire C18), 99.5 % purity and 11.871 min. (XBridge phenyl C18), 99.3% purity.



tert-Butyl 2-((2-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-(isobutylcarbamoyl)phenoxy)methyl)pyrrolidine-1-carboxylate

- 5 **[00389]** ^1H NMR (400 MHz, CD_3OD) δ ppm 1.04 (d, $J=6.53$ Hz, 6 H), 1.48 (s, 9 H), 1.65 - 1.84 (m, 2 H), 1.91 - 2.12 (m, 3 H), 3.02 (s, 3 H), 3.06 - 3.21 (m, 1 H), 3.27 (d, $J=7.28$ Hz, 2 H), 3.29 - 3.34 (m, 1 H), 4.09 (br. s., 1 H), 4.18 - 4.30 (m, 2 H), 7.26 (d, $J=7.53$ Hz, 1 H), 7.29 - 7.37 (m, 2 H), 7.58 (br. s., 1 H), 7.68 (d, $J=8.53$ Hz, 1 H), 7.82 - 7.96 (m, 3 H), 7.99 - 8.08 (m, 2 H). LCMS m/z 666.32 (M+Na), Rt 2.716 min.
- 10 HPLC Rt 11.711 min. (Sunfire C18), 98.4 % purity and 12.663 min. (XBridge phenyl C18), 98.8 % purity.




- 15 2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(pyrrolidin-2-ylmethoxy)phenyl)-*N*-methylbenzofuran-3-carboxamide, TFA.

- [00390]** To a 10mL RBF was added dichloroethane (1 mL), *tert*-butyl 2-((2-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-(isobutylcarbamoyl)phenoxy)methyl)pyrrolidine-1-carboxylate (10.2 mg, 15.8 μmol) and TFA, trifluoroacetic acid, (800 μL). The solution was stirred for 30 minutes at
- 20 room temperature, then evaporated on the rotovap.. The product was diluted with

dichloroethane and evaporated once more to give a white solid (99% yield). ¹H NMR (400 MHz, CD₃OD) δ ppm 1.04 (d, *J*=6.53 Hz, 6 H), 1.93 - 2.12 (m, 4 H), 2.24 - 2.37 (m, 1 H), 3.00 (s, 3 H), 3.13 - 3.22 (m, 1 H), 3.25 - 3.30 (m, 2 H), 3.30 - 3.36 (m, 1 H), 4.10 (dd, *J*=7.15, 2.89 Hz, 1 H), 4.29 (dd, *J*=10.67, 7.15 Hz, 1 H), 4.51 (dd, *J*=10.54, 3.26 Hz, 1 H), 7.28 (d, *J*=8.53 Hz, 1 H), 7.35 (t, *J*=8.78 Hz, 2 H), 7.60 (dd, *J*=8.53, 1.51 Hz, 1 H), 7.73 (d, *J*=8.53 Hz, 1 H), 7.92 - 8.08 (m, 5 H). LCMS *m/z* 544.22 (M+H), Rt 1.577 min. HPLC Rt 6.775 min. (Sunfire C18), 99.7 % purity and 11.724 min. (XBridge phenyl C18), 100 % purity.


10



2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(pyrrolidin-3-ylmethoxy)phenyl)-*N*-methylbenzofuran-3-carboxamide, TFA


[00391] ¹H NMR (400 MHz, THF-*d*₈) δ ppm 0.93 (d, *J*=6.78 Hz, 6 H), 1.77 - 1.98 (m, 2 H), 2.10 (dd, *J*=13.05, 6.78 Hz, 1 H), 2.76 - 2.86 (m, 1 H), 2.88 - 2.98 (m, 3 H), 3.18 (t, *J*=6.40 Hz, 5 H), 3.55 (br. s., 1 H), 4.02 - 4.26 (m, 2 H), 7.08 (d, *J*=8.53 Hz, 1 H), 7.23 (t, *J*=8.78 Hz, 2 H), 7.48 (dd, *J*=8.53, 1.76 Hz, 1 H), 7.59 (d, *J*=8.53 Hz, 1 H), 7.70 (t, *J*=5.77 Hz, 1 H), 7.80 - 7.89 (m, 2 H), 7.94 (dd, *J*=9.79, 1.76 Hz, 2 H), 7.99 (dd, *J*=8.91, 5.40 Hz, 2 H). HPLC Rt 6.130 min. (Sunfire C18), 98.9 % purity and 10.184 min. (XBridge phenyl C18), 98.6 % purity. LCMS *m/z* 544.18 (M+H), Rt 1.557min.

20




2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(piperidin-3-ylmethoxy)phenyl)-*N*-methylbenzofuran-3-carboxamide, TFA

[00392] ¹H NMR (400 MHz, THF-d₈) δ ppm 0.93 (d, *J*=6.78 Hz, 6 H), 1.40 - 1.57 (m, 1 H), 1.75 - 2.00 (m, 4 H), 2.33 (br. s., 1 H), 2.80 - 3.00 (m, 5 H), 3.18 (t, *J*=6.40 Hz, 2 H), 3.32 (d, *J*=12.05 Hz, 1 H), 3.45 (d, *J*=10.79 Hz, 1 H), 3.90 - 4.12 (m, 2 H), 7.03 (d, *J*=8.53 Hz, 1 H), 7.22 (t, *J*=8.78 Hz, 2 H), 7.47 (dd, *J*=8.53, 1.51 Hz, 1 H), 7.58 (d, *J*=8.53 Hz, 1 H), 7.71 (t, *J*=5.65 Hz, 1 H), 7.75 - 7.86 (m, 2 H), 7.92 (s, 2 H), 8.01 (dd, *J*=8.78, 5.52 Hz, 2 H). LCMS *m/z* 558.20 (M+H), Rt 1.595min. HPLC Rt 6.443 min. (Sunfire C18), 99.2 % purity and 10.418 min. (XBridge phenyl C18), 99.2 % purity.



5-(2-(3-Amino-3-oxopropoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide


[00393] ¹H NMR (400 MHz, THF-d₈) δ ppm 0.88 - 0.97 (m, 6 H), 1.77 (dt, *J*=6.71, 3.29 Hz, 1 H), 1.89 (dt, *J*=13.36, 6.74 Hz, 1 H), 2.65 (br. s., 1 H), 2.96 (s, 3 H), 3.10 - 3.21 (m, 3 H), 3.60 - 3.65 (m, 1 H), 6.90 (d, *J*=8.28 Hz, 1 H), 7.16 - 7.25 (m, 2 H), 7.48 - 7.56 (m, 1 H), 7.66 - 7.73 (m, 2 H), 7.73 - 7.80 (m, 2 H), 7.84 (t, *J*=5.40 Hz, 1 H), 7.89 (br. s., 1 H), 7.92 - 8.03 (m, 3 H). LCMS Rt 1.835min., *m/z* 532.26 (M+H). HPLC Rt 7.465 min. (Sunfire C18), 100 % purity and 10.929 min. (XBridge phenyl C18), 92.9 % purity.



2-(4-Fluorophenyl)-5-(2-(2-hydroxyethoxy)-5-(isobutylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide

- [00394] To a small screw cap vial was added 2-(4-fluorophenyl)-5-(2-hydroxy-5-(isobutylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide (92 mg, 0.2 mmol) in DMF (4 mL), (2-Bromoethoxy)-*tert*-butyldimethylsilane (0.129 mL, 0.600 mmol), and DBU (0.121 mL, 0.800 mmol). The vial was capped and shaken at 80 °C overnight. The DMF was removed under a stream of nitrogen to give a tan oil which was taken up in 6 mL of acetonitrile and purified using a Shimadzu preparative HPLC employing acetonitrile/water/10mM ammonium acetate where solvent A was 5% acetonitrile / 95% H₂O / 10mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10mM ammonium acetate with a PHENOMENEX® Luna 10µm C18 30x100mm column at a gradient of 40-100% B and a flow rate of 30 mL/min. over 8 minutes with a 10 minute hold. The solvent was removed on the rotovap to give 44mgs of the TBS protected alcohol as a clear colorless oil. LCMS *m/z* 619.47 (M+H), Rt 3.123 min., 96% purity. To the TBS protected alcohol was then added 2.5mL of tetrahydrofuran along with 2 eq. of 1 M HCl solution (0.14mmol, 140µL). The mixture was stirred for 1 hour at room temperature. The reaction mixture was transferred to a separatory funnel, diluted with ethyl acetate, washed with sodium bicarbonate, brine and dried over magnesium sulfate. The organic solvent was evaporated and the product placed under vacuum. The crude product was diluted with 2mL of acetonitrile, and purified using a Shimadzu preparative HPLC employing acetonitrile/water/ammonium acetate where solvent A was 5% acetonitrile / 95% H₂O / 10mM ammonium acetate and solvent B was 5% H₂O / 95% acetonitrile / 10mM ammonium acetate with a XBridge C18 5µm OBD 19 x 100mm column at a gradient of 30-100% B and a flow rate of 20 mL/min. over 7 minutes with a 13 minute hold. 18.3mgs of a white solid (17% yield, 2 steps) was obtained after solvent evaporation. ¹H NMR (400 MHz, THF-d₈) δ ppm 0.93 (d, *J* = 6.78 Hz, 6 H), 1.80 - 1.98 (m, 1 H), 2.91 (d, *J* = 4.77 Hz, 3 H), 3.13 - 3.23 (m, 2 H), 3.79 (t, *J* = 4.89 Hz, 2 H), 4.10 (t, *J* = 4.89 Hz, 2 H), 7.08 (d, *J* = 8.53 Hz, 1 H), 7.21 (t, *J* = 8.78 Hz, 2 H), 7.52 (br. s., 1 H), 7.52 - 7.54 (m, 2 H), 7.59 (br. s., 1 H), 7.84 (dd, *J* = 8.53, 2.26 Hz, 1 H), 7.92 (d, *J* = 2.26 Hz, 1 H), 8.02 (s, 1 H), 8.09 - 8.20 (m, 2 H). LCMS *m/z* 505.36 (M+H), Rt 2.013min. HPLC Rt 8.901 min. (Sunfire C18), 92.5 % purity and 11.479

min. (XBridge phenyl C18), 92.0 % purity. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5µm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute.




5-(2-(2-Aminoethoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00395] To a 2 dram vial was added 2-(4-fluorophenyl)-5-(2-hydroxy-5-(isobutylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide (92.0 mg, 0.20 mmol) in 3 mL of DMF along with 2-(2-bromoethyl) isoindoline-1,3-dione (152 mg, 0.600 mmol) and DBU (0.120 mL, 0.800 mmol). The vial was capped and shaken at 75 °C over night. The crude reaction mixture was then evacuated to near dryness,

taken up in 6 mL of acetonitrile and purified using a Shimadzu preparative HPLC employing acetonitrile/water/0.1%TFA where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 5 μ m C18 30x100mm column at a
5 gradient of 40-100% B and a flow rate of 40 mL/min. over 10 minutes with a 10 minute hold to give 5-(2-(2-(1,3-dioxoisindolin-2-yl)ethoxy)-5-(isobutyl carbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide as a white solid (30mgs, 23% yield). ¹H NMR (400 MHz, DMF-d₇) δ ppm 0.93 (d, J =6.78 Hz, 6 H), 1.86 - 1.99 (m, 1 H), 2.97 (d, J =4.77 Hz, 3 H), 3.14 - 3.26 (m, 2 H),
10 4.06 (t, J =5.90 Hz, 2 H), 4.47 (t, J =5.90 Hz, 2 H), 7.33 (d, J =9.29 Hz, 1 H), 7.36 - 7.49 (m, 4 H), 7.74 - 7.86 (m, 5 H), 7.97 - 8.02 (m, 2 H), 8.11 - 8.17 (m, 2 H), 8.20 (d, J =4.27 Hz, 1 H), 8.42 (s, 1 H). LCMS m/z 634.25 (M+H), Rt 2.408 min. HPLC Rt 9.339 min. (Sunfire C18), 100 % purity and 11.696 min. (Gemini C18), 98.9 % purity. The LC/MS data was obtained on a Shimadzu analytical LC /
15 MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5 μ m C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was
20 determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 30-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1
25 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3 μ m 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 30-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10 mM
30 ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. To a 100mL RBF fitted with a reflux condenser was added 5-(2-(2-(1,3-dioxoisindolin-2-yl)ethoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-

fluorophenyl)-*N*-methylbenzofuran-3-carboxamide (26.4 mg, 0.042 mmol) in methanol and anhydrous hydrazine (1.308 μ L, 0.042 mmol) solution (Aldrich, 215155-50G). The flask was placed in a pre-equilibrated oil bath and refluxed for 2 hours. The crude product was concentrated on the rotovap to remove methanol, diluted with dichloromethane, washed with a 0.5M sodium hydroxide solution and extracted. The solvent was removed and the crude product was purified using the Shimadzu preparative HPLC employing acetonitrile/water/0.1%TFA mentioned above with a gradient of 20-100%B to give (13mgs, 58%) of a white solid. ¹H NMR (400 MHz, CD₃OD) δ ppm 0.94 (d, *J*=6.78 Hz, 6 H), 1.91 (dt, *J*=13.55, 6.78 Hz, 1 H), 2.91 (s, 3 H), 3.18 (d, *J*=7.28 Hz, 2 H), 3.33 (t, *J*=5.02 Hz, 2 H), 4.30 (t, *J*=5.14 Hz, 2 H), 7.21 (d, *J*=8.78 Hz, 1 H), 7.26 (t, *J*=8.78 Hz, 2 H), 7.50 - 7.59 (m, 1 H), 7.60 - 7.68 (m, 1 H), 7.81 - 8.00 (m, 5 H). LCMS *m/z* 504.31 (M+H), Rt 1.538 min. HPLC Rt 6.435 min. (Sunfire C18), 97.1 % purity and 11.376 min. (XBridge phenyl C18), 100 % purity.



2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(2-ureidoethoxy)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00396] To a 2 dram vial was added 5-(2-(2-aminoethoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide (22.7 mg, 0.045 mmol) in ethanol (2 mL) along with water (0.667 mL) and potassium cyanate (5.34 μ L, 0.135 mmol). The vial was sealed and the mixture heated to 80 °C with shaking for 24 hours. 3 additional equivalents of potassium cyanate was added to the reaction mixture and the vial re-capped and heated for 3 days. The crude reaction mixture was evaporated, diluted with acetonitrile, filtered and purified using a Shimadzu preparative HPLC employing acetonitrile/water/0.1%TFA where solvent

A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 5 μ m C18 30x100mm column at a gradient of 30-100% B and a flow rate of 40 mL/min. over 8 minutes with a 6 minute hold. The solvent was evaporated to give 10mgs


5 (40%) of a white solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5 μ m C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% TFA/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% TFA/ 10% HPLC grade acetonitrile), in 3 minutes with a 1

10 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/ 0.1%TFA with a gradient of 20-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile),

15 in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a PHENOMENEX® Gemini C18 3 μ m 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 20-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC


20 grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 0.94 (d, *J*=6.53 Hz, 6 H), 1.82 - 1.98 (m, 1 H), 2.88 (d, *J*=4.77 Hz, 3 H), 3.14 - 3.23 (m, 2 H), 3.47 (q, *J*=4.94 Hz, 2 H), 4.03 (t, *J*=4.52 Hz, 2 H), 5.55 (br. s., 1 H), 6.18 (br. s., 1 H), 7.03 (d, *J*=8.53 Hz, 1 H),

25 7.21 - 7.32 (m, 2 H), 7.46 - 7.51 (m, 1 H), 7.51 - 7.56 (m, 1 H), 7.56 - 7.62 (m, 1 H), 7.80 (dd, *J*=8.53, 2.26 Hz, 1 H), 7.84 (d, *J*=4.52 Hz, 1 H), 7.91 - 8.02 (m, 3 H), 8.22 (d, *J*=1.25 Hz, 1 H). LCMS Rt 1.988 min., *m/z* 547.24 (M+H). HPLC Rt 8.126 min. (Sunfire C18), 99.7 % purity and 11.214 min. (Gemini C18), 99.5 % purity.



5-(2-(3-(1,3-Dioxoisindolin-2-yl)propoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide


- [00397] ¹H NMR (400 MHz, THF-d₈) δ ppm 0.93 (d, *J*=6.78 Hz, 6 H), 1.81 - 1.97 (m, 1 H), 2.09 (m, 2 H), 2.90 (d, *J*=4.77 Hz, 3 H), 3.12 - 3.26 (m, 2 H), 3.79 (t, *J*=6.65 Hz, 2 H), 4.11 (t, *J*=5.90 Hz, 2 H), 7.03 (d, *J*=8.78 Hz, 1 H), 7.16 - 7.28 (m, 2 H), 7.45 (d, *J*=4.27 Hz, 1 H), 7.48 - 7.51 (m, 1 H), 7.51 - 7.56 (m, 1 H), 7.59 (dd, *J*=8.78, 1.76 Hz, 1 H), 7.65 - 7.74 (m, 4 H), 7.79 - 7.90 (m, 3 H), 8.08 - 8.24 (m, 2 H). LCMS *m/z* 648.19 (M+H), Rt 2.458 min. HPLC Rt 10.158 min. (Sunfire C18), 99.4 %
- 10 purity and 12.111 min. (Gemini C18), 99.7 % purity.



5-(2-(2-Aminoethoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

- [00398] ¹H NMR (400 MHz, THF-d₈) δ ppm 0.93 (d, *J*=6.53 Hz, 6 H), 1.82 - 1.93 (m, 1 H), 2.15 (m, 2 H), 2.91 (d, *J*=4.52 Hz, 3 H), 3.08 - 3.24 (m, 4 H), 4.17 (t, *J*=5.65 Hz, 2 H), 7.06 (d, *J*=8.53 Hz, 1 H), 7.18 - 7.28 (m, 2 H), 7.47 (dd, *J*=8.53, 1.76 Hz, 1 H), 7.53 - 7.66 (m, 2 H), 7.82 (dd, *J*=8.53, 2.26 Hz, 2 H), 7.90 (d, *J*=2.26 Hz, 1 H), 7.95 (d, *J*=1.51 Hz, 1 H), 7.97 - 8.05 (m, 2 H), 8.28 (br. s., 2 H). LCMS Rt 1.537
- 15 min., *m/z* 518.16 (M+H). HPLC Rt 10.734 min. (Sunfire C18), 99.2 % purity and
- 20

10.881 min. (Gemini C18), 99.3 % purity. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a PHENOMENEX® Gemini C18 3µm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute.



5-(2-(Difluoromethoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

[00399] To a small microwave vial was added 2-(4-fluorophenyl)-5-(2-hydroxy-5-(isobutylcarbamoyl) phenyl)-*N*-methylbenzofuran-3-carboxamide (23.02 mg, 0.05 mmol), acetonitrile (400 µL), water (400 µL), and 2-chloro-2,2-difluoro-1-phenylethanone (47.6 mg, 0.250 mmol). The vial was sealed and the reaction mixture subjected to microwave heating (BIOTAGE® Initiator) at 110 °C for 8 minutes. The crude reaction mixture was further diluted with acetonitrile, filtered, and purified

using a Shimadzu preparative HPLC employing acetonitrile/water/0.1%TFA where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 5µm C18 30x100mm column at a gradient of 30-100% B and a flow rate of 40 mL/min. over 10 minutes with a 10 minute hold. The solvent was evaporated to give product (35%) as a white solid. ¹H NMR (500 MHz, THF-d₈) δ ppm 0.86 - 1.01 (m, 6 H), 1.89 (dt, *J* = 13.50, 6.83 Hz, 1 H), 2.90 (d, *J* = 4.58 Hz, 3 H), 3.12 - 3.28 (m, 2 H), 6.61 - 7.04 (m, 1 H), 7.18 - 7.27 (m, 2 H), 7.31 (d, *J* = 8.54 Hz, 1 H), 7.49 (dd, *J* = 8.55, 1.83 Hz, 1 H), 7.53 (d, *J* = 4.27 Hz, 1 H), 7.59 (d, *J* = 8.55 Hz, 1 H), 7.78 (t, *J* = 5.49 Hz, 1 H), 7.82 (d, *J* = 1.22 Hz, 1 H), 7.91 (dd, *J* = 8.55, 2.44 Hz, 1 H), 7.98 (d, *J* = 2.14 Hz, 1 H), 8.09 - 8.17 (m, 2 H). LCMS *m/z* 511.21 (M+H), Rt 2.393 min. HPLC Rt 12.213 min. (Sunfire C18), 99.3 % purity and 15.427 min. (XBridge C18), 99.8 % purity. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 30-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters Phenyl XBridge C18 3.5µm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 30-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute.


3-Bromo-*N*-isobutyl-5-isopropoxybenzamide

[00400] To a large screw top vial was added 3-bromo-5-hydroxybenzoic acid (1 g, 4.61 mmol), pyridine (10 mL), *N*1-((ethylimino)methylene)-*N*3,*N*3-dimethylpropane-1,3-diamine, HCl (0.972 g, 5.07 mmol) (EDAC) along with 2-methylpropan-1-amine (0.504 mL, 5.07 mmol). The vial was capped and the mixture shaken over night. The reaction mixture was acidified with 10 mL of an ice cold 1 M HCl solution. The mixture was diluted with dichloromethane, extracted, washed with brine and dried over magnesium sulfate. The reaction mixture was filtered then added to the top of a 240g Thomson silica gel cartridge. The product was eluted with 0-12% (3000mL) methanol in dichloromethane to give 3-bromo-5-hydroxy-*N*-isobutylbenzamide (95%) as a yellow solid. LCMS Rt 1.632 min., *m/z* 273.99 (M+H), 93% purity. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 30-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. To a sealed tube was added 3-bromo-5-hydroxy-*N*-isobutylbenzamide (380.4 mg, 1.398 mmol), DMF (15 mL), 2-iodopropane (0.210 mL, 2.097 mmol), and potassium carbonate (290 mg, 2.097 mmol). The tube was sealed and heated to 90 °C overnight. The reaction mixture was cooled, transferred to a separatory funnel, diluted with ethyl acetate and extracted. The organic solution was washed with 1M HCl, brine, dried over magnesium sulfate, filtered and evaporated to dryness. The resulting orange oil was taken up in dichloromethane and purified using the BIOTAGE® Horizon with a 110g Thomson silica gel column employing 0-5% methanol and 2000mL of solvent to give a near quantitative yield of 3-bromo-*N*-isobutyl-5-isopropoxybenzamide as a light yellow solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions:


Waters Sunfire 5 μ m C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was
5 determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 30-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1
10 mL/minute. ¹H NMR (400 MHz, CDCl₃) δ ppm 0.87 - 1.04 (m, 6 H), 1.23 - 1.37 (m, 6 H), 1.79 - 2.00 (m, 1 H), 3.25 (t, *J*=6.40 Hz, 2 H), 4.57 (dt, *J*=12.05, 6.02 Hz, 1 H), 6.29 (br. s., 1 H), 7.08 - 7.19 (m, 1 H), 7.21 - 7.26 (m, 1 H), 7.38 (s, 1 H). LCMS Rt 2.413 min., *m/z* 315.01 (M+H), 95% purity.

15 3-Bromo-*N*-isobutyl-4-(trifluoromethoxy)benzamide
[00401] To a large screw top vial was added previously synthesized 3-bromo-4-(trifluoromethoxy)benzoic acid (100 mg, 0.351 mmol), pyridine (5 mL), 2-methylpropan-1-amine (0.038 mL, 0.386 mmol), *N*1-((ethylimino)methylene)-*N*3,*N*3-dimethylpropane-1,3-diamine, HCl (EDAC) (74.0 mg, 0.386 mmol) and
20 HATU, 2-(7-aza-1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (400 mg, 1.053 mmol). The vial was capped and shaken overnight at room temperature. The crude reaction mixture was diluted with methanol and purified using a Shimadzu preparative HPLC employing methanol/water/0.1%TFA where solvent A was 10% methanol / 90% water / 0.1%
25 trifluoroacetic acid and solvent B was 10% water / 90% methanol / 0.1% trifluoroacetic acid with a PHENOMENEX® Luna 10 μ m C18 30x100mm column at a gradient of 30-100% B and a flow rate of 40 mL/min. over 9 minutes with a 11 minute hold to give 75mgs (62%) of a yellow solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the
30 following set of conditions: Waters Sunfire 5 μ m C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/

10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a PHENOMENEX® Gemini C18 3 μ m 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, CD₃OD) δ ppm 0.98 - 1.11 (m, 6 H), 1.91 - 2.09 (m, 1 H), 3.22 - 3.30 (m, 2 H), 7.57 (dd, J =8.53, 1.51 Hz, 1 H), 7.96 (dd, J =8.53, 2.26 Hz, 1 H), 8.25 (d, J =2.01 Hz, 1 H), 8.68 (br. s., 1 H). HPLC Rt 17.141 min. (Sunfire C18), 99.5 % purity and 15.912 min. (Gemini C18), 100 % purity. LCMS Rt 2.367 min., m/z 341.99 (M+H).




20 3-Bromo-*N*-(1-phenylcyclopropyl)-4-(trifluoromethoxy)benzamide
[00402] ¹H NMR (400 MHz, CD₃OD) δ ppm 1.40 (d, J = 4.52 Hz, 4 H), 7.16 - 7.30 (m, 1 H), 7.32 - 7.41 (m, 4 H), 7.58 (dd, J = 8.66, 1.38 Hz, 1 H), 7.99 (dd, J = 8.66, 2.13 Hz, 1 H), 8.28 (d, J = 2.01 Hz, 1 H), 9.42 (br. s., 1 H). LCMS Rt 2.56 min., m/z 401.97 (M+H). HPLC Rt 15.171 min. (Sunfire C18), 98.8 % purity and 16.066 min. (Gemini C18), 100 % purity.



3-Bromo-*N*-(1-(pyridin-2-yl)cyclopropyl)-4-(trifluoromethoxy)benzamide

[00403] ^1H NMR (400 MHz, CD_3OD) δ ppm 1.70 - 1.80 (m, 2 H), 1.80 - 1.91 (m, 2 H), 7.57 (dd, $J=8.78$, 1.25 Hz, 1 H), 7.76 - 7.88 (m, 2 H), 8.03 (dd, $J=8.53$, 2.26 Hz, 1 H), 8.33 (d, $J=2.01$ Hz, 1 H), 8.43 (t, $J=8.03$ Hz, 1 H), 8.63 (d, $J=5.52$ Hz, 1 H). LCMS Rt 1.420 min, m/z 402.95 (M+H). HPLC Rt 5.611 min. (Sunfire C18), 93.8 % purity and 11.206 min. (Gemini C18), 98.4 % purity.



10 2-(4-Fluorophenyl)-*N*-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzofuran-3-carboxamide


[00404] To a sealed tube was added 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoro methanesulfonate (2.000 g, 4.79 mmol), dioxane (20 mL), triethylamine (1.993 mL, 14.38 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (4.87 g, 19.17 mmol), and finally PdCl₂(dppf) (0.235 g, 0.144 mmol). The vial was flushed with N₂, sealed and heated overnight in an oil bath at 80 °C. The reaction mixture was cooled, diluted with dichloromethane, and washed with a 0.1M HCl solution then brine. The brown mixture was pulled through a plug of 1:1 magnesium sulfate/CELITE® to give a dark brown solid after solvent evaporation. The crude product was taken up in 50mL of dichloromethane and added to the top of a pre-equilibrated 240g Thomson silica gel cartridge. The product was eluted with 0-2% methanol in dichloromethane to give a 80% yield of 2-(4-fluorophenyl)-*N*-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzofuran-3-carboxamide as a tan solid. ^1H NMR (400 MHz, THF- d_8) δ ppm 1.34 (s, 12 H), 2.92 - 2.95 (m, 3 H), 7.20 (t, $J=8.91$ Hz, 2 H), 7.50 (d, $J=8.28$ Hz, 2

15

20


25

H), 7.74 (dd, $J=8.28$, 1.00 Hz, 1 H), 8.08 - 8.13 (m, 2 H), 8.14 (s, 1 H). LCMS m/z 396.18 (M+H), Rt 2.455 min., 90% purity.



5 2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-isopropoxyphenyl)-*N*-methylbenzofuran-3-carboxamide


[00405] To a medium sized microwave vial was added 1 (465 mg, 1.0 mmol), dioxane (15 mL), water (1.500 mL), 3-bromo-*N*-isobutyl-5-isopropoxybenzamide (377 mg, 1.200 mmol), dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (82
10 mg, 0.200 mmol), potassium phosphate, tribasic (849 mg, 4.00 mmol) and finally palladium(II) acetate (44.9 mg, 0.200 mmol). The vial was capped and subjected to microwave heating (150 °C) in a BIOTAGE® Initiator for 13 minutes. The reaction mixture was diluted with 150mL of dichloromethane, washed with a 1M HCl
15 solution, then water and finally brine. The solution was filtered through pad of 1:1 CELITE®/magnesium sulfate then evaporated to give a brown oil. The crude product was taken up in dichloromethane and added to the top of a pre-equilibrated 100g BIOTAGE® silica gel cartridge. The product was eluted with a 0-3% methanol in dichloromethane solvent mixture to give product as a light tan solid (51%). ¹H NMR (400 MHz, THF-*d*₈) δ ppm 0.95 (d, $J=6.53$ Hz, 6 H), 1.35 (d, $J=6.02$ Hz, 6 H), 1.83 -
20 1.98 (m, 1 H), 2.90 - 2.98 (m, 3 H), 3.14 - 3.29 (m, 2 H), 4.66 - 4.82 (m, 1 H), 7.18 - 7.25 (m, 2 H), 7.26 - 7.29 (m, 1 H), 7.38 - 7.42 (m, 1 H), 7.48 (m, 1 H), 7.58 - 7.65 (m, 2 H), 7.65 - 7.72 (m, 2 H), 7.96 (d, $J=1.00$ Hz, 1 H), 8.08 - 8.16 (m, 2 H). LCMS Rt 2.588 min., m/z 503.25 (M+H), 98% purity.



2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(trifluoromethoxy)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00406] The LC/MS data was obtained on a Shimadzu analytical LC /


- 5 MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% TFA/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% TFA/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu
- 10 analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5mm 4.6 x 150mm column employing water/acetonitrile/ 0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was
- 15 then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a PHENOMENEX® Phenyl XBridge C18 3.5mm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate /
- 20 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 0.94 (dd, *J*=6.78, 2.26 Hz, 6 H), 1.82 - 1.97 (m, 1 H), 2.90 (d, *J*=4.77 Hz, 3 H), 3.12 - 3.24 (m, 2 H), 7.17 - 7.29 (m, 2 H), 7.47 (dd, *J*=8.53, 1.76 Hz, 2 H), 7.61 (d, *J*=8.53 Hz, 1 H), 7.71 - 7.81 (m, 2 H), 7.83 (d, *J*=1.26 Hz, 1 H), 7.92 - 7.98 (m, 1 H), 7.99 - 8.05 (m, 1 H), 8.07 - 8.15 (m, 2 H).
- 25 H). LCMS Rt 2.565min., *m/z* 529.13 (M+H). HPLC Rt 11.166 min. (Sunfire C18), 99.5 % purity and 11.813 min. (Phenyl XBridge C18), 86.7 % purity.



2-(4-Fluorophenyl)-*N*-methyl-5-(5-(1-phenylcyclopropylcarbamoyl)-2-(trifluoromethoxy) phenyl)benzofuran-3-carboxamide

[00407] ^1H NMR (400 MHz, THF- d_8) δ ppm 1.20 - 1.39 (m, 4 H), 2.89 (d, $J=4.52$ Hz, 3 H), 7.06 - 7.15 (m, 1 H), 7.17 - 7.27 (m, 4 H), 7.29 - 7.35 (m, 2 H), 7.44 (br. s., 1 H), 7.47 (m, 2 H), 7.61 (d, $J=8.53$ Hz, 1 H), 7.83 (d, $J=1.26$ Hz, 1 H), 7.98 (dd, $J=8.66, 2.38$ Hz, 1 H), 8.05 (d, $J=2.01$ Hz, 1 H), 8.08 - 8.15 (m, 2 H), 8.50 (br. s., 1 H). LCMS Rt 2.796 min., m/z 589.23 (M+H). HPLC Rt 11.419 min. (Sunfire C18), 98.9 % purity and 12.424 min. (Phenyl XBridge C18), 100 % purity.


10



2-(4-Fluorophenyl)-*N*-methyl-5-(5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)-2-(trifluoromethoxy)phenyl)benzofuran-3-carboxamide


[00408] ^1H NMR (400 MHz, THF- d_8) δ ppm 1.21 - 1.33 (m, 2 H), 1.62 - 1.70 (m, 2 H), 2.89 (d, $J=4.77$ Hz, 3 H), 7.01 (m, 1 H), 7.18 - 7.28 (m, 2 H), 7.40 (d, $J=8.03$ Hz, 1 H), 7.43 (br. s., 1 H), 7.46 - 7.58 (m, 3 H), 7.62 (d, $J=8.53$ Hz, 1 H), 7.86 (d, $J=1.26$ Hz, 1 H), 8.04 (dd, $J=8.66, 2.38$ Hz, 1 H), 8.07 - 8.17 (m, 3 H), 8.36 - 8.42 (m, 1 H), 8.57 (br. s., 1 H). LCMS Rt 1.768 min., m/z 590.13 (M+H). HPLC Rt 7.645 min. (Sunfire C18), 99.0 % purity and 12.041 min. (Phenyl XBridge C18), 99.9 % purity.

20



2-(4-Fluorophenyl)-5-(3-hydroxy-5-(isobutylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide


- [00409]** To a 250mL RBF was added 2-(4-fluorophenyl)-5-(3-
- 5 (isobutylcarbamoyl)-5-isopropoxyphenyl)-N-methylbenzofuran-3-carboxamide (1.3409 g, 2.67 mmol) in dichloromethane (20 mL). The flask was sealed with a septa, placed under N₂ and stirred for 5 minutes. To this mixture was then added (cold) 1M trichloroborane (8.00 mL, 8.00 mmol) in dichloromethane. The solution was stirred at room temperature for 6 hours. The reaction mixture was cooled to 0 °C
- 10 and methanol was added to quench the reaction. The flask was allowed to warm to room temperature and the volatiles were removed to give a quantitative yield of a tan solid. ¹H NMR (400 MHz, CD₃OD) δ ppm 1.06 (d, *J* = 6.78 Hz, 6 H), 1.97 - 2.12 (m, 1 H), 3.01 - 3.12 (m, 3 H), 3.29 (t, *J* = 6.53 Hz, 2 H), 7.27 - 7.40 (m, 4 H), 7.64 (s, 1 H), 7.72 (s, 2 H), 7.98 (s, 1 H), 8.03 (dd, *J* = 8.66, 5.40 Hz, 2 H), 8.56 (br. s., 1 H).
- 15 LCMS Rt 2.157 min., *m/z* 461.03 (M+H), 97.6% purity.



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-methoxyphenyl)-N-methylbenzofuran-3-carboxamide


- 20 **[00410]** The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5μm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in
- 25 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters

Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/0.1%TFA with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters Phenyl XBridge C18 3.5 μ m 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 0.87 - 1.03 (m, 6 H), 1.83 - 1.99 (m, 1 H), 2.93 (d, J =4.77 Hz, 3 H), 3.16 - 3.25 (m, 2 H), 3.88 (s, 3 H), 7.18 - 7.26 (m, 2 H), 7.29 - 7.32 (m, 1 H), 7.42 (dd, J =2.38, 1.38 Hz, 1 H), 7.50 (br. s., 1 H), 7.57 - 7.66 (m, 2 H), 7.71 (br. s., 2 H), 7.97 (d, J =1.25 Hz, 1 H), 8.08 - 8.16 (m, 2 H). LCMS m/z 475.22 (M+H), Rt 2.373 min.. HPLC Rt 10.268 min. (Sunfire C18), 96.7 % purity and 12.104 min. (XBridge phenyl C18), 99.2 % purity.




5-(3-(2-(Dimethylamino)ethoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-
N-methylbenzofuran-3-carboxamide

[00411] ¹H NMR (400 MHz, THF-d₈) δ ppm 0.95 (d, J = 6.78 Hz, 6 H), 1.87 - 1.98 (m, 1 H), 2.89 (s, 6 H), 2.93 (d, J = 4.52 Hz, 3 H), 3.21 (t, J = 6.40 Hz, 2 H), 3.47 - 3.54 (m, 2 H), 4.54 - 4.64 (m, 2 H), 7.22 (t, J = 8.66 Hz, 2 H), 7.42 (s, 1 H), 7.51 (br. s., 1 H), 7.58 (d, J = 5.27 Hz, 1 H), 7.61 (s, 1 H), 7.62 - 7.69 (m, 1 H), 7.80 (s, 1 H), 7.83 (br. s., 1 H), 7.98 (s, 1 H), 8.12 (dd, J = 8.91, 5.40 Hz, 2 H). LCMS Rt 1.543 min., m/z 532.28 (M+H). HPLC Rt 6.816 min. (Sunfire C18), 96.0 % purity and 12.073 min. (Phenyl XBridge C18), 98.2 % purity.



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-(2-(pyridin-3-yl)ethoxy)phenyl)-*N*-methylbenzofuran-3-carboxamide


- 5 **[00412]** ^1H NMR (400 MHz, THF- d_8) δ ppm 0.94 (d, J = 6.53 Hz, 6 H), 1.83 - 1.98 (m, 1 H), 2.92 (d, J = 4.27 Hz, 3 H), 3.13 - 3.30 (m, 4 H), 4.32 - 4.47 (m, 2 H), 7.22 (t, J = 8.66 Hz, 2 H), 7.32 (s, 1 H), 7.41 - 7.53 (m, 3 H), 7.55 - 7.67 (m, 2 H), 7.72 (br. s., 2 H), 7.91 - 8.01 (m, 2 H), 8.11 (dd, J = 8.03, 5.52 Hz, 2 H), 8.55 (br. s., 1 H), 8.72 (br. s., 1 H). LCMS Rt 1.632 min., m/z 566.26 (M+H). HPLC Rt 7.216 min. (Sunfire
- 10 C18), 98.1 % purity and 12.073 min. (Phenyl XBridge C18), 99.0 % purity.



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-(2-(piperidin-3-yl)ethoxy)phenyl)-*N*-methylbenzofuran-3-carboxamide


- 15 **[00413]** The LC/MS data was obtained on a Waters Acquity SDS analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Acquity UPLC BEH 1.7 μ m C18, 2.1 x 50mm column, with a gradient of 2-98%B (B = 100% HPLC grade acetonitrile/ 0.05% TFA), (A = 100% HPLC grade water / 0.05% TFA), in 2.2 minutes at a rate of 0.8 mL/minute. HPLC purity was
- 20 determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/ 0.1%TFA with a gradient of 20-100% B (B = 95% HPLC grade acetonitrile/ 0.1%

trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, CD₃OD) δ ppm 0.99 (d, *J*=6.78 Hz, 6 H), 1.36 (dd, *J*=12.30, 3.01 Hz, 1 H), 1.69 - 1.89 (m, 3 H), 1.91 - 2.16 (m, 4 H),
 5 2.77 (t, *J*=12.17 Hz, 1 H), 2.87 - 2.95 (m, 1 H), 3.23 (d, *J*=7.03 Hz, 2 H), 3.29 - 3.40 (m, 4 H), 3.43 - 3.52 (m, 1 H), 4.19 (t, *J*=6.02 Hz, 2 H), 7.24 (t, *J*=8.78 Hz, 2 H), 7.36 (dd, *J*=10.54, 1.51 Hz, 2 H), 7.58 - 7.68 (m, 2 H), 7.70 (s, 1 H), 7.87 - 7.98 (m, 3 H). LCMS *m/z* 572.16 (M+H). HPLC Rt 6.518 min. (Sunfire C18), 98% purity.



5-(3-(4-Aminobutoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide


[00414] ¹H NMR (400 MHz, CD₃OD) δ ppm 0.99 (d, *J*=6.78 Hz, 6 H), 1.86 - 2.04 (m, 5 H), 2.95 - 3.00 (m, 3 H), 3.06 (t, *J*=7.15 Hz, 2 H), 3.21 - 3.27 (m, 2 H), 4.19 (t, *J*=5.40 Hz, 2 H), 7.23 - 7.31 (m, 2 H), 7.38 (dd, *J*=3.76, 1.25 Hz, 2 H), 7.64 - 7.70 (m, 2 H), 7.71 (s, 1 H), 7.91 - 7.99 (m, 3 H), 8.60 (br. s., 1 H). LCMS *m/z* 532.00 (M+H). HPLC Rt 6.386 min. (Sunfire C18), 100 % purity.



[00415] ¹H NMR (400 MHz, CD₃OD) δ ppm 1.06 (d, *J*=6.78 Hz, 6 H), 2.03 (d, *J*=6.78 Hz, 1 H), 3.05 (s, 3 H), 3.31 (d, *J*=7.03 Hz, 2 H), 4.62 (t, *J*=4.77 Hz, 2 H),

4.79 (br. s., 2 H), 7.35 (t, $J=8.78$ Hz, 2 H), 7.49 (d, $J=2.76$ Hz, 2 H), 7.68 (s, 1 H), 7.73 - 7.77 (m, 2 H), 7.83 (s, 1 H), 7.88 (s, 1 H), 7.98 - 8.07 (m, 3 H), 9.17 (s, 1 H). LCMS m/z 555.00 (M+H). HPLC Rt 6.295 min. (Sunfire C18), 95.2% purity.


5



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-(2-(pyridin-4-yl)ethoxy)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00416] ^1H NMR (400 MHz, CD_3OD) δ ppm 1.05 (d, $J=6.53$ Hz, 6 H), 1.95 - 2.09 (m, 1 H), 3.04 (s, 3 H), 3.24 - 3.33 (m, 2 H), 3.54 (t, $J=5.90$ Hz, 2 H), 4.60 (t, $J=5.77$ Hz, 2 H), 7.27 - 7.38 (m, 2 H), 7.41 - 7.49 (m, 2 H), 7.71 - 7.75 (m, 2 H), 7.78 (t, $J=1.51$ Hz, 1 H), 7.96 - 8.05 (m, 3 H), 8.12 (d, $J=6.53$ Hz, 2 H), 8.80 (d, $J=6.78$ Hz, 2 H). LCMS m/z 566.00 (M+H). HPLC Rt 6.4921 min. (Sunfire C18), 98.6% purity.


15



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-(prop-2-ynyloxy)phenyl)-*N*-methylbenzofuran-3-carboxamide


[00417] ^1H NMR (400 MHz, CD_3OD) δ ppm 1.07 (d, $J=6.78$ Hz, 6 H), 1.94 - 2.18 (m, 1 H), 3.00 - 3.13 (m, 4 H), 3.30 (d, $J=7.03$ Hz, 2 H), 4.94 - 4.98 (m, 2 H), 7.27 - 7.42 (m, 2 H), 7.47 - 7.59 (m, 2 H), 7.68 - 7.79 (m, 2 H), 7.82 (t, $J=1.51$ Hz, 1 H), 7.98 - 8.11 (m, 3 H). LCMS m/z 499.00 (M+H). HPLC Rt 9.984min. (Sunfire C18), 99.4% purity.

20




5-(3-(Cyclopropylmethoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

[00418] ^1H NMR (400 MHz, CD_3OD) δ ppm 0.48 (d, $J=14.81$ Hz, 2 H), 0.72 (d, $J=7.78$ Hz, 2 H), 1.06 (d, $J=6.53$ Hz, 6 H), 1.51 - 1.59 (m, 1 H), 1.98 - 2.10 (m, 1 H), 3.05 (s, 3 H), 3.30 (d, $J=7.03$ Hz, 2 H), 4.04 (d, $J=6.78$ Hz, 2 H), 7.33 (t, $J=8.66$ Hz, 2 H), 7.43 (s, 2 H), 7.49 (br. s., 1 H), 7.75 (d, $J=9.04$ Hz, 3 H), 7.97 - 8.09 (m, 3 H). LCMS m/z 515.17 (M+H). HPLC Rt 10.878 min. (Sunfire C18), 91.4% purity.




2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-(pyridin-3-ylmethoxy)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00419] ^1H NMR (400 MHz, CD_3OD) δ ppm 1.06 (d, $J=6.78$ Hz, 6 H), 2.03 (dt, $J=13.55, 6.78$ Hz, 1 H), 3.04 (s, 3 H), 3.30 (d, $J=7.03$ Hz, 2 H), 5.52 (s, 2 H), 7.33 (t, $J=8.78$ Hz, 2 H), 7.59 (dd, $J=6.40, 1.38$ Hz, 2 H), 7.69 - 7.80 (m, 2 H), 7.84 (s, 1 H), 7.96 - 8.09 (m, 4 H), 8.64 (d, $J=8.28$ Hz, 1 H), 8.83 (d, $J=4.52$ Hz, 1 H), 9.02 (s, 1 H). LCMS m/z 552.05 (M+H). HPLC Rt 6.401 min. (Sunfire C18), 100% purity.




2-(4-Fluorophenyl)-5-(3-(furan-3-ylmethoxy)-5-(isobutylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00420] ^1H NMR (400 MHz, CD_3OD) δ ppm 1.06 (d, $J=6.53$ Hz, 6 H), 1.96 - 2.14 (m, 1 H), 3.06 (s, 3 H), 3.30 (d, $J=7.03$ Hz, 2 H), 5.19 (s, 2 H), 6.64 (s, 1 H), 7.33 (t, $J=8.78$ Hz, 2 H), 7.51 (s, 2 H), 7.59 (br. s., 1 H), 7.70 - 7.82 (m, 4 H), 8.01 (d, $J=11.54$ Hz, 3 H). LCMS m/z 541.00 ($\text{M}+\text{H}$). HPLC Rt 10.426 min. (Sunfire C18), 90.0% purity.




2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-(2-(piperidin-4-yl)ethoxy)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00421] ^1H NMR (400 MHz, CD_3OD) δ ppm 1.06 (d, $J=6.53$ Hz, 6 H), 1.96 - 2.14 (m, 1 H), 3.06 (s, 3 H), 3.30 (d, $J=7.03$ Hz, 2 H), 5.19 (s, 2 H), 6.64 (s, 1 H), 7.33 (t, $J=8.78$ Hz, 2 H), 7.51 (s, 2 H), 7.59 (br. s., 1 H), 7.70 - 7.82 (m, 4 H), 8.01 (d, $J=11.54$ Hz, 3 H). LCMS m/z 572.17 ($\text{M}+\text{H}$). HPLC Rt 6.571 min. (Sunfire C18), 95.8 % purity.



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-propoxyphenyl)-*N*-methylbenzofuran-3-carboxamide

[00422] ¹H NMR (400 MHz, THF-d₈) δ ppm 0.87 - 0.98 (m, 6 H), 1.07 (t, *J*=7.40 Hz, 3 H), 1.79 - 1.96 (m, 3 H), 2.93 (d, *J*=4.52 Hz, 3 H), 3.21 (t, *J*=6.40 Hz, 2 H), 4.05 (t, *J*=6.53 Hz, 2 H), 7.22 (t, *J*=8.66 Hz, 2 H), 7.30 (br. s., 1 H), 7.39 - 7.56 (m, 2 H), 7.56 - 7.79 (m, 4 H), 7.97 (s, 1 H), 8.12 (dd, *J*=8.53, 5.52 Hz, 2 H). LCMS *m/z* 503.15 (M+H). HPLC Rt 11.141 min. (Sunfire C18), 98.9 % purity.




10

2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-ethoxyphenyl)-*N*-methylbenzofuran-3-carboxamide

[00423] ¹H NMR (400 MHz, CD₃OD) δ ppm 1.06 (d, *J*=6.78 Hz, 6 H), 1.47 - 1.62 (m, 3 H), 1.92 - 2.15 (m, 1 H), 3.05 (s, 3 H), 3.30 (d, *J*=7.03 Hz, 2 H), 4.26 (q, *J*=6.94 Hz, 2 H), 7.33 (t, *J*=8.78 Hz, 2 H), 7.43 (s, 2 H), 7.70 - 7.83 (m, 3 H), 7.97 - 8.09 (m, 3 H). LCMS *m/z* 489.00 (M+H). HPLC Rt 10.464 min. (Sunfire C18), 93.7% purity.


15



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-(2-methoxyethoxy)phenyl)-*N*-methylbenzofuran-3-carboxamide


20

- [00424] ^1H NMR (400 MHz, THF- d_8) δ ppm 0.86 - 1.05 (m, 6 H), 1.82 - 2.02 (m, 1 H), 2.86 - 3.04 (m, 3 H), 3.21 (t, $J=6.40$ Hz, 2 H), 3.34 - 3.45 (m, 3 H), 3.72 (t, $J=4.77$ Hz, 2 H), 4.21 (t, $J=4.77$ Hz, 2 H), 7.22 (t, $J=8.78$ Hz, 2 H), 7.33 (s, 1 H), 7.42 (s, 1 H), 7.49 (br. s., 1 H), 7.55 - 7.83 (m, 4 H), 7.97 (s, 1 H), 8.12 (dd, $J=8.78, 5.52$ Hz, 2 H). LCMS m/z 519.10 (M+H). HPLC Rt 9.676min. (Sunfire C18), 100% purity.



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-(2-(2-methyl-1H-imidazol-1-yl)ethoxy)phenyl)-N-methylbenzofuran-3-carboxamide

- 10 [00425] ^1H NMR (400 MHz, CD_3OD) δ ppm 0.99 (d, $J=6.53$ Hz, 6 H), 1.90 - 2.03 (m, 1 H), 2.78 (s, 3 H), 2.94 - 3.02 (m, 3 H), 3.23 (d, $J=7.03$ Hz, 2 H), 4.53 (t, $J=4.89$ Hz, 2 H), 4.65 (t, $J=4.89$ Hz, 2 H), 7.22 - 7.32 (m, 2 H), 7.38 (d, $J=1.51$ Hz, 2 H), 7.46 (d, $J=2.01$ Hz, 1 H), 7.63 - 7.69 (m, 3 H), 7.75 (t, $J=1.51$ Hz, 1 H), 7.91 - 8.00 (m, 3 H). LCMS m/z 569.12 (M+H). HPLC Rt 6.340 min. (Sunfire C18), 100%
15 purity.




(S)-2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-(pyrrolidin-2-ylmethoxy)phenyl)-N-methylbenzofuran-3-carboxamide

- 20 [00426] ^1H NMR (400 MHz, CD_3OD) δ ppm 1.06 (d, $J=6.78$ Hz, 6 H), 1.98 - 2.12 (m, 2 H), 2.16 - 2.32 (m, 2 H), 2.34 - 2.48 (m, 1 H), 3.04 (s, 3 H), 3.31 (d, $J=7.03$ Hz, 2 H), 3.44 - 3.55 (m, 2 H), 4.12 - 4.22 (m, 1 H), 4.34 (dd, $J=10.54, 8.28$ Hz, 1 H),

4.51 - 4.62 (m, 1 H), 7.27 - 7.42 (m, 2 H), 7.49 - 7.59 (m, 2 H), 7.71 - 7.82 (m, 2 H), 7.85 (s, 1 H), 7.97 - 8.10 (m, 3 H). LCMS m/z 544.12 (M+H). HPLC Rt 6.326 min. (Sunfire C18), 95.8 % purity.


5



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-((5-methylisoxazol-3-yl)methoxy)phenyl)-N-methylbenzofuran-3-carboxamide

[00427] ^1H NMR (400 MHz, THF- d_8) δ ppm 0.92 - 0.99 (m, 6 H), 1.83 - 1.99 (m, 1 H), 2.40 (s, 3 H), 2.90 - 2.98 (m, 3 H), 3.17 - 3.27 (m, 2 H), 5.18 - 5.25 (m, 1 H), 6.17 - 6.25 (m, 1 H), 7.17 - 7.27 (m, 2 H), 7.41 - 7.46 (m, 1 H), 7.47 - 7.54 (m, 2 H), 7.57 - 7.68 (m, 3 H), 7.68 - 7.74 (m, 1 H), 7.76 (d, $J=1.51$ Hz, 1 H), 7.98 (d, $J=1.26$ Hz, 1 H), 8.07 - 8.19 (m, 2 H). LCMS m/z 556.00 (M+H). HPLC Rt 10.106 min. (Sunfire C18), 90.0% purity.


15



2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-((5-methylisoxazol-3-yl)methoxy)phenyl)-N-methylbenzofuran-3-carboxamide


[00428] ^1H NMR (500 MHz, THF- d_8) δ ppm 0.98 (d, $J=6.71$ Hz, 6 H), 1.88 - 2.01 (m, 1 H), 2.92 - 3.00 (m, 3 H), 3.20 - 3.27 (m, 2 H), 5.17 (s, 2 H), 6.42 (dd, $J=3.05$, 1.83 Hz, 1 H), 6.53 (d, $J=3.36$ Hz, 1 H), 7.21 - 7.30 (m, 3 H), 7.43 (d, $J=1.53$ Hz, 1 H), 7.55 (d, $J=12.51$ Hz, 1 H), 7.59 - 7.66 (m, 3 H), 7.67 - 7.71 (m, 1 H), 7.78 (s, 1

H), 8.02 (s, 1 H), 8.13 - 8.18 (m, 2 H). LCMS m/z 541.17 (M+H). HPLC Rt 10.401 min. (Sunfire C18), 90.0% purity.




- 5 5-(3-(Cyclobutylmethoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

[00429] ^1H NMR (500 MHz, THF- d_8) δ ppm 0.95 (d, $J=6.71$ Hz, 6 H), 1.86 - 2.02 (m, 6 H), 2.10 - 2.21 (m, 2 H), 2.87 - 2.97 (m, 3 H), 3.20 (d, $J=6.71$ Hz, 2 H), 4.07 (d, $J=6.71$ Hz, 2 H), 7.23 (t, $J=8.85$ Hz, 2 H), 7.32 (s, 1 H), 7.43 (s, 1 H), 7.57 - 7.63 (m, 2 H), 7.63 - 7.68 (m, 1 H), 7.73 (s, 1 H), 7.79 - 7.86 (m, 1 H), 7.99 (s, 1 H), 8.09 - 8.16 (m, 2 H). LCMS m/z 529.00 (M+H). HPLC Rt 11.771 min. (Sunfire C18), 94.2% purity.



- 15 2-(4-Fluorophenyl)-5-(3-(isobutylcarbamoyl)-5-((5-methyl-1,3,4-oxadiazol-2-yl)methoxy)phenyl)-*N*-methylbenzofuran-3-carboxamide


[00430] ^1H NMR (400 MHz, THF- d_8) δ ppm 0.90 - 1.02 (m, 6 H), 1.84 - 2.00 (m, 1 H), 2.50 (s, 3 H), 2.94 (d, $J=4.77$ Hz, 3 H), 3.17 - 3.27 (m, 2 H), 5.39 (s, 2 H), 7.18 - 7.29 (m, 2 H), 7.46 - 7.56 (m, 3 H), 7.58 - 7.68 (m, 2 H), 7.71 (br. s., 1 H), 7.79 (s, 1 H), 8.00 (d, $J=1.51$ Hz, 1 H), 8.08 - 8.21 (m, 2 H). LCMS m/z 557.11 (M+H). HPLC Rt 8.964 min. (Sunfire C18), 92.0% purity.



5-(3-(2-(1*H*-1,2,4-Triazol-1-yl)ethoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide


[00431] ¹H NMR (400 MHz, THF-*d*₈) δ ppm 0.87 - 1.01 (m, 6 H), 1.83 - 1.98 (m, 1 H), 2.93 (d, *J*=4.52 Hz, 3 H), 3.13 - 3.26 (m, 2 H), 4.49 (t, *J*=5.14 Hz, 2 H), 4.61 (t, *J*=5.02 Hz, 2 H), 7.19 - 7.27 (m, 2 H), 7.28 - 7.33 (m, 1 H), 7.39 - 7.42 (m, 1 H), 7.43 - 7.52 (m, 1 H), 7.57 - 7.66 (m, 2 H), 7.71 - 7.77 (m, 1 H), 7.81 (s, 1 H), 7.96 (d, *J*=1.00 Hz, 1 H), 8.06 - 8.17 (m, 3 H), 8.30 (s, 1 H). LCMS *m/z* 556.11 (M+H). HPLC Rt 7.969 min. (Sunfire C18), 92.0% purity.

10



5-(3-(Cyanomethoxy)-5-(isobutylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide


[00432] ¹H NMR (500 MHz, THF-*d*₈) δ ppm 0.96 (d, *J*=6.71 Hz, 6 H), 1.85 - 1.98 (m, 1 H), 2.85 - 2.98 (m, 3 H), 3.16 - 3.27 (m, 2 H), 5.11 (s, 2 H), 7.18 - 7.29 (m, 2 H), 7.42 - 7.49 (m, 1 H), 7.54 (s, 1 H), 7.60 - 7.71 (m, 2 H), 7.79 - 7.88 (m, 2 H), 8.00 (s, 1 H), 8.08 - 8.19 (m, 2 H). LCMS *m/z* 500.00 (M+H). HPLC Rt 9.584 min. (Sunfire C18), 95.9% purity.



2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)biphenyl-3-yl)-N-methylbenzofuran-3-carboxamide

[00433] To a BIOTAGE® microwave vial was added 1,4-dioxane (2.0 mL), water
 5 (200 µL), dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (16.42 mg, 0.040 mmol), 5-(3-chloro-5-(isobutylcarbamoyl) phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (96 mg, 0.2 mmol), potassium phosphate tribasic (170 mg, 0.800 mmol), palladium(II) acetate (8.98 mg, 0.040 mmol), and phenylboronic acid (73.2 mg, 0.600 mmol). The vial was capped, degassed, flushed
 10 with N₂ and heated in the microwave for 15 minutes at 150 °C. The solvent was removed in a Thermo/Savant SPEEDVAC® and the crude product was dissolved in DMF (1.8 mL) and purified by preparative HPLC using a Shimadzu Prep HPLC employing acetonitrile/water/0.1%TFA where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/
 15 0.1% trifluoroacetic acid with a Waters Sunfire 5µm C18 30x100mm column at a gradient of 30-100% B and a flow rate of 40 mL/min. over 8 minutes with a 10 minute hold. The tubes with desired product were evaporated overnight in a Savant/Thermo SPEEDVAC®. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following
 20 set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% TFA/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% TFA/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18
 25 3.5µm 4.6 x 150mm column employing water/acetonitrile/ 0.1%TFA with a gradient of 20-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5%


HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3 μ m 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 20-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, CD₃OD) δ ppm 0.99 (d, *J*=6.78 Hz, 6 H), 1.92 - 2.05 (m, 1 H), 2.91 - 3.03 (m, 3 H), 3.21 - 3.27 (m, 2 H), 7.25 (t, *J*=8.78 Hz, 2 H), 7.36 - 7.42 (m, 1 H), 7.49 (t, *J*=7.53 Hz, 2 H), 7.65 - 7.70 (m, 1 H), 7.75 (d, *J*=8.28 Hz, 3 H), 7.91 - 7.98 (m, 2 H), 8.00 (d, *J*=1.51 Hz, 1 H), 8.03 - 8.10 (m, 3 H). LCMS *m/z* 521.33 (M+H), Rt 2.715 min. HPLC (Sunfire C18) Rt 11.531 min, 95% purity and (XBridge phenyl C18) Rt 12.868 min., 92 % purity.



2-(4-Fluorophenyl)-5-(4-hydroxy-3-(isobutylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00434] To a 350mL sealed tube was added 2-(4-fluorophenyl)-5-(3-(isobutylcarbamoyl)-4-methoxyphenyl)-*N*-methylbenzofuran-3-carboxamide (1.14 g, 2.4 mmol), dichloroethane (250 mL) and boron tribromide-methyl sulfide complex (6.0 g, 19.2 mmol). The vessel was sealed and the mixture heated with stirring at 90 °C overnight. The reaction mixture was cooled to 0 °C and 100mL of cold methanol was added and the mixture stirred for 30minutes then evaporated to near dryness. The addition of methanol followed by evaporation was repeated to give a tan solid (78%). The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5 μ m C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% TFA/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% TFA/ 10% HPLC grade acetonitrile), in 3 minutes with a 1

minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/ 0.1%TFA with a gradient of 40-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Gemini C18 3 μ m 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 50-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10 mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (500 MHz, THF-d₈) δ ppm 0.97 (d, *J*=6.71 Hz, 6 H), 1.83 - 2.07 (m, 1 H), 2.92 (d, *J*=4.88 Hz, 3 H), 3.24 (t, *J*=6.41 Hz, 2 H), 6.96 (d, *J*=8.55 Hz, 1 H), 7.23 (t, *J*=8.70 Hz, 2 H), 7.50 - 7.55 (m, 1 H), 7.55 - 7.59 (m, 2 H), 7.67 (dd, *J*=8.55, 2.14 Hz, 1 H), 7.89 (s, 1 H), 7.99 (d, *J*=2.14 Hz, 1 H), 8.09 (dd, *J*=8.70, 5.34 Hz, 2 H), 8.35 (br. s., 1 H). LCMS *m/z* 461.18 (M+H), Rt 2.613 min. HPLC (Sunfire C18) Rt 10.033 min., 100% purity and (Gemini C18) Rt 9.748 min., 100 % purity.




20 2-(4-Fluorophenyl)-N-methyl-5-(5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)-2-(trifluoromethyl)phenyl)benzofuran-3-carboxamide

[00435] To a BIOTAGE® microwave vial was added 2-(4-fluorophenyl)-N-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzofuran-3-carboxamide (39.5 mg, 0.1 mmol), dioxane (2 mL), water (0.200 mL), 3-chloro-N-(1-(pyridin-2-yl)cyclopropyl)-4-(trifluoromethyl)benzamide (37.5 mg, 0.110 mmol) (prepared from the coupling of 3-chloro-4-(trifluoromethyl)benzoic acid with 1-(pyridin-2-

yl)cyclopropanamine dihydrochloride using HATU and N,N-Diisopropylethylamine in DMF at r.t.), dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (S-Phos, 8.21 mg, 0.020 mmol), tribasic potassium phosphate, (85 mg, 0.400 mmol) and finally palladium(II) acetate (4.49 mg, 0.020 mmol). The vial was capped and subjected to microwave heating (100 °C) for 10 minutes. After cooling the reaction mixture, the solvent was removed and the crude product was purified using a Shimadzu preparative HPLC employing acetonitrile/water/ trifluoroacetic acid where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 5µm C18 19 x 150mm column at a gradient of 20-100% B and a flow rate of 25 mL/min. over 20 minutes with a 5 minute hold. The solvent was removed yielding 11.2mgs (20% yield) of the desired pyridylcarboxamide as a yellow solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade methanol/ 0.1% trifluoroacetic acid / 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid / 10% HPLC grade methanol), in 4 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/ 0.1% trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Gemini C18 3.0µm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 1.22 - 1.33 (m, 2 H), 1.63 - 1.69 (m, 2 H), 2.87 (d, *J*=4.77 Hz, 3 H), 7.03 (dd, *J*=7.40, 4.89 Hz, 1 H), 7.23 (t, *J*=8.66 Hz, 2 H), 7.33 (d, *J*=8.28 Hz, 1 H), 7.40 (d, *J*=7.53 Hz, 2 H), 7.52 - 7.63 (m, 2 H), 7.73 (d, *J*=1.25 Hz, 1 H),

7.90 (d, $J=8.03$ Hz, 1 H), 7.97 (s, 1 H), 8.05 - 8.16 (m, 3 H), 8.40 (d, $J=4.77$ Hz, 1 H), 8.69 (s, 1 H). LCMS R_t = 2.193min., m/z 574.3 (M+H). HPLC R_t = 7.435 min. (Sunfire C18), 97.5 % purity and 11.823 min. (Gemini C18), 100 % purity.



5

2-(4-Fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(2-(morpholin-2-yl)ethoxy)phenyl)-
N-methylbenzofuran-3-carboxamide, TFA

[00436] To a 2 dram vial was added 2-(4-fluorophenyl)-5-(2-hydroxy-5-(isobutylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide (46.0 mg, 0.1 mmol), DMF (2 mL), 4.0 equivalents (60 μ L, 0.400mmol) of DBU, 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.4mmol) and 4.0 equivalents of *tert*-butyl 2-(2-bromoethyl)morpholine-4-carboxylate (236 mg, 0.400 mmol). The vial was capped and the reaction mixture heated for eighteen hours at 85 °C. The crude product was purified using a Shimadzu preparative HPLC employing

15 acetonitrile/water/trifluoroacetic acid where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 5 μ m C18 19 x 150 mm column at a gradient of 20-100% B and a flow rate of 25 mL/min. over 20 minutes with a 10 minute hold. The solvent mixture was removed on the rotovap and the resulting

20 white solid (19.2mgs) was taken up in 2mL of dichloroethane containing 200 μ L of trifluoroacetic acid. The acid mixture was stirred for 60minutes. The volatiles were then removed, the process repeated again giving 20mgs (29% yield, 2 steps) of 2-(4-fluorophenyl)-5-(5-(isobutylcarbamoyl)-2-(2-(morpholin-2-yl)ethoxy)phenyl)-N-methylbenzofuran-3-carboxamide, TFA as a white solid. The NMR spectrum was

25 recorded at room temperature using a Bruker DRX400 spectrometer. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC

(ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 3µm C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1% trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5µm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 0.93 (d, *J*=6.53 Hz, 6 H), 1.87 (m, 3 H), 2.90 (d, *J*=4.77 Hz, 3 H), 3.08 - 3.12 (m, 2 H), 3.16 - 3.20 (m, 2 H), 3.31 (d, *J*=9.54 Hz, 2 H), 3.95 - 4.11 (m, 3 H), 4.23 - 4.31 (m, 1 H), 4.35 (br. s., 1 H), 7.08 (d, *J*=8.78 Hz, 1 H), 7.25 (t, *J*=8.66 Hz, 2 H), 7.45 (dd, *J*=8.53, 1.76 Hz, 1 H), 7.54 (t, *J*=5.65 Hz, 1 H), 7.62 (d, *J*=8.53 Hz, 1 H), 7.84 (dd, *J*=8.53, 2.26 Hz, 1 H), 7.88 (d, *J*=2.01 Hz, 1 H), 7.91 (d, *J*=4.02 Hz, 1 H), 7.98 - 8.07 (m, 3 H). LCMS *m/z* 574.5 (M+H), *R*_t = 2.390 min. HPLC (Sunfire C18) *R*_t = 6.870 min., 99.3% purity and (XBridge phenyl C18) *R*_t = 10.973 min., 99.2% purity.

25


tert-Butyl 2-(2-bromoethyl)morpholine-4-carboxylate

[00437] To a 25mL round-bottomed flask was added 2-(morpholin-2-yl)ethanol (100 mg, 0.762 mmol), DCM (1 mL), and triethylamine (0.106 mL, 0.762 mmol). Di-*tert*-butyl dicarbonate (0.177 mL, 0.762 mmol) in DCM (1 mL) was then added dropwise via syringe. The mixture was stirred at room temperature under nitrogen for 3 hours. Volatiles were removed and NMR was taken of the colorless oil (176 mgs, 100% yield, 96% purity). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.39 (s, 9 H),

30

1.47 - 1.61 (m, 2 H), 2.83 (br. s., 1 H), 3.28 - 3.42 (m, 3 H), 3.46 (q, $J=6.10$ Hz, 2 H), 3.68 (d, $J=11.29$ Hz, 1 H), 3.76 (d, $J=10.38$ Hz, 2 H), 4.45 (t, $J=5.04$ Hz, 1 H).

[00438] To a 25mL round-bottomed flask at 0 °C was added *tert*-butyl 2-(2-hydroxyethyl)morpholine-4-carboxylate (0.176 g, 0.762 mmol), DCM (4 mL), 1*H*-imidazole (0.104 g, 1.524 mmol), perbromomethane (0.379 g, 1.143 mmol), and triphenylphosphine (0.190 g, 0.723 mmol). The mixture was stirred overnight slowly reaching room temperature. The yellow solution was further diluted with 50 mL of DCM, washed with water, brine, dried over sodium sulfate, and filtered. The crude product was then pushed through a plug of silica gel and the solvent was removed to give 213mgs of a light yellow oil. ^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.40 (s, 9 H), 1.94 (q, $J=6.86$ Hz, 1 H), 2.56 - 2.66 (m, 1 H), 2.76 - 2.91 (m, 1 H), 3.35 - 3.47 (m, 4 H), 3.50 - 3.61 (m, 1 H), 3.68 (br. s., 1 H), 3.74 - 3.86 (m, 2 H).




15 5-(2-(2-(Dimethylamino)ethoxy)-5-(1-phenylcyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide, TFA

[00439] To a small microwave vial was added 2-(4-fluorophenyl)-5-(2-hydroxy-5-(1-phenylcyclopropyl carbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide (11.3mgs, 0.022 mmol) (obtained from the de-methylation of the methoxy precursor using Boron tribromide-methyl sulfide complex (1,2-dichloroethane, 90 °C)), dioxane (2 mL), triphenylphosphine (105 mg, 0.400 mmol), 2-(dimethylamino)ethanol (0.025 mL, 0.250 mmol), and di-*tert*-butyl azodicarboxylate (69.1 mg, 0.300 mmol). The vial was crimped and the reaction mixture subjected to microwave heating (140 °C) for 20 minutes in a BIOTAGE® Initiator. The solvent was removed under a stream of nitrogen, the crude product taken up in 2mL of acetonitrile and purified using a Shimadzu preparative HPLC employing acetonitrile/water/ trifluoroacetic acid where


solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Sunfire 5 μ m C18 19 x 150mm column at a gradient of 20-100% B and a flow rate of 20 mL/min. over 20 minutes with a 5 minute hold. The solvent was removed to give 14.5mgs (90% yield) of 5-(2-(2-(dimethylamino)ethoxy)-5-(1-phenylcyclopropyl carbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide, TFA salt as a white solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Sunfire 5 μ m C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade methanol/ 0.1% TFA/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% TFA/ 10% HPLC grade methanol), in 4 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/ 0.1% trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Gemini C18 3.0 μ m 4.6 x 150mm column employing water/methanol/ 10 mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10 mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10 mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The NMR spectrum was recorded at room temperature using a Bruker DRX400 spectrometer. Chemical shifts were reported in ppm relative to the deuterated solvent used. Coupling constants were reported in hertz. Peak multiplicity was reported using the following abbreviations: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), m (multiplet), br (broad). ¹H NMR (400 MHz, THF-d₈) δ ppm 1.22 - 1.27 (m, 2 H), 1.28 - 1.33 (m, 2 H), 2.70 (s, 6 H), 2.90 (d, *J*=4.52 Hz, 3 H), 3.41 - 3.46 (m, 2 H), 4.47 - 4.53 (m, 2 H), 7.06 - 7.12 (m, 1 H), 7.14 - 7.27 (m, 5 H), 7.28 - 7.35 (m, 2 H), 7.47 (dd, *J*=8.53, 1.76 Hz, 1 H), 7.54 - 7.61 (m, 2 H), 7.89 (dd, *J*=8.53, 2.26 Hz, 1 H), 7.94 (dd, *J*=4.02, 2.01 Hz, 2 H), 8.03 - 8.10 (m, 2 H), 8.28 (s, 1 H). LCMS *m/z*

592.4 (M+H), Rt = 2.065 min. HPLC Rt = 7.025 min. (Sunfire C18), 95.2 % purity and 11.979 min. (Gemini C18), 95.7 % purity.



- 5 5-(2-(2-(Dimethylamino)ethoxy)-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-
2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide, TFA
- [00440] The LC/MS data was obtained on a Shimadzu analytical LC /
MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions:
Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC
10 grade methanol/ 0.1% trifluoroacetic acid / 10% HPLC grade water), (A = 90%
HPLC grade water / 0.1% trifluoroacetic acid / 10% HPLC grade methanol), in 4
minutes with a 1 minute hold at a rate of 0.8 mL/minute. HPLC purity was
determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters
Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/ 0.1%
15 trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/
0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water /
0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10
minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an
orthogonal solvent system and column using a Shimadzu analytical LC with a
20 PHENOMENEX® Gemini C18 3.0µm 4.6 x 150mm column employing
water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B =
95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water),
(A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade
methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR
25 (400 MHz, THF-d₈) δ ppm 1.32 - 1.37 (m, 2 H), 1.59 - 1.65 (m, 2 H), 2.77 (s, 6 H),
2.90 (d, J=4.77 Hz, 3 H), 3.47 - 3.54 (m, 2 H), 4.48 - 4.55 (m, 2 H), 7.17 (d, J=8.53


Hz, 1 H), 7.20 - 7.27 (m, 2 H), 7.31 (dd, $J=6.90, 5.65$ Hz, 1 H), 7.49 - 7.59 (m, 2 H), 7.61 - 7.70 (m, 2 H), 7.86 (td, $J=7.78, 1.51$ Hz, 1 H), 7.94 (dd, $J=8.53, 2.26$ Hz, 1 H), 7.97 (d, $J=1.00$ Hz, 1 H), 7.99 - 8.09 (m, 3 H), 8.54 (d, $J=4.27$ Hz, 1 H), 9.07 (s, 1 H). LCMS Rt = 2.412 min., m/z 593.4 (M+H). HPLC Rt = 5.185 min. (Sunfire C18), 96.4
 5 % purity and 11.558 min. (Gemini C18), 98.2 % purity.



2-(4-Fluorophenyl)-5-(2-methoxy-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-
N-methylbenzofuran-3-carboxamide

10 **[00441]** The LC/MS data was obtained on a Shimadzu analytical LC /
 MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions:
 PHENOMENEX® Luna 10 μ M C18, 3.0 x 50mm column, with a gradient of 0-
 100%B (B = 90% HPLC grade methanol/ 0.1% trifluoroacetic acid / 10% HPLC
 grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid / 10% HPLC
 15 grade methanol), in 4 minutes with a 1 minute hold at a rate of 5 mL/minute. HPLC
 purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a
 Waters Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/ 0.1%
 trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/
 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water /
 20 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10
 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an
 orthogonal solvent system and column using a Shimadzu analytical LC with a
 PHENOMENEX® Gemini C18 3.0 μ m 4.6 x 150mm column employing
 water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B =
 25 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water),
 (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade
 methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ^1H NMR


(400 MHz, DMSO- d_6) δ ppm 1.31 - 1.40 (m, 2 H), 1.56 - 1.65 (m, 2 H), 2.82 (d, $J=4.52$ Hz, 3 H), 3.85 (s, 3 H), 7.24 (d, $J=8.53$ Hz, 1 H), 7.30 (dd, $J=6.78, 5.52$ Hz, 1 H), 7.39 (t, $J=8.91$ Hz, 2 H), 7.46 (d, $J=8.03$ Hz, 1 H), 7.52 (dd, $J=8.53, 1.76$ Hz, 1 H), 7.68 - 7.75 (m, 2 H), 7.86 (s, 1 H), 7.93 - 8.02 (m, 4 H), 8.45 (d, $J=4.52$ Hz, 1 H),
 5 8.49 (d, $J=4.27$ Hz, 1 H), 9.23 (s, 1 H). LCMS Rt = 2.557 min., m/z 536.10 (M+H).
 HPLC Rt = 6.683 min. (Sunfire C18), 96.3 % purity and 11.493 min. (Gemini C18), 99.5 % purity.



10 2-(4-Fluorophenyl)-5-(2-hydroxy-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-
N-methylbenzofuran-3-carboxamide

[00442] To a 100mL round-bottomed flask equipped with a reflux condenser was added 2-(4-fluorophenyl)-5-(2-methoxy-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide (400 mg,
 15 0.747 mmol), DCE (42 mL) and boron tribromide-methyl sulfide complex (1868 mg, 5.97 mmol). The solution was placed under nitrogen and stirred overnight at 90 °C. The reaction mixture was cooled to room temperature, quenched with methanol and evaporated to near dryness. The mixture was taken up in 10 mL of methanol and purified using a Shimadzu preparative HPLC employing methanol/water/0.1%
 20 trifluoroacetic acid where solvent A was 10% methanol / 90% water / 0.1% trifluoroacetic acid and solvent B was 10% water / 90% methanol / 0.1% trifluoroacetic acid with a PHENOMENEX® Luna 10 μ m C18 30x100mm column at a gradient of 40-100% B and a flow rate of 40 mL/min. over 10 minutes with a 5 minute hold. The solvent was evaporated giving 234mgs (60% yield) of 2-(4-fluorophenyl)-5-(2-hydroxy-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-*N*-
 25 methylbenzofuran-3-carboxamide as a white solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Sunfire 5 μ m C18, 4.6 x 50mm column, with a gradient

of 0-100%B (B = 90% HPLC grade methanol/ 0.1% trifluoroacetic acid / 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid / 10% HPLC grade methanol), in 4 minutes with a 1 minute hold at a rate of 4 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 1.25 - 1.31 (m, 2 H), 1.59 - 1.66 (m, 2 H), 2.90 (d, *J*=4.52 Hz, 3 H), 6.91 (d, *J*=8.53 Hz, 1 H), 7.08 (dd, *J*=6.90, 5.40 Hz, 1 H), 7.17 - 7.24 (m, 2 H), 7.45 - 7.65 (m, 5 H), 7.79 (dd, *J*=8.41, 2.13 Hz, 1 H), 7.88 (d, *J*=1.25 Hz, 1 H), 7.93 (d, *J*=2.01 Hz, 1 H), 8.08 - 8.17 (m, 2 H), 8.39 - 8.45 (m, 1 H), 8.49 (br. s., 1 H). LCMS Rt = 1.495 min., *m/z* 522.33 (M+H), 94% purity.



10

2-(4-Fluorophenyl)-5-(2-(2-hydroxyethoxy)-5-(1-


phenylcyclopropylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00443] To a small screw cap vial was added 2-(4-fluorophenyl)-5-(2-hydroxy-5-(1-phenylcyclopropyl carbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide (19.5 mg, 0.037 mmol) in DMF (1.3 mL), (2-bromoethoxy)(*tert*-butyl)dimethylsilane (0.024 mL, 0.112 mmol), and DBU (1,8-diazabicyclo [5.4.0]undec-7-ene, 0.023 mL, 0.150 mmol). The vial was capped and shaken at 80 °C for 18 hours. The DMF was removed under a stream of nitrogen to give 5-(2-(2-(*tert*-butyldimethylsilyloxy)ethoxy)-5-(1-phenylcyclopropyl carbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-

methylbenzofuran-3-carboxamide as a tan oil. To the mixture was then added 1.3mL of tetrahydrofuran along with 2 eq. of 1 M HCl (0.075 mL, 0.075 mmol). The solution was stirred for 1 hour at room temperature. The reaction mixture was transferred to a separatory funnel, diluted with ethyl acetate, washed sequentially with sodium bicarbonate, brine and dried over magnesium sulfate. The product mixture was filtered and the solvent was evaporated. The crude product was taken up in 1.8 mL of acetonitrile and 200μL of DMF and purified using a Shimadzu preparative

25

HPLC employing acetonitrile/water/ trifluoroacetic acid where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Sunfire C18 19 x 150mm column at a gradient of 20-100% B and a flow rate of 20 mL/min. over 20 minutes with a 5 minute hold. 15.2mgs of 2-(4-fluorophenyl)-5-(2-(2-hydroxyethoxy)-5-(1-phenylcyclopropyl carbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide (70% yield, 2 steps) was obtained after solvent evaporation. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade methanol/ 0.1% trifluoroacetic acid / 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid / 10% HPLC grade methanol), in 4 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1% trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Gemini C18 3.0µm 4.6 x 150mm column employing water/methanol / 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 1.20 - 1.27 (m, 2 H), 1.28 - 1.36 (m, 2 H), 2.87 - 2.96 (m, 3 H), 3.75 - 3.83 (m, 3 H), 4.10 (t, *J*=4.89 Hz, 2 H), 7.04 - 7.13 (m, 2 H), 7.16 - 7.25 (m, 4 H), 7.29 - 7.35 (m, 2 H), 7.43 (d, *J*=4.27 Hz, 1 H), 7.51 - 7.59 (m, 2 H), 7.87 (dd, *J*=8.53, 2.26 Hz, 1 H), 7.94 (d, *J*=2.26 Hz, 1 H), 8.02 (s, 1 H), 8.11 - 8.18 (m, 2 H), 8.25 (s, 1 H). LCMS Rt = 2.671min., *m/z* 565.3 (M+H). HPLC Rt = 9.454 min. (Sunfire C18), 95.0 % purity and 11.611 min. (Gemini C18), 99.7 % purity.




2-(4-Fluorophenyl)-5-(2-(2-hydroxyethoxy)-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide

[00444] The LC/MS data was obtained on a Shimadzu analytical LC /

- 5 MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 3µm C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. HPLC
- 10 purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5mm 4.6 x 150mm column employing water/acetonitrile/0.1% trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10
- 15 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5µm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC
- 20 grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 1.23 - 1.29 (m, 2 H), 1.62 - 1.68 (m, 2 H), 2.91 (d, *J*=4.77 Hz, 3 H), 3.80 (t, *J*=4.77 Hz, 2 H), 4.13 (t, *J*=4.89 Hz, 2 H), 6.99 (m, 1 H), 7.14 (d, *J*=8.53 Hz, 1 H), 7.17 - 7.25 (m, 2 H), 7.37 - 7.47 (m, 2 H), 7.49 - 7.61 (m, 3 H), 7.93 (dd, *J*=8.53, 2.26
- 25 Hz, 1 H), 8.00 (d, *J*=2.26 Hz, 1 H), 8.03 - 8.06 (m, 1 H), 8.11 - 8.18 (m, 2 H), 8.33 (s, 1 H), 8.35 - 8.41 (m, 1 H). LCMS *m/z* 566.4 (M+H), *R*_t = 2.038 min. HPLC (Sunfire


C18) Rt = 5.916min., 100% purity and (XBridge phenyl C18) Rt = 10.474min., 100% purity.



5 5-(2-(2-Amino-2-oxoethoxy)-5-(1-phenylcyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

[00445] To a small screw cap vial was added 2-(4-fluorophenyl)-5-(2-hydroxy-5-(1-phenylcyclopropyl carbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide (15.6 mg, 0.030 mmol) in DMF (2 mL), 2-bromoacetamide (41.4 mg, 0.300 mmol), and
 10 DBU (1,8-diazabicyclo [5.4.0]undec-7-ene, 0.060 mL, 0.400 mmol). The vial was capped and shaken at 75 °C overnight. The crude reaction mixture was cooled, evaporated, taken up in 2 mL of acetonitrile and purified using a Shimadzu preparative HPLC employing acetonitrile/water/ trifluoroacetic acid where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10%
 15 water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a XTERRA® C18 19 x 100mm column at a gradient of 25-100% B and a flow rate of 25 mL/min. over 12 minutes with a 8 minute hold. The solvent was evaporated overnight giving 9.9mgs (54.9% yield) of carboxamide as a white solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the
 20 following set of conditions: Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile / 0.1% trifluoroacetic acid / 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid / 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm
 25 with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/ 0.1% trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade

acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Gemini C18 3.0 μ m 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10 mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 1.21 - 1.26 (m, 2 H), 1.26 - 1.33 (m, 2 H), 2.87 - 2.92 (m, 3 H), 4.47 (s, 2 H), 7.05 - 7.13 (m, 2 H), 7.15 - 7.25 (m, 4 H), 7.27 - 7.34 (m, 2 H), 7.45 - 7.51 (m, 1 H), 7.52 - 7.61 (m, 2 H), 7.84 - 7.92 (m, 2 H), 7.93 - 8.00 (m, 2 H), 8.09 - 8.20 (m, 3 H), 8.29 (s, 1 H). LCMS Rt = 2.522min., *m/z* 578.3(M+H). HPLC Rt = 8.693 min. (Sunfire C18), 91.0 % purity and 11.423 min. (Gemini C18), 92 % purity.




5-(2-(2-Amino-2-oxoethoxy)-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

[00446] The LC/MS data was obtained on a Shimadzu analytical LC /

MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 3 μ m C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile / 0.1% trifluoroacetic acid / 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid / 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/ 0.1%


trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/
0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water /
0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10
minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an
5 orthogonal solvent system and column using a Shimadzu analytical LC with a
PHENOMENEX® Gemini C18 3.0 μ m 4.6 x 150mm column employing
water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B =
95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water),
(A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade
10 methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR
(400 MHz, THF-d₈) δ ppm 1.25 - 1.37 (m, 2 H), 1.57 - 1.67 (m, 2 H), 2.88 - 2.96 (m,
3 H), 4.49 (s, 2 H), 6.51 (br. s., 1 H), 6.79 (br. s., 1 H), 7.10 (d, *J*=8.78 Hz, 1 H), 7.17
- 7.27 (m, 3 H), 7.52 - 7.66 (m, 4 H), 7.72 - 7.82 (m, 1 H), 7.94 (dd, *J*=8.53, 2.26 Hz,
1 H), 7.99 (s, 1 H), 8.03 (d, *J*=2.26 Hz, 1 H), 8.08 - 8.18 (m, 2 H), 8.50 (d, *J*=4.27 Hz,
15 1 H), 8.91 (br. s., 1 H). LCMS Rt = 2.578min., *m/z* 580.3 (M + 2H). HPLC Rt = 9.368
min. (Sunfire C18), 96.0 % purity and 10.756 min. (Gemini C18), 97.9 % purity.



5-(2-(2-Aminoethoxy)-5-(1-phenylcyclopropylcarbamoyl)phenyl)-2-(4-
20 fluorophenyl)-*N*-methylbenzofuran-3-carboxamide, TFA
[00447] To a 2 dram vial was added 2-(4-fluorophenyl)-5-(2-hydroxy-5-(1-
phenylcyclopropylcarbamoyl) phenyl)-*N*-methylbenzofuran-3-carboxamide (40.2 mg,
0.078 mmol) in 3 mL of DMF along with 3 eq. of 2-(2-bromoethyl)isoindoline-1,3-
dione (58.8 mg, 0.232 mmol) and 4 eq. of DBU (1,8-diaza bicyclo [5.4.0]undec-7-
25 ene, 0.046 mL, 0.308 mmol). The vial was capped and shaken at 75 °C over night.
The crude reaction mixture was evaporated, taken up in 2 mL of acetonitrile and
purified using a Shimadzu preparative HPLC employing acetonitrile/water/ 0.1%

trifluoroacetic acid where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a XTERRA® C18 19 x 100mm column at a gradient of 25-100% B and a flow rate of 25 mL/min. over 12 minutes with a 8 minute hold. The solvent was evaporated yielding 10.7mgs of the phthalimide intermediate as a white solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade methanol/ 0.1% trifluoroacetic acid / 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid / 10% HPLC grade methanol), in 4 minutes with a 1 minute hold at a rate of 4 mL/minute. LCMS *m/z* 694.4 (M+H), *Rt* = 3.128 min., 93.7% purity. To a small screw cap vial was added the phthalimide intermediate, 5-(2-(2-(1,3-dioxoisindolin-2-yl)ethoxy)-5-(1-phenylcyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide (10.7 mg, 0.015 mmol) in 2mL of methanol and anhydrous hydrazine (0.780 µL, 0.025 mmol). The vial was placed in a pre-equilibrated oil bath set to 75°C and the solution refluxed for 90minutes. The product was cooled to room temperature and the solvent was evaporated. The resulting oil was diluted with 10mL of DCM, washed with 1mL of 0.5M NaOH and extracted. The solvent was evaporated and the crude product was taken up in 1.8 mL of acetonitrile and 200µL of DMF and purified using a Shimadzu preparative HPLC employing acetonitrile/water/ trifluoroacetic acid where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Sunfire C18 19 x 150mm column at a gradient of 20-100% B and a flow rate of 20 mL/min. over 20 minutes with a 5 minute hold. The solvent was evaporated giving 7.0 mgs (14% yield, 2 steps) of 5-(2-(2-aminoethoxy)-5-(1-phenylcyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide, TFA as a white solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Sunfire 5µm C18, 4.6 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade methanol/ 0.1% trifluoroacetic acid / 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid / 10% HPLC

grade methanol), in 4 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/ 0.1% trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Gemini C18 3.0 μ m 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 1.21 - 1.27 (m, 2 H), 1.28 - 1.35 (m, 2 H), 2.89 (d, *J*=4.77 Hz, 3 H), 3.39 (t, *J*=4.77 Hz, 2 H), 4.38 (t, *J*=5.02 Hz, 2 H), 7.05 - 7.13 (m, 1 H), 7.16 - 7.28 (m, 5 H), 7.29 - 7.35 (m, 2 H), 7.49 - 7.60 (m, 2 H), 7.62 (br. s., 1 H), 7.87 (dd, *J*=8.53, 2.26 Hz, 1 H), 7.96 - 8.05 (m, 3 H), 8.07 (d, *J*=1.00 Hz, 1 H), 8.30 (s, 1 H). LCMS Rt = 2.023 min., *m/z* 564.3 (M+H). HPLC Rt = 6.931 min. (Sunfire C18), 100 % purity and 11.423 min. (Gemini C18), 98.9 % purity.



5-(2-(2-Aminoethoxy)-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide, 2 TFA

[00448] The LC/MS data was obtained on a Shimadzu analytical LC /
 25 MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions:
 PHENOMENEX® Luna 3 μ m C18, 2 x 50mm column, with a gradient of 0-100%B

(B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a

5 Waters Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/0.1%trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was

10 then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5 μ m 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5%

15 HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 1.23 - 1.33 (m, 2 H), 1.60 - 1.67 (m, 2 H), 2.89 (d, *J*=4.77 Hz, 3 H), 3.41 (t, *J*=5.14 Hz, 2 H), 4.40 (t, *J*=5.14 Hz, 2 H), 6.58 (br. s., 2 H), 7.01 - 7.11 (m, 1 H), 7.16 - 7.29 (m, 3 H), 7.46 (d, *J*=8.03 Hz, 1 H), 7.52 - 7.70 (m, 4 H), 7.93 (dd, *J*=8.53, 2.26 Hz, 1 H), 7.98 - 8.05 (m, 3 H), 8.07 (s, 1 H),

20 8.41 (d, *J*=4.77 Hz, 1 H), 8.56 (s, 1 H). LCMS *m/z* 565.4 (M+H), *R*_t = 1.628 min. HPLC (Sunfire C18) *R*_t = 5.048 min., 99.9% purity and (XBridge phenyl C18) *R*_t = 10.531 min., 100% purity.

5-Bromo-2,4-dimethoxy-*N*-(1-(pyridin-2-yl)cyclopropyl)benzamide

25 **[00449]** To a 250mL round-bottomed flask was added chloroform (60 mL) along with 2,4-dimethoxybenzoic acid (2.0 g, 10.98 mmol). The solution was cooled to 0 °C and bromine (0.566 mL, 10.98 mmol) was added dropwise over 5 minutes. The solution was allowed to warm to room temperature and stirred overnight. The resulting solid was filtered, washed with cold chloroform and dried under vacuum to

30 give 2.49g (8.6mmol, 78% yield) of 5-bromo-2,4-dimethoxybenzoic acid as a yellow solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions:

PHENOMENEX® Luna 3µm C18, 2 x 30mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 2 minutes with a 1 minute hold at a rate of 1.0 mL/minute. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 3.88 (s, 3 H), 3.95 (s, 3 H), 6.78 (s, 1 H), 7.86 (s, 1 H). LCMS Rt = 1.453min., *m/z* 262.99 (M+H), 93% purity.

[00450] To a 2 dram vial was added 5-bromo-2,4-dimethoxybenzoic acid (1.044 g, 4mmol), DMF (48.2 mL), *N,N*-Diisopropylethylamine (2.79 mL, 16.00 mmol), 1-(pyridin-2-yl)cyclopropanamine, 2 HCl (0.911 g, 4.40 mmol), and finally HATU (2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethyl isouronium hexafluorophosphate(V), 6.08 g, 16.00 mmol). The vial was capped and shaken for 16 hours at room temperature. The crude reaction mixture was diluted with 10mL of DCM, washed with 5mL of 1M HCl, extracted, washed with 20mL of brine, and dried over magnesium sulfate. The solution was pushed through a plug of silica gel and evaporated to dryness. Trituration with 20mL of diethyl ether gave 1.6grams of 5-bromo-2,4-dimethoxy-*N*-(1-(pyridin-2-yl)cyclopropyl)benzamide as a tan solid (76% yield). ¹H NMR (400 MHz, THF-d₈) δ ppm 1.22 - 1.32 (m, 2 H), 1.59 - 1.67 (m, 2 H), 3.94 (s, 3 H), 4.02 (s, 3 H), 6.72 (s, 1 H), 7.09 (m, 1 H), 7.47 (d, *J*=8.03 Hz, 1 H), 7.62 (td, *J*=7.72, 1.88 Hz, 1 H), 8.20 (s, 1 H), 8.39 - 8.52 (m, 2 H). LCMS Rt = 2.162 min., *m/z* 379.2 (M+2H), 96 % purity.

5-Bromo-2-methoxy-4-methylbenzoic acid

[00451] The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 30mm column, with a gradient of 0-100%B (B = 90% HPLC grade methanol/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade methanol), in 2 minutes with a 1 minute hold at a rate of 4 mL/minute. Yellow solid, 63.5% yield. LCMS Rt = 1.545 min., *m/z* 246.99 (M+H), 90 % purity. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.21 - 2.44 (m, 3 H), 3.82 (s, 3 H), 7.17 (s, 1 H), 7.78 (s, 1 H), 12.72 (br. s., 1 H).

5-Bromo-2-methoxy-4-methyl-N-(1-(pyridin-2-yl)cyclopropyl)benzamide

- [00452] The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 3µm C18, 2.0 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. Tan solid, 68% yield, 100% purity. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.34 - 1.42 (m, 2 H), 1.58 - 1.66 (m, 2 H), 2.39 (s, 3 H), 3.96 (s, 3 H), 7.05 (s, 1 H), 7.40 (dd, *J*=6.90, 5.90 Hz, 1 H), 7.76 (d, *J*=8.03 Hz, 1 H), 7.97 (td, *J*=7.78, 1.76 Hz, 1 H), 8.10 (s, 1 H), 8.60 (d, *J*=5.27 Hz, 1 H), 8.88 (s, 1 H). LCMS Rt = 3.525 min., *m/z* 362.88 (M+H), 98 % purity.

Methyl 4-hydroxy-2-methoxybenzoate

- [00453] To a 250mL Erlenmeyer flask was added methyl 4-amino-2-methoxybenzoate (7.5 g, 41.4 mmol) and a 25% solution of sulfuric acid (40 mL, 188 mmol). The solution was cooled to 0°C and a saturated solution of sodium nitrite (4.29 g, 62.2 mmol) was added drop wise. The orange mixture was stirred for 15 minutes. The resulting diazonium solution was then very slowly poured into a 1L flask containing 500mL of 3% sulfuric acid. The solution was stirred for 5 minutes then transferred to a separatory funnel. The reaction mixture was diluted with 150mL of DCM, extracted, dried over magnesium sulfate and concentrated. to a red solid. The resulting solid was triturated with hexane to give 5.71 grams of the desired phenol as a red powder (73% yield). The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 30mm column, with a gradient of 0-100%B (B = 90% HPLC grade methanol/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade methanol), in 2 minutes with a 1 minute hold at a rate of 4 mL/minute. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 3.67 - 3.72 (m, 3 H), 3.74 (s, 3 H), 6.39 (dd, *J*=8.66, 2.13 Hz, 1 H), 6.45 (d, *J*=2.13 Hz, 1 H), 7.59 (d, *J*=8.66 Hz, 1 H). LCMS Rt = 1.070 min., *m/z* 183.09 (M+H), 96% purity.

Methyl 4-(2-amino-2-oxoethoxy)-5-bromo-2-methoxybenzoate

[00454] To a sealed tube was added 2-bromoacetamide (2.272 g, 16.47 mmol), DMF (50 mL), cesium carbonate (7.15 g, 21.96 mmol) and methyl 4-hydroxy-2-methoxybenzoate (1.00 g, 5.49 mmol). The tube was sealed and heated for 16 hours at 85 °C. The reaction mixture was diluted with DCM, washed sequentially with 10mL of 1M HCl, water, and brine. The solution was dried over sodium sulfate, filtered and the solvent removed to give 1.2 grams of methyl 4-(2-amino-2-oxoethoxy)-2-methoxybenzoate (78% yield) as a yellow powder. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 30mm column, with a gradient of 0-100%B (B = 90% HPLC grade methanol/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade methanol), in 2 minutes with a 1 minute hold at a rate of 4 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 3.71 - 3.76 (m, 3 H), 3.80 - 3.84 (m, 3 H), 4.45 (s, 2 H), 6.56 (dd, *J*=8.66, 2.38 Hz, 1 H), 6.65 (d, *J*=2.26 Hz, 1 H), 6.77 (br. s., 1 H), 6.92 (br. s., 1 H), 7.75 (d, *J*=8.78 Hz, 1 H). LCMS Rt = 1.385 min., *m/z* 240.2 (M+H), 92% purity.

[00455] To a 250mL round-bottomed flask was added methyl 4-(2-amino-2-oxoethoxy)-2-methoxybenzoate (1.2 g, 5.14 mmol) and chloroform (40 mL). The mixture was placed under a nitrogen atmosphere and cooled to 0 °C. Bromine (0.263 mL, 5.14 mmol) was added drop wise (in 3mL of chloroform) and the solution was allowed to warm to room temperature overnight. The orange solid was cooled with an ice bath, filtered, washed sequentially with cold chloroform, then diethyl ether. The product was dried under vacuum giving 1.7 grams (91% yield) of methyl 4-(2-amino-2-oxoethoxy)-5-bromo-2-methoxybenzoate as an orange solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 30mm column, with a gradient of 0-100%B (B = 90% HPLC grade methanol/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade methanol), in 2 minutes with a 1 minute hold at a rate of 4 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 3.76 (s, 3 H), 3.88 (s,

3 H), 4.63 (s, 2 H), 6.76 (s, 1 H), 7.10 (br. s., 2 H), 7.96 (s, 1 H). LCMS Rt = 1.793 min., *m/z* 319.1 (M+H), 90% purity.

5-*(2,4-Dimethoxy-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide*

[00456] To a microwave vial was added 5-bromo-2,4-dimethoxy-*N*-(1-(pyridin-2-yl)cyclopropyl)benzamide (41.5 mg, 0.110 mmol), 2-(4-fluorophenyl)-*N*-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzofuran-3-carboxamide (39.5 mg, 0.1 mmol), dioxane (2.00 mL), water (0.200 mL), dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (S-Phos, 8.21 mg, 0.020 mmol), tribasic potassium phosphate (85 mg, 0.400 mmol) and palladium(II) acetate (4.49 mg, 0.020 mmol). The solvent was removed and the crude reaction mixture was taken up in 2 mL of acetonitrile and purified using a Shimadzu preparative HPLC employing acetonitrile/water/ trifluoroacetic acid where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 3.5µm C18 4.6x150mm column at a gradient of 20-100% B and a flow rate of 25 mL/min. over 20 minutes with a 10 minute hold. The solvent was evaporated giving 18.1mgs (30.4% yield) of the desired pyridylcarboxamide as a yellow solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 10µm C18, 3.0 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade methanol/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade methanol), in 4 minutes with a 1 minute hold at a rate of 5 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1% trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a PHENOMENEX® Gemini C18 3.0 µm 4.6 x

150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute
 5 hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 1.26 - 1.37 (m, 2 H), 1.60 - 1.67 (m, 2 H), 2.89 (d, *J*=4.77 Hz, 3 H), 3.87 (s, 3 H), 4.07 (s, 3 H), 6.78 (s, 1 H), 7.10 - 7.23 (m, 3 H), 7.39 - 7.44 (m, 1 H), 7.46 - 7.52 (m, 2 H), 7.57 (d, *J*=7.78 Hz, 1 H), 7.68 (td, *J*=7.72, 1.63 Hz, 1 H), 7.74 (d, *J*=1.25 Hz, 1 H), 8.09 (s, 1 H), 8.11 - 8.19 (m, 2 H), 8.47 (d, *J*=4.52 Hz, 1 H), 8.59 (s, 1 H). LCMS *m/z* 566.2 (M+H), Rt
 10 = 2.608 min. HPLC (Sunfire C18) Rt = 6.816min, 93.9% purity and (Gemini C18) Rt = 11.676min., 95.8% purity.

2-(4-Fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide

15 **[00457]** Alternative synthesis. To a sealed tube was added 5-bromo-2-methoxy-4-methyl-*N*-(1-(pyridin-2-yl)cyclopropyl) benzamide (1.9024 g, 5.27 mmol), dioxane (70 mL), 2-(4-fluorophenyl)-*N*-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzofuran-3-carboxamide (2.529 g, 6.40 mmol), cesium carbonate (2.57 g, 7.90 mmol), water (14.00 mL) and finally tetrakis(triphenylphosphine)palladium(0) (0.304
 20 g, 0.263 mmol). The vessel was sealed and heated for 16 hours at 85 °C in an oil bath. The mixture was cooled to room temperature, diluted with 20 ml of DCM and pushed through a plug of CELITE®. The resulting dark solution was concentrated to a grey oil. To this residue was added 20 ml of 0.5N HCl, followed by 20 ml of water. The flask was cooled in an ice bath for 30minutes and the resulting solids were
 25 collected by filtration and washed with 10 ml of water and dried under vacuum. The crude product was taken up in 1:1 ethyl acetate/ hexane and pushed through a plug of silica gel. Solvent was removed giving 1.65grams of the product as a light tan solid.

Methyl 4-(2-amino-2-oxoethoxy)-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxybenzoate

30 **[00458]** To a sealed tube was added methyl 4-(2-amino-2-oxoethoxy)-5-bromo-2-methoxybenzoate (318 mg, 1.0 mmol), dioxane (30 mL), water (6.00 mL), 2-(4-


fluorophenyl)-N-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzofuran-3-carboxamide (593 mg, 1.500 mmol), cesium carbonate (489 mg, 1.500 mmol), and tetrakis(triphenylphosphine)palladium(0) (23.11 mg, 0.020 mmol). The vessel was sealed and the mixture heated overnight at 85 °C. The reaction mixture was cooled, diluted with 200mL of DCM, washed sequentially with 50mL of 1M HCl then brine. The product was extracted and the resulting yellow solution was evaporated to dryness. The aqueous layers were combined, cooled for 5 minutes in an ice bath and the solids that formed were filtered and dried under vacuum. The solids were then combined and triturated sequentially with diethyl ether then ice cold acetonitrile (10mL each) giving 171.6mgs (30% yield) of methyl 4-(2-amino-2-oxoethoxy)-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxybenzoate as a white solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 3µm C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/ 0.1% trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters Phenyl XBridge C18 3.5µm 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, CD₃OD) δ ppm 3.04 (s, 3 H), 3.92 (s, 3 H), 4.03 (s, 3 H), 4.71 (s, 2 H), 6.85 (s, 1 H), 7.33 (t, *J*=8.78 Hz, 2 H), 7.57 - 7.64 (m, 1 H), 7.66 - 7.73 (m, 1 H), 7.87 (s, 1 H), 7.96 (s, 1 H), 8.00 - 8.08 (m, 2 H). LCMS *m/z* 507.3 (M+H), *R*_t = 2.635 min. HPLC *R*_t =

8.193 min. (Sunfire C18), 100 % purity and Rt = 10.678 min. (Phenyl XBridge C18), 100 % purity.

4-(2-Amino-2-oxoethoxy)-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxybenzoic acid

[00459] To a 50mL round-bottomed flask was added methyl 4-(2-amino-2-oxoethoxy)-5-(2-(4-fluorophenyl)-3-(methyl carbamoyl)benzofuran-5-yl)-2-methoxybenzoate (171.6 mg, 0.295 mmol) in a 1:1 mixture of methanol (7mL) and THF (7 mL). To this solution was then added 4 eq. of 1M aqueous sodium hydroxide (1.2 mL, 1.2 mmol). The reaction mixture was stirred overnight at room temperature. Solvent was removed and the crude product was diluted with 50mL of 1:1 DCM/ethyl acetate, washed sequentially with 10mL of 1M HCl then brine. The product solution was dried over sodium sulfate, filtered and evaporated to dryness. The aqueous layers were combined, cooled in an ice bath and the product that formed on the sides of the flask were filtered and dried under vacuum. The solids were combined, taken up in 10mL of DMF and purified using a Shimadzu preparative HPLC employing methanol/water/ trifluoroacetic acid where solvent A was 10% methanol / 90% water / 0.1% trifluoroacetic acid and solvent B was 10% water / 90% methanol / 0.1% trifluoroacetic acid with a PHENOMENEX® Luna 10µm C18 30x100mm column at a gradient of 40-100% B and a flow rate of 40 mL/min. over 12 minutes with a 10 minute hold. Solvent was removed giving 87mgs (60% yield) of 4-(2-amino-2-oxoethoxy)-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxybenzoic acid as a white powder. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 30mm column, with a gradient of 0-100%B (B = 90% HPLC grade methanol/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade methanol), in 2 minutes with a 1 minute hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/ 0.1% trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A =

95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile),
 in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was
 then confirmed with an orthogonal solvent system and column using a Shimadzu
 analytical LC with a Waters XBridge phenyl C18 3.5µm 4.6 x 150mm column
 5 employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-
 100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC
 grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5%
 HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1
 mL/minute. ¹H NMR (400 MHz, DMF-d₇) δ ppm 2.97 (d, *J*=4.52 Hz, 3 H), 4.02 (s, 3
 10 H), 4.79 (s, 2 H), 6.97 (s, 1 H), 7.31 (br. s., 1 H), 7.38 - 7.46 (m, 2 H), 7.51 (br. s., 1
 H), 7.67 - 7.77 (m, 2 H), 7.92 (s, 1 H), 7.95 (s, 1 H), 8.09 - 8.16 (m, 2 H), 8.35 (d, 1
 H). LCMS *m/z* 493.00 (M+H), Rt = 1.618 min. HPLC (Sunfire C18) Rt = 7.108 min,
 100% purity and (XBridge phenyl C18) Rt = 6.383 min., 99.3% purity.




15
 5-(2-(2-Amino-2-oxoethoxy)-4-methoxy-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

[00460] To a 25mL flask was added 4-(2-amino-2-oxoethoxy)-5-(2-(4-
 20 fluorophenyl)-3-(methyl carbamoyl)benzofuran-5-yl)-2-methoxybenzoic acid (48.8
 mg, 0.099 mmol), DMF (2 mL), *N*-ethyl-*N*-diisopropylpropan-2-amine (0.069 mL,
 0.396 mmol), 1-(pyridin-2-yl)cyclopropanamine (19.94 mg, 0.149 mmol) and finally
 HATU (2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethyl isouronium
 hexafluorophosphate(V), 151 mg, 0.396 mmol). The flask was sealed with a septa,
 25 placed under N₂ and stirred at room temperature overnight. The crude product was
 purified using a Shimadzu preparative HPLC employing acetonitrile/water/
 trifluoroacetic acid where solvent A was 10% acetonitrile / 90% water/ 0.1%
 trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1%


trifluoroacetic acid with a Waters Sunfire 5 μ m C18 19 x 150mm column at a gradient of 20-100% B and a flow rate of 25 mL/min. over 22 minutes with a 8 minute hold. The solvent was removed giving 53.0mgs (87% yield) of 5-(2-(2-amino-2-oxoethoxy)-4-methoxy-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl) phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide as a yellow powder. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 3 μ m C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/0.1% trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5 μ m 4.6 x 150mm column employing water/methanol/10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, DMF-d₇) δ ppm 1.46 - 1.53 (m, 2 H), 1.69 - 1.76 (m, 2 H), 2.96 (d, *J*=4.77 Hz, 3 H), 4.16 (s, 3 H), 4.82 (s, 2 H), 7.04 (s, 1 H), 7.34 (br. s., 1 H), 7.36 - 7.48 (m, 3 H), 7.52 (br. s., 1 H), 7.66 - 7.78 (m, 3 H), 7.92 - 8.01 (m, 2 H), 8.03 (d, *J*=2.76 Hz, 1 H), 8.08 - 8.14 (m, 2 H), 8.36 (d, *J*=4.77 Hz, 1 H), 8.57 - 8.62 (m, 1 H), 8.94 (s, 1 H). LCMS *m/z* 609.5 (M+H), *R*_t = 2.030 min. HPLC (Sunfire C18) *R*_t = 5.800 min, 99.4% purity and (XBridge phenyl C18) *R*_t = 9.546 min., 99.7% purity.

30



2-(4-Fluorophenyl)-5-(4-hydroxy-2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide


[00461] To a 250mL round-bottomed flask was added 2-(4-fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide (1.0008 g, 1.821 mmol), and DCM (18 mL). The solution was placed under an atmosphere of nitrogen and cooled to 0 °C. To the mixture was added dropwise 1M trichloroborane (9.10 mL, 9.10 mmol). The mixture was allowed to slowly warm to room temperature overnight. The reaction mixture was cooled to 0 °C and 100mL of cold methanol was added and the mixture stirred for 30minutes then evaporated to near dryness. The addition of methanol followed by evaporation was repeated to give a tan solid (82% yield). The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 3µm C18, 2 x 50mm column, with a gradient of 0-100%B (B = 95% HPLC grade acetonitrile/ 10mM Ammonium acetate/ 5% HPLC grade water), (A = 95% HPLC grade water / 10mM Ammonium acetate/ 5% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 1.26 - 1.37 (m, 2 H), 1.57 - 1.66 (m, 2 H), 2.28 (s, 3 H), 3.02 (d, *J*=4.02 Hz, 3 H), 6.77 (s, 1 H), 7.18 (t, *J*=8.78 Hz, 3 H), 7.32 (d, *J*=8.28 Hz, 1 H), 7.51 (d, *J*=8.53 Hz, 1 H), 7.69 - 7.79 (m, 1 H), 7.83 - 7.97 (m, 3 H), 8.08 (s, 1 H), 8.22 - 8.39 (m, 4 H), 8.66 (br. s., 1 H). LCMS *m/z* 536.5 (M+H), 534.4 (M - H), *R*_t = 3.446 min., 90% purity.



2-(4-Fluorophenyl)-5-(4-isopropoxy-2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide, TFA [00462]

To a microwave vial was added 2-(4-fluorophenyl)-5-(4-hydroxy-2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide (16.6 mg, 0.031 mmol), dioxane (2 mL), triphenylphosphine (32.5 mg, 0.124 mmol), (*E*)-di-*tert*-butyl diazene-1,2-dicarboxylate (21.41 mg, 0.093 mmol) and propan-2-ol (5.92 μ L, 0.077 mmol). The vial was sealed and subjected to microwave heating (140°C) for 20 minutes. The crude product was purified using a Shimadzu preparative HPLC employing acetonitrile/water/ trifluoroacetic acid where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 5 μ m C18 19 x 150mm column at a gradient of 20-100% B and a flow rate of 25 mL/min. over 20 minutes with a 5 minute hold. The solvent was removed giving 6mgs (25% yield) of 2-(4-fluorophenyl)-5-(4-isopropoxy-2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-*N*-methylbenzofuran-3-carboxamide as a colorless powder. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 3 μ m C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5 μ m 4.6 x 150mm column employing water/acetonitrile/0.1% trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10


minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5 μ m 4.6 x 150mm column employing water/methanol/ 10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 1.24 - 1.31 (m, 2 H), 1.46 (d, *J*=6.02 Hz, 6 H), 1.64 - 1.69 (m, 2 H), 2.29 (s, 3 H), 2.89 (d, *J*=4.52 Hz, 3 H), 4.83 - 4.95 (m, 1 H), 6.98 - 7.04 (m, 1 H), 7.07 (s, 1 H), 7.16 - 7.24 (m, 2 H), 7.26 (dd, *J*=8.28, 1.76 Hz, 1 H), 7.47 (d, *J*=8.03 Hz, 2 H), 7.52 - 7.59 (m, 2 H), 7.62 (d, *J*=1.26 Hz, 1 H), 7.95 (s, 1 H), 8.11 - 8.19 (m, 2 H), 8.36 - 8.43 (m, 1 H), 8.61 (s, 1 H). LCMS *m/z* 578.4 (M+H), *Rt* = 2.746 min. HPLC (Sunfire C18) *Rt* = 7.695 min, 98.38% purity and (XBridge phenyl C18) *Rt* = 12.003 min., 95.9 % purity.



Methyl 2-chloro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoate

[00463] To a 150mL sealed tube was added 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (0.5 g, 1.198 mmol), dioxane (7.18 mL), water (1.437 mL), tetrakis (triphenylphosphine)palladium(0) (0.028 g, 0.024 mmol), 4-chloro-3-(methoxycarbonyl) phenyl boronic acid (0.385 g, 1.797 mmol), and cesium carbonate (0.586 g, 1.797 mmol). The tube was sealed and heated in an oil bath overnight at 85 °C. The reaction mixture was cooled; the crude product was diluted with 100mL of ethyl acetate, washed sequentially with 50mL of water then brine. The product solution was dried over magnesium sulfate and filtered. Solvent was evaporated to give a crude yellow solid. The solid was triturated with diethyl ether (30mL x2) and hexane (30mL x1) then dried under vacuum to give 394mgs of a ivory colored solid (53% yield). The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at


220nm using the following set of conditions: PHENOMENEX® Luna 3µm C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute
 5 hold at a rate of 0.8 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 2.92 (d, *J*=4.77 Hz, 3 H), 3.91 (s, 3 H), 7.18 - 7.27 (m, 2 H), 7.52 - 7.55 (m, 1 H), 7.57 (d, *J*=8.53 Hz, 1 H), 7.63 (d, *J*=1.25 Hz, 2 H), 7.82 (dd, *J*=8.41, 2.38 Hz, 1 H), 7.96 - 8.00 (m, 1 H), 8.09 - 8.17 (m, 3 H). LCMS *m/z* 438.3 (M+H), *R*_t = 3.518 min., 90 %purity.



Methyl 2'-chloro-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)biphenyl-2-carboxylate


[00464] To a microwave vial was added dioxane (6 mL), water (0.600 mL), dicyclohexyl(2',6'-dimethoxy biphenyl-2-yl)phosphine (S-Phos, 16.42 mg, 0.040
 15 mmol), methyl 2-chloro-5-(2-(4-fluorophenyl)-3-(methyl carbamoyl)benzofuran-5-yl)benzoate (87.6 mg, 0.2 mmol), tribasic potassium phosphate (0.170 g, 0.800 mmol), palladium(II) acetate (8.98 mg, 0.040 mmol), and 2-chlorophenylboronic acid (0.094 g, 0.600 mmol). The vial was capped, degassed, flushed with N₂ and heated in the microwave for 10 minutes at 130 °C. The solvent was removed and the crude
 20 reaction mixture was taken up in 4 mL of acetonitrile and purified using a Shimadzu preparative HPLC employing acetonitrile/water/ trifluoroacetic acid where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 5µm C18 19x150mm column at a gradient of 20-100% B and a flow rate of 25 mL/min. over 20
 25 minutes with a 10 minute hold. The solvent was removed to give 43.8mgs (80%yield) of methyl 2'-chloro-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)biphenyl-2-carboxylate as a yellow solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna

3 μ m C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm
 2.92 - 2.97 (m, 3 H), 3.60 - 3.62 (m, 3 H), 7.19 - 7.26 (m, 2 H), 7.27 - 7.34 (m, 3 H),
 7.37 (d, *J*=8.03 Hz, 1 H), 7.41 - 7.45 (m, 1 H), 7.46 - 7.52 (m, 1 H), 7.62 - 7.67 (m, 1
 H), 7.68 - 7.73 (m, 1 H), 7.92 (dd, *J*=7.91, 2.13 Hz, 1 H), 8.05 (d, *J*=1.25 Hz, 1 H),
 8.12 - 8.19 (m, 2 H), 8.29 (d, *J*=2.01 Hz, 1 H). LCMS *m/z* 514.2 (M+H), *R*_t=3.908
 min., 93% purity.



2'-Chloro-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)biphenyl-2-carboxylic acid


[00465] To a 25mL round-bottomed flask was added methyl 2'-chloro-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)biphenyl-2-carboxylate (43.8
 mg, 0.079 mmol), methanol (1 mL), THF (1 mL) and 8 equivalents of a 1M solution
 of sodium hydroxide (0.63 mL, 0.63 mmol). The mixture was stirred at room
 temperature for 48 hours. The crude product was diluted with 20mL of ethyl acetate,
 made acidic with 0.5M HCl, extracted, washed with brine, dried over sodium sulfate,
 filtered and evaporated to dryness giving 47.2mgs (96% yield) of 2'-chloro-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-5-methylbiphenyl-2-carboxylic
 acid as yellow solid. The LC/MS data was obtained on a Shimadzu analytical LC /
 MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions:
 PHENOMENEX® Luna 3 μ m C18, 2 x 50mm column, with a gradient of 0-100%B
 (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade
 water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade
 acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. LCMS
m/z 500.2 (M+H), *R*_t = 3.426 min., 90% purity.



5-(2'-Chloro-2-(1-(pyridin-2-yl)cyclopropylcarbamoyl)biphenyl-4-yl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

[00466] To a 25mL flask was added 2'-chloro-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)biphenyl-2-carboxylic acid (39.6 mg, 0.079 mmol), DMF (2 mL), *N*-ethyl-*N,N*-isopropylpropan-2-amine (0.055 mL, 0.317 mmol), 1-(pyridin-2-yl) cyclopropanamine (15.94 mg, 0.119 mmol), and finally HATU (2-(3H-[1,2,3]triazolo [4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate (V), (120 mg, 0.317 mmol). The flask was sealed and the mixture stirred over night at room temperature. The crude product was purified using a Shimadzu preparative HPLC employing acetonitrile/water/ trifluoroacetic acid where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 5µm C18 19 x 150mm column at a gradient of 20-100% B and a flow rate of 25 mL/min. over 20 minutes with a 10 minute hold. Solvent was removed giving 40.7mgs (70% yield) of 5-(2'-chloro-2-(1-(pyridin-2-yl)cyclopropylcarbamoyl)biphenyl-4-yl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide as a white solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 3µm C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1% trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A =


95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile),
 in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was
 then confirmed with an orthogonal solvent system and column using a Shimadzu
 analytical LC with a Waters XBridge phenyl C18 3.5µm 4.6 x 150mm column
 5 employing water/methanol/10mM ammonium bicarbonate with a gradient of 10-
 100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC
 grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5%
 HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1
 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 0.90 - 1.10 (m, 2 H), 1.42 - 1.53 (m,
 10 2 H), 2.94 (d, *J*=4.52 Hz, 3 H), 7.11 (dd, *J*=6.90, 5.40 Hz, 1 H), 7.18 - 7.27 (m, 2 H),
 7.30 - 7.43 (m, 5 H), 7.44 - 7.49 (m, 1 H), 7.52 - 7.58 (m, 1 H), 7.59 - 7.67 (m, 2 H),
 7.73 (dd, *J*=8.53, 1.76 Hz, 1 H), 7.81 (dd, *J*=7.78, 2.01 Hz, 1 H), 7.95 - 8.01 (m, 2 H),
 8.06 (d, *J*=1.51 Hz, 1 H), 8.09 - 8.17 (m, 2 H), 8.41 (d, *J*=4.02 Hz, 1 H). LCMS *m/z*
 617.3 (M+H), *R*_t = 2.765 min. HPLC (Sunfire C18) *R*_t = 7.823 min, 100% purity and
 15 (XBridge phenyl C18) *R*_t = 11.871 min., 99.8% purity.



Methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-hydroxy-4-
 methylbenzoate

20 **[00467]** To a 100mL round-bottomed flask was added methyl 5-(2-(4-
 fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxy-4-methylbenzoate
 (350.5 mg, 0.783 mmol) in DCM (8 mL). To this solution was then added, under
 nitrogen, a 1M solution of boron trichloride (3.92 mL, 3.92 mmol) and the mixture
 was stirred overnight at room temperature. The reaction mixture was cooled in an ice
 25 bath and 10mL of methanol was slowly added. The solvent was removed under
 vacuum. The flask was again cooled, 25mL of ice cold methanol was added and the
 resulting solid was filtered to give 264.5mgs (78% yield) of methyl 5-(2-(4-
 fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-hydroxy-4-methylbenzoate as
 an ivory colored solid. The LC/MS data was obtained on a Shimadzu analytical LC /
 30 MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions:

PHENOMENEX® Luna 3µm C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid / 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid / 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. ¹H NMR (400 MHz, DMF-d₇) δ ppm 2.30 (s, 3 H), 2.95 (d, *J*=4.77 Hz, 3 H), 3.98 (s, 3 H), 7.02 (s, 1 H), 7.38 - 7.48 (m, 3 H), 7.68 - 7.73 (m, 2 H), 7.76 (d, *J*=8.53 Hz, 1 H), 8.08 - 8.15 (m, 2 H), 8.33 (br. s., 1 H). LCMS Rt = 3.636, *m/z* 434.3 (M+H), 100% purity.




10 Methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methyl-2-(trifluoromethylsulfonyloxy)benzoate

[00468] To a 25mL round-bottomed flask was added methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-hydroxy-4-methylbenzoate (260 mg, 0.600 mmol), DCM (6 mL), triethylamine (0.166 mL, 1.200 mmol) and 1,1,1-trifluoro-*N*-phenyl-*N*-(trifluoromethylsulfonyl)methanesulfonamide (321 mg, 0.900 mmol). The solution was stirred overnight at room temperature. To the reaction mixture was then added DMF (6mL) along with triethylamine (0.166 mL, 1.200 mmol) and 1,1,1-trifluoro-*N*-phenyl-*N*-(trifluoromethylsulfonyl)methanesulfonamide (321 mg, 0.900 mmol). The mixture was heated to 65 °C for forty eight hours. The crude product mixture was returned to room temperature, diluted with 100mL of DCM, washed sequentially with 50mL of cold 0.1M HCl, water and brine. The solvent was evaporated and the resulting crude product was triturated with 10mL of diethyl ether (x2) to give 180.7mgs (44.7% yield) of an ivory colored solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 3µm C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute

hold at a rate of 0.8 mL/minute. ^1H NMR (500 MHz, DMSO- d_6) δ ppm 2.37 (s, 3 H), 2.82 (d, $J=4.58$ Hz, 3 H), 3.88 (s, 3 H), 7.36 - 7.47 (m, 3 H), 7.56 - 7.65 (m, 2 H), 7.78 (d, $J=8.54$ Hz, 1 H), 7.91 (s, 1 H), 7.95 - 8.05 (m, 2 H), 8.47 (d, 1 H). LCMS m/z 566.3 (M+H), R_t = 3.913 min., 90% purity.

5




Methyl 2'-chloro-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-5-methylbiphenyl-2-carboxylate

[00469] To a small sealed tube was added methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methyl-2-(trifluoromethylsulfonyloxy)benzoate (67.3 mg, 0.1 mmol), dioxane (3 mL), water (0.600 mL), 2-chlorophenylboronic acid (18.76 mg, 0.120 mmol), cesium carbonate (32.6 mg, 0.100 mmol) and tetrakis(triphenylphosphine)palladium(0) (2.311 mg, 2.000 μ mol). The tube was sealed and heated overnight at 80 $^{\circ}$ C. The reaction was cooled to room temperature, filtered through a plug of CELITE $^{\circledR}$ and concentrated to near dryness under a stream of nitrogen. The crude reaction mixture was taken up in 6 mL of acetonitrile and purified using a Shimadzu preparative HPLC employing acetonitrile/water/ trifluoroacetic acid where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 3.5 μ m C18 19 x 150mm column at a gradient of 30-100% B and a flow rate of 25 mL/min. over 20 minutes with a 10 minute hold. The solvent was removed giving 48mgs (89% yield) of methyl 2'-chloro-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-5-methylbiphenyl-2-carboxylate as a white solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS $^{\circledR}$ Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX $^{\circledR}$ Luna 3 μ m C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid / 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid / 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of


0.8 mL/minute. ¹H NMR (500 MHz, THF-d₈) δ ppm 2.35 (s, 3 H), 2.91 (d, *J*=4.58 Hz, 3 H), 3.57 (s, 3 H), 7.21 - 7.26 (m, 3 H), 7.27 - 7.30 (m, 1 H), 7.30 - 7.34 (m, 2 H), 7.38 (dd, *J*=8.39, 1.68 Hz, 1 H), 7.41 - 7.44 (m, 1 H), 7.50 (d, *J*=4.27 Hz, 1 H), 7.63 (d, *J*=8.24 Hz, 1 H), 7.75 (d, *J*=1.53 Hz, 1 H), 7.92 (s, 1 H), 8.13 - 8.19 (m, 2 H).

5 LCMS *m/z* 528.4 (M+H), *Rt* = 4.036 min., 98.3% purity.



2'-Chloro-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-5-methylbiphenyl-2-carboxylic acid


10 **[00470]** To a 25mL round-bottomed flask was added methyl 2'-chloro-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-5-methylbiphenyl-2-carboxylate (48 mg, 0.091 mmol), THF (2.2 mL), methanol (2.2 mL), and aqueous 1M sodium hydroxide (0.728 mL, 0.728 mmol). The flask was sealed and stirred at room temperature for 48 hours. Volatiles were removed and the crude product was diluted with 30mL of ethyl acetate, washed sequentially with 10mL of 1M HCl, brine, dried over sodium sulfate, filtered and evaporated to dryness. The resulting product was trituated with 10mL of diethyl ether giving 47.2mgs (96% yield) of 2'-chloro-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-5-methylbiphenyl-2-carboxylic acid as a yellow solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 3μm C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. ¹H NMR (400 MHz, DMF-d₇) δ ppm 2.42 (s, 3 H), 2.97 (d, *J*=4.52 Hz, 3 H), 7.30 (s, 1 H), 7.39 - 7.48 (m, 5 H), 7.50 - 7.57 (m, 2 H), 7.78 - 7.85 (m, 2 H), 7.99 (s, 1 H), 8.10 - 8.17 (m, 2 H), 8.35 - 8.43 (m, 1 H). LCMS *m/z* 514.3 (M+H), *Rt* = 3.950 min., 95.4% purity.



5-(2'-Chloro-5-methyl-2-(1-(pyridin-2-yl)cyclopropylcarbamoyl)biphenyl-4-yl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide, TFA


[00471] To a 25mL flask was added 2'-chloro-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-5-methylbiphenyl-2-carboxylic acid (47.2 mg, 0.087 mmol), DMF (2 mL), *N*-ethyl-*N,N*-diisopropyl propan-2-amine (0.061 mL, 0.349 mmol), 1-(pyridin-2-yl)cyclopropanamine (17.56 mg, 0.131 mmol) and finally HATU (2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V), 133 mg, 0.349 mmol). The flask was sealed with a septa, placed under N₂ and stirred at room temperature for 5 hours. The crude product was purified using a Shimadzu preparative HPLC employing acetonitrile/water/trifluoroacetic acid where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 5μm C18 19 x 150mm column at a gradient of 30-100% B and a flow rate of 25 mL/min. over 20 minutes with a 10 minute hold. The solvent was evaporated to give 66.1mgs (92% yield) of 5-(2'-chloro-5-methyl-2-(1-(pyridin-2-yl)cyclopropyl carbamoyl)biphenyl-4-yl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide as a white solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 3μm C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5μm 4.6 x 150mm column employing water/acetonitrile/ trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95%

HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5µm 4.6 x 150mm column employing
 5 water/methanol/10mM ammonium bicarbonate with a gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 0.85 - 0.96 (m, 1 H), 0.99 - 1.09 (m, 1 H), 1.38 - 1.53 (m, 2 H), 2.33 (s, 3 H), 2.90 (d, *J*=4.52 Hz, 3 H), 7.07 - 7.14 (m, 1 H), 7.20 - 7.28 (m, 3 H), 7.30 - 7.36 (m, 3 H), 7.37 - 7.42 (m, 2 H), 7.44 - 7.49 (m, 1 H), 7.56 (d, *J*=4.52 Hz, 1 H), 7.58 - 7.65 (m, 3 H), 7.77 (d, *J*=1.51 Hz, 1 H), 7.89 (s, 1 H), 8.10 - 8.18 (m, 2 H), 8.37 - 8.42 (m, 1 H). LCMS *m/z* 631.39 (M+H), *R*_t = 2.925 min. HPLC (Sunfire C18) *R*_t = 8.118 min, 99.9% purity and (XBridge phenyl C18) *R*_t =
 15 11.519min., 100% purity.



2-Chloro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid
[00472] Alternative Procedure: To a 150mL sealed tube was added 2-(4-
 20 fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (1.0 g, 2.4 mmol), dioxane (14.4 mL), water (2.9 mL), tetrakis(triphenyl phosphine)palladium(0) (0.055 g, 0.048 mmol), 5-borono-2-chlorobenzoic acid (0.720 g, 3.59 mmol), and cesium carbonate (1.171 g, 3.59 mmol). The tube was sealed and heated in an oil bath overnight at 85 °C. The reaction mixture was cooled,
 25 diluted with 150mL of ethyl acetate, washed sequentially with 20mL of 0.5M HCl then brine. The product solution was filtered through a plug of CELITE® then evaporated to dryness. The resulting solid was taken up in 10mL of 1:1 DMF and acetonitrile and purified using a Shimadzu preparative HPLC employing acetonitrile/water/ trifluoroacetic acid where solvent A was 10% acetonitrile / 90%
 30 water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/


0.1% trifluoroacetic acid with a Waters Sunfire 3.5 μ m C18 4.6x150mm column at a gradient of 50-100% B and a flow rate of 40 mL/min. over 20 minutes with a 5 minute hold. Solvent was evaporated giving 319.5mgs (32 %yield) of 2-chloro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid as a white powder. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 10 μ m C18, 3.0 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade methanol/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade methanol), in 4 minutes with a 1 minute hold at a rate of 5 mL/minute. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.83 - 2.91 (m, 3 H), 7.35 - 7.45 (m, 2 H), 7.65 (d, *J*=8.53 Hz, 1 H), 7.69 - 7.75 (m, 1 H), 7.76 - 7.82 (m, 1 H), 7.85 - 7.93 (m, 2 H), 7.98 - 8.05 (m, 2 H), 8.08 (d, *J*=2.26 Hz, 1 H), 8.43 - 8.53 (m, 1 H), 13.50 (br. s., 1 H). LCMS *m/z* 424.0 (M+H), *Rt* = 3.105min., 100% purity.



5-(4-Chloro-3-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-methylbenzofuran-3-carboxamide

[00473] To a 250mL round-bottomed flask was added 2-chloro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (0.299 g, 0.705 mmol), 1-(pyridin-2-yl)cyclopropanamine (0.142 g, 1.058 mmol), DMF (8.50 mL), *N*-ethyl-*N,N*-diisopropylpropan-2-amine (0.493 mL, 2.82 mmol), and HATU (2-(3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V), 1.073 g, 2.82 mmol). The flask was sealed, placed under N₂ and stirred overnight at room temperature. The reaction mixture was diluted with 50mL of ethyl acetate, washed with 5mL of 1M HCl, extracted, dried over magnesium sulfate, filtered and evaporated to a red oil. The crude reaction mixture was then evacuated to near dryness, taken up in 8 mL of 1: 1 methanol and DMF and

purified using a Shimadzu preparative HPLC employing methanol/water/
trifluoroacetic acid where solvent A was 10% methanol / 90% water / 0.1%
trifluoroacetic acid and solvent B was 10% water / 90% methanol / 0.1%
trifluoroacetic acid with a PHENOMENEX® Luna 10µm C18 30x100mm column at
5 a gradient of 50-100% B and a flow rate of 40 mL/min. over 8 minutes with a 7
minute hold. Solvent was evaporated giving 261.3 mgs (66.4% yield) of 5-(4-chloro-
3-(1-(pyridin-2-yl)cyclopropyl carbamoyl)phenyl)-2-(4-fluorophenyl)-*N*-
methylbenzofuran-3-carboxamide as a light yellow solid. The LC/MS data was
obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at
10 220nm using the following set of conditions: Waters Sunfire 5µm C18, 4.6 x 50mm
column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1%
trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1%
trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 3 minutes with a 1 minute
hold at a rate of 4 mL/minute. HPLC purity was determined using a Shimadzu
15 analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm
column employing water/acetonitrile/0.1% trifluoroacetic acid with a gradient of 20-
100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC
grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC
grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The
20 HPLC purity was then confirmed with an orthogonal solvent system and column
using a Shimadzu analytical LC with a PHENOMENEX® Gemini C18 3.0µm 4.6 x
150mm column employing water/methanol/ 10mM ammonium bicarbonate with a
gradient of 20-100% B (B = 95% HPLC grade methanol/ 10mM ammonium
bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM
25 ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute
hold at a rate of 1 mL/minute. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.33 - 1.40 (m,
2 H), 1.56 - 1.64 (m, 2 H), 2.83 - 2.91 (m, 3 H), 7.27 (dd, *J*=6.78, 5.27 Hz, 1 H), 7.35
- 7.45 (m, 2 H), 7.63 (d, *J*=8.28 Hz, 1 H), 7.69 - 7.96 (m, 7 H), 7.97 - 8.06 (m, 2 H),
8.50 (d, *J*=4.52 Hz, 2 H), 9.34 (s, 1 H). LCMS *m/z* 540.39 (M+H), *R*_t = 1.643min.,
30 94.2% purity. HPLC (Sunfire C18) *R*_t = 6.388min, 94% purity and (Gemini C18) *R*_t
= 11.238min., 99.6% purity.




Methyl 2'-carbamoyl-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)biphenyl-2-carboxylate

- [00474] To a microwave vial was added dioxane (9 mL), water (0.900 mL), 2-carbamoylphenylboronic acid (148 mg, 0.900 mmol), methyl 2-chloro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoate (131 mg, 0.3 mmol), tribasic potassium phosphate (255 mg, 1.200 mmol), dicyclohexyl (2',6'-dimethoxybiphenyl-2-yl)phosphine (S-Phos, 24.63 mg, 0.060 mmol), and palladium(II) acetate (13.47 mg, 0.060 mmol). The vial was capped, degassed, flushed with N₂ and heated in the microwave for 13 minutes at 130 °C. The reaction mixture was filtered and solvent removed under a stream of nitrogen. The crude product was then taken up in 4 mL of acetonitrile and purified using a Shimadzu preparative HPLC employing acetonitrile/water/ trifluoroacetic acid where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 5µm C18 19x150mm column at a gradient of 20-100% B and a flow rate of 25 mL/min. over 20 minutes with a 10 minute hold. The solvent was removed giving 58.3mgs (36% yield) of methyl 2'-carbamoyl-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)biphenyl-2-carboxylate as a yellow solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 3µm C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. ¹H NMR (400 MHz, THF-d₈) δ ppm 2.93 (d, *J*=4.52 Hz, 3 H), 3.62 (s, 3 H), 6.35 (br. s., 2 H), 7.09 - 7.15 (m, 1 H), 7.22 (t, *J*=8.91 Hz, 2 H), 7.31 - 7.43 (m, 3 H), 7.52 (d, *J*=4.27 Hz, 1 H), 7.58 - 7.71 (m, 3 H),


7.81 (dd, $J=8.03, 2.01$ Hz, 1 H), 8.01 (d, $J=1.25$ Hz, 1 H), 8.09 - 8.20 (m, 3 H).

LCMS m/z 523.3 (M+H), R_t = 3.051 min., 96% purity.



5 2'-Carbamoyl-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)biphenyl-
2-carboxylic acid

[00475] To a 25mL round-bottomed flask was added methyl 2'-carbamoyl-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)biphenyl-2-carboxylate (58.3 mg, 0.107 mmol), methanol (1 mL), THF (1 mL) and 8 equivalents of a 1M solution
10 of sodium hydroxide (0.856 mL, 0.856 mmol). The mixture was diluted with 20mL of ethyl acetate, made acidic with 0.5M HCl and the crude product was extracted, washed with brine, and dried over sodium sulfate. The product solution was filtered and evaporated to dryness giving 52mgs (98% yield) of 2'-carbamoyl-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)biphenyl-2-carboxylic acid as a
15 yellow solid. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 3 μ m C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade
20 acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. LCMS m/z 509.3 (M+H), R_t = 2.695 min., 90% purity.



4-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-N2-(1-(pyridin-2-yl)cyclopropyl) biphenyl-2,2'-dicarboxamide, TFA

[00476] To a 25mL round-bottomed flask was added 2'-carbamoyl-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)biphenyl-2-carboxylic acid (52mg, 0.104 mmol), DMF (2 mL), *N*-ethyl-*N,N*-isopropylpropan-2-amine (0.075 mL, 0.429 mmol), 1-(pyridin-2-yl)cyclopropanamine (21.57 mg, 0.161 mmol) and finally HATU (2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluoro phosphate (V), 163 mg, 0.429 mmol). The flask was sealed and the mixture stirred at room temperature over night. The crude product was purified using a Shimadzu preparative HPLC employing acetonitrile/water/trifluoroacetic acid where solvent A was 10% acetonitrile / 90% water/ 0.1% trifluoroacetic acid and solvent B was 10% water / 90% acetonitrile/ 0.1% trifluoroacetic acid with a Waters Sunfire 5µm C18 19 x 150mm column at a gradient of 20-100% B and a flow rate of 25 mL/min. over 20 minutes with a 10 minute hold. The solvent was evaporated giving 2 rotomers as shown above. The LC/MS data was obtained on a Shimadzu analytical LC / MICROMASS® Platform LC (ESI+) at 220nm using the following set of conditions: PHENOMENEX® Luna 3µm C18, 2 x 50mm column, with a gradient of 0-100%B (B = 90% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 10% HPLC grade water), (A = 90% HPLC grade water / 0.1% trifluoroacetic acid/ 10% HPLC grade acetonitrile), in 4 minutes with a 1 minute hold at a rate of 0.8 mL/minute. HPLC purity was determined using a Shimadzu analytical LC at 254nm and 256nm with a Waters Sunfire C18 3.5µm 4.6 x 150mm column employing water/acetonitrile/0.1% trifluoroacetic acid with a gradient of 10-100% B (B = 95% HPLC grade acetonitrile/ 0.1% trifluoroacetic acid/ 5% HPLC grade water), (A = 95% HPLC grade water / 0.1% trifluoroacetic acid/ 5% HPLC

grade acetonitrile), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute. The HPLC purity was then confirmed with an orthogonal solvent system and column using a Shimadzu analytical LC with a Waters XBridge phenyl C18 3.5 μ m 4.6 x 150mm column employing water/methanol/10mM ammonium bicarbonate with a
5 gradient of 10-100% B (B = 95% HPLC grade methanol/ 10mM ammonium bicarbonate / 5% HPLC grade water), (A = 95% HPLC grade water / 10mM ammonium bicarbonate / 5% HPLC grade methanol), in 10 minutes with a 10 minute hold at a rate of 1 mL/minute.

[00477] Isomer A: ^1H NMR (400 MHz, THF- d_8) δ ppm 0.53 - 0.79 (m, 2 H), 1.36
10 (d, $J=4.27$ Hz, 2 H), 2.95 (d, $J=4.52$ Hz, 3 H), 6.79 (br. s., 1 H), 6.88 - 7.00 (m, 2 H), 7.16 - 7.26 (m, 4 H), 7.39 (td, $J=7.72$, 1.88 Hz, 1 H), 7.46 - 7.53 (m, 3 H), 7.57 - 7.61 (m, 1 H), 7.61 - 7.65 (m, 2 H), 7.69 (ddd, $J=10.23$, 8.22, 1.88 Hz, 2 H), 7.91 (d, $J=2.01$ Hz, 1 H), 8.04 (d, $J=1.51$ Hz, 1 H), 8.13 - 8.19 (m, 2 H), 8.25 - 8.31 (m, 1 H), 9.01 (s, 1 H). LCMS m/z 625.4 (M+H), R_t = 2.310 min. HPLC (Sunfire C18) R_t =
15 6.796 min, 100% purity and (XBridge phenyl C18) R_t = 10.793 min., 100% purity.

[00478] Isomer B: ^1H NMR (400 MHz, THF- d_8) δ ppm 0.64 - 0.92 (m, 2 H), 1.39
(d, $J=4.02$ Hz, 2 H), 2.93 (d, $J=4.77$ Hz, 3 H), 6.76 (br. s., 1 H), 6.88 (dd, $J=6.90$,
5.14 Hz, 1 H), 6.96 (d, $J=8.03$ Hz, 1 H), 7.11 - 7.18 (m, 1 H), 7.20 - 7.30 (m, 3 H),
7.31 - 7.43 (m, 3 H), 7.50 (br. s., 1 H), 7.59 (dd, $J=7.15$, 1.88 Hz, 1 H), 7.62 - 7.67
20 (m, 1 H), 7.68 - 7.76 (m, 2 H), 7.82 (dd, $J=7.78$, 2.01 Hz, 1 H), 7.92 (d, $J=1.76$ Hz, 1 H), 8.07 (d, $J=1.76$ Hz, 1 H), 8.09 - 8.17 (m, 2 H), 8.26 (d, $J=4.27$ Hz, 1 H), 8.98 (s, 1 H). LCMS m/z 625.4 (M+H), R_t = 2.275 min. HPLC (Sunfire C18) R_t = 6.688 min,
100% purity and (XBridge phenyl C18) R_t = 10.821 min., 100% purity.

25 Ethyl 4-fluoro-2-(4-fluorophenyl)-5-hydroxybenzofuran-3-carboxylate

[00479] To a mixture of ethyl 2-(4-fluorophenyl)-5-hydroxybenzofuran-3-
carboxylate (500 mg, 1.665 mmol) in acetonitrile (10 mL) at r.t. under N_2 was added
1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane tetrafluoroborate (708
mg, 1.998 mmol). The mixture was stirred at r.t. (the mixture turned bright yellow in
30 color) for 20 hours. The mixture was evaporated. The residue was added with 10 ml
 H_2O . The aqueous decanted, and the residue further washed with 2 x 5 ml H_2O . The
mixture was dissolved in MeOH (about 10 ml), and the insoluble filtered. The filtrate

was purified by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 60, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5,

5 Fraction Collection: 6.44 - 7.24 min. (UV detection at 220 nm). The desired fractions were combined and evaporated to give a yellow solid. The yellow solid was further purified by BIOTAGE® Horizon flash chromatography (0 to 70% EtOAc/Hexane, 3 x 80 g silica gel column) to give a light yellow solid (108.9 mg). ¹H NMR (500 MHz, CD₃OD) δ 7.95 (m, 2H), 7.26 (t overlapping with dd, 2H), 7.25 (dd, 1H), 7.03 (t, *J* =

10 8.39, 1H), 4.39 (q, *J* = 7.17, 2H), 1.36 (t, *J* = 7.17, 3H). ¹⁹F NMR (470.45 MHz, CD₃OD) δ 112.36, 142.29. The position of the F atom at C4 was confirmed by ¹H-¹H through bond correlation between H6 and H7, ¹H-¹³C HMBC and F-C4 coupling in ¹³C NMR (125.75 MHz, CD₃OD) (δ 144.8 ppm, d, *J* = 247, C4). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and

15 Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) *m/z* (M+H)⁺ = 319.14, HPLC *R*_t = 1.718 min. The minor fractions collected at about 7.69 - 8.20 min. was confirmed by

20 ¹H-¹H through bond correlation, ¹H-¹³C HMBC and F-C6 coupling in ¹³C NMR (125.75 MHz, CD₃OD) (δ 152.5 ppm, d, *J* = 242 Hz, C6) to be the isomer of the F-atom at C6 (C4 : C6 about 3:1 based on preparative HPLC %area of the UV trace); ¹H NMR (500 MHz, CD₃OD) δ 8.04 (dd, *J* = 8.55, 5.49, 2H), 7.59 (d, *J* = 8.85, 1H), 7.38 (d, *J* = 10.07, 1H), 7.25 (t, *J* = 8.70, 2H), 4.40 (q, *J* = 7.17, 2H), 1.41 (t, *J* = 7.17, 3H).

25 ¹⁹F NMR (470.45 MHz, CD₃OD) δ 112.29, 138.52. LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50

30 mm, S10; (ES+) *m/z* (M+H)⁺ = 319.14, HPLC *R*_t = 1.798 min.

4-Fluoro-2-(4-fluorophenyl)-5-hydroxybenzofuran-3-carboxylic acid

[00480] To a mixture of ethyl 4-fluoro-2-(4-fluorophenyl)-5-hydroxybenzofuran-3-carboxylate (108.9 mg, 0.342 mmol) in a mixture of MeOH (2 mL)/THF (2 mL) at r.t. under N₂ was added sodium hydroxide (1.0 mL, 1.0 mmol) (1 M aq.). The mixture was stirred at 100 °C for 1.5 hours. The mixture was cooled to r.t., added with 1.5 ml 1N HCl, and then added 10 ml H₂O. The white precipitates were filtered and washed with 3 x 2 ml H₂O and dried (73 mg). ¹H NMR (500 MHz, CD₃OD) δ 7.98 (m, 2H), 7.25 (t overlapping with dd, 2H), 7.24 (dd, 1H), 7.02 (t, *J* = 8.39, 1H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) *m/z* (M+H)⁺ = 291.01, HPLC R_t = 1.478 min.


4-Fluoro-2-(4-fluorophenyl)-5-hydroxy-N-methylbenzofuran-3-carboxamide
[00481] To a mixture of 4-fluoro-2-(4-fluorophenyl)-5-hydroxybenzofuran-3-carboxylic acid (73 mg, 0.252 mmol), methylamine, HCl (25.5 mg, 0.377 mmol), HOBT hydrate (65.5 mg, 0.428 mmol) and EDC hydrochloride (87 mg, 0.453 mmol) at r.t. under N₂ was added N,N-diisopropylethylamine (0.220 mL, 1.258 mmol). The mixture was stirred at r.t. for 16 hours. After concentration, the mixture was added with 5 ml 1N HCl, and then 14 ml H₂O. The white solid was filtered and washed with 3 x 5 ml H₂O and dried (64 mg). ¹H NMR (500 MHz, CD₃OD) δ 7.89 (dd, *J* = 8.09, 5.34, 2H), 7.25 (t overlapping with dd, 2H), 7.23 (dd, 1H), 6.99 (t, *J* = 8.55, 1H), 2.96 (s, 3H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) *m/z* (M+H)⁺ = 304.06, HPLC R_t = 1.262 min.

30

4-Fluoro-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl
trifluoromethanesulfonate

[00482] To a white suspension of 4-fluoro-2-(4-fluorophenyl)-5-hydroxy-N-methylbenzofuran-3-carboxamide (64 mg, 0.211 mmol) in CH₂Cl₂ (2 mL) at r.t. under N₂ was added triethylamine (0.059 mL, 0.422 mmol). The mixture was cooled to 0 °C, and then added 1,1,1-trifluoro-N-phenyl-N-

- 5 (trifluoromethylsulfonyl)methanesulfonamide (113 mg, 0.317 mmol). The mixture was then stirred at r.t. (the white suspension turned into a light yellow solution after stirring for about 10 min) for 2 hours 35 min. The mixture was left standing at r.t. overnight, and then evaporated. The residue was cooled in an ice-water bath, added with 2 ml H₂O. The solids were filtered and washed with 3 x 2 ml H₂O, and dried (94
10 mg). ¹H NMR (500 MHz, CD₃OD) δ 7.95 (m, 2H), 7.59 (dd, *J* = 9.00, 1.00, 1H), 7.50 (dd, *J* = 9.00, 7.50, 1H), 7.30 (t, *J* = 8.55, 2H), 2.99 (s, 3H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100,
15 Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) *m/z* (M+H)⁺ = 436.04, HPLC *R*_t = 1.678 min.



- 20 Methyl 5-(4-fluoro-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxy-4-methylbenzoate


- [00483]** A mixture of the above prepared 4-fluoro-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (assumed 0.211 mmol), methyl 2-methoxy-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
25 (0.078 g, 0.253 mmol), (Ph₃P)₄Pd (0.024 g, 0.021 mmol) and cesium carbonate (0.103 g, 0.317 mmol) in a mixture of H₂O (0.2 mL)/1,4-dioxane (1 mL) was stirred at 95 °C for 2 hours 30 min. The mixture was left standing at r.t. overnight. The mixture was diluted with 3.5 ml 1,4-dioxane, filtered through a Whatman PVDF 0.45 um disk (with 3 x 1 ml washing). The filtrate was concentrated. The mixture was added with

3.5 ml 1N HCl, and then 6 ml H₂O (yellow solid deposited on the wall of the flask).

The aqueous was decanted, and the residue washed with 3 x 2 ml H₂O and dried.

LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90%


- 5 H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 466.27, HPLC R_t = 1.708 min.



10

5-(4-Fluoro-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxy-4-methylbenzoic acid

- [00484]** To the above prepared methyl 5-(4-fluoro-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxy-4-methylbenzoate (assumed 0.211 mmol) in a mixture MeOH (2 mL)/THF (2 mL) at r.t. under N₂ was added sodium hydroxide (0.84 mL, 0.84 mmol). The mixture was stirred at r.t. for 24 hours. The mixture was added with 2 ml 1N HCl, and concentrated until off white solids formed. The mixture was added with 5 ml H₂O, the solids filtered and washed with 3 x 2 ml H₂O and dried (75.1 mg). ¹H NMR (500 MHz, CD₃OD) δ 7.95 (m, 2H), 7.73 (s, 1H), 7.51 (d, *J* = 8.24, 1H), 7.30-7.25 (t overlapping with m, 3H), 7.13 (s, 1H), 3.99 (s, 3H), 2.96 (s, 3H), 2.28 (s, 3H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 452.23, HPLC R_t = 1.582.
- 15
- 20
- 25




4-Fluoro-2-(4-fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide

[00485] To a mixture of 5-(4-fluoro-2-(4-fluorophenyl)-3-

- 5 (methylcarbamoyl)benzofuran-5-yl)-2-methoxy-4-methylbenzoic acid (30 mg, 0.066 mmol), 1-(pyrimidin-2-yl)cyclopropanamine, TFA (33.1 mg, about 75% pure, assumed 0.133 mmol,) and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethylisouronium tetrafluoroborate (64.0 mg, 0.199 mmol) in DMF (1 mL) at r.t. under N₂ was added N,N-diisopropylethyl amine (0.058 mL, 0.332 mmol). The
- 10 mixture was stirred at r.t. for 20 hours. The mixture was diluted with MeOH and purified by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5,
- 15 UV detection at 220 nm, Fraction Collection: 7.25-7.73 min. The residue after evaporation of the combined fractions was further purified by preparative TLC (two of 500 um x 20 x 20 cm plates, 5% MeOH/CH₂Cl₂) to give 4-fluoro-2-(4-fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide as a white
- 20 solid. Analytical TLC R_f = 0.32 (5% MeOH/CH₂Cl₂). ¹H NMR (500 MHz, CD₃OD) δ 8.65 (d, *J* = 4.88, 2H), 7.95 (m, 2H), 7.89 (s, 1H), 7.50 (d, *J* = 8.55, 1H), 7.28 (t, *J* = 8.70, 2H), 7.28-7.25 (m overlapping with t, 1H), 7.23 (t, *J* = 4.88, 1H), 7.17 (s, 1H), 4.09 (s, 3H), 2.95 (s, 3H), 2.30 (s, 3H), 1.79 (m, 2H), 1.51 (m, 2H). ¹⁹F NMR (470.45 MHz, CD₃OD) δ 112.81, 123.16. LC/MS were performed by using Shimadzu-VP
- 25 instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES⁺) *m/z* (M+H)⁺ = 569.38, HPLC R_t = 1.660 min. Analytical HPLC were


performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 6.29 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 5.18 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5%H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 9.39 min.



4-Fluoro-2-(4-fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(pyrimidin-2-yl)propylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide

[00486] 4-Fluoro-2-(4-fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(pyrimidin-2-yl)propylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide was formed as a minor side product during the synthesis of 4-fluoro-2-(4-fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide as described above, and was isolated during purification by preparative reverse phase HPLC (Fraction Collection: 7.82 - 8.48 min). ¹H NMR (500 MHz, DMSO-d₆) δ 9.08 (d, *J* = 7.32, 1H), 8.87 (d, *J* = 4.88, 2H), 8.70 (q, *J* = 4.58, 1H), 7.94 (m, 2H), 7.78 (s, 1H), 7.62 (d, *J* = 8.24, 1H), 7.46 (t, *J* = 4.88, 1H), 7.42 (t, *J* = 9.00, 2H), 7.30 (dd, *J* = 8.39, 7.17, 1H), 7.24 (s, 1H), 5.16 (m, 1H), 4.08 (s, 3H), 2.80 (d, *J* = 4.58, 3H), 2.24 (s, 3H), 1.97 (m, 2H), 0.82 (t, *J* = 7.32, 3H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) *m/z* (M+H)⁺ = 571.35, HPLC R_t = 1.743 min. Analytical HPLC were performed by using Shimadzu-VP instrument with

UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5%H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μ m, 4.6 x 150 mm, R_t = 7.33 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 5.69 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5%H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 10.23 min.



5-(5-(Ethylcarbamoyl)-4-methoxy-2-methylphenyl)-4-fluoro-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00487] 5-(5-(Ethylcarbamoyl)-4-methoxy-2-methylphenyl)-4-fluoro-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide was formed as a minor side product during the synthesis of 4-fluoro-2-(4-fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide as described above, and was isolated during purification by preparative TLC (the band right above the major product band). ¹H NMR (500 MHz, CD₃OD) δ 7.95 (m, 2H), 7.81 (s, 1H), 7.51 (d, *J* = 8.55, 1H), 7.30-7.25 (t overlapping with dd, 3H), (7.13 (s, 1H), 4.04 (s, 3H), 3.46 (q, *J* = 7.17, 2H), 2.95 (s, 3H), 2.28 (s, 3H), 1.25 (t, *J* = 7.17, 3H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES⁺) *m/z* (M+H)⁺ = 479.30, HPLC R_t = 1.670 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95%

MeCN-5% H_2O -0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm , 4.6 x 150 mm, R_t = 6.94 min; Column: XBridge phenyl 3.5 μm , 4.6 x 150 mm, R_t = 5.31 min.


Analytical HPLC method: Solvent A = 5% MeOH-95% H_2O -10 mM NH_4HCO_3 ,

- 5 Solvent B = 95% MeOH-5% H_2O -10 mM NH_4HCO_3 , Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μm , 4.6 x 150 mm, R_t = 9.20 min.

Methyl 2,4-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate


- 10 **[00488]** A mixture of methyl 5-iodo-2,4-dimethylbenzoate (1 g, 3.45 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.050 g, 4.14 mmol), potassium acetate (1.015 g, 10.34 mmol) and $\text{PdCl}_2(\text{dppf})(\text{Cl}_2\text{CH}_2)$ ([1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), dichloromethane) (0.284 g, 0.345 mmol) in DMF (25 mL) under N_2 was stirred at 100 $^\circ\text{C}$ for 20 hours. The
- 15 mixture was cooled to r.t., added with 30 ml H_2O . The dark solid was filtered and washed with 3 x 5 ml H_2O and dried. The solid was purified by BIOTAGE® Horizon flash chromatography (0 to 70% EtOAc/Hexane) to give the product as a white solid (442.7 mg). ^1H NMR (500 MHz, CD_3OD) δ 8.26 (s, 1H), 7.11 (s, 1H), 3.88 (s, 3H), 2.56 (s, 3H), 2.53 (s, 3H), 1.37 (s, 12H). LC/MS were performed by using Shimadzu-
- 20 VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H_2O -0.1% TFA, Solvent B = 90% MeOH-10% H_2O -0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z ($\text{M}+\text{H}$) $^+$ = 291.14, HPLC R_t = 1.933 min.

25



3-(4-Fluoro-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoic acid

[00489] LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 422.19, HPLC R_t = 1.653 min.




4-Fluoro-2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00490] Purification was performed by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 6.80-7.18 min. (UV detection at 220 nm). The material obtained was further purified by preparative TLC (500 um x 20 x 20 cm plate, 5% MeOH/CH₂Cl₂). Analytical TLC R_f = 0.35 (5% MeOH/CH₂Cl₂). ¹H NMR (500 MHz, CD₃OD) δ 8.64 (d, *J* = 4.88, 2H), 7.96 (m, 2H), 7.90 (dd, *J* = 7.93, 1.83, 1H), 7.84 (d, *J* = 1.83, 1H), 7.54 (d, *J* = 8.54, 1H), 7.46 (d, *J* = 7.93, 1H), 7.34-7.27 (m overlapping with t, 3H), 7.22 (t, *J* = 4.88, 1H), 2.96 (s, 3H), 2.29 (s, 3H), 1.77 (m, 2H), 1.46 (m, 2H). ¹⁹F NMR (470.45 MHz, CD₃OD) δ 112.72, 123.10. LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 539.32, HPLC R_t = 1.585 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95%

MeCN-5% H_2O -0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm , 4.6 x 150 mm, R_t = 5.64 min; Column: XBridge phenyl 3.5 μm , 4.6 x 150 mm, R_t = 4.66 min.

Analytical HPLC method: Solvent A = 5% MeOH-95% H_2O -10 mM NH_4HCO_3 ,

- 5 Solvent B = 95% MeOH-5% H_2O -10 mM NH_4HCO_3 , Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μm , 4.6 x 150 mm, R_t = 8.43 min.




- 10 5-(5-(*tert*-Butylcarbamoyl)-4-methoxy-2-methylphenyl)-4-fluoro-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00491] Purification was performed by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H_2O -0.1% TFA, Solvent B = 90% MeOH-10% H_2O -0.1% TFA, Start %B = 50, Final %B = 100,

- 15 Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 8.68 - 9.29 min. (UV detection at 220 nm). ^1H NMR (500 MHz, CD_3OD) δ 7.88 (dd, J = 8.55, 5.19, 2H), 7.72 (s, 1H), 7.43 (d, J = 8.55, 1H), 7.23–7.17 (overlapping m, 3H), 7.06 (s, 1H), 3.98 (s, 3H), 2.89 (s, 3H), 2.20 (s, 3H), 1.41 (s, 9H). LC/MS were performed by using Shimadzu-
- 20 VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H_2O -0.1% TFA, Solvent B = 90% MeOH-10% H_2O -0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z ($\text{M}+\text{H}$) $^+$ = 507.33, HPLC R_t = 1.837 min. Analytical HPLC were
- 25 performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H_2O -0.1% TFA, Solvent B = 95% MeCN-5% H_2O -0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm , 4.6 x 150 mm, R_t = 10.19 min; Column: XBridge phenyl 3.5 μm , 4.6 x 150 mm, R_t = 7.50

min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5%H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 11.25 min.


5



Methyl 5-(4-fluoro-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2,4-dimethylbenzoate


[00492] LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 450.11, HPLC R_t = 1.852 min.

15



5-(4-Fluoro-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2,4-dimethylbenzoic acid


[00493] ¹H NMR (500 MHz, CD₃OD) δ 7.95 (m, 2H), 7.80 (s, 1H), 7.51 (d, *J* = 8.55, 1H), 7.30-7.25 (s and overlapping m, 4H), 2.96 (s, 3H), 2.63 (s, 3H), 2.23 (s, 3H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 436.09, HPLC R_t = 1.735 min.



5-(2,4-Dimethyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)-4-fluoro-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00494] Purification was performed by Shimadzu-VP preparative reverse phase


- 5 HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Sunfire Prep C18 19 x 100 5um, Fraction Collection: 6.93 - 7.43 min. (UV detection at 220 nm). ¹H NMR (500 MHz, DMSO-d₆, peaks were generally broad) δ 8.93 (s, 1H), 8.71 (broad s, 1H), 8.68 (m, 2H), 7.93 (m, 2H), 7.65 (m, 1H), 7.44 (m, 2H), 7.33 (m, 2H), 7.27 (m, 1H), 7.25 (m, 1H), 2.81 (s, 3H), 2.45 (s, 3H), 2.17 (s, 3H), 1.57 (s, 2H), 1.33 (s, 2H). ¹⁹F NMR (470.45 MHz, DMSO-d₆) δ 110.88, 121.61. LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 553.22, HPLC R_t = 1.645 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 um, 4.6 x 150 mm, R_t = 6.26 min; Column: XBridge phenyl 3.5 um, 4.6 x 150 mm, R_t = 5.23 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 um, 4.6 x 150 mm, R_t = 9.00 min.



Methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2,4-dimethylbenzoate

[00495] LC/MS were performed by using Shimadzu-VP instrument with UV
 5 detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 432.10, HPLC R_t = 1.928 min.


10



5-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2,4-dimethylbenzoic acid


[00496] LC/MS were performed by using Shimadzu-VP instrument with UV
 15 detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 418.10, HPLC R_t = 1.810 min.

20



5-(2,4-Dimethyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

- [00497] Purification was performed by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Sunfire Prep C18 19 x 100 5um, Fraction Collection: 7.75 - 8.16 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 8.67 (d, *J* = 4.88, 2H), 7.97 (m, 2H), 7.65 (s overlapped with d, 1H), 7.64 (d, *J* = 8.50, 1H), 7.50 (s, 1H), 7.38 (dd, *J* = 8.55, 1.83, 1H), 7.28 (t, *J* = 8.85, 2H), 7.24 (t, *J* = 4.88, 1H), 7.22 (s, 1H), 2.95 (s, 3H), 2.52 (s, 3H), 2.30 (s, 3H), 1.76 (m, 2H), 1.46 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) *m/z* (M+H)⁺ = 535.23, HPLC *R*_t = 1.722 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 um, 4.6 x 150 mm, *R*_t = 7.24 min; Column: XBridge phenyl 3.5 um, 4.6 x 150 mm, *R*_t = 5.62 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 um, 4.6 x 150 mm, *R*_t = 9.24 min.




5-(5-(1-Cyanocyclopropylcarbamoyl)-4-methoxy-2-methylphenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00498] LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10%

MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 498.21, HPLC R_t = 1.647 min.


5



2-(4-Fluorophenyl)-5-(5-(1-(N-hydroxycarbamimidoyl)cyclopropylcarbamoyl)-4-methoxy-2-methylphenyl)-N-methylbenzofuran-3-carboxamide


[00499] Purification was performed by Shimadzu-VP preparative reverse phase

- 10 HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 30, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 6.82 - 7.62 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 7.96 (dd, *J* = 8.24, 5.80, 2H), 7.88 (s, 1H), 7.63 (d, *J* = 8.24, 1H), 7.57 (s, 1H), 7.32 (d, *J* = 8.54, 1H), 7.28 (t, *J* = 8.70, 2H), 7.13 (s, 1H), 4.05 (s, 3H), 2.96 (s, 3H), 2.36 (s, 3H), 1.67 (m, 2H), 1.50 (m, 2H).
- 15 LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 531.22, HPLC R_t = 1.457 min.
- 20



- 25 2-(4-Fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(5-methyl-1,2,4-oxadiazol-3-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide


[00500] 2-(4-Fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(5-methyl-1,2,4-oxadiazol-3-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide was prepared from 2-(4-fluorophenyl)-5-(5-(1-(N-hydroxycarbamimidoyl)cyclopropylcarbamoyl)-4-methoxy-2-methylphenyl)-N-methylbenzofuran-3-carboxamide under similar conditions as described but using PhMe as a solvent. The crude mixture was purified by preparative TLC (20 x 20 cm x 500 um plates, 5% MeOH/CH₂Cl₂) to give the product, which was further purified by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 7.95 - 8.47 min. (UV detection at 220 nm). Analytical TLC R_f = 0.38 (5% MeOH/CH₂Cl₂). ¹H NMR (500 MHz, CD₃OD) δ 7.97 (dd, *J* = 7.93, 5.49, 2H), 7.87 (s, 1H), 7.62 (d, *J* = 8.24, 1H), 7.58 (s, 1H), 7.33 (d, *J* = 8.55, 1H), 7.27 (t, *J* = 8.39, 2H), 7.11 (s, 1H), 4.05 (s, 3H), 2.96 (s, 3H), 2.54 (s, 3H), 2.36 (s, 3H), 1.60 (m, 2H), 1.45 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES⁺) m/z (M+H)⁺ = 555.34, HPLC R_t = 1.735 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 um, 4.6 x 150 mm, R_t = 7.75 min; Column: XBridge phenyl 3.5 um, 4.6 x 150 mm, R_t = 5.93 min. Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃, Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: XBridge phenyl 3.5 um, 4.6 x 150 mm, R_t = 11.98 min.



5-(2-Chloro-5-(1-cyanocyclopropylcarbamoyl)-4-methoxyphenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00501] LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 518.20, 520.18, HPLC R_t = 1.692 min.


10



5-(2-Chloro-5-(1-(N-hydroxycarbamimidoyl)cyclopropylcarbamoyl)-4-methoxyphenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide


[00502] LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 551.21, HPLC R_t = 1.478 min.

20



5-(2-Chloro-4-methoxy-5-(1-(5-methyl-1,2,4-oxadiazol-3-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00503] The mixture first purified by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 60, Final %B = 100, Gradient time = 5 min, Stop time = 6 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 50 mm S5, Fraction Collection: 3.85 - 4.21 min. (UV detection at 220 nm). The residue obtained after evaporation of the desired fractions was further purified by preparative TLC (5% MeOH/CH₂Cl₂, 20 cm x 20 cm x 0.5 mm plates). ¹H NMR (500 MHz, CD₃OD) δ 7.98 (dd overlapping with s, *J* = 5.19, 2H), 7.97 (s, 1H), 7.71 (d, *J* = 1.22, 1H), 7.65 (d, *J* = 8.55, 1H), 7.45 (dd, *J* = 8.55, 1.83, 1H), 7.36 (s, 1H), 7.28 (t, *J* = 8.85, 2H), 4.05 (s, 3H), 2.96 (s, 3H), 2.54 (s, 3H), 1.61 (m, 2H), 1.46 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) *m/z* (M+H)⁺ = 575.10, HPLC *R*_t = 1.817 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm, 4.6 x 150 mm, *R*_t = 7.92 min; Column: XBridge phenyl 3.5 μm, 4.6 x 150 mm, *R*_t = 6.21 min.




25 2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(5-phenyl-1,2,4-oxadiazol-3-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00504] The mixture was first purified by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 50, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column:

Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 9.11 - 9.39 min. (UV detection at 220 nm) to isolate the desired product. The residue after evaporation of the desired fractions was further purified by preparative TLC (5% MeOH/CH₂Cl₂, 20 cm x 20 cm x 0.5 mm plate). Analytical TLC R_f = 0.52 (5% MeOH/CH₂Cl₂). ¹H NMR (500 MHz, CD₃OD) δ 8.11 (d, *J* = 7.02, 2H), 7.99 (m, 2H), 7.84 (s, 1H), 7.83 (m overlapping with s, 1H), 7.68–7.64 (overlapping m, 3 H), 7.60–7.57 (overlapping m, 2 H), 7.45 (d, *J* = 8.55, 1H), 7.40 (d, *J* = 8.24, 1.83, 1H), 7.28 (m, 2H), 2.96 (s, 3H), 2.36 (s, 3H), 1.72 (m, 2H), 1.50 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®.

HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 4 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) *m/z* (M+H)⁺ = 587.20, HPLC R_t = 1.950 min.




15

3-Fluoro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid


[00505] LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) *m/z* (M+H)⁺ = 408.15, HPLC R_t = 1.757 min.

20



25 5-(3-Fluoro-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide


[00506] The product precipitated from the reaction mixture during the coupling of 3-fluoro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid (0.068 mmol scale) with 1-(pyridin-2-yl)cyclopropanamine dihydrochloride (TBTU, iPr₂NET, DMF, r.t.). The mixture was diluted with 4 ml H₂O, the off white solid
 5 filtered and washed with 3 x 2 ml H₂O. The solid was further washed with 3 x 1 ml MeOH and dried. ¹H NMR (500 MHz, DMSO-d₆) δ 9.50 (s, 1H), 8.52 (d, *J* = 4.58, 1H), 8.47 (d, *J* = 3.97, 1H), 8.17 (s, 1H), 8.03-8.00 (overlapping m, 3H), 7.83 (overlapping m, 3H), 7.73 (d, 1H), 7.70 (dt overlapping with d, 1H), 7.43-7.40 (overlapping m, 3H), 7.17 (dd, *J* = 6.87, 5.34, 1H), 2.88 (d, *J* = 4.27, 3H), 1.59 (m,
 10 2H), 1.32 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES⁺) *m/z* (M+H)⁺ = 524.25, HPLC *R*_t = 1.512 min.



Ethyl 2-fluoro-3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoate


[00507] LC/MS were performed by using Shimadzu-VP instrument with UV
 20 detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10%H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES⁺) *m/z* (M+H)⁺ = 436.01, HPLC *R*_t = 1.820 min.

25



2-Fluoro-3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)benzoic acid

[00508] LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 408.01, HPLC R_t = 1.623 min.



5-(2-Fluoro-3-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00509] The product was obtained as a TFA salt after purification by Shimadzu-VP preparative reverse phase HPLC using the separation method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 10 min, Stop time = 12 min, Flow Rate = 25 mL/min, Column: Waters-Sunfire 19 x 100 mm S5, Fraction Collection: 8.11 - 8.43 min. (UV detection at 220 nm). ¹H NMR (500 MHz, CD₃OD) δ 8.64 (d, *J* = 5.19, 1H), 8.42 (t, *J* = 7.78, 1H), 7.97 (dd, *J* = 8.24, 5.49, 2H), 7.91 (d, *J* = 8.24, 1H), 7.88 (s, 1H), 7.80 (q, *J* = 6.61, 2H), 7.76 (t, *J* = 7.17, 1H), 7.71 (d, *J* = 8.55, 1H), 7.60 (d, *J* = 8.24, 1H), 7.43 (t, *J* = 7.78, 1H), 7.29 (t, *J* = 8.55, 2H), 2.97 (s, 3H), 1.84 (m, 2H), 1.74 (m, 2H). LC/MS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH-90% H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O-0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H)⁺ = 524.08, HPLC R_t = 1.417 min. Analytical HPLC were performed by using Shimadzu-VP instrument with UV detection at 220 nm and 254 nm. Analytical HPLC method: Solvent A = 5% MeCN-95% H₂O-0.1% TFA, Solvent B = 95% MeCN-5% H₂O-0.1% TFA, Start %B = 10, Final %B = 100, Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column: Sunfire C18, 3.5 μm, 4.6 x 150

mm, R_t = 8.57 min; Column: XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 9.09 min.
Analytical HPLC method: Solvent A = 5% MeOH-95% H₂O-10 mM NH₄HCO₃,
Solvent B = 95% MeOH-5% H₂O-10 mM NH₄HCO₃, Start %B = 50, Final %B = 100,
Gradient time = 15 min, Stop time = 18 min, Flow Rate = 1 ml/min, Column:

5 XBridge phenyl 3.5 μ m, 4.6 x 150 mm, R_t = 12.08 min.

Ethyl 3-(4-Fluorophenyl)-3-oxopropanoate

[00510] To a suspension of diethyl carbonate (7.69 g, 65.14 mmol, 1.8 eq) and
NaH (hexane washed) (90.47 mmol, 2.5 eq) in dry THF (30 ml) p-
10 fluoroacetophenone (36.19 mmol) was added dropwise at 60 °C. The reaction was
maintained at gentle reflux by adjusting the temperature and the addition rate
(exothermic). After the addition was complete, the reaction was heated at reflux for 4
h, and then cooled to room temperature. The reaction mixture was poured carefully
into ice cold acetic acid (6.0 ml) and water (20 ml). The product was extracted with
15 ether, and the combined ether layers were washed with saturated aqueous
bicarbonate, brine and dried. Ether was evaporated and the crude product was purified
by silica gel (60-120) column chromatography using 2 % EtOAc/hexane as eluent.
Yield : 7.3 g (96 %). ¹H NMR (400MHz, CDCl₃): δ 1.27 (t, 3H, J = 7.12 Hz), 3.96
(s, 2H), 4.24 (q, 2H, J = 7.12 Hz), 7.17 (t, 2H, J = 7.59 Hz), 7.98 (m, 2H). LCMS :
20 (ES⁺) m/z = 211(M+H).

Ethyl 2-(4-fluorophenyl)-5-hydroxybenzofuran-3-carboxylate

[00511] To a stirred solution of zinc chloride (8.39 g, 1.14 mmol, 1 eq) in toluene
at ambient temperature, ethyl 3-(4-fluorophenyl)-3-oxopropanoate (13 g, 2.74 mmol,
25 1 eq) was added and stirred at 70 °C for 15 min. Benzoquinone (6.66 g, 0.72 mmol, 1
eq) was added portion wise into the reaction mixture and stirred at the same
temperature for 15-20 min. Dean-stark apparatus was assembled and the reaction
mixture was heated at 140 °C for 12 h and cooled to ambient temperature. Reaction
completion was judged by TLC. EtOAc was added to the reaction mass and filtered
30 through the filter paper, to remove the inorganic material. Brine was added to the
reaction mixture (filtrate) and extracted, dried over sodium sulphate and concentrated
to get the crude material. Further it was purified by column chromatography using 10

% EtOAc/Hexane system. Yield : 8.0 g (43 %). ¹H NMR (400MHz, CDCl₃): δ 1.38-1.42 (t, 3H, *J* = 7.14 Hz), 4.37-4.42 (q, 2H, *J* = 7.13 Hz), 5.2 (br s, 1H), 6.87-6.9 (q, 1H, *J* = 3.81 Hz), 7.14-7.18 (q, 2H, *J* = 5.82 Hz), 7.36-7.39 (d, 1H, *J* = 8.80 Hz), 7.50-7.51 (d, 1H, *J* = 2.56 Hz), 8.00-8.03 (m, 2H). LCMS : (ES+) *m/z* = 301(M+H).

5

2-(4-Fluorophenyl)-5-hydroxybenzofuran-3-carboxylic acid

[00512] To a mixture of 2-(4-fluorophenyl)-5-hydroxybenzofuran-3-carboxylate (1 g, 3.5 mmol, 1 eq) in a 1:1 mixture of MeOH/THF at ambient temperature was added 5 eq. of NaOH and heated to 60 °C for 3 h. The mixture was cooled to ambient temperature and to 0 °C in an ice-water bath, it was acidified slowly with 1.5 N HCl and then concentrated. The mixture with white precipitates was diluted with water and filtered to get the solid. It is further washed with water and dried in vacuum. Yield : 0.9 g (94.6 %). ¹H NMR (400MHz, DMSO-*d*₆): δ 6.82-6.85 (m, 1H), 7.35-7.40 (m, 3H), 7.46-7.49 (d, 1H, *J* = 8.84 Hz), 8.02-8.05 (m, 2H), 9.4 (s, 1H), 13.05 (s, 1H). LCMS : (ES-) *m/z* = 271.1

15

2-(4-Fluorophenyl)-5-hydroxy-N-methylbenzofuran-3-carboxamide

[00513] To a mixture of 2-(4-fluorophenyl)-5-hydroxybenzofuran-3-carboxylic acid (1 g, 3.7mmol, 1 eq), methylamine in THF (2 M solution) (0.689 g, 21.5 mmol, 1 eq), HOBT (0.83 g, 6.2 mmol, 1.7 eq), EDC.HCl (1.24 g, 6.6 mmol, 1.8 eq) in DMF at ambient temperature under nitrogen was added Diisopropyl ethylamine (2.32 g, 18.5 mmol, 3.0 eq). The clear mixture was stirred at ambient temperature for 12 h. The LCMS indicated the desired product. The mixture was concentrated cooled in an ice-water bath, further diluted with water. The white solid was filtered and washed with water and dried in vacuum. Yield : 0.85 g (90 %). ¹H NMR (400MHz, DMSO-*d*₆): δ 2.81-2.82 (d, 3H, *J* = 4.5Hz), 6.80-6.83 (m, 1H), 6.94-6.95 (d, 1H, *J* = 2.3 Hz), 7.34-7.38 (t, 2H, *J* = 8.7 Hz), 7.44-7.47 (d, 1H, *J* = 8.8 Hz), 7.90-7.93 (m, 2H), 8.39-8.40 (d, 1H, *J* = 4.4 Hz), 9.3 (s, 1H). LCMS : (ES+) *m/z* = 286.1(M+H).

25

[00514] To a mixture of 2-(4-fluorophenyl)-5-hydroxy-N-methylbenzofuran-3-carboxamide (5 g, 17.5 mmol, 1 eq) in Dichloromethane (50 ml) at ambient

30

temperature under N₂ was added triethylamine (2.6 g, 26 mmol, 1.5 eq). The mixture was cooled to 0 °C and then added 1,1,1-trifluoro-N-phenyl-N(trifluoromethylsulphonyl) methane sulphonamide (7.5 g, 21 mmol, 1.2 eq). The mixture was then stirred at ambient temperature for 12 h. The reaction mixture was concentrated, diluted with water and extracted with EtOAc. The organic layer is further washed twice with water, dried over sodium sulphate and concentrated to get the product. The product was further purified by column chromatography using 230-400 silica gel and 50 % EtOAc/Hexane. Yield : 6.2 g (85 %). ¹H NMR (400MHz, DMSO-d₆): δ 2.83-2.84 (d, 3H, *J* = 4.6 Hz), 7.40-7.44 (t, 2H, *J* = 8.9 Hz), 7.51-7.53 (m, 1H), 7.75-7.76 (d, 1H, *J* = 2.52 Hz), 7.88-7.90 (d, 1H, *J* = 8.96 Hz), 7.94-7.98 (m, 2H), 8.51-8.52 (d, 1H, *J* = 4.6 Hz). LCMS : (ES+) *m/z* = 418(M+H).

3-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoate
[00515] To a mixture of 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (3.5 g, 8.4 mmol, 1 eq), boronic acid (1.95 g, 10.1 mmol, 1.2 eq), in 1,4-dioxane/H₂O (5:1) was added cesium carbonate (8.21 g, 26 mmol, 3 eq) and the nitrogen gas was passed through the mixture for 10 min. Then tetrakis(triphenylphosphine) palladium (0.97 g, 0.8 mmol, 0.1 eq) was added to the reaction mixture and the nitrogen gas was again passed through the mixture for 10 min. The above reaction mixture was heated in microwave for one hour at 90 °C. About 50 ml of water is added to the reaction mixture and extracted with EtOAc. The organic layer was further washed twice with water and dried over sodium sulphate and concentrated to get the product. The product obtained was further purified by column chromatography using 40 % EtOAc/Hexane as eluent. Yield; 1.5 g (40 %) ¹H NMR (400MHz, DMSO-d₆): δ 2.32 (s, 3H), 2.81-2.82 (d, 3H, *J* = 4.56 Hz), 3.85 (s, 3H), 7.39-7.43 (t, 2H, *J* = 8.9 Hz), 7.39-7.43 (m, 1H), 7.49-7.51 (d, 1H, *J* = 8.16 Hz), 7.56 (s, 1H), 7.75-7.77 (d, 1H, *J* = 8.6), 7.83 (s, 1H), 7.89-7.91 (d, 1H, *J* = 7.82 Hz), 7.98-8.02 (m, 2H), 8.48-8.49 (d, 1H, *J* = 4.6 Hz). LCMS : (ES+) *m/z* = 418 (M+H).


3-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoic acid
[00516] To a mixture of methyl 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoate (1 g, 2.4 mmol, 1 eq) in a 1:1

mixture of MeOH/THF at ambient temperature was added 5 eq. of NaOH and heated to 60 °C for 5 h. The mixture was cooled to ambient temperature and then in an ice-water bath, quenched slowly with 1.5 N HCl and then concentrated. The mixture with white precipitates was diluted with water and filtered to get the solid. It is further washed with water and dried in vacuum. Yield : 0.850 g (90 %). This acid was also prepared by the coupling of 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate with 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (Cs_2CO_3 , $(\text{Ph}_3)_4\text{Pd}$, $\text{H}_2\text{O}/1,4\text{-dioxane}$ (1:5), 90 °C) in a similar manner as described. ^1H NMR (400MHz, DMSO-d_6): δ 2.32 (s, 3H), 2.82-2.83 (d, 3H, J = 4.6 Hz), 7.36-7.48 (m, 6H), 7.56-7.57 (d, 1H, J = 1.44 Hz), 7.75-7.77 (d, 1H, J = 8.48 Hz), 7.81-8.03 (m, 2H), 8.46-8.48 (d, 1H, J = 4.7 Hz), 12.92 (s, 1H). LCMS : (ES+) m/z = 404.0 (M+H).

1-(Pyrimidin-2-yl)cyclopropanamine

[00517] 2-Cyano pyrimidine (5 g, 47.6 mmol, 1 eq) was taken in a Dry THF under Argon atmosphere, then titanium isopropoxide (17 ml, 57.1 mmol, 1.2 eq) was added slowly at ambient temperature and the reaction mixture was stirred for 15 mins. Ethyl magnesium bromide (1M solution) in THF (107 ml, 809 mmol, 2.5 eq) was added via syringe slowly at ambient temperature, (During the addition of EtMgBr reaction mass becomes black). Then the reaction mass was stirred for an hour. $\text{BF}_3 \cdot \text{EtO}$ (16.7 ml, 119.0 mmol, 2.5 eq) was added slowly through syringe at 0 °C. The mixture was allowed to attain ambient temperature and stirred for another one hour. 50 ml of Water was added to the reaction mixture and filtered through the CELITE® and washed the bed with water and Ethyl acetate. The reaction mass was basified with 10 % NaOH solution (pH = 9) then extracted with DCM and washed with brine solution. The required product was purified by silica gel (230-400) column chromatography using DCM/methanol as the eluent. Yield : 2.1 g (30 %). ^1H NMR (400MHz, DMSO-d_6): δ 1.49-1.52 (m, 2H), 1.59-1.62 (m, 2H), 7.47-7.49 (t, 1H, J = 4.80), 8.83-8.84 (d, 2H, J = 4.80).

30



2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

- [00518]** To a mixture of 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoic acid (0.1 g, 0.25 mmol, 1 eq), 1-(pyrimidin-2-yl)cyclopropanamine (0.041 g, 0.3 mmol, 1.2 eq) (60 % purity), HOBT (0.057 g, 0.42 mmol, 1.7 eq), EDC.HCl (0.086 g, 0.44 mmol, 1.8 eq) in DCM at ambient temperature under nitrogen was added Diisopropylethylamine (0.16 g, 1.3 mmol). The clear mixture was stirred at ambient temperature for 12 h. The mixture was concentrated, diluted with water and extracted with EtOAc. The organic layer was further washed with water, dried over sodium sulphate and concentrated. The product obtained was further purified by column chromatography (neutral alumina) using 0.5 % Methanol/DCM and finally purified by preparative HPLC. Yield : 0.15 g (14 %). ¹H NMR (400MHz, DMSO-d₆): δ 1.33-1.36 (m, 2H), 1.59-1.61 (m, 2H), 2.31(s, 3H), 2.82-2.83 (d, 3H, *J* = 4.8 Hz), 7.26-7.29 (t, 1H, *J* = 4.8 Hz), 7.39-7.45 (m, 4H), 7.59 (s, 1H), 7.76-7.78 (d, 1H, *J* = 8.4 Hz), 7.86-7.87 (d, 2H, *J* = 4.4 Hz), 7.98-8.02 (m, 2H), 8.47-8.50 (m, 1H), 8.67-8.68 (d, 2H, *J* = 4.8 Hz), 9.20 (s, 1H). LCMS : (ES+) *m/z* = 521.2 (M+H). Column : Ascentis Express C18 (5X2.1mm-2.7μm). Mphase A : 2% MeCN -98% H₂O-10mM NH₄COOH. Mphase B : 98% MeCN – 2% H₂O-10mM NH₄COOH. Flow : 1mL/Min.

Time	%A	%B
0.0	100.0	0
1.5	0.0	100.0
3.2	0.0	100.0
3.6	100.0	0.0

RT min : 1.908, wavelength:220nm.

HPLC Method:

Column : ZORBAX® C18 (4.6X150mm-5.0μm)

A : Buffer : 20mM Ammonium acetate

B : Methanol

Flow : 1ml/min

Time	B%
0	10
12	100
15	100

Wavelength : 254 nm, RT min :19.7

5 Wavelength : 220 nm, RT min :19.7

HPLC Method:

Sunfire C18 (4.6X150)mm, 3.5 micron

Buffer : 0.05% TFA in water pH 2.5

10 Mobile Phase A : Buffer : MeCN (95:5)

Mobile Phase B : ACN :Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
12	100
15.	100

Wavelength : 254 nm, RT min :17.2

Wavelength : 220 nm, RT min :17.2

15

HPLC Method:

XBridge phenyl (4.6X150)mm, 3.5 micron

Buffer : 0.05% TFA in water pH 2.5

Mobile Phase A : Buffer : MeCN (95:5)

20 Mobile Phase B : MeCN :Buffer (95:5)

Flow : 1ml/min

Time	B%

Time	B%
0	10
12	100
15	100

Wavelength : 254 nm, RT min :15.764

Wavelength : 220 nm, RT min :15.764

3-Fluoro-5-iodo-4-methylbenzoic acid

- 5 **[00519]** 3-Fluoro-4-methylbenzoic acid (1 g, 6.48 mmol, 1 eq) was dissolved in trifluoromethanesulphonic acid (10 ml) and the reaction was cooled to 0 °C. To the above solution *N*-iodosuccinimide (1.46 g, 6.48 mmol, 1 eq) was added in portion and the reaction was stirred at room temperature for 14 h. Later the above solution was poured into 50 ml of ice water, the solid obtained was filtered. The solid was
- 10 dissolved in ethylacetate, washed with sodiumthiosulphate solution and brine, the organic layer was concentrated to get the desired product as light brown solid. Yield : 1.5 g (83 %). ¹H NMR (400MHz, CDCl₃): δ 2.35 (s, 3H), 7.68 (d, 1H, *J* = 8 Hz), 8.14 (s, 1H). 13.50 (br, 1H).


15 Methyl 3-fluoro-5-iodo-4-methylbenzoate

- [00520]** 3-Fluoro-5-iodo-4-methylbenzoic acid (1.3 g, 4.6 mmol, 1 eq) was dissolved in methanol and treated with conc. Sulphuric acid (0.49 ml, 9.2 mmol, 2 eq). The above solution was stirred at 50 °C for 15 h. Later on solvent was removed and to the resulting residue diethylether was added and the organic layer was washed
- 20 with 10 % sodium bicarbonate solution and water. Finally, the organic layer was concentrated and purified by flash silica gel column chromatography using 240-400 silica gel and using 10 % EtOAc in hexane as the eluent. Yield : 1 g (77 %). ¹H NMR (400MHz CDCl₃). δ 2.39 (s, 3H), 3.90 (s, 3H), 7.64 (d, 1H, *J* = 8 Hz), 8.25 (s, 1H).

25 Methyl 3-fluoro-4-methyl-5-(3,3,4,4-tetramethylborolan-1-yl)benzoate

- [00521]** A mixture of methyl 3-fluoro-5-iodo-4-methylbenzoate (0.85 g, 2.89 mmol, 1 eq), potassium acetate (1.41 g, 14.45 mmol, 5 eq), bispinacolatodiboron (1.1

g, 4.33 mmol, 1.5 eq) and 1,1-bis (diphenylphosphino)ferrocene)-dichloropalladium (II) (0.047 g, 0.057 mmol, 0.02 eq) were dissolved in DMF and the reaction was stirred at 90 °C for 18 h. Later solvent was removed, water was added and extracted with dichloromethane, organic layer was washed with 2 M HCl, 10 % lithium chloride and brine. The organic layer was concentrated and hexane was added. The solid obtained was filtered and dried to get the desired product as a white solid. Yield : 0.35 g, (41 %). ¹H NMR (400MHz CDCl₃): δ 1.35(s, 12H), 2.49 (s, 3H), 3.90 (s, 3H), 7.69-7.71 (d, 1H, *J* = 8 Hz), 8.18 (s, 1H).).




Methyl 3-fluoro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoate

[00522] To a mixture of 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (0.5 g, 1.2 mmol, 1 eq), boronic ester (0.42 g, 1.4 mmol, 1.2 eq) in 1,4-dioxane/H₂O (5:1) was added cesium carbonate (1.17 g, 3.6 mmol, 3 eq) and the nitrogen gas was passed through the solution for 10 min. Then tetrakis(triphenylphosphine) palladium (0.14 g, 0.12 mmol, 0.1 eq) was added to the reaction mixture and the nitrogen gas was passed again through the solution for 15 min. The above reaction mixture was heated in microwave for one hour at 90 °C. About 100 ml of water is added to the reaction mixture and extracted with EtOAc. The organic layer was further washed twice with water, dried and concentrated to get the product. The product obtained was further purified by column chromatography using 40 % EtOAc/Hexane as the eluent. Yield : 0.5 g (40 %). ¹H NMR (400MHz, DMSO-d₆): δ 2.23 (d, 3H, *J* = 1.9 Hz), 2.82-2.83 (d, 3H, *J* = 4.6 Hz), 3.8 (s, 3H), 7.39-7.43 (t, 2H, *J* = 8.4 Hz), 7.39-7.43 (1H, m), 7.61 (s, 1H), 7.70-7.72 (d, 2H, *J* = 7.2 Hz), 7.78-7.80 (d, 1H, *J* = 8.4 Hz), 7.99-8.03 (m, 2H), 8.49-8.51 (d, 1H, *J* = 4.7 Hz). LCMS : (ES⁺) *m/z* = 436 (M+H). PHENOMENEX® Luna C18 (4.6X3.0mm-5.0μm). Mphase A : 10% CH₃OH -90% H₂O-10mM NH₄Oac. Mphase B : 90% CH₃OH -10% H₂O-10mM NH₄Oac. Flow : 5 ml/Min.

Time	%B
0.0	0.0
2.0	100.0
3.0	0.0

RT min : 2.135, wavelength: 220nm




3-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoic acid

- 5 **[00523]** To a mixture of methyl 3-fluoro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoate (0.3 g, 0.68 mmol, 1 eq) in a 1:1 mixture of MeOH/THF at ambient temperature was added 5 eq. of NaOH and heated to 60 °C for 5 h. The mixture was cooled to ambient temperature and then cooled in an ice-water bath. It was acidified slowly with 1.5 N HCl and then
- 10 concentrated. The mixture with white precipitates was diluted with water and filtered to get the solid. It is further washed with water and dried in vacuum. Yield : 0.2 g (60 %). ¹H NMR (400MHz, DMSO-d₆): δ 2.22 (s, 3H), 2.82-2.84 (d, 3H, *J* = 4.6 Hz), 7.39-7.43 (m, 3H), 7.61 (s, 1H), 7.66-7.70 (d, 1H, *J* = 8.6 Hz), 7.66-7.70 (m, 1H), 7.78-7.80 (d, 1H, *J* = 8.5 Hz), 8.01-8.03 (m, 2H), 8.49-8.51 (d, 1H, *J* = 4.76 Hz), 13.2
- 15 (s, 1H). LCMS : (ES-) *m/z* = 420.0 (M-H). CHROMOLITH® SpeedROD C18 (4.6X3.0mm-5.0μm). Mphase A : 10% CH₃OH -90% H₂O-0.1% TFA. Mphase B : 90% CH₃OH -10% H₂O-0.1% TFA. Flow : 5 ml/Min.

Time	%B
0.0	0.0
2.0	100.0
3.0	0.0

RT min : 2.040, wavelength: 220 nm.

[00524] 2-Cyano pyridine (5 g, 48.0 mmol, 1 eq) was taken in dry THF under Argon atmosphere. To this mixture was added slowly Titanium isopropoxide (17 ml, 57.6 mmol, 1.2 eq) at ambient temperature. The reaction mass was stirred for 15 mins. Ethyl Magnesium Bromide (1 M solution) in THF (107 ml, 809 mmol, 2.5 eq) was added via syringe slowly at room temperature, (During the addition of EtMgBr reaction mass becomes black). Then the reaction mass stirred for an hour and BF₃.Et₂O (16.7 ml, 120.0 mmol, 2.5 eq) was added slowly at 0 °C. After the completion of addition process, reaction mass was allowed to attain ambient temperature and the stirring continued for one more hour. Finally, 50 ml of water was added and the reaction mass was filtered through the CELITE®. The bed was further washed with water and Ethyl acetate. The filtrate was basified with 10 % NaOH solution (pH = 9) then extracted with DCM and washed with brine solution, the required product was purified by silica gel (60-120) column chromatography using DCM/methanol as the eluent. Yield : 1.3 g (23 %). ¹H NMR (400MHz, CDCl₃): δ 1.12-1.14 (m, 2H), 1.27-1.29 (m, 2H), 2.12 (broad s, 2H), 7.03-7.07 (t, 1H), 7.33-7.35 (d, 1H), 7.60-7.62 (t, 1H), 8.48-8.49 (d, 1H).



5-(3-Fluoro-2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

[00525] To a mixture of 3-fluoro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methyl benzoic acid (0.2 g, 0.47 mmol, 1 eq), 1-(pyridin-2-yl)cyclopropanamine (0.075 g, 5.5mmol, 1.2 eq) (60 % purity), HOBT (0.81 g, 0.015 mmol, 1.7 eq), EDC.HCl (0.16 g, 0.083 mmol, 1.8 eq) in DCM at ambient temperature and under nitrogen was added Diisopropylethylamine (0.30 g, 2.3 mmol, 5.0 eq). The clear mixture was stirred at ambient temperature for 12 h. The mixture was concentrated, diluted with water and extracted with EtOAc. The organic layer is further washed with water, dried over sodium sulphate and concentrated. The product obtained was further purified by column chromatography (neutral alumina) using 0.5 % Methanol/DCM and further purification was done using preparative

HPLC. Yield : 0.1 g (50 %). ^1H NMR (400MHz, CDCl_3): δ 1.39-1.42 (m, 2H), 1.67-1.70(m, 2H), 2.21-2.22 (d, 3H, $J = 2.24$ Hz), 2.9-3.0 (d, 3H, $J = 4.88$ Hz), 5.98-5.99 (s, 1H), 7.06-7.09 (dd, 1H, $J = 5.2, 7.2$ Hz), 7.18-7.36 (m, 5H), 7.53-7.62 (m, 4H), 7.76 (d, 1H, $J = 1.36$ Hz), 7.94-7.97 (m, 2H), 8.4 (s, 1H). LCMS : (ES+) $m/z = 538.2$ (M+H). LCMS Method : Column : Atlantis dC18 (50X4.6mm-5 μm). A: 10mM NH_4OAc . B : acetonitrile. Flow : 1mL/Min.

Time	%B
0.0-3.0	30-95
3.0-4.0	95
4.0-4.5	95-30
4.5-6.0	30

RT min : 3.665, wavelength:220nm

HPLC Method Info:

- 10 Sunfire C18 (4.6X150)mm, 3.5 micron
 Buffer : 0.05% TFA in water pH 2.5
 Mobile Phase A : Buffer : MeCN (95:5)
 Mobile Phase B : MeCN :Buffer (95:5)
 Flow : 1ml/min

Time	B%
0	10
12	100
15	100

- 15 Wavelength : 254 nm, RT min :10.441
 Wavelength : 220 nm, RT min :10.441
 Purity : 96%

XBridge phenyl (4.6X150)mm, 3.5 micron

- 20 Buffer : 0.05% TFA in water pH 2.5
 Mobile Phase A : Buffer : MeCN (95:5)
 Mobile Phase B : MeCN : Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
12	100
15	100

Wavelength : 254 nm, RT min :9.592

Wavelength : 220 nm, RT min :9.592

Purity : 95.9 %

5

Methyl 3,5-dihydroxy-4-methylbenzoate

- [00526]** 3,5-Dihydroxy-4-methylbenzoic acid (5.0 g, 29.79 mmol, 1.0 eq) and PTSA (1.13 g, 5.94 mmol, 0.2 eq) were dissolved in 50 ml of methanol, and the mixture was heated to reflux for 6 h. Methanol was evaporated. The resultant solid was washed with 10 % sodium bicarbonate solution. The aqueous solution was extracted thrice with ethyl acetate. The combined organic layer was dried over sodium sulphate and evaporated under vacuum. Yield : 5.25 g (96 %). ¹H NMR (400MHz, DMSO-d₆): δ 1.98 (s, 3H), 3.78 (s, 3H), 6.93(s, 2H), 9.53(s, 2H). LCMS : (ES+) m/z = 183 (M+H) Method: Column : PHENOMENEX® Luna C18 (4.6x30) mm, 5 micron. Mphase A : 10% MeOH – 90% H₂O – 10mM NH₄OAc. Mphase B : 90% MeOH –10% H₂O – 10mM NH₄OAc. Flow : 5 ml/min

Time (min.)	%A	%B
0.0	100.0	0.0
2.0	0.0	100.0
3.0	0.0	0.0

RT min : 0.956

Wavelength : 220 nm

20

Methyl 3-(benzyloxy)-5-hydroxy-4-methylbenzoate

- [00527]** Methyl 3,5-dihydroxy-4-methylbenzoate (3.5 g, 19.22 mmol, 1.0 eq) was dissolved in 300 ml of DMF. To this solution potassium carbonate (2.52 g, 18.26 mmol, 0.95 eq) was added. To this stirred suspension, benzyl bromide (3.12 g, 18.26

mmol, 0.95 eq) (diluted with 50ml of DMF) was added dropwise over a period of 3 h. The solution was stirred overnight at ambient temperature. Then DMF was evaporated under reduced pressure. The residue was washed with water and the product was extracted thrice with DCM. The combined DCM layers was dried over sodium sulphate and evaporated under vacuum. The required product was purified by silica gel (240-400) column chromatography using 10 % ethyl acetate/hexane as the eluent. Yield : 1.6 g (30 %). ¹H NMR (400MHz, DMSO-d₆): δ 2.07 (s, 3H), 3.81 (s, 3H), 5.14 (s, 2H), 7.08 (s, 1H), 7.14 (s, 1H), 7.33-7.35 (d, 1H, *J* = 7.04 Hz), 7.39-7.42 (t, 2H, *J* = 7.40 Hz), 7.46-7.48 (d, 2H, *J* = 7.48 Hz), 9.78 (s, 1H).

10

Methyl 3-(benzyloxy)-4-methyl-5-(trifluoromethylsulfonyloxy)benzoate
[00528] Methyl 3-(benzyloxy)-5-hydroxy-4-methylbenzoate (3.0 g, 11.02 mmol, 1.0 eq) was dissolved in DCM followed by *N*-phenyl bis (trifluoromethylsulphonimide) (5.9 g, 16.53 mmol, 1.5 eq). To this stirred solution TEA (3.34 g, 33.06 mmol, 3.0 eq) was added dropwise. The resultant solution was stirred overnight at ambient temperature. To this reaction mass water was added and the DCM layer was separated. The aqueous layer was extracted twice with DCM. The combined DCM layer was dried over sodium sulphate and evaporated. The resultant oil was purified by silica gel (60-120) column chromatography using 5 % ethyl acetate/hexane as the eluent. Yield : 4.0 g (80 %). ¹H NMR (400MHz, DMSO) : δ 2.26 (s, 3H), 3.90 (s, 3H), 5.77 (s, 2H), 7.36-7.39 (d, 1H, *J* = 8.20 Hz), 7.43-7.45 (t, 2H, *J* = 7.60 Hz), 7.51 (s, 3H), 7.70 (s, 1H).


25

Methyl 3-(benzyloxy)-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate

[00529] To the solution of methyl 3-(benzyloxy)-4-methyl-5-(trifluoromethylsulfonyloxy)benzoate (1.2 g, 2.96 mmol, 1.0 eq) in 1,4-dioxane was added PdCl₂(dppf) in DCM complex (242 mg, 0.296 mmol, 0.1 eq) followed by bis(pinacolato)diboron (1.5 g, 5.93 mmol, 2.0 eq). To this stirred solution TEA (1.5 g, 14.83 mmol, and 5.0 eq) was added. The reaction mixture was slowly heated to 110 °C and maintained for two days in a sealed tube. 1,4-Dioxane was evaporated under reduced pressure. To the residue water was added and the aqueous layer was

30

extracted thrice with DCM. The combined DCM layer was dried over sodium sulphate and evaporated under vacuum. The crude was purified by silica gel (60-120) column chromatography using 1% ethyl acetate/hexane as the eluent. Yield : 0.8 g (70 %). ¹H NMR (400MHz, CDCl₃): δ 1.39 (s, 12H), 2.53 (s, 3H), 3.91 (s, 3H), 5.17 (s, 2H), 7.33-7.35 (d, 1H, *J* = 7.36 Hz), 7.39-7.42 (t, 2H, *J* = 7.50 Hz), 7.48-7.50 (d, 2H, *J* = 7.40 Hz), 7.67-7.68 (d, 1H, *J* = 1.20 Hz), 8.00-8.01 (d, 1H, *J* = 1.40 Hz).




Methyl 3-(benzyloxy)-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoate

[00530] To a mixture of 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (0.5 g, 1.2mmol, 1 eq), boronic ester (0.55 g, 1.4 mmol, 1.2 eq), in 1,4-dioxane/H₂O (5:1) was added cesium carbonate (1.37 g, 4.2 mmol, 3eq) and the nitrogen gas was passed through the solution for 10 min. Then tetrakis(triphenylphosphine)palladium (0.12 g, 0.16 mmol, 0.1 eq) was added to the reaction mixture and the nitrogen gas was passed again for 15 min. The above reaction mixture was heated in microwave for one hour at 90 °C. About 100 ml of water is added to the reaction mixture and extracted with EtOAc. The organic layer was further washed twice with water and dried over sodium sulphate and concentrated to get the product. The product obtained was further purified by column chromatography using 60-120 silica gel and 40 % EtOAc/Hexane system. Yield : 0.3 g (48 %). ¹H NMR (400MHz, DMSO-d₆): δ 2.20 (s, 3H), 2.82-2.83 (d, 3H, *J* = 4.6 Hz), 3.8 (s, 3H), 5.3 (s, 2H), 7.39-7.46 (m, 6H), 7.52-7.56 (m, 4H), 7.62 (s, 1H), 7.76-7.78 (d, 1H, *J* = 8.44 Hz), 7.99-8.03 (m, 2H), 8.49-8.50 (d, 1H, *J* = 4.52 Hz). LCMS : (ES+) *m/z* = 524.0 (M+H). CHROMOLITH® SpeedROD C18 (4.6X3.0mm-5.0μm). Mphase A : 10% CH₃OH -90% H₂O-0.1% TFA. Mphase B : 90% CH₃OH -10% H₂O-0.1% TFA. Flow : 5 ml/Min.

Time	%B
0.0	0.0

Time	%B
2.0	100.0
3.0	0.0

RT min : 2.303, wavelength : 220 nm




3-(Benzyloxy)-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoic acid

5
[00531] To a mixture of methyl 3-(benzyloxy)-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoate (0.3 g, 0.57mmol, 1 eq) in a 1:1 mixture of MeOH/THF at ambient temperature was added 5 eq. of NaOH, and the resulting mixture was heated to 60 °C for 5h. The mixture was cooled to ambient
10 temperature and then cooled in ice-water bath. The reaction mixture was acidified with 1.5 N HCl and then concentrated. The mixture with white precipitates was diluted with water and filtered to get the solid. It is further washed with water and dried in vacuum. Yield : 0.2 g (70 %). ¹H NMR (400MHz, DMSO-d₆): δ 2.19 (s, 3H), 2.82-2.83 (d, 3H, *J* = 4.56 Hz), 5.27 (s, 2H), 7.34-7.46 (m, 6H), 7.50-7.55 (m, 4H),
15 7.60 (s, 1H), 7.75-7.77 (d, 1H, *J* = 8.44 Hz), 7.99-8.03 (m, 2H), 8.49-8.50 (d, 1H), 13.0 (s, 1H). LCMS : (ES+) *m/z* = 510 (M+H). Ascentis Express C18 (5.0X2.1-2.7μm). Mphase A : 2% MeCN -98% H₂O-10mM NH₄COOH. Mphase B : 98% MeCN -2% H₂O-10mM NH₄COOH. Flow : 5 ml/Min.

Time	%A	%B
0.0	100.0	0.0
1.5	0.0	100.0
3.2	0.0	100.0
3.6	100.0	0.0


RT min : 1.963, wavelength : 220 nm



5-(3-(Benzyloxy)-2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

- [00532]** To a mixture of 3-(benzyloxy)-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoic acid (0.2 g, 0.40 mmol, 1 eq), 1-(pyridin-2-yl)cyclopropanamine (0.064 g, 0.47 mmol, 1.2 eq) (60 % purity), HOBT (0.68 g, 0.012 mmol, 1.7 eq), EDC.HCl (0.064 g, 0.72 mmol, 1.8 eq) in DCM at ambient temperature under nitrogen was added Diisopropylethylamine (0.26 g, 2.0 mmol, 5.0 eq). The clear mixture was stirred at ambient temperature for 12 h. The mixture was concentrated, diluted with water and extracted with EtOAc. The organic layer was further washed with water, dried over sodium sulphate and concentrated. The product obtained was further purified by column chromatography (neutral alumina) using 0.5 % Methanol/DCM and preparative HPLC. Yield : 0.17 g (70 %). ¹H NMR (400MHz, DMSO-d₆): δ 1.26-1.27 (m, 2H), 1.54-1.56 (m, 2H), 2.18 (s, 3H), 2.81-2.82 (s, 3H), 5.26 (s, 2H) 7.13-7.15 (q, 1H, *J* = 4.4 Hz), 7.30-7.43 (m, 6H), 7.58 (d, 4H), 7.65-7.69 (t, 2H, *J* = 3.9 Hz), 7.74-7.79 (d, 1H, *J* = 8.0 Hz), 7.97-8.01 (m, 2H), 8.43-8.48 (dd, 2H, *J* = 4.89 Hz), 9.186 (s, 1H). LCMS : (ES⁺) *m/z* = 626 (M+H) Ascentis Express C18 (5.0X2.1-2.7μm). Mphase A : 2% MeCN -98% H₂O-10mM NH₄COOH. Mphase B : 98% MeCN -2% H₂O-10mM NH₄COOH. Flow : 5 ml/Min.

Time	%A	%B
0.0	100.0	0.0
1.5	0.0	100.0
3.2	0.0	100.0
3.6	100.0	0.0



2-(4-Fluorophenyl)-5-(3-hydroxy-2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-N-ethylbenzofuran-3-carboxamide

- [00533]** To a solution of 3-(benzyloxy)-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoic acid (0.17 g, 0.27 mmol, 1 eq) in DCM was added BCl₃ in DCM (0.32 g, 2.7 mmol, 10 eq). The clear mixture was stirred at ambient temperature for overnight. LCMS showed the desired product. The mixture was quenched with 10 % NaHCO₃ and extracted with EtOAc. The organic layer is further washed with water, dried over sodium sulphate and concentrated. The product obtained was further purified by column chromatography (neutral alumina) using 0.5 % Methanol/DCM and it was further purified with preparative HPLC. Yield : 0.048 g (33 %). ¹H NMR (400MHz, DMSO-d₆): δ 1.22-1.24 (m, 2H), 1.51-1.53 (m, 2H), 2.09 (s, 3H), 2.82-2.83 (s, 3H, *J* = 4.4 Hz), 7.12-7.15 (q, 1H), 7.30-7.32 (d, *J* = 8 Hz, 1H), 7.37-7.43 (m, 5H), 7.58 (s, 1H), 7.65-7.69 (t, 1H, *J* = 8 Hz), 7.74-7.76 (d, 1H, *J* = 8.8 Hz), 7.97-8.01 (m, 2H), 8.43-8.48 (dd, 2H, *J* = 16, 4.8 Hz), 9.18 (s, 1H), 9.77 (s, 1H). LCMS : (ES+) *m/z* = 536.2 (M+H). Column : Ascentis Express C18 (5X2.1mm-2.7μm). Mphase A : 2% MeCN -98% H₂O-10mM NH₄COOH. Mphase B : 98% MeCN – 2% H₂O-10mM NH₄COOH. Flow : 1mL/Min.

Time	%A	%B
0.0	100.0	0
1.5	0.0	100.0
3.2	0.0	100.0
3.6	100.0	0.0

RT min : 1.862, wavelength:220nm

- 20 HPLC Method Info:
 Sunfire C18 (4.6X150)mm, 3.5 micron
 Buffer : 0.05% TFA in water pH 2.5
 Mobile Phase A : Buffer : MeCN (95:5)
 Mobile Phase B : MeCN : Buffer (95:5)
 25 Flow : 1ml/min

Time	B%

Time	B%
0	10
12	100
15	100

Wavelength : 254 nm, RT min :9.255

Wavelength : 220 nm, RT min :9.255

Purity : 95.2%

5 XBridge phenyl (4.6X150)mm, 3.5 micron

Buffer : 0.05% TFA in water pH 2.5

Mobile Phase A : Buffer : MeCN (95:5)

Mobile Phase B : MeCN :Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
12	100
15	100

10 Wavelength : 254 nm, RT min :9.046

Wavelength : 220 nm, RT min :9.046

Purity : 95.8%

2-Fluoro-3-iodo-4-methylbenzonitrile

- 15 **[00534]** A solution of 2,2,6,6-tetramethyl-4-piperidine (TMP) (550 mg, 3.93 mmol, 2.1 eq) in THF (5 ml) was cooled to -78 °C under nitrogen atmosphere. N-Butyl lithium (1.6 M in hexane, 1.52 ml, 3.96 mmol, 2.1 eq) was added slowly maintaining the temperature below -70 °C. After addition, the reaction mixture was warmed to -50 °C. and stirred for one hour. The clear solution became turbid indicating the salt
- 20 formation. The reaction mixture was cooled to -80 °C, and a solution of 2-fluoro-4-methylbenzonitrile (250 mg, 1.85 mmol, 1.0 eq) in THF (1 ml) was slowly added maintaining temperature below -70 °C. The mixture was then warmed to -50 °C. and stirred for 30 minutes. The mixture was re-cooled to -78 °C. and a saturated solution

of iodine (516 mg, 2.03 mmol, 1.1 eq) in THF (1 ml) was added slowly maintaining the temperature below -70 °C. After addition, the mixture was warmed to ambient temperature. The reaction mixture was poured into a saturated solution of Na₂S₂O₃ (10 ml) and stirred for 30 minutes. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The organic layers were combined, washed with brine and dried over sodium sulphate. The volatiles were evaporated under reduced pressure. The crude product was purified under silica gel (60-120) column chromatography using 0.5 % ethyl acetate/hexane as eluent. Yield : 187 mg (38 %).
¹H NMR (400MHz, CDCl₃): δ 2.55 (s, 3H), 7.13-7.15 (d, 1H, *J* = 7.92 Hz), 7.48-7.50 (t, 1H, *J* = 4.80 Hz).

2-Fluoro-3-iodo-4-methylbenzoic acid


[00535] A mixture of 2-fluoro-3-iodo-4-methylbenzonitrile (450 mg, 1.71 mmol, 1.0 eq) in dioxane 2 ml and 60 % sulphuric acid (2 ml) was heated at 115 °C. in an oil bath for 12 h. After the mixture was cooled to room temperature, it was poured on to 10 g of ice. The tan solid was filtered, washed with water followed by ethyl acetate. The solid collected was dried to afford 2-fluoro-3-iodo-4-methylbenzoic acid as a tan crystalline solid. The filtrate was transferred to a separatory funnel. The ethyl acetate layer was separated, washed with brine, dried over sodium sulphate and concentrated to afford additional 2-fluoro-3-iodo-4-methylbenzoic acid. Yield : 450 mg (93 %).
¹H NMR (400MHz, DMSO-d₆): δ 2.48 (s, 3H), 7.27-7.29 (d, 1H, *J* = 8.00 Hz), 7.74-7.78 (t, 1H, *J* = 7.82 Hz), 13.2 (b, 1H).

Methyl 2-fluoro-3-iodo-4-methylbenzoate

[00536] To the solution of 2-fluoro-3-iodo-4-methylbenzoic acid (450 mg, 1.6 mmol, 1.0 eq) in methanol (5 ml), catalytic amount of conc.HCl (0.1 ml) was added. The resultant solution was heated to reflux at 80 °C for overnight. Methanol was evaporated. To this residue, water was added and the aqueous layer was extracted thrice with ethyl acetate. The combined ethyl acetate extracts were dried over sodium sulphate, filtered and evaporated to afford methyl 2-fluoro-3-iodo-4-methylbenzoate. Yield: 450 mg (95 %).
¹H NMR (400MHz, DMSO): δ 2.49 (s, 3H), 3.85 (s, 3H),

7.30-7.32 (d, 1H, $J = 7.84$ Hz), 7.76-7.80 (t, 1H, $J = 7.82$ Hz). LCMS : (ES+) $m/z = 295$ (M+H).

- Methyl 2-fluoro-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
- 5 **[00537]** To the solution of methyl 2-fluoro-3-iodo-4-methylbenzoate (1.1 g, 3.74 mmol, 1.0 eq) in DMSO was added [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium (305 mg, 0.37 mmol, 0.1 eq) followed by bis(pinacolato)diboron (1.9 g, 7.48 mmol, 2.0 eq). To this solution potassium acetate (1.83 g, 18.7 mmol, 5.0 eq) was added and nitrogen gas was passed through for 10 minutes. The resultant
- 10 solution was irradiated with microwave at 80 °C for 40 minutes. Reaction mixture was quenched with brine solution. The aqueous layer was extracted thrice with ethyl acetate. The combined organic layer was dried over sodium sulphate and the clear ethyl acetate layer was evaporated under vacuum. The crude was purified by silica gel (60-120) column chromatography using 1 % ethyl acetate/hexane as eluent. Yield :
- 15 400 mg (36 %). ^1H NMR (400MHz, CDCl_3): δ 1.38 (s, 12H), 2.46 (s, 3H), 3.89 (s, 3H), 6.98-7.00 (d, 1H, $J = 7.84$ Hz), 7.81-7.85 (t, 1H, $J = 7.82$ Hz). LCMS : (ES+) $m/z = 295$ (M+H).



- 20 Methyl 2-fluoro-3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoate


- [00538]** To a mixture of 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (0.4 g, 0.96 mmol, 1 eq), boronic ester (0.366 g, 1.24 mmol, 1.3 eq), in 1,4-dioxane/ H_2O (5:1) was added cesium carbonate (0.938 g, 2.87
- 25 mmol, 3 eq) and the nitrogen gas was passed through for 10 min. Then tetrakis(triphenylphosphine) palladium (0.111 g, 0.095 mmol, 0.1 eq) was added to the reaction mixture and nitrogen gas was again passed through the mixture for 15 min. The above reaction mixture was heated in microwave for one hour at 90 °C. About 100 ml of water is added to the reaction mixture and extracted with EtOAc. The
- 30 organic layer was further washed twice with water and dried over sodium sulphate,

concentrated to get the product. The product obtained was further purified by column chromatography using 60-120 silica gel and 25 % EtOAc/Hexane as eluent. Yield : 0.320 g (76 %). ¹H NMR (400MHz, DMSO-d₆) : δ 2.19 (s, 3H), 2.81-2.82 (d, 3H, *J* = 4.64 Hz), 3.85 (s, 3H), 7.31-7.34 (d, 2H, *J* = 8.28 Hz), 7.39-7.44 (t, 2H, *J* = 8.90 Hz), 7.54 (s, 1H), 7.79-7.85 (m, 2H), 7.97-8.01 (m, 2H), 8.45-8.46 (d, 1H, *J* = 4.32 Hz). LCMS : (ES+) *m/z* = 436 (M+H). Method: Column : CHROMOLITH® SpeedRod C18 (4.6x30)mm, 5 micron. Mphase A : 10% MeOH – 90% H₂O – 0.1% TFA. Mphase B : 90% MeOH – 10% H₂O – 0.1% TFA. Flow : 5 ml/min.

Time (min.)	%A	%B
0.0	100.0	0.0
2.0	0.0	100.0
3.0	0.0	0.0

RT min : 2.034

10 Wavelength : 220 nm



2-Fluoro-3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoic acid

15 **[00539]** To a mixture of methyl 3-fluoro-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoate (0.320 g, 1 eq) in a 1:1 mixture of MeOH/THF, 1 M solution of NaOH (0.088 g, 2.20 mmol, 3.0 eq) was added and heated to 90 °C for 3h. The mixture was cooled to ambient temperature and then in an ice-water bath. It was acidified with 1.5 N HCl and then volatiles were

20 evaporated. The mixture with white precipitate was diluted with water and filtered to get the product. It was further washed with water and dried in vacuum. Yield : 0.220 g (71 %). ¹H NMR (400MHz, DMSO-d₆) : δ 2.17 (s, 3H), 2.81-2.82 (d, 3H, *J* = 4.60 Hz), 7.28-7.33 (m, 2H, *J* = 4.33 Hz), 7.39-7.44 (m, 2H, *J* = 8.88 Hz), 7.53 (d, 1H, *J* = 1.24 Hz), 7.78-7.83 (m, 2H, *J* = 5.93 Hz), 7.97-8.01 (m, 2H), 8.45-8.47 (d, 1H, *J* =


25 4.60 Hz), 13.13 (s, 1H). LCMS : (ES+) *m/z* = 422.0 (M+H). Method: Column :

CHROMOLITH® SpeedRod C18 (4.6x30)mm, 5 micron. Mphase A : 10% MeOH – 90% H₂O – 0.1% TFA. Mphase B : 90% MeOH – 10% H₂O – 0.1% TFA. Flow : 5 ml/min.

Time (min.)	%A	%B
0.0	100.0	0.0
2.0	0.0	100.0
3.0	0.0	0.0

RT min : 1.961

5 Wavelength : 220 nm



5-(2-Fluoro-6-methyl-3-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide

- 10 **[00540]** To the solution of 2-fluoro-3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoic acid (0.1 g, 0.273 mmol, 1.0 eq) in DMF (5.0 ml), 1-(pyridin-2-yl)cyclopropanamine (0.038 g, 0.285 mmol, 1.2 eq), TBTU (0.130 g, 0.403 mmol, 1.7 eq) and DIPEA (0.154 g, 1.187 mmol, 5.0 eq) were added. Mixture was stirred at ambient temperature for 12 h under nitrogen
- 15 atmosphere. DMF was concentrated and to this residue water was added and extracted with ethyl acetate. The combined organic layer was dried over sodium sulphate and ethyl acetate was evaporated. The crude was purified by preparative TLC eluted with hexane/EtOAc (5:5). The product was further purified by recrystallization with DCM and hexane. Yield : 0.045 g (39 %). ¹H NMR (400MHz, DMSO-d₆): δ 1.23-1.25 (m, 2H), 1.51-1.54 (m, 2H), 2.18 (s, 3H), 2.81-2.82 (d, 3H, *J* = 4.0 Hz), 7.13-7.15 (t, 1H, *J* = 3.78 Hz), 7.27-7.29 (d, 1H, *J* = 8.00 Hz), 7.33-7.35 (d, 1H, *J* = 4.26 Hz), 7.39-7.44 (m, 3H, *J* = 5.26 Hz), 7.56-7.60 (t, 2H, *J* = 7.56 Hz), 7.68-7.72 (m, 1H), 7.80-7.82 (d, 1H, *J* = 8.44 Hz), 7.96-8.00 (m, 2H), 8.43-8.49 (m, 2H), 9.12 (s, 1H). LCMS : (ES⁺) *m/z* = 538.0 (M+H). Method: Column : CHROMOLITH® SpeedRod C18
- 20

(4.6x30) mm, 5 micron. Mphase A : 10% MeOH – 90% H₂O – 0.1% TFA. Mphase B : 90% MeOH –10% H₂O – 0.1% TFA. Flow : 5 ml/min.

Time (min.)	%A	%B
0.0	100.0	0.0
2.0	0.0	100.0
3.0	0.0	0.0

RT min : 1.813

Wavelength : 220 nm

5

HPLC Method:

Column : Sunfire C18 (4.6X150)mm, 3.5 micron

Buffer : 0.05% TFA in water pH 2.5

Mobile Phase A : Buffer : MeCN (95:5)

10 Mobile Phase B : MeCN :Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
12	100
15	100

Wavelength : 254 nm, RT min :10.566 (Purity : 98.287%)

Wavelength : 220 nm, RT min :10.041 (Purity : 97.3%)

15 Column : XBridge phenyl (4.6X150)mm, 3.5 micron

Buffer : 0.05% TFA in water pH 2.5

Mobile Phase A : Buffer : MeCN (95:5)

Mobile Phase B : MeCN :Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
12	100

Time	B%
15	100

Wavelength : 254 nm, RT min : 10.041 (Purity : 98.3%)

Wavelength : 220 nm, RT min : 10.041 (Purity : 97.3%)

2-Methyloxazole-4-carbonitrile


- 5 **[00541]** Ethylacetimidate hydrochloride (25 g, 340 mmol, 1 eq) and aminoacetonitrile (38.5 g, 410 mmol, 1.2 eq) were suspended in dichloromethane (300 ml) at room temperature. Triethylamine (148.4 ml, 380 mmol, 1.1 eq) was added dropwise over 1 h. After the completion of addition, the reaction mixture was cooled to 0 °C, water (125 ml) was added, organic layer was separated and the aq. layer was
- 10 extracted with 50 ml of dichloromethane. The combined dichloromethane mixture was concentrated to 50 ml. Diethyl ether (500 ml) was added to this solution, which was then cooled to 0 °C. To the above solution ethylformate (13.93 g, 190 mmol, 0.55 eq) was added followed by the addition of Potassium *tert*-butoxide (20.6 g, 172 mmol, 0.51 eq). The reaction was allowed to stir at room temperature for 90 minutes
- 15 and at 50 °C for 90 minutes. Chlorotrimethylsilane (56.5g, 520 mmol, 1.5 eq) was added at reflux condition and the reaction was stirred at 50 °C for 5 h. Later water was added and the product was extracted with dichloromethane and the organic layer was washed with water and purified by column chromatography yielding product as colorless oil. Yield : 6 g (16 %) overall yield. ¹H NMR (400MHz, DMSO-d₆): δ 2.5
- 20 (s, 3H), 8.07 (s, 1H).

1-(2-Methyloxazol-4-yl)cyclopropanamine

- [00542]** 2-Methyloxazole-4-carbonitrile (5 g, 46.1 mmol, 1 eq) was dissolved in dry THF at room temperature, and to which titanium(IV) isopropoxide (16 ml, 655
- 25 mmol, 1.2 eq) was added dropwise over a period of 15 minutes. The resulting mixture was stirred for 10 min and ethyl magnesium bromide (85 ml, 17 volumes) was added slowly dropwise at ambient temperature and the reaction was stirred for 1 h. Later BF₃.etherate (16.7 ml, 115 mmol, 2.5 eq) was added slowly at ambient temperature and the above solution was stirred at ambient temperature for 3 h. Finally water was
- 30 added and the pH was brought to 10 using 10 % sodium hydroxide solution. The

reaction mixture was extracted with dichloromethane, concentrated and purified by combiflash chromatography. Yield : 1.5 g (20 %). ¹H NMR (400MHz, DMSO-d₆): δ 0.93 (m, 2H), 1.00 (m, 2H), 1.98 (br s, 2H), 2.39 (s, 3H), 7.33 (s, 1H). LCMS : (ES+) m/z = 138.9 (M+H).

5



2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(1-methyl-1H-pyrazol-3-yl)
cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00543] To a mixture of 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-
10 yl)-4-methylbenzoic acid (0.15 g, 0.37 mmol, 1 eq), 1-(2-methyloxazol-4-
yl)cyclopropanamine (0.066 g, 0.47, 1.2 eq), HOBT (0.092 g, 0.68 mmol, 1.7 eq),
EDC.HCl (0.14 g, 0.73 mmol, 1.8 eq) in DCM at ambient temperature under nitrogen
was added Diisopropylethylamine (0.26 g, 2.2 mmol, 5.0 eq). The clear mixture was
stirred at ambient temperature for 12 h. The mixture was concentrated, diluted with
15 water and extracted with EtOAc. The organic layer is further washed with water,
dried over sodium sulphate and concentrated. The product obtained was further
purified by column chromatography (neutral alumina) using 0.5 % Methanol/DCM as
an eluent followed by preparative HPLC. Yield : 0.02 g (20 %). ¹H NMR (400MHz,
DMSO-d₆): δ 1.10-1.13 (m, 2H), 1.21-1.24 (m, 2H), 2.29 (s, 3H), 2.33 (s, 3H), 2.81-
20 2.82 (d, 3H, *J* = 4.6 Hz), 7.38-7.43 (m, 4H), 7.57 (s, 1H), 7.61 (s, 1H), 7.75-7.71 (d,
1H, *J* = 8.4 Hz), 7.80-7.81 (s and m, 2H), 7.97-8.01 (m, 2H), 8.47-8.48 (d, 1H, *J* =
4.76 Hz), 9.1 (s, 1H). LCMS : (ES+) m/z = 524.2 (M+H). LCMS Method :
CHROMOLITH® SpeedROD C18 (4.6X3.0mm-5.0μm). Mphase A : 2% MeCN -
98% H₂O-10mM NH₄COOH. Mphase B : 98% MeCN – 2% H₂O-10mM
25 NH₄COOH. Flow : 1mL/Min.

Time	%B
0.0	0.0
2.0	100.0
3.0	100.0

RT min : 2.018, wavelength : 220 nm

HPLC Method:

Sunfire C18 (4.6X150) mm, 3.5 micron

5 Buffer : 0.05% TFA in water pH 2.5

Mobile Phase A : Buffer : MeCN (95:5)

Mobile Phase B : MeCN : Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
12	100
15	100

Wavelength : 254 nm, RT min :10.757

10 Wavelength : 220 nm, RT min :10.757

Purity: 96.7%

XBridge phenyl (4.6X150)mm, 3.5 micron

Buffer : 0.05% TFA in water pH 2.5

15 Mobile Phase A : Buffer : MeCN (95:5)

Mobile Phase B : MeCN : Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
12	100
15	100


Wavelength : 254 nm, RT min :9.993

Wavelength : 220 nm, RT min :9.993

20 Purity: 96.7%

1-(Pyrimidin-5-yl)cyclopropanamine

[00544] 5-Cyano pyrimidine (5 g, 47.6 mmol, 1 eq) was taken in a Dry THF under Argon atmosphere, then Titanium isopropoxide (17 ml, 57.1 mmol, 1.2 eq) was added slowly at ambient temperature and the resulting mass was stirred for 15 mins. To the above stirred solution was added Ethyl magnesium bromide (1 M solution in THF, 107 ml, 809.3 mmol, 2.5 eq) slowly via syringe at ambient temperature. (During the addition of EtMgBr reaction mass turned black). Then the reaction mass was stirred for an hour, $\text{BF}_3 \cdot \text{EtO}$ (16.7 ml, 119.0 mmol, 2.5 eq) was added slowly through syringe at 0 °C. Then the reaction was allowed to attain ambient temperature and the stirring was continued for another one hour. Finally the reaction was quenched by adding 50ml of water and the reaction mass was passed through CELITE® and the bed was washed with water and Ethyl acetate. The filtrate was basified with 10 % NaOH solution (pH = 9) and then extracted with DCM and washed with brine solution. The required product was purified by silica gel (60-120) column chromatography using DCM/methanol as the eluent. Yield: 0.1 g (5 %) ^1H NMR (400MHz, DMSO-d_6) : 1.04-1.08 (q, 2H, $J = 3.96$ Hz), 1.18-1.25 (q, 2H, $J = 3.96$ Hz), 8.26 (d, 2H), 9.05 (s, 1H). LCMS : (ES+) $m/z = 136$ (M+H).



20 2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyrimidin-5-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00545] To a mixture of 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoic acid (0.1 g, 0.25 mmol, 1 eq), 1-(pyrimidin-5-yl)cyclopropanamine (0.041 g, 0.3 mmol, 1.2 eq) (60 % purity), HOBT (0.057 g, 0.42 mmol, 1.7 eq), EDC.HCl (0.086 g, 0.44 mmol, 1.8 eq) in DCM at ambient temperature under nitrogen was added Diisopropylethylamine (0.162 g, 1.2 mmol, 5.0 eq). The clear mixture was stirred at ambient temperature for overnight. The mixture was concentrated, diluted with water and extracted with EtOAc. The organic layer is further washed with water, dried over sodium sulphate and concentrated. The product obtained was further purified by column chromatography (neutral alumina) using 0.5 % Methanol/DCM and finally it was purified by preparative HPLC. Yield :

- 0.02 g (20 %). ^1H NMR (400MHz, DMSO- d_6) : δ 1.34-1.35 (m, 2H), 1.41-1.42 (m, 2H), 2.29 (s, 3H), 2.81-2.82 (d, 3H, $J = 4.56$ Hz), 7.38-7.45 (m, 4H), 7.58 (d, 1H, $J = 0.96$ Hz), 7.75 (d, 1H, $J = 8.4$ Hz), 7.81 (s, 1H), 7.83 (m, 1H), 7.98-8.01 (m, 2H), 8.46-8.47 (d, 1H, $J = 4.6$ Hz), 8.64 (s, 2H), 9.01 (s, 1H), 9.31 (s, 1H). LCMS : (ES+) $m/z = 521.2(\text{M}+\text{H})$. LCMS Method : Column : Ascentis Express C18 (5X2.1mm-2.7 μm). Mphase A : 2% ACN -98% H_2O -10mM NH_4COOH . Mphase B : 98% ACN – 2% H_2O -10mM NH_4COOH . Flow : 1mL/Min.

Time	%A	%B
0.0	100.0	0
1.5	0.0	100.0
3.2	0.0	100.0
3.6	100.0	0.0

RT min : 1.825, wavelength: 220 nm

- 10 HPLC Method:
 Sunfire C18 (4.6X150)mm, 3.5 micron
 Buffer : 0.05% TFA in water pH 2.5
 Mobile Phase A : Buffer : MeCN (95:5)
 Mobile Phase B : MeCN :Buffer (95:5)
- 15 Flow : 1ml/min

Time	B%
0	10
12	100
15	100

Wavelength : 254 nm, RT min :10.061

Wavelength : 220 nm, RT min :10.061

Purity : 92.3 %

- 20 XBridge phenyl (4.6X150)mm, 3.5 micron
 Buffer : 0.05% TFA in water pH 2.5
 Mobile Phase A : Buffer : MeCN (95:5)

Mobile Phase B : MeCN :Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
12	100
15	100


Wavelength : 254 nm, RT min :9.542

Wavelength : 220 nm, RT min :9.542

5 Purity : 92.5 %

1-(1-Methyl-1H-pyrazol-3-yl)cyclopropanamine

[00546] Ethyl magnesium bromide (2.5 mol, 1 M in ether) was added at -78 °C to a solution of a 1-methyl-1H-pyrazole-3-carbonitrile (0.5 g, 1 mmol) and Ti(Oi-Pr)₄ (1.1 mmol) in Et₂O (5 mL). The yellow solution was stirred for 10 min. After the solution was warmed to ambient temperature (1 h), BF₃.OEt₂ (2 mmol) was added. After the mixture was stirred for 1 h, 1 N HCl and ether were added. NaOH (10 %) was added to the resulting two clear phases and the mixture was extracted with ether. The combined ether layers were dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (Et₂O). ¹H NMR (400MHz, CDCl₃): δ 0.94-1.05 (m, 4H), 2.32 (s, 2H), 3.83 (s, 3H), 5.92 (d, 1H), 7.23-7.24 (d, 1H). LCMS : (ES+) m/z observed 137.7.



20 2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(1-methyl-1H-pyrazol-3-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00547] To a mixture of 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoic acid (0.15 g, 0.37 mmol, 1 eq), 1-(1-methyl-1H-pyrazol-3-yl)cyclopropanamine (0.061 g, 0.44 mmol, 1.2 eq), HOBt (0.057 g, 0.42 mmol, 1.7 eq), EDC.HCl (0.086 g, 0.44 mmol, 1.8 eq) in DCM at ambient temperature under

25

nitrogen was added diisopropylethylamine (0.16 g, 1.2mmol, 5.0 eq). The clear mixture was stirred at ambient temperature for 12 h. The mixture was concentrated, diluted with water and extracted with EtOAc. The organic layer was further washed with water, dried over sodium sulphate and concentrated. The product obtained was

5 further purified by column chromatography (neutral alumina) using 0.5 % Methanol/DCM and finally by preparative HPLC. Yield : 0.06 g (40 %) ¹H NMR (400MHz, DMSO-d₆): δ 1.12-1.16 (m, 2H), 1.20-1.23 (m, 2H), 2.29 (s, 3H), 2.82-2.83 (d, 3H, *J* = 4.64 Hz), 3.37 (s, 3H), 5.9-6.0 (d, 1H, *J* = 2.12 Hz), 7.39-7.48 (m, 5H), 7.58 (d, 1H, *J* = 1.68 Hz), 7.75-7.77 (d, 1H, *J* = 9.7 Hz), 7.81-7.83 (t, 2H, *J* =

10 2.87 Hz), 7.98-8.46 (m, 2H), 8.47-8.48 (d, 1H, *J* = 4.52 Hz), 9.14 (s, 1H). LCMS : (ES+) *m/z* = 523.2 (M+H). LCMS Method : Column : Ascentis Express C18 (5X2.1mm-2.7μm). Mphase A : 2% MeCN -98% H₂O-10mM NH₄COOH. Mphase B : 98% MeCN – 2% H₂O-10mM NH₄COOH. Flow : 1mL/Min.

Time	%A	%B
0.0	100.0	0.0
1.0	70.0	30.0
2.5	0.0	100.0
4.0	0.0	100.0

RT min : 1.882, wavelength : 220 nm

15

HPLC Method Info:

Sunfire C18 (4.6X150)mm, 3.5 micron

Buffer : 0.05% TFA in water pH 2.5

Mobile Phase A : Buffer : MeCN (95:5)

20 Mobile Phase B : MeCN :Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
25	100
30	100

Wavelength : 254 nm, RT min :16.999

Wavelength : 220 nm, RT min :16.999

Purity: 96%

XBridge phenyl (4.6X150)mm, 3.5 micron

5 Buffer : 0.05% TFA in water pH 2.5

Mobile Phase A : Buffer : MeCN (95:5)

Mobile Phase B : MeCN :Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
12	100
15	100

Wavelength : 254 nm, RT min :15.556

10 Wavelength : 220 nm, RT min :15.556

Purity: 97 %

Methyl 2-methoxy-4-methylbenzoate


[00548] Methyl 2-methoxy-4-methylbenzoic acid (1.5 g, 9.0 mmol, 1 eq) was
 15 dissolved in DMF, methyl iodide (0.86 ml, 13.5 mmol, 1.5 eq) was added to it
 followed by the addition of potassium carbonate (3.11 g, 22.5 mmol, 2.5 eq). The
 above mixture was stirred at room temperature for 12 h. Finally, the reaction mixture
 was passed through CELITE®. The filtrate was evaporated and water was added and
 the product was extracted with ethyl acetate. The organic layer was washed with
 20 water and concentrated. Yield : 1.6 g (98 %). ¹H NMR (400MHz, CDCl₃): δ 2.31 (s,
 3H), 3.86 (s, 3H), 3.89 (s, 3H), 6.77 (s, 1H), 6.79 (d, 1H), 7.14 (d, 1H).

Methyl 5-iodo-2-methoxy-4-methylbenzoate

[00549] Methyl 2-methoxy-4-methylbenzoate (1.5 g, 8.32 mmol, 1 eq) was
 25 dissolved in methanol. To this solution was added dropwise iodine monochloride
 (6.75 g, 41.6 mmol, 5 eq) in methanol at room temperature. The reaction mixture was
 heated at 50 °C for 15 h. Finally, methanol was concentrated, diluted with water and

extracted with ethyl acetate. The organic layer was washed with 0.1 N HCl (50 ml), water (100 ml) and brine solution (100 ml). The product was purified by column chromatography using 60-120 silica gel and using 5% ethyl acetate/hexane as eluent. Yield : 1.7 g (80 %). ¹H NMR (400MHz, CDCl₃): δ 2.44 (s, 3H), 3.86 (s, 3H), 3.88 (s, 3H), 6.86 (s, 1H), 8.20 (s, 1H). LCMS : (ES+) m/z = 307.0 (M+H).


Methyl 2-methoxy-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
[00550] Methyl 5-iodo-2-methoxy-4-methylbenzoate (1.5 g, 4.9 mmol, 1 eq), Bispinacolatodiboron (1.49 g, 5.8 mmol, 1.2 eq), potassium acetate (1.44 g, 14.7 mmol, 3 eq) and Pd(dppf)Cl₂ (0.4 g, 0.49 mmol, 0.1 eq) were dissolved in DMF. Nitrogen gas was passed through the mixture for 10 minutes and the mixture was stirred at 90 °C for 14 hours. Later the solution was passed through CELITE®. The filtrate was evaporated and diluted with water and extracted with ethyl acetate and purified by column chromatography using 60-120 silica gel and using 20 % ethyl acetate/hexane as eluent. Yield : 1.2 g (80 %). ¹H NMR (400MHz, CDCl₃): δ 1.33 (s, 12H), 2.56 (s, 3H), 3.86 (s, 3H), 3.91 (s, 3H), 6.75 (s, 1H), 8.21 (s, 1H). LCMS : (ES+) m/z = 307.2 (M+H).



Methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxy-4-methylbenzoate

[00551] Methyl-2-methoxy-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (1.2 g, 3.92 mmol, 1 eq), 2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl trifluoromethanesulfonate (1.6 g, 3.92 mmol, 1 eq), Cesium carbonate (3.8 g, 11.7 mmol, 3 eq) and Tetrakis triphenylphosphinepalladium (0.13 g, 0.11 mmol, 0.03 eq) were dissolved in 1,4-dioxane/water and the above solution was stirred at 90 °C for 10 h. Then the reaction mixture was diluted with water and product was extracted with ethyl acetate and purified by combiflash chromatography using 40 % ethyl acetate/hexane as eluent. Yield : 0.95 g (55 %). ¹H NMR (400MHz, DMSO-d₆): δ 2.3 (s, 3H), 2.82 (d, J = 4.6

Hz, 3H), 3.78 (s, 3H), 3.88 (s, 3H), 7.15 (s, 1H), 7.51 (s, 1H), 7.64 (m, 2H), 7.65 (m, 2H), 7.74 (d, 1H, $J = 8.48$ Hz), 8.00-8.01 (m, 2H), 8.48 (d, 1H). LCMS : (ES+) $m/z = 448$ (M+H).



5

5-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxy-4-methylbenzoic acid

[00552] Methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxy-4-methylbenzoate (0.9 g, 2 mmol, 1 eq) and sodium hydroxide (0.4 g, 10 mmol, 5 eq) were dissolved in methanol/water (20/5 ml) and the reaction was stirred at 50 °C for 10 h. Then the reaction mixture was concentrated and diluted with water and the pH of the solution was brought to 3 by using Conc HCl. The solid obtained was filtered and dried overnight. Yield : 0.72 g (82 %). ^1H NMR (400MHz, DMSO- d_6): δ 2.29 (s, 3H), 2.87 (d, 3H), 3.87 (s, 3H), 7.09 (s, 1H), 7.40-7.60 (m, 3H), 7.57 (m, 2H), 7.65 (d, 1H, $J = 8.74$ Hz), 7.98-8.01 (m, 2H), 8.46 (q, 1H, $J = 4.40$ Hz), 12.5 (br s, 1H). LCMS : (ES+) $m/z = 434$ (M+H) Method : Mphase A : water; Mphase B : 0.1% acetone in water; Flow : 2mL/Min.

15

Time	%B
0-20	100


RT min : 1.741

Wavelength : 220 nm

20

[00553] Additional LCMS were performed by using Shimadzu-VP instrument with UV detection at 220 nm and Waters MICROMASS®. HPLC method: Solvent A = 10% MeOH 90% H_2O 0.1% TFA, Solvent B = 90% MeOH 10% H_2O 0.1% TFA, Start %B = 0, Final %B = 100, Gradient time = 2 min, Stop time = 3 min, Flow Rate = 5 ml/min, Column: PHENOMENEX® Luna, 3.0 x 50 mm, S10; (ES+) m/z (M+H) $^+ = 434.10$, HPLC $R_t = 1.653$ min.

25



2-(4-Fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide

- [00554]** To a mixture of 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxy-4-methylbenzoic acid (0.2 g, 0.46 mmol, 1 eq), 1-(pyrimidin-2-yl)cyclopropanamine (0.074 g, 0.55 mmol, 1.2 eq), HOBt (0.105 g, 0.77 mmol, 1.7 eq), EDC.HCl (0.0158 g, 0.82 mmol, 1.8 eq), in DCM at ambient temperature and under nitrogen atmosphere was added diisopropylethylamine (0.297 g, 2.2 mmol, 5.0 eq). The clear mixture was stirred at ambient temperature for 12 h. The mixture was concentrated, diluted with water and extracted with EtOAc. The organic layer was further washed with water, dried over sodium sulphate and concentrated. The product obtained was further purified by column chromatography (neutral alumina) using 0.5 % Methanol/DCM and preparative HPLC. Yield : 0.055 g (45%). ¹H NMR (400MHz, DMSO-d₆): δ 1.43-1.44 (m, 2H), 1.59-1.62 (m, 2H), 2.31 (s, 3H), 2.81-2.82 (d, 3H, *J* = 4.56 Hz), 4.01 (s, 3H), 7.17 (s, 1H), 7.26-7.29 (t, 1H, *J* = 4.8 Hz), 7.33-7.36 (dd, 1H, *J* = 8.4, 4 Hz), 7.38-7.43 (t, 2H, *J* = 8.8 Hz), 7.50-7.51 (d, 1H, *J* = 1.6 Hz), 7.72-7.76 (m, 2H), 7.97-8.01 (m, 2H), 8.48-8.49 (d, 1H, *J* = 4.4 Hz), 8.7 (d, 2H, *J* = 4.8 Hz), 8.87 (s, 1H). LCMS : (ES⁺) *m/z* = 551.2 (M+H). Column : Ascentis Express C18 (5X2.1mm-2.7μm). Mphase A : 2% MeCN -98% H₂O-10mM NH₄COOH.
- Mphase B : 98% MeCN – 2% H₂O-10mM NH₄COOH. Flow : 1mL/Min

Time	%A	%B
0.0	100.0	0.0
1.0	70.0	30.0
2.5	0.0	100.0
4.0	0.0	100.0

RT min : 1.946, wavelength:220nm

HPLC Method:

Sunfire C18 (4.6X150)mm, 3.5 micron

Buffer : 0.05% TFA in water pH 2.5

Mobile Phase A : Buffer : MeCN (95:5)

Mobile Phase B : MeCN :Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
25	100
30	100

5 Wavelength : 254 nm, RT min :18.209

Wavelength : 220 nm, RT min :18.209

Purity: 99.4%

XBridge phenyl (4.6X150)mm, 3.5 micron

10 Buffer : 0.05% TFA in water pH 2.5

Mobile Phase A : Buffer : MeCN (95:5)

Mobile Phase B : MeCN :Buffer (95:5)


Flow : 1ml/min

Time	B%
0	10
25	100
30	100

Wavelength : 254 nm, RT min :16.549

15 Wavelength : 220 nm, RT min :16.549

Purity: 99.5 %



20 2-(4-Fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(2-methyloxazol-4-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide

- [00555]** 5-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxy-4-methylbenzoic acid (0.15 g, 0.34 mmol, 1 eq), 1-(2-methyloxazol-4-yl)cyclopropanamine (0.047 g, 0.34 mmol, 1 eq), EDCI.HCl (0.076 g, 0.4 mmol, 1.2 eq), HOBT (0.054 g, 0.4 mmol, 2 eq) and TEA (0.14 ml, 1.02 mmol, 3 eq) were dissolved in dichloromethane and the reaction was stirred at room temperature for 14 h. The reaction was diluted with water and the product was extracted with dichloromethane and purified by preparative HPLC yielding the desired product. Yield: 47 mg (25 %) ¹H NMR (400MHz, DMSO-d₆): δ 1.12-1.15 (m, 2H), 1.21-1.24 (m, 2H), 2.29 (s, 3H), 2.34 (s, 3H), 2.81-2.82 (d, 3H, *J* = 4.60 Hz), 3.95 (s, 3H), 7.12 (s, 1H), 7.31-7.32 (m, 1H), 7.34-7.40 (t, 2H, *J* = 3.21 Hz), 7.56 (s, 1H), 7.61 (s, 1H), 7.71 (s, 1H), 7.73 (s, 1H), 7.97-8.01 (m, 2H), 8.46-8.48 (m, 1H), 8.67 (s, 1H). LCMS : (ES⁺) *m/z* = 554.2 (M+H). Column : Ascentis Express C18 (5X2.1mm-2.7μm). Mphase A : 2% ACN -98% H₂O-10mM NH₄COOH. Mphase B : 98% ACN – 2% H₂O-10mM NH₄COOH. Flow : 1mL/Min

Time	%A	%B
0.0	100.0	0
1.0	70.0	30.0
2.5	0.0	100.0
4.0	0.0	100.0

- RT min : 1.964, wavelength : 220 nm

HPLC Method:

Sunfire C18 (4.6X150)mm, 3.5 micron

Buffer : 0.05% TFA in water pH 2.5

- Mobile Phase A : Buffer : MeCN (95:5)

Mobile Phase B : MeCN :Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
12	100
15	100

Wavelength : 254 nm, RT min :11.403

Wavelength : 220 nm, RT min :11.402

Purity: 98.8 %

5 XBridge phenyl (4.6X150)mm, 3.5 micron

Buffer : 0.05% TFA in water pH 2.5

Mobile Phase A : Buffer : MeCN (95:5)

Mobile Phase B : MeCN :Buffer (95:5)


Flow : 1ml/min

Time	B%
0	10
12	100
15	100

10 Wavelength : 254 nm, RT min :10.588

Wavelength : 220 nm, RT min :10.588

Purity : 98.96 %



15 2-(4-Fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(1-methyl-1H-pyrazol-3-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide

[00556] To a mixture of 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxy-4-methylbenzoic acid (0.15 g, 0.35 mmol, 1 eq), 1-(1-methyl-1H-pyrazol-3-yl)cyclopropanamine (0.058 g, 0.42 mmol, 1.2 eq), HOBT (0.08 g, 0.069

20 mmol, 1.7 eq), EDC.HCl (0.073 g, 0.014mmol, 1.8 eq), in DCM at ambient temperature under nitrogen was added Diisopropylethylamine (0.297 g, 2.2 mmol, 5.0 eq). The clear mixture was stirred at ambient temperature for 12 h. The mixture was concentrated, diluted with water and extracted with EtOAc. The organic layer is further washed with water, dried over sodium sulphate and concentrated. The product
25 obtained was further purified by column chromatography (neutral alumina) using 0.5

% Methanol/DCM and the final purification was done by preparative HPLC. Yield : 0.06 g (45 %) ¹H NMR (400MHz, DMSO-d₆) : δ 1.18-1.20 (m, 4H), 2.29 (s, 3H), 2.81-2.82 (d, 3H, *J* = 4.64 Hz), 3.73 (s, 3H), 3.96 (s, 3H), 6.06-6.07 (d, 1H, *J* = 2.4 Hz), 7.12 (s, 1H), 7.32-7.34 (dd, 1H, *J* = 8.4, 1.6 Hz), 7.38.-7.42 (t, 2H, *J* = 8.8 Hz), 7.48.-7.49 (d, 2H, *J* = 2.34 Hz), 7.59 (s, 1H), 7.71-7.73 (d, 1H, *J* = 8.4 Hz), 7.97-7.97-8.01 (m, 2H), 8.47-8.48 (d, 1H, *J* = 4.8 Hz), 8.69 (s, 1H). LCMS : (ES+) *m/z* = 553.2 (M+H). Column : Ascentis Express C18 (5X2.1mm-2.7μm). Mphase A : 2% MeCN -98% H₂O-10mM NH₄COOH. Mphase B : 98% MeCN – 2% H₂O-10mM NH₄COOH. Flow : 1mL/Min.

Time	%A	%B
0.0	100.0	0
1.5	0.0	100.0
3.2	0.0	100.0

10 RT min : 1.937, wavelength : 220 nm

HPLC Method:

Sunfire C18 (4.6X150)mm, 3.5 micron

Buffer : 0.05% TFA in water pH 2.5

15 Mobile Phase A : Buffer : MeCN (95:5)

Mobile Phase B : MeCN :Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
12	100
15	100

Wavelength : 254 nm, RT min :11.289

Wavelength : 220 nm, RT min :11.289

20 Purity: 99.3 %

XBridge phenyl (4.6X150)mm, 3.5 micron

Buffer : 0.05% TFA in water pH 2.5

Mobile Phase A : Buffer : MeCN (95:5)

Mobile Phase B : MeCN :Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
12	100
15	100


Wavelength : 254 nm, RT min :10.548

5 Wavelength : 220 nm, RT min :10.548

Purity: 99.5 %

1-(1-Methyl-1H-imidazol-4-yl) cyclopropanamine

- [00557] 1-Methyl-1H-imidazole-4-carbonitrile (0.5 g, 4.6 mmol, 1 eq) was
 10 dissolved in THF, and to which titanium isopropoxide (1.6 g, 5.6 mmol, 2.5 eq) was
 added dropwise over 15 minutes. The mixture was stirred for 15 minutes at room
 temperature, and then ethyl magnesium bromide (1.6 g, 11.5 mmol, 2.5 eq) was
 added at room temperature over 15 minutes. The reaction mixture was stirred for 1 h.
 BF₃ etherate (0.8 g, 5.6 mmol, 2.2 eq) was added and the mixture stirred at room
 15 temperature for 1 h. 1 N NaOH solution was added to the mixture to bring the pH to
 9-10. Reaction mass was filtered through CELITE® and the filtrate washed with
 DCM. The organic mixture was concentrated and the residue purified by flash
 chromatography on silica gel using 10 % chloroform/ methanol. Yield: 0.6 g ¹H NMR
 (400MHz, CDCl₃): δ 0.97 (t, *J* = 3.4 Hz, 2H), 1.00 (t, *J* = 3.4 Hz, 2H), 3.63 (s, 3H),
 20 7.28 (s, 1H), 7.31 (s, 1H). LCMS : (ES+) *m/z* = 138.2 (M+H).



2-(4-Fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(1-methyl-1H-imidazol-4-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide

- [00558]** 5-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxy-4-methylbenzoic acid (0.2 g, 1 eq), 1-(1-methyl-1H-imidazol-4-yl) cyclopropanamine (0.07 g, 1.1 eq), EDCI.HCl (0.13 g, 1.5 eq), HOBT (0.094 g, 1.5 eq) and TEA (0.19 ml, 3 eq) were dissolved in dichloromethane and the above solution was stirred at room temperature for 18 h. Later water was added and organic layer was separated. The organic layer was washed with water and the crude product was purified by Prep. HPLC. Yield : 24.69 mg (10 %) ¹H NMR (400MHz, CDCl₃): δ 1.39 (s, 4H), 2.30 (s, 3H), 2.99-3.01 (d, *J* = 4.6 Hz, 3H), 3.81 (s, 3H), 4.04 (s, 3H), 5.90 (s, 1H), 6.87 (s, 1H), 7.16-7.25 (m, 3H), 7.24 (s, 1H), 7.51 (d, *J* = 8.4 Hz, 1H), 7.65 (s, 1H), 7.98-7.99 (m, 3H), 8.29 (s, 1H), 8.95 (s, 1H). LCMS : (ES+) *m/z* = 553.2 (M+H). Method: Column : Ascentis Express C18 (5X2.1mm-2.7μm). Mphase A : 2% ACN -98% H₂O-10mM NH₄COOH. Mphase B : 98% ACN – 2% H₂O-10mM NH₄COOH. Flow : 1mL/Min.

Time	%A	%B
0.0	100.0	0
1.5	0.0	100.0
3.2	0.0	100.0

RT min : 1.854

- 15 Wavelength : 220 nm

HPLC Column:

Sunfire C18 (4.6X150)mm, 3.5 micron

Buffer : 0.05% TFA in water pH 2.5

- 20 Mobile Phase A : Buffer : MeCN (95:5)

Mobile Phase B : MeCN :Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
25	100
30	100

Wavelength : 254 nm, RT min :11.685

Wavelength : 220 nm, RT min : 11.685

Purity : 99.1%

HPLC Column:

5 XBridge phenyl (4.6X150)mm, 3.5 micron

Buffer : 0.05% TFA in water pH 2.5

Mobile Phase A : Buffer: MeCN (95:5)

Mobile Phase B : 0.05% TFA in MeCN : Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
25	100
30	100

10 Wavelength : 254 nm, RT min :13.396

Wavelength : 220 nm, RT min : 13.396

Purity : 96.5%

Preparative HPLC Method:

15 Column : Symmetry C18 (19X250X10 μ)

Mobile Phase: 0.1% TFA (A), MeCN (B)

Gradient:

Time	Flow	A	B
0	15ml/min	95	5
10	15ml/min	55	45

RT: 10.5 min

20 1-(5-Methylisoxazol-3-yl)cyclopropanamine


[00559] 5-Methylisoxazole-3-carbonitrile (1.0 g, 1 mmol) was dissolved in THF.

Ti (Oi-Pr) 4 (1.2 mmol) was added dropwise over a period of 5-10 min and the

reaction mixture was stirred at r.t for 15 min. It was then cooled down to 0 °C and

EtMgBr (2.5 mmol) was added dropwise over a period of 10-15min. It was stirred at

0 °C for 15 min. and then stirred at rt for 1 hr. The mixture was cooled again to 0 °C and BF₃OEt₂ (2 mmol) was added dropwise over a period of 5-10 min at 0 °C. After the mixture was stirred for 10min at 0 °C and 1hr at rt, 1 N NaOH was added at 0 °C. DCM was added to the reaction mixture which was then stirred for 5-10 min. This alkaline solution was filtered through CELITE® and washed with DCM. The organic layer was concentrated and residue purified by flash chromatography on silica gel using 10 % chloroform/ methanol. Yield: 0.6g ¹H NMR (400MHz, CDCl₃): δ 0.96-1.05 (m, 4H), 2.36 (s, 3H), 5.59 (s, 1H). LCMS : (ES+) m/z observed 138.7.



2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(5-methylisoxazol-3-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide

[00560] To a mixture of 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoic acid (0.15 g, 0.37 mmol, 1 eq), amine (0.06 g, 0.43 mmol, 1.2 eq), HOBT (0.084 g, 0.62 mmol, 1.7 eq), EDC.HCl (0.127 g, 0.087 mmol, 1.8 eq) in DCM at ambient temperature under nitrogen was added Diisopropylethylamine (0.239 g, 1.8 mmol, 5.0 eq). The clear mixture was stirred at ambient temperature for 12 h. LCMS showed the desired product. The mixture was concentrated, diluted with water and extracted with EtOAc. The organic layer is further washed with water, dried over sodium sulphate, filtered and then concentrated. The product obtained was further purified by column chromatography (neutral alumina) using 0.5% Methanol/DCM and preparative HPLC. Yield : 0.03 g (20 %). ¹H NMR (400MHz, DMSO-d₆): δ 1.24-1.29 (m, 4H), 2.29 (s, 3H), 2.32 (s, 3H), 2.81-2.82 (d, 3H, *J* = 4.6 Hz), 6.05 (s, 1H), 7.38-7.44 (m, 4H), 7.57 (d, 1H, *J* = 1.6 Hz), 7.75-7.82 (m, 3H), 7.97-8.0 (m, 2H), 8.46-8.47 (m, 1H), 9.24 (s, 1H). LCMS : (ES+) m/z = 524.2 (M+H). LCMS Method : Column : Ascentis Express C18 (5X2.1mm-2.7μm). Mphase A : 2% ACN -98% H₂O-10mM NH₄COOH. Mphase B : 98% ACN – 2% H₂O-10mM NH₄COOH. Flow : 1mL/Min

Time	%A	%B

Time	%A	%B
0.0	100.0	0
1.5	0.0	100.0
3.2	0.0	100.0

RT min : 1.966, wavelength : 220nm

HPLC Method:

Column : Atlantis T3 (4.6X150mm-5.0µm)

5 A : Buffer : 20mM Ammonium acetate in Water

B : MeCN

Flow : 1ml/min

Time	B%
20	0
35	5
35	30
100	35
100	40

Wavelength : 254 nm, RT min :15.155

Wavelength : 220 nm, RT min :15.155

10

HPLC Method:

Sunfire C18 (4.6X150)mm, 3.5 micron

Buffer : 0.05% TFA in water pH 2.5

Mobile Phase A : Buffer : MeCN (95:5)

15 Mobile Phase B : ACN :Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
12	100
15	100

Wavelength : 254 nm, RT min :18.678

Wavelength : 220 nm, RT min :18.678

Purity: 99.4%

XBridge phenyl (4.6X150)mm, 3.5 micron

5 Buffer : 0.05% TFA in water pH 2.5

Mobile Phase A : Buffer : ACN (95:5)

Mobile Phase B : ACN :Buffer (95:5)

Flow : 1ml/min

Time	B%
0	10
12	100
15	100

Wavelength : 254 nm, RT min :17.135

10 Wavelength : 220 nm, RT min :17.135

Purity: 99.5%

5-Methylthiazole-2-carbaldehyde

[00561] To a solution of BuLi (5 mmol) in ether at -78 °C was added dropwise a
 15 solution of 5-methylthiazole (5 mol) in ether at -78 °C for 1.5 hours. A solution of
 DMF (5 mmol) in ether was added at once and the reaction was allowed to warm to
 room temperature and stirred overnight. Ice was added to the mixture followed by the
 slow addition of 4 N HCl. The mixture was extracted with ether. The aq. layer was
 brought to pH 7.5 with solid NaHCO₃ and extracted with ether. The combined ethereal
 20 extracts was dried, filtered and concentrated to get crude residue, which was purified
 by flash chromatography on silica gel using 10 % EtOAc / Hexane. Yield: 6 g ¹H
 NMR (400MHz, CDCl₃): δ 2.56 (s, 3 H), 7.79 (s, 1H), 9.90 (s, 1H). LCMS : (ES+)
 m/z = 128 (M+H).

25 5-Methylthiazole-2-carbaldehyde oxime

[00562] To a solution of 5-methylthiazole-2-carbaldehyde (4.8 mmol) in DCM was
 added pyridine (4.8 mmol) and HONH₂.HCl (4.8 mmol). The reaction mixture was

stirred at ambient temperature for 12 hours, then diluted with DCM and extracted with water. The organic extract was dried, filtered and concentrated to obtain crude oxime. Yield: 6 g; LCMS : (ES+) m/z = 143 (M+H).

5

5-Methylthiazole-2-carbonitrile

[00563] 5-Methylthiazole-2-carbaldehyde oxime (4.2 mmol) was dissolved in DCM and added with CDI (4.3 mmol) portionwise. The reaction mixture and stir at rt overnight, and then added with water. The mixture was extracted with DCM, and the organic layer was dried and concentrated to get the crude residue, which was purified
10 by flash chromatography on silica gel using 10 % EtOAc / Hexane. Yield : 3.2 g; ¹H NMR (400MHz, CDCl₃): δ 2.59 (s, 3 H), 7.71 (s, 1H).

1-(5-Methylthiazol-2-yl)cyclopropanamine

[00564] 5-Methylthiazole-2-carbonitrile (1.0 g, 1 mmol) was dissolved in THF.
15 Ti(Oi-Pr)₄ (1.2 mmol) was added dropwise to the mixture over a period of 5-10min and the reaction mixture was stirred at rt for 15 min. It was then cooled down to 0 °C and EtMgBr (2.5 mmol) was added dropwise over a period of 10-15 min. The reaction mixture was stirred again at 0 °C for 15 min. and then stirred at ambient temperature for 1 h. BF₃·OEt₂ (2.5 mmol) was then added dropwise over a period of
20 5-10 min to the mixture that was cooled again to 0 °C. After the mixture was stirred for 10 min at 0 °C and 1 h at ambient temperature, 1 N NaOH was added to the mixture cooled to 0 °C. DCM was added to the reaction mixture and stirred for 5-10 min. This alkaline solution was filtered through CELITE® and washed with DCM. The organic layer was concentrated and the residue purified by flash chromatography
25 on silica gel using 10 % chloroform / methanol. Yield : 0.6 g; ¹H NMR (400MHz, CDCl₃): δ 1.20 (m, 2H) 1.31 (m, 2H), 2.40 (s, 3H), 7.26 (s, 1H). LCMS : (ES+) m/z observed 154.7.

2-(4-Fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(5-methylthiazol-2-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide
30 **[00565]** 5-(2-(4-Fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxy-4-methylbenzoic acid (0.2 g, 1 eq), 1-(5-methylthiazol-2-yl)cyclopropanamine (0.07



- g, 1 eq), EDCI.HCl (0.13 g, 1.5 eq), HOBT (0.094 g, 1.5 eq) and TEA (0.19 ml, 3 eq) were dissolved in dichloromethane and the above solution was stirred at room temperature for 18 h. Then water was added to the mixture and the organic layer was separated. The organic layer was washed with water and the product was purified by
- 5 Prep. HPLC. Yield : 65 mg (25 %) ¹H NMR (400MHz, CDCl₃): δ 1.43-1.46 (m, 2H), 1.74-1.77 (m, 2H), 2.32 (s, 3H), 2.37 (s, 3H), 3.01-3.03 (d, *J* = 5.2 Hz, 3H), 4.04 (s, 3H), 5.89 (m, 1H), 6.91 (s, 1H), 7.16 (t, 2H), 7.27 (m, 2H), 7.51 (d, *J* = 4 Hz, 1H), 7.66 (s, 1H), 8.00 (m, 2H), 8.13 (s, 1H), 8.7 (s, 1H). LCMS : (ES⁺) *m/z* = 570.2 (M+H).
- 10 **[00566]** General procedure: 5-(5-(1-Cyanocyclopropylcarbamoyl)-2-methylphenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (448 mg) was dissolved in butan-1-ol (22.50 mL) and distributed evenly into 15 pre-weighed hydrazides in microwave vials (2-5mL size) and followed by adding K₂CO₃ (8.85 mg) as a solid. The vial was flashed with argon and capped, then heated at 165 °C for
- 15 30 minutes in a BIOTAGE® microwave reactor. The samples were dried by SPEEDVAC®, dissolved in DMF (1.8 mL) and purified by preparative HPLC. Purification method: Cw313a (19x100mm): Solvent A = 5:95 MeCN:Water; Solvent B = 95:5 MeCN:Water; Modifier = 10 mM NH₄OAc; 0' (25 mL/min) = 30% B, 0.5' (12.5 mL/min) = 30% B, 2' (12.5 mL/min) = 30% B, 2.5' = 30% B, 22' = 95% B, 36'
- 20 = 95% B. HPLC purity was determined using a Waters ZQ with ESCi mass spectrometer. Solvent A = 5:95 MeCN:Water; Solvent B = 95:5 MeCN:Water; Modifier = 10 mM NH₄OAc. Retention time was recorded in minutes.


Analytical Method A:

- 25 Waters XBridge 4.6x50mm 5 um C18v


Time	B%	Flow (mL/min)
0.00'	5	2.00
8.00'	95	2.00
9.00'	95	2.00
9.01'	5	2.00
10.00	5	2.00

Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	4.73	89.3	587.33	A
	4.76	90.6	587.33	A
	5.44	88.5	620.37	A
	5.4	93.4	616.33	A
	5.37	100	620.187	A
	3.85	98.3	553.181	A
	5	100	616.218	A
	5.84	88.8	620.29	A
	4.86	100	616.166	A
	4.28	100	552.208	A
	4.32	100	552.207	A


Structure	HPLC Rt	% Purity	Obs. MS Ion	HPLC Method
	4.37	95	587.153	A
	4.94	94.9	578.118	A




- [00567]** ¹H NMR (600 MHz, <DMSO-d₆_CDCl₃>) δ ppm 1.41 (br. s., 2 H) 1.62 (br. s., 2 H) 2.28 - 2.47 (m, 3 H) 2.89 (d, *J*=4.69 Hz, 3 H) 7.29 - 7.51 (m, 5 H) 7.66 (s, 1 H) 7.75 (d, *J*=8.79 Hz, 1 H) 7.86 - 7.99 (m, 2 H) 8.05 (dd, *J*=8.20, 5.86 Hz, 2 H) 8.44 (d, *J*=4.10 Hz, 1 H) 8.61 (br. s., 1 H) 9.17 (s, 1 H) 9.32 (br. s., 2 H).




- [00568]** ¹H NMR (600 MHz, <DMSO-d₆_CDCl₃>) δ ppm 1.42 (br. s., 2 H) 1.61 (br. s., 2 H) 2.22 - 2.44 (m, 3 H) 2.56 - 2.63 (m, 3 H) 7.32 - 7.55 (m, 4 H) 7.66 (s, 1 H) 7.76 (d, *J*=8.79 Hz, 1 H) 7.89 - 8.03 (m, 2 H) 8.04 (dd, *J*=8.50, 5.57 Hz, 2 H) 8.44 (d, *J*=4.10 Hz, 1 H) 8.66 (d, *J*=4.10 Hz, 2 H) 9.33 (br. s., 1 H) 14.09 (br. s., 1 H).




- [00569]** ¹H NMR (600 MHz, <DMSO-d₆_CDCl₃>) δ ppm 1.42 (br. s., 2 H) 1.60 (br. s., 2 H) 2.37 (s, 3 H) 2.89 (d, *J*=4.10 Hz, 3 H) 7.31 - 7.51 (m, 4 H) 7.51 - 7.59 (m, 1 H) 7.66 (s, 1 H) 7.75 (d, *J*=8.20 Hz, 1 H) 7.80 - 7.94 (m, 2 H) 8.05 (dd, *J*=8.20, 5.86 Hz, 2 H) 8.27 (s, 1 H) 8.44 (d, *J*=4.10 Hz, 1 H) 9.31 (br. s., 1 H) 13.93 (br. s., 1 H).




[00570] ^1H NMR (600 MHz, $\text{DMSO-d}_6\text{-CDCl}_3$) δ ppm 1.40 (br. s., 2 H) 1.60 (br. s., 2 H) 2.36 (s, 3 H) 2.89 (d, $J=4.69$ Hz, 3 H) 3.86 (s, 3 H) 7.23 - 7.49 (m, 5 H) 7.53 (br. s., 1 H) 7.55 - 7.62 (m, 1 H) 7.65 (s, 1 H) 7.75 (d, $J=8.20$ Hz, 1 H) 7.90 (d, $J=8.20$ Hz, 1 H) 8.05 (dd, $J=8.20, 5.86$ Hz, 1 H) 8.27 (s, 1 H) 8.44 (d, $J=4.69$ Hz, 1 H) 9.31 (br. s., 1 H) 13.77 (br. s., 1 H).




[00571] ^1H NMR (600 MHz, $\text{DMSO-d}_6\text{-CDCl}_3$) δ ppm 1.40 (br. s., 2 H) 1.60 (br. s., 2 H) 2.37 (s, 3 H) 2.89 (d, $J=4.69$ Hz, 3 H) 7.32 - 7.54 (m, 4 H) 7.65 (s, 1 H) 7.75 (d, $J=8.79$ Hz, 1 H) 7.85 - 7.96 (m, 1 H) 7.96 - 8.11 (m, 3 H) 8.27 (s, 1 H) 8.43 (br. s., 1 H) 9.31 (s, 1 H) 13.84 (br. s., 1 H).



[00572] ^1H NMR (600 MHz, $\text{DMSO-d}_6\text{-CDCl}_3$) δ ppm 1.39 (br. s., 2 H) 1.57 (br. s., 2 H) 2.36 (s, 3 H) 2.89 (d, $J=4.69$ Hz, 3 H) 7.36 - 7.60 (m, 3 H) 7.75 (d, $J=8.20$ Hz, 1 H) 7.85 - 7.96 (m, 1 H) 8.04 (dd, $J=8.20, 5.27$ Hz, 2 H) 8.27 (s, 1 H) 8.43 (d, $J=4.69$ Hz, 1 H) 9.27 (br. s., 1 H) 14.10 (br. s., 1 H).



[00573] ^1H NMR (600 MHz, $\text{DMSO-d}_6\text{-CDCl}_3$) δ ppm 1.41 (br. s., 2 H) 1.61 (br. s., 2 H) 2.37 (s, 3 H) 2.89 (d, $J=4.69$ Hz, 3 H) 7.28 - 7.58 (m, 4 H) 7.65 (s, 1 H) 7.75 (d, $J=8.79$ Hz, 1 H) 7.86 - 8.02 (m, 1 H) 8.02 - 8.18 (m, 3 H) 8.27 (s, 1 H) 8.44 (d, $J=4.10$ Hz, 1 H) 9.31 (br. s., 1 H) 13.90 (br. s., 1 H).




[00574] ^1H NMR (600 MHz, $\text{DMSO-d}_6\text{-CDCl}_3$) δ ppm 1.39 (br. s., 2 H) 1.59 (br. s., 2 H) 2.36 (br. s., 3 H) 2.89 (d, $J=4.10$ Hz, 3 H) 3.85 (s, 3 H) 6.99 (m, 2H) 7.29 - 7.54 (m, 4 H) 7.65 (s, 1 H) 7.75 (d, $J=8.20$ Hz, 1 H) 7.82 - 7.99 (m, 3 H) 7.99 - 8.14 (m, 2 H) 8.27 (s, 1 H) 8.43 (br. s., 1 H) 9.29 (s, 1 H) 13.63 (br. s., 1 H).

[00575] It will be evident to one skilled in the art that the present disclosure is not limited to the foregoing illustrative examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

CLAIMS

We claim:

1. A compound of formula I



I

- R^1 is R^5R^6N ; alkoxy; (alkoxycarbonylamino)alkoxy; (alkylphenyl)alkoxy; (carboxy)alkenyl; (alkoxycarbonyl)alkenyl; (benzyloxycarbonyl)alkenyl; ((N-dimethylbenzyl)aminocarbonyl)alkenyl; or phenyl where said phenyl is substituted with 1-2 substituents selected from the group consisting of halo, cyano, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (carboxy)alkyl, alkoxy, hydroxyalkyloxy, alkoxyalkyloxy, benzyloxy, tetrahydropyranyloxy, carboxy, alkoxycarbonyl, alkylsulfonyl, (carboxy)alkenyl, (alkoxycarbonyl)alkenyl, alkylcarboxamido, alkoxycarboxamido, alkylsulfamido, (alkylsulfamido)alkyl, Ar^5 , $SO_2NR^{15}R^{16}$, and $CONR^7R^8$; and where said phenyl is also substituted with 0-2 substituents selected from the group consisting of halo; nitro; alkyl; cycloalkyl; haloalkyl; aminoalkyl; hydroxyalkyl; alkoxyalkyl; hydroxy; alkoxy; OR^{17} ; cycloalkoxy; amino; alkylamino; dialkylamino; alkylcarboxamido; alkoxycarboxamido; alkoxyalkylcarboxamido; furanyl, thienyl, or pyrazolyl substituted with 0-2 alkyl substituents; pyridinyl substituted with 0-2 halo, cyano, alkyl, hydroxy, alkoxy, amino, or alkylaminocarbonyl substituents; pyrimidinyl; pyrimidinedionyl; aminopyrimidinyl; indolyl; isoquinolinyl; and phenyl substituted with 0-2 substituents selected from the group consisting of halo, alkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxy, amino, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarboxamido, carboxyalkenyl, and phenyl;
- R^2 is hydrogen, halo, nitro, amino, phenyl, or R^5R^6N ;
- R^3 is cyano, alkoxycarbonyl, (cycloalkyl)oxycarbonyl, (alkylsulfonyl)aminocarbonyl, $CONR^{11}R^{12}$, $(R^{11})(R^{12})NCONH$, triazolyl, thiazolyl, or tetrazolyl;




R^4 is phenyl substituted with 0-2 halo substituents;

R^5 is hydrogen, alkyl, or alkylsulfonyl;

R^6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or alkylsulfonyl;

R^7 is hydrogen, alkyl, alkenyl, alkynyl, cyanoalkyl, haloalkyl, hydroxyalkyl,

- 5 dihydroxyalkyl, alkoxyalkyl, oxoalkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkyl)alkyl, cycloalkyl, (alkyl)cycloalkyl, (hydroxyalkyl)cycloalkyl, (tetrahydrofuranyl)alkyl, (tetrahydropyranyl)alkyl, (carboxy)alkyl, (alkoxycarbonyl)alkyl, (alkenyloxycarbonyl)alkyl, (alkoxycarbonyl)hydroxyalkyl, (CONR¹³R¹⁴)alkyl, (CONR¹³R¹⁴)(hydroxyalkyl)alkyl, 10 (CONR¹³R¹⁴)cycloalkyl, (alkylcarbonyl)aminoalkyl, (phenyl)alkyl, (pyridinyl)alkyl,


alkylsulfonyl, phenylsulfonyl, Ar², Ar³, , , , or




R^8 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;

or R^7R^8N taken together is azetidiny, pyrrolidinyl, piperidinyl, piperazinyl,

- 15 morpholinyl, dihydroindolyl, or isoindolyl, and is substituted with 0-2 substituents selected from alkyl, hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxy, carboxy, alkoxy carbonyl, dialkylcarboxamido, alkylcarbonylamino, alkoxy carbonylamino, pyridinyl, and phenyl where said phenyl is substituted with 0-2 halo or alkyl substituents;

- 20 or where R^7R^8N taken together is , (quinuclidinyl)amino, (quinuclidinyl)(alkyl)amino, (methylpyrrolidinyl)(alkyl)amino, ((imidazolyl)alkyl)(hydroxyalkyl)amino, (alkylthiazolyl)amino, ((carboxamido)cyclopentanyl)amino, ((halophenyl)cyclopentanyl)amino, 3H-spiro(isobenzofuranyl)piperidinyl, (hydroxyindanyl)amino, or



R^9 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;

R^{10} is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;

or R⁹ and R¹⁰ taken together is ethylene, propylene, butylene, pentylene, or hexylene;

R¹¹ is hydrogen, alkyl, or cycloalkyl;

R¹² is hydrogen, alkyl, or cycloalkyl;

5 or R¹¹ and R¹² taken together with the nitrogen to which they are attached is azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl;

R¹³ is hydrogen, alkyl, cyanoalkyl, haloalkyl, alkenyl, alkynyl, or thiazolyl;

R¹⁴ is hydrogen or alkyl;

R¹⁵ is hydrogen, alkyl, hydroxyalkyl, cycloalkyl, or benzyl;

10 R¹⁶ is hydrogen or alkyl;

or R¹⁵ and R¹⁶ taken together with the nitrogen to which they are attached is azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl;

R¹⁷ is haloalkyl, cyanoalkyl, (cycloalkyl)alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, (R¹⁸)alkyl, (Ar⁴)alkyl, alkynyl, or aminocycloalkyl;

15 R¹⁸ is CONH₂, H₂NCONH, dibenzylamino, phthalimido, amino, alkylamino, dialkylamino, azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl where azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl is substituted with 0-3 alkyl or alkoxy carbonyl substituents;

R¹⁹ is cyano, hydroxyalkyl, morpholinylalkyl, carboxy, alkoxy carbonyl, 20 cycloalkylsulfoxamido, ((alkyl)pyrazolyl)amino, ((alkyl)isoxazolyl)amino, (thiadiazolyl)amino, (triazinyl)amino, or alkynylaminocarbonyl;

R²⁰ is hydrogen, halo, alkyl, or alkoxy;

R²¹ is hydrogen, halo, alkyl, or alkoxy;

Ar¹ is phenyl, naphthalenyl, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, 25 isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, oxadiathiazolyl, triazolyl, tetrazolyl, pyrazinyl, pyrimidinyl, or benzothiazolyl, and is substituted with 0-2 substituents selected from halo, alkyl, cycloalkyl, haloalkyl, alkoxyalkyl, hydroxy, alkoxy, amino, alkylamino, dialkylamino, aminocarbonyl, pyridinyl, phenyl, halophenyl, alkylphenyl, and alkoxyphenyl;

30 Ar² is phenyl, biphenyl, or pyridinyl, and is substituted with 0-2 substituents selected from halo, alkyl, cyano, hydroxy, alkoxy, and carboxy;

Ar³ is pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, oxathiadiazolyl, pyrimidinyl, or pyrizinyl, and is substituted with 0-2 substituents selected from hydroxy, alkyl, hydroxyalkyl, and CONR¹³R¹⁴;

Ar⁴ is furanyl, thienyl, pyrrolyl, pyrazolyl, isoxazolyl, isothiazolyl, 5 imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridinyl, indolyl, or phenyl, and is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, hydroxyl, and alkoxy; and

Ar⁵ is pyrrolyl, imidazolyl, or oxadiazolyl, and is substituted with 0-2 substituents selected from alkyl, carboxy, alkoxycarbonyl, benzyl, and phenyl; 10 or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 where R²⁰ and R²¹ are hydrogen.

3. A compound of claim 2 where 15 R¹ is R⁵R⁶N; (carboxy)alkenyl; (alkoxycarbonyl)alkenyl; (benzyloxycarbonyl)alkenyl; or phenyl where said phenyl is substituted with 1-2 substituents selected from the group consisting of cyano, alkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxyalkyloxy, alkoxyalkyloxy, haloalkyl, benzyloxy, carboxy, alkoxycarbonyl, alkylsulfonyl, (carboxy)alkenyl, (alkoxycarbonyl)alkenyl, 20 alkylcarboxamido, alkoxycarboxamido, alkylsulfamido, (alkylsulfamido)alkyl, tetrahydropyranyloxy, Ar⁵, SO₂NR¹⁵R¹⁶, and CONR⁷R⁸; and where said phenyl is also substituted with 0-1 substituents selected from the group consisting of halo; alkyl; hydroxyalkyl; alkoxyalkyl; hydroxyl; alkoxy; OR¹⁷; cycloalkoxy; amino; alkylamino; dialkylamino; alkylcarboxamido; alkoxyalkylcarboxamido; furanyl; 25 indolyl; isoquinolinyl; pyridinyl substituted with 0-2 halo, alkyl, hydroxy, or alkoxy substituents; pyrazolyl substituted with 0-2 alkyl substituents; and phenyl substituted with 0-2 halo, alkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarboxamido, carboxyalkenyl, or phenyl substituents; 30 R² is hydrogen, nitro, or R⁵R⁶N;





R^3 is cyano, alkoxycarbonyl, (cycloalkyl)oxycarbonyl, (alkylsulfonyl)aminocarbonyl, $\text{CONR}^{11}\text{R}^{12}$, $(\text{R}^{11})(\text{R}^{12})\text{NCONH}$, triazolyl, thiazolyl, or tetrazolyl;

R^4 is phenyl substituted with 0-2 halo substituents;

5 R^5 is hydrogen, alkyl, or alkylsulfonyl;


R^6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or alkylsulfonyl;

R^7 is hydrogen, alkyl, alkenyl, alkynyl, cyanoalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, oxoalkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkyl)alkyl, cycloalkyl, (alkyl)cycloalkyl, (hydroxyalkyl)cycloalkyl, (tetrahydrofuranyl)alkyl, (tetrahydropyranyl)alkyl, (carboxy)alkyl, (alkoxycarbonyl)alkyl, (alkoxycarbonyl)hydroxyalkyl, $(\text{CONR}^{13}\text{R}^{14})$ alkyl, (alkylcarbonyl)aminoalkyl, (phenyl)alkyl, (pyridinyl)alkyl, alkylsulfonyl,

phenylsulfonyl, Ar^2 , Ar^3 , , , , or ;

R^8 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;

15 or $\text{R}^7\text{R}^8\text{N}$ taken together is azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or dihydroindolyl, and is substituted with 0-2 substituents selected from alkyl, hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxy, carboxy, alkoxycarbonyl, dimethylcarboxamido, alkylcarbonylamino, alkoxycarbonylamino, pyridinyl, and phenyl where phenyl is substituted with 0-2 substituents selected from halo and alkyl;

20 or where $\text{R}^7\text{R}^8\text{N}$ taken together is , (quinuclidinyl)(alkyl)amino, (methylpyrrolidinyl)(alkyl)amino, (alkylthiazolyl)amino, ((carboxamido)cyclopentanyl)amino, ((halophenyl)cyclopentanyl)amino, or (hydroxyindanyl)amino;

R^9 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;

25 R^{10} is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;

or R^9 and R^{10} taken together is ethylene, propylene, butylene, or pentylene;

R^{11} is hydrogen, alkyl, or cycloalkyl;


R^{12} is hydrogen, alkyl, or cycloalkyl;

30 or R^{11} and R^{12} taken together with the nitrogen to which they are attached is azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl;


- R¹³ is hydrogen, alkyl, cyanoalkyl, alkenyl, or alkynyl;
R¹⁴ is hydrogen or alkyl;
R¹⁵ is hydrogen or alkyl;
R¹⁶ is hydrogen or alkyl;
5 R¹⁷ is haloalkyl, hydroxyalkyl, alkoxyalkyl, alkynyl, (R¹⁸)alkyl or (Ar⁴)alkyl;
R¹⁸ is CONH₂, dibenzylamino, amino, alkylamino, dialkylamino, azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl where azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl is substituted with 0-3 substituents selected from alkyl and alkoxy carbonyl;
10 R¹⁹ is cyano, ((alkyl)pyrazolyl)amino, ((alkyl)isoxazolyl)amino (thiadiazolyl)amino, or (triazinyl)amino;
Ar¹ is phenyl, naphthalenyl, pyridinyl, thienyl, thiazolyl, or pyrazinyl, and is substituted with 0-2 substituents selected from alkyl, halo, hydroxy, alkoxy, amino, alkylamino, and dialkylamino;
15 Ar² is phenyl, biphenyl, or pyridinyl, and is substituted with 0-2 substituents selected from halo, alkyl, cyano, hydroxy, and alkoxy;
Ar³ is pyrazolyl isoxazolyl, thiazolyl, pyrimidinyl, or pyridinyl, and is substituted with 0-2 substituents selected from alkyl and hydroxyalkyl;
Ar⁴ is pyrrolyl, imidazolyl, pyridinyl, indolyl, or phenyl, and is substituted
20 with 0-2 substituents selected from halo, alkyl, hydroxyl, and alkoxy; and
Ar⁵ is pyrrolozyl, imidazolyl, or oxadiazolyl and is substituted with 0-2 substituents selected from alkyl, carboxy, alkoxy carbonyl, benzyl, and phenyl; or a pharmaceutically acceptable salt thereof.
- 25 4. A compound of claim 2 where
R¹ is alkoxy; (alkoxy carbonylamino)alkoxy; (alkylphenyl)alkoxy; (carboxy)alkenyl; ((N-dimethylbenzyl)aminocarbonyl)alkenyl; or phenyl where said phenyl is substituted with 1-2 substituents selected from the group consisting of halo, cyano, alkyl, haloalkyl, hydroxyalkyl, (carboxy)alkyl, alkoxy, hydroxyalkoxy, 30 tetrahydropyranyloxy, carboxy, alkoxy carbonyl, (carboxy)alkenyl, alkylcarboxamido, alkoxy carboxamido, (alkylsulfamido)alkyl, Ar⁵, SO₂NR¹⁵R¹⁶, and CONR⁷R⁸; and where said phenyl is also substituted with 0-2 substituents selected from the group

consisting of halo; nitro; alkyl; cycloalkyl; haloalkyl; aminoalkyl; hydroxy; alkoxy; OR¹⁷; cycloalkoxy; amino; alkoxy-carboxamido; furanyl, thienyl, or pyrazolyl substituted with 0-2 alkyl substituents; pyridinyl substituted with 0-2 halo, cyano, alkyl, hydroxy, alkoxy, amino, or alkylaminocarbonyl substituents; pyrimidinyl; 5 pyrimidinedionyl; aminopyrimidinyl; indolyl; isoquinolinyl; and phenyl substituted with 0-2 substituents selected from halo, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, amino, carboxy, aminocarbonyl, alkylaminocarbonyl, alkylcarboxamido, and carboxyalkenyl;

- R² is hydrogen, halo, nitro, amino, phenyl, or R⁵R⁶N;
 10 R³ is CONR¹¹R¹²;
 R⁴ is phenyl substituted with 0-2 halo substituents;
 R⁵ is hydrogen or alkylsulfonyl;
 R⁶ is hydrogen, alkyl, hydroxyalkyl, or alkylsulfonyl;
 R⁷ is hydrogen, alkyl, alkynyl, cyanoalkyl, haloalkyl, hydroxyalkyl,
 15 dihydroxyalkyl, alkoxyalkyl, oxoalkyl, (dialkylamino)alkyl, (cycloalkyl)alkyl, cycloalkyl, (alkyl)cycloalkyl, (hydroxyalkyl)cycloalkyl, (tetrahydrofuranyl)alkyl, (tetrahydropyranyl)alkyl, (carboxy)alkyl, (alkoxycarbonyl)alkyl, (alkenyloxycarbonyl)alkyl, (alkoxycarbonyl)hydroxyalkyl, (CONR¹³R¹⁴)alkyl, (CONR¹³R¹⁴)(hydroxyalkyl)alkyl, (CONR¹³R¹⁴)cycloalkyl,
 20 (alkylcarbonyl)aminoalkyl, (phenyl)alkyl, alkylsulfonyl, phenylsulfonyl, Ar², Ar³,
 $\begin{array}{c} R^9 \quad R^{10} \\ \diagdown \quad \diagup \\ * \quad C \\ \diagup \quad \diagdown \\ R^{19} \end{array}, \begin{array}{c} R^9 \quad R^{10} \\ \diagdown \quad \diagup \\ * \quad C \\ \diagup \quad \diagdown \\ Ar^1 \end{array}, \begin{array}{c} R^9 \quad R^{10} \\ \diagdown \quad \diagup \\ * \quad C \\ \diagup \quad \diagdown \\ CH_2 \end{array} Ar^1, \text{ or } \begin{array}{c} \diagup \quad \diagdown \\ * \quad C \\ \diagdown \quad \diagup \end{array} Ar^1;$
 R⁸ is hydrogen, alkyl, or alkoxyalkyl;
 or R⁷R⁸N taken together is azetidiny, pyrrolidiny, piperidiny, piperaziny, morpholinyl, dihydroindolyl, or isoindoliny, and is substituted with 0-2 substituents
 25 selected from alkyl, hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxy-carbonyl, dialkylcarboxamido, alkylcarbonylamino, pyridinyl, and phenyl where said phenyl is substituted with 0-2 halo or alkyl substituents;

or where R⁷R⁸N taken together is , (quinuclidiny)amino,
 (quinuclidiny)(alkyl)amino, (methylpyrrolidiny)(alkyl)amino,
 30 ((imidazolyl)alkyl)(hydroxyalkyl)amino, (alkylthiazolyl)amino,

((carboxamido)cyclopentanyl)amino, ((halophenyl)cyclopentanyl)amino,
3H-spiro(isobenzofuranyl)piperidinyl, (hydroxyindanyl)amino, or



R^9 is hydrogen, alkyl, or hydroxyalkyl;

5 R^{10} is hydrogen or alkyl;

or R^9 and R^{10} taken together is ethylene or propylene;

R^{11} is alkyl;

R^{12} is hydrogen;

R^{13} is hydrogen, alkyl, cyanoalkyl, haloalkyl, alkenyl, or thiazolyl;

10 R^{14} is hydrogen or alkyl;

R^{15} is alkyl, hydroxyalkyl, cycloalkyl, or benzyl;

R^{16} is hydrogen;

or R^{15} and R^{16} taken together with the nitrogen to which they are attached is
azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl;

15 R^{17} is haloalkyl, cyanoalkyl, (cycloalkyl)alkyl, hydroxyalkyl, alkoxyalkyl,
aminoalkyl, (R^{18})alkyl, (Ar^4)alkyl, alkynyl, or aminocycloalkyl;

R^{18} is $CONH_2$, H_2NCONH , dibenzylamino, phthalimido, amino,
dialkylamino, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl where azetidiny,
pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl is substituted with 0-3 alkyl or
20 alkoxy carbonyl substituents;

R^{19} is cyano, hydroxyalkyl, morpholinylalkyl, carboxy, alkoxy carbonyl,
cycloalkylsulfoxamido, ((alkyl)pyrazolyl)amino, ((alkyl)isoxazolyl)amino,
(thiadiazolyl)amino, (triazinyl)amino, or alkynylaminocarbonyl;

Ar^1 is phenyl, naphthalenyl, pyridinyl, furanyl, pyrazolyl, isoxazolyl,
25 imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyrazinyl,
pyrimidinyl, or benzothiazolyl, and is substituted with 0-2 substituents selected from
halo, alkyl, cycloalkyl, haloalkyl, alkoxyalkyl, hydroxy, alkoxy, amino,
aminocarbonyl, pyridinyl, phenyl, halophenyl, alkylphenyl, and alkoxyphenyl;

Ar^2 is phenyl, biphenyl, or pyridinyl, and is substituted with 0-2 substituents
30 selected from halo, alkyl, cyano, hydroxy, alkoxy, and carboxy;

Ar³ is pyrazolyl, isoxazolyl, thiazolyl, triazolyl, pyrimidinyl, or pyrizinyl, and is substituted with 0-2 substituents selected from hydroxy, alkyl, and CONR¹³R¹⁴;

Ar⁴ is furanyl, pyrrolyl, pyrazolyl, isoxazolyl, imidazolyl, oxadiazolyl, triazolyl, pyridinyl, indolyl, or phenyl, and is substituted with 0-2 substituents
5 selected from halo, alkyl, haloalkyl, and hydroxy; and

Ar⁵ is pyrrolyl, imidazolyl, or oxadiazolyl, and is substituted with 0-2 substituents selected from alkyl, alkoxycarbonyl, benzyl, and phenyl;
or a pharmaceutically acceptable salt thereof.

10 5. A compound of claim 2 where R¹ is phenyl substituted with 1 CONR⁷R⁸ substituent and also substituted with 0-2 halo, alkyl, or alkoxy substituents; R² is hydrogen, halo, or R⁵R⁶N; R³ is CONR¹¹R¹²; R⁴ is monofluorophenyl; R⁵ is alkylsulfonyl; R⁶ is hydroxyalkyl; R⁷ is ; R⁸ is hydrogen; R⁹ is alkyl; R¹⁰ is alkyl or R⁹ and R¹⁰ taken together is ethylene or propylene; R¹¹ is alkyl; R¹² is
15 hydrogen; and Ar¹ is phenyl, pyridinyl, pyrimidinyl, isoxazolyl, oxazolyl, or oxadiazolyl, and is substituted with 0-1 halo or alkyl substituents; or a pharmaceutically acceptable salt thereof.

20 6. A compound of claim 1 where R¹ is phenyl substituted with 1-2 substituents selected from the group consisting of halo, cyano, alkyl, haloalkyl, hydroxyalkyl, (carboxy)alkyl, alkoxy, hydroxyalkyloxy, tetrahydropyranyloxy, carboxy, alkoxycarbonyl, (carboxy)alkenyl, alkylcarboxamido, alkoxycarboxamido, (alkylsulfamido)alkyl, Ar⁵, SO₂NR¹⁵R¹⁶, and CONR⁷R⁸; and where said phenyl is also substituted with 0-2 substituents selected from the group consisting of halo;
25 nitro; alkyl; cycloalkyl; haloalkyl; aminoalkyl; hydroxy; alkoxy; OR¹⁷; cycloalkoxy; amino; alkoxycarboxamido; furanyl, thienyl, or pyrazolyl substituted with 0-2 alkyl substituents; pyridinyl substituted with 0-2 halo, cyano, alkyl, hydroxy, alkoxy, amino, or alkylaminocarbonyl substituents; pyrimidinyl; pyrimidinedionyl; aminopyrimidinyl; indolyl; isoquinolinyl; and phenyl substituted with 0-2 substituents
30 selected from halo, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, amino, carboxy, aminocarbonyl, alkylaminocarbonyl, alkylcarboxamido, and carboxyalkenyl.

7. A compound of claim 1 where R¹ is phenyl substituted with 1 CONR⁷R⁸ substituent and also substituted with 0-2 halo, alkyl, or alkoxy substituents.

8. A compound of claim 7 where R⁷ is  and at least one of R⁹ and R¹⁰ is not hydrogen.

9. A compound of claim 1 selected from the group consisting of
- 2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide;
- 10 4-fluoro-2-(4-fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide;
- 4-fluoro-2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide;
- 2-(4-fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(pyrimidin-2-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide;
- 15 2-(4-fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide;
- 2-(4-fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(5-methyl-1,2,4-oxadiazol-3-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide;
- 20 2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide;
- 5-(3-fluoro-2-methyl-5-(1-(pyridin-2-yl)cyclopropylcarbamoyl)phenyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide;
- 2-(4-fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(5-methylthiazol-2-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide;
- 25 2-(4-fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(5-methylisoxazol-3-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide;
- 2-(4-fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-(5-methyloxazol-2-yl)cyclopropylcarbamoyl)phenyl)-N-methylbenzofuran-3-carboxamide;
- 30 2-(4-fluorophenyl)-6-(N-(2-hydroxyethyl)methylsulfonamido)-N-methyl-5-(3-(2-phenylpropan-2-ylcarbamoyl)phenyl)benzofuran-3-carboxamide

2-(4-fluorophenyl)-6-(N-(2-hydroxyethyl)methylsulfonamido)-N-methyl-5-(3-(1-phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide; and

2-(4-fluorophenyl)-5-(3-(1-(4-fluorophenyl)cyclopropylcarbamoyl)phenyl)-6-(N-(2-hydroxyethyl)methylsulfonamido)-N-methylbenzofuran-3-carboxamide;

5 or a pharmaceutically acceptable salt thereof.

10. A composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

10 11. A method of treating hepatitis C infection comprising administering a therapeutically effective amount of a compound of claim 1 to a patient.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2009/056166

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D307/84 C07D405/04 C07D405/10 C07D405/12 C07D407/12
C07D409/12 C07D413/10 C07D413/12 C07D417/10 C07D417/12
C07D453/00 C07D491/10 A61K31/14 A61P31/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004/041201 A (VIROPHARMA INC [US]; WYETH CORP [US]; BURNS CHRISTOPHER J [US]; DEL VE) 21 May 2004 (2004-05-21) cited in the application claim 1; examples 43,178,179; table 1	1-11
A	WO 2008/024843 A (VIROPHARMA INC [US]; WYETH CORP [US] VIROPHARMA INC [US]; WYETH CORP [US]) 28 February 2008 (2008-02-28) examples 1-4	1-11



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 February 2010

Date of mailing of the international search report

23/02/2010

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Seelmann, Ingo

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2009/056166

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GRINEV, A. N. ET AL: "Aminomethyl and aminoethyl derivatives of 5-methoxybenzofuran" XP002566940 retrieved from STN Database accession no. 1963:469003 RN 94004-97-4, 94623-08-2, 95220-34-1 abstract & ZHURNAL OBSHCHEI KHIMII , 33(5), 1436-42 CODEN: ZOKHA4; ISSN: 0044-460X, 1963, -----	1,2,4
P,X	WO 2009/101022 A (HOFFMANN LA ROCHE [CH]; LABADIE SHARADA SHENVI [US]; LIN CLARA JEOU JE) 20 August 2009 (2009-08-20) example 1; compounds A-5B -----	1,2,4

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2009/056166

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-3(part), 4, 5-8(part), 9, 10(part), 11(part)
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-3,5-8,10,11(all part)

subject-matter relating to compounds with R3=cyano

2. claims: 1-3,5-8,10,11(all part)

subject-matter relating to compounds with R3=alkoxycarbonyl

3. claims: 1-3,5-8,10,11(all part)

subject-matter relating to compounds with
R3=(cycloalkyl)oxycarbonyl

4. claims: 1-3,5-8,10,11(all part)

subject-matter relating to compounds with
R3=(alkylsulfonyl)aminocarbonyl

5. claims: 1-3(part),4,5-8(part),9,10(part),11(part)

subject-matter relating to compounds with R3=CONR11R12

6. claims: 1-3,5-8,10,11(all part)

subject-matter relating to compounds with R3=(R11)(R12)NCONH

7. claims: 1-3,5-8,10,11(all part)

subject-matter relating to compounds with R3=triazolyl,
thiazolyl or tetrazolyl

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2009/056166

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2004041201 A	21-05-2004	AU 2003290584 A1	07-06-2004
		BR 0315937 A	13-09-2005
		CA 2504344 A1	21-05-2004
		EC SP055801 A	22-11-2005
		EP 1581207 A2	05-10-2005
		JP 2006510736 T	30-03-2006
		KR 20050065661 A	29-06-2005
		MX PA05004608 A	20-09-2005
		NI 200500090 A	25-05-2006
		NZ 539727 A	31-01-2008
		ZA 200503501 A	25-10-2006
WO 2008024843 A	28-02-2008	AR 062453 A1	12-11-2008
		CL 24902007 A1	07-03-2008
		PA 8744101 A1	23-04-2009
		US 2008075695 A1	27-03-2008
WO 2009101022 A	20-08-2009	US 2009208449 A1	20-08-2009